US20030175311A1 - Recombinant coccidiosis vaccines - Google Patents

Recombinant coccidiosis vaccines Download PDF

Info

Publication number
US20030175311A1
US20030175311A1 US10/267,430 US26743002A US2003175311A1 US 20030175311 A1 US20030175311 A1 US 20030175311A1 US 26743002 A US26743002 A US 26743002A US 2003175311 A1 US2003175311 A1 US 2003175311A1
Authority
US
United States
Prior art keywords
protein
surface antigen
monoclonal antibody
ala
kilodaltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/267,430
Inventor
Mary-Helen Binger
Richard Chizzonite
Richard Kramer
Peter Lomedico
Stephen McAndrew
Werner Altenburger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Products LLC
Original Assignee
Alpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Inc filed Critical Alpharma Inc
Priority to US10/267,430 priority Critical patent/US20030175311A1/en
Publication of US20030175311A1 publication Critical patent/US20030175311A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/455—Eimeria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • This application relates to the use of recombinant DNA technology to produce antigens of Eimeria protozoan parasites. These recombinantly produced antigens can be used, through various routes of administration, to protect poultry against coccidiosis.
  • Coccidiosis is a costly disease of poultry caused by intracellular protozoan parasites of the genus Eimeria.
  • the disease is endemic in the large, intensive poultry breeding establishments in this country, and the estimated cost of control of the disease through chemotherapy exceeds $100 million each year.
  • Resistance to the anti-coccidial drugs develops, necessitating a continuing development of new agents, at a time when drug development is becoming increasingly expensive and consumer acceptance of drug residues in food animals is diminishing.
  • Schenkel et al. identified a number of antigens against which the antibodies were directed. By pre-incubating E. tenella sporozoites with these antibodies and then introducing the treated sporozoites into the ceca of chickens, Schenkel et al. were able to show some reduction in cecal lesion scores, compared to untreated sporozoite controls.
  • recombinant DNA molecules can be used to produce the product specified by the inserted gene sequence only if a number of conditions are met. Foremost is the requirement that the recombinant molecule be compatible with, and thus capable of autonomous replication in, the host cell.
  • Escherichia coli as a host organism, because it is compatible with a wide range of recombinant plasmids.
  • the recombinant DNA molecule is introduced into the host by transformation, transduction or transfection.
  • Detection of the presence of recombinant plasmids in host cells may be conveniently achieved through the use of plasmid marker activities, such as antibiotic resistance.
  • plasmid marker activities such as antibiotic resistance.
  • a host bearing a plasmid coding for the production of an ampicillin-degrading enzyme could be selected from unaltered cells by growing the host in a medium containing ampicillin.
  • Further advantage may be taken of antibiotic resistance markers where a plasmid codes for a second antibiotic-degrading activity at a site where the selected restriction endonuclease makes its cut and the foreign gene sequence is inserted.
  • Host cells containing properly recombinant plasmids will then be characterized by resistance to the first antibiotic but sensitivity to the second.
  • the foreign gene sequence must be fused in proper relationship to a signal region in the plasmid for DNA transcription called a promoter.
  • the foreign DNA may carry its own promoter, as long as it is recognized by the host.
  • the promoter is a DNA sequence that directs the binding of RNA polymerase and therefore “promotes” the transcription of DNA to messenger RNA (mRNA).
  • the ultimate production of the desired gene product will be dependent upon-the effectiveness of translation from mRNA to protein. This, in turn, is dependent upon the efficiency of ribosomal binding to the mRNA.
  • the ribosome-binding site on mRNA includes an initiation codon (AUG) and an upstream Shine-Dalgarno (SD) sequence. This sequence, containing 3-9 nucleotides and located 3-11 nucleotides from the AUG codon, is complementary to the 3′ end of E. coli 16S ribosomal RNA (rRNA) [Shine and Dalgarno, Nature 254:34 (1975)].
  • Expression of the ⁇ -galactosidase gene results in the production of a fusion protein containing 114 kd of ⁇ -galactosidase and a carboxy terminal polypeptide encoded by the cDNA insert, provided that the insert contains an open reading frame in the same register as the reading frame for ⁇ -galactosidase.
  • a phage containing a gene whose product is recognized by a monoclonal or a polyclonal antiserum can thus be identified by immunologic screening of the library following induction of expression of the fusion protein using ⁇ -D-thiogalactopyranoside (IPTG) to inactivate the lacZ repressor.
  • IPTG ⁇ -D-thiogalactopyranoside
  • This expression vector system combines the efficiency of the phage system in packaging DNA and introducing it into E. coli cells with an increased stability of polypeptide fusions with ⁇ -galactosidase.
  • a subunit of the whole infectious organism is delivered to the host animal in an immunologically relevant context.
  • the subunit might be a protein purified from the parasite, a recombinant protein or protein fragment expressed in a heterologous system, a synthetic peptide comprising a single neutralizing determinant or a protein introduced by a viral vector such as vaccinia.
  • the host immune system mounts a specific response to the subunit without ever being exposed to the whole parasite. Upon challenge with a virulent dose of the infectious organism, the host immune system mounts a successful defense, instructed only by the vaccine subunit to which it had been previously exposed.
  • This invention provides purified proteins or fragments thereof having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen.
  • this-invention provides proteins or fragments thereof having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28, 37, 120 or greater than 200 kilodaltons and specifically binds to one or more monoclonal antibodies deposited with the American Type Culture Collection and assigned accession Nos. HB 9707 through HB 9712.
  • This invention further provides the foregoing deposited monoclonal antibodies.
  • This invention still further provides DNA sequences or fragments thereof encoding proteins or fragments thereof having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28, 37, 120 or greater than 200 kilodaltons and specifically binds to one or more monoclonal antibodies deposited with the American Type Culture Collection and assigned accession Nos. HB 9707 through HB 9712: recombinant vectors containing and capable of directing the expression of such DNA sequences or fragments in compatible host organisms: and microorganisms containing such vectors which are capable of expressing the DNA sequences or fragments.
  • This invention still further provides a method for producing a protein or fragment thereof having one or more immunoreactive and/or antigenic determinants of an Eimeria tenella surface antigen, which method comprises:
  • This invention still further provides vaccines for protecting poultry against coccidiosis comprising one or more of the proteins or fragments thereof of the invention and a physiologically acceptable carrier.
  • This invention still further provides vaccines for protecting poultry against coccidiosis comprising a viral vector containing a DNA sequence or fragment thereof coding for a protein or fragment thereof of the invention, which viral vector is capable of expressing the DNA sequence or fragment, and a physiologically acceptable carrier.
  • This invention still further provides a method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine of the invention to a young fowl which is susceptible to coccidiosis.
  • FIG. 1 shows the results of an E. tenella sporozoite ELISA.
  • Dilutions of immune mouse serum (MS 107-2; ⁇ ) and control mouse serum (X) were incubated with 4 ⁇ 10 4 live purified sporozoites.
  • Specific antibody bound to the sporozoites was detected with a peroxidase-conjugated anti-mouse IgG antibody and the peroxidase substrate o-phenylenediamine.
  • the OD 492 nm was read in a Titertek Multiscan® plate reader.
  • FIG. 2 shows the results of a Western blot assay performed with proteins solubilized from E. tenella sporozoites. Solubilized sporozoite proteins were separated by reducing SDS-polyacrylamide gel electrophoresis in 12.5% gels, transferred to nitrocellulose membranes and reacted with each antibody. The specific proteins recognized by each antibody were visualized with a peroxidase-conjugated anti-mouse IgG antibody and the peroxidase substrate 4-chloro-1-naphthol. The antibody which was reacted with each strip is noted at the top of the strip.
  • FIG. 3 shows the results-of a Western blot assay performed with proteins solubilized from sporozoites and merozoites of E. tenella, and from sporozoites of E. acervulina .
  • Various monoclonal antibodies and sera were incubated with nitrocellulose bound Eimeria proteins and visualized as explained in the description of FIG. 2.
  • the monoclonal antibodies used included 3A5 (1), 20C6 (2), 7D1 (3), 13A6 (4), 6A5 (5) and a control antibody that was unreactive to the Eimeria proteins.
  • the sera used included mouse No. 107-2 immune serum (7) and control serum (8).
  • FIG. 4 shows in the left panel the results- of an immunoprecipitation assay with 125 I-labeled surface proteins of E. tenella sporozoites. Sporozoite surface proteins were labeled by either the IODOGEN or IODOBEADS method, solubilized and visualized following SDS-polyacrylamide gel electrophoresis in 12.5% gels by autoradiography.
  • the right panel shows the results of immunoprecipitation of 125 I-labeled sporozoite surface proteins by serum from mice immunized with live sporozoites.
  • Immune mouse sera (105-1, 105-2, 105-3, 107-1, 107-2 and 107-3) and control mouse serum (Control) were incubated with 125 I-sporozoite surface proteins, and the immune complexes were captured by an anti-mouse antibody coupled to agarose.
  • the immune complexes were solubilized with Laemmli sample buffer, separated by SDS-gel electrophoresis in 12.5% gels and visualized by autoradiography.
  • M represents the molecular weights of standard marker proteins in kilodaltons.
  • FIG. 5 shows the results of immunoprecipitation of 125 I-sporozoite surface proteins by monoclonal antibodies. The procedure for identifying the 125 I-proteins bound by each antibody is explained in the description of FIG. 4. Specific sporozoite monoclonal antibodies used and control antibody (control) are indicated at the top of each gel lane. Molecular weights of standard marker proteins are shown in kilodaltons.
  • FIG. 6 shows phase contrast micrographs and immunofluorescence staining pattern micrographs using various monoclonal antibodies, of air-dried E. tenella sporozoite slide preparations.
  • the left sides of panels A, B. C and D are phase contrast micrographs showing intact elongated sporozoites with a large posterior refractile body (PRB), a small anterior refractile body (ARB) and the apical end (A) opposite the posterior refractile body.
  • PRB posterior refractile body
  • ARB small anterior refractile body
  • A apical end opposite the posterior refractile body.
  • the right sides of panels A, B, C and D show slides which were treated with monoclonal antibodies 14C3 (specific for surface antigens). 6A5 (specific for surface and refractile body protein).
  • 11D2 specific for-sporozoite apical tip
  • control antibody respectively.
  • the antibodies bound to the preparations were localized with rhodamine-conjugated anti-mouse antibodies, visualized by epifluorescence using a Leitz Dialux 22® microscope. All micrographs are 630 ⁇ .
  • FIG. 7 shows antibody staining of intracellular sporozoites and the developing parasite in chicken kidney cells.
  • Chicken kidney cells were infected with sporozoites, and at the indicated times after infection the cells were processed for antibody staining. The cultures were washed before fixation to remove any extracellular sporozoites.
  • Phase contrast and corresponding immunofluorescence micrographs were made using antibodies 7D4, 8A2, 7B2 and 15A3 as indicated. The antibodies bound to the preparations were localized with rhodamine-conjugated anti-mouse antibodies, visualized by epifluorescence. All micrographs are 630 ⁇ .
  • FIG. 8 shows antibody staining of intracellular sporozoites and the developing parasite in chicken kidney cells. Phase contrast micrographs and corresponding immunofluorescence micrographs were made using monoclonal antibodies 14B1 and 19D6, immune chick sera and fluorescent second antibodies, at the indicated times.
  • FIG. 9 shows the neutralization of intracellular sporozoite development by anti-sporozoite antibodies.
  • Purified E. tenella sporozoites were preincubated for 1 hour at 40° C. with either control antibody (X) or anti-sporozoite antibodies 7D4 ( ⁇ ), 8A2 ( ⁇ ), 14B1 ( ⁇ ) or 6A5 ( ⁇ ) and-then allowed to infect MDBK cell cultures. Sporozoites were also preincubated with media ( ⁇ ) or with the anti-coccidial drug, lasalocid (*).
  • FIG. 10 shows the results of SDS-polyacrylamide gel electrophoretic/Western Blot analysis of 65 Kd- ⁇ -galactosidase fusion protein samples or other samples as noted.
  • the Western Blot analysis was carried out using murine anti- ⁇ -galactosidase antibody (panel A) or pooled monoclonal antibodies 7D1, 7D4 and 20C6 (panel B) in conjunction with goat anti-mouse HPOD conjugate.
  • the lanes in both panels represent (1) ⁇ -galactosidase, (m) prestained molecular weight markers, the sizes of which are indicated to the left of plate A in kd, (2) total cell pellet protein, (3) protein released from the cell pellet by sonication and (4) protein solubilized by guanidine-HCl from the pellet after sonication.
  • FIG. 11 is a schematic representation of plasmid pEV/2-4, a 65 kd protein expression plasmid containing a 1.7 kb EcoRI DNA insert from phage ⁇ 2-4. Positions of various restriction enzyme sites in the insert are shown relative to the EcoRI site, including PstI (P, at bp 53 and 776), KpnI (K, at bp 202), BstNI (B, at bp 584, 1303 and 1412) and Sau3A (S, at bp 1017 and 1439).
  • PstI P, at bp 53 and 776
  • KpnI K, at bp 202
  • BstNI B, at bp 584, 1303 and 1412
  • Sau3A Sau3A
  • FIG. 12 is a map of pEV3-SEQ, containing a polylinker with the indicated sites inserted between the EcoRI and SalI sites of pEV-vrf3.
  • FIG. 13 is a restriction map of cDNA clones encoding proteins recognized by monoclonal antibody 6A5. Restriction endonuclease sites used for Maxam-Gilbert DNA sequence analysis of the 1.1 kb cDNA are shown. The EcoRI site in parentheses is at the end of the 0.9 kb cDNA. The bar above the map shows the open reading frame predicted from the DNA sequence, with the potential signal peptide filled in. The lines below the map indicate the exoIII deletions used for chain-termination sequence analysis.
  • FIG. 14 is the nucleotide sequence of the 1.1 kb cDNA molecule encoding the 20 kd protein recognized by monoclonal antibody 6A5.
  • FIG. 15 is the amino acid sequence of the protein of FIG. 14, predicted from the nucleotide sequence of that figure.
  • FIG. 16 is the nucleotide sequence of the 1.7 kb cDNA molecule encoding the 65 kd protein recognized by monoclonal antibodies 7D1, 7D4 and 20C6.
  • FIG. 17 is the amino acid sequence of the protein of FIG. 16, predicted from the nucleotide sequence of that figure and confirmed by sequence analysis of tryptic peptides produced from the expressed 65 kd protein. Regions in the overall amino acid sequence corresponding to some of these peptides are shown underlined. The determined sequences of these peptides are overlined.
  • FIG. 18 is the nucleotide sequence of the 1.1 kb cDNA molecule encoding the 28 kd protein recognized by monoclonal antibody 8A2.
  • FIG. 19 is the amino acid sequence of the protein of FIG. 18, predicted from the nucleotide sequence of that figure.
  • FIG. 20 is the nucleotide sequence of the 3.2 kb cDNA molecule encoding the protein recognized by monoclonal antibody 7B2.
  • FIG. 21 is the amino acid sequence of the protein of FIG. 20, predicted from the nucleotide sequence of that figure.
  • FIG. 22 is an SDS polyacrylamide gel electrophoretic analysis of the immunoaffinity-purified 65 kd protein. The gel was visualized by Coomassie blue stain and by Western blot analysis. Lanes 2 and 4 and 3 and 5 contain the purified protein from two preparations Lanes 1 and 6 contain a mixture of molecular weight marker proteins having the molecular weights shown to the left and right of the figure.
  • FIG. 23 is an HPLC elution profile of a ⁇ -mercaptoethanol reduced (panel A) and unreduced (panel B) tryptic digest of the 65 kd protein, showing absorbance at 215 m ⁇ as a function of column retention time.
  • FIG. 24 shows restriction maps of four elements of the basic vector used for recombination of genes coding for coccidial antigens into vaccinia virus. These elements include the 7.5K promoter element (a and b, left), the TK locus (a and b, right), part of plasmid PUC8 (c) and the polycloning site from M13tg131 (d). The direction of transcription of the viral 7.5K and TK promoters is from left to right (i.e. from the BglII to the EcoRI restriction site in the polylinker.
  • FIG. 25 shows the amino acid sequence of the N-terminus of the Eimeria antigen recognized by monoclonal antibody 8A2 (A) expressed from a construct containing the AUG translation start codon in the polylinker element of the vector of FIG. 24, and (B) fused to the malarial 190 kd leader segment (first 34 amino acids) and the polylinker of the cloning vector of FIG. 24 (next 13 amino acids).
  • A the amino acid sequence of the N-terminus of the Eimeria antigen recognized by monoclonal antibody 8A2
  • A expressed from a construct containing the AUG translation start codon in the polylinker element of the vector of FIG. 24, and (B) fused to the malarial 190 kd leader segment (first 34 amino acids) and the polylinker of the cloning vector of FIG. 24 (next 13 amino acids).
  • the first 19 amino acids at the N-terminus may be cleaved at the position indicated by a colon.
  • FIG. 26 is the nucleotide sequence of the DNA molecule encoding the approximately 20 kD protein recognized by monoclonal antibody 6A5 (ATCC Accession No. HB9711). This sequence represents the coding sequence only and encodes the amino acid sequence of FIG. 15.
  • FIG. 26 is the subsequence from about nucleotide 91 to about nucleotide 741 of the sequence of FIG. 14. The first seven and last seven nucleotides of the sequence of FIG. 14 are derived from linker sequences used in the cloning procedure.
  • FIG. 27 is the nucleotide sequence of the DNA molecule encoding the approximately 65 kD protein recognized by-monoclonal antibody 7D4 (ATCC Accession No. HB 9707). This sequence represents the coding sequence only and encodes the amino acid sequence of FIG. 17 from about residue 20,to about 325.
  • FIG. 27 is the subsequence from about nucleotide 62 to about nucleotide 982 of the sequence of FIG. 16.
  • FIG. 28 is the amino acid sequence of the protein of FIG. 27 predicted from the nucleotide sequence of FIG. 27. This sequence is a subsequence of the sequence of FIG. 17 from about residue 20 to about 325. The 1st approximately 20 amino acids of FIG. 17 may result from an artifact during cDNA synthesis which caused “looping back” of a more internal sequence. Therefore, this sequence represents a more accurate sequence of the protein of FIG. 27.
  • FIG. 29 is the nucleotide sequence of the DNA molecule encoding the approximately 28 to approximately 37 kD protein recognized by monoclonal antibody 8A2 (ATCC Accession No. HB 9710). This sequence represents a resequencing of the DNA molecule from which the sequence of FIG. 18 was derived.
  • FIG. 30 is the nucleotide subsequence of the sequence of FIG. 29 which represents the coding sequence only as represented by FIG. 31.
  • FIG. 31 is the amino acid sequence of the protein of FIG. 29 deduced from the nucleotide sequence of FIG. 29. The resequencing suggests that the protein of FIG. 29 is approximately 37 kD.
  • FIG. 32 is the sequence of FIG. 31 from which the first three amino acids have been deleted. These three amino acids are encoded by nucleotides from linkers and are therefore artifacts of the cloning process.
  • FIG. 33 is the nucleotide sequence of the DNA molecule encoding the approximately 45 kD protein recognized by monoclonal antibody 7B2 (ATCC Accession No. HB 9712). This sequence represents the coding sequence only and encodes the amino acid sequence of FIG. 21 beginning at residue three.
  • FIG. 33 is the subsequence from about nucleotide 9 to about nucleotide 3005 of the sequence of FIG. 20. The first seven and last seven nucleotides of the sequence of FIG. 20 are derived from linker sequences used in the cloning procedure.
  • FIG. 34 is the sequence of FIG. 21 from which the first two amino acids have been deleted. These two amino acids are encoded by nucleotides from linkers and are therefore artifacts of the cloning process.
  • 20 kd protein means a recombinant or synthetic protein having an apparent molecular weight of about 20 kilodaltons in SDS polyacrylamide gel electrophoresis which binds specifically to monoclonal antibody 6A5.
  • This antibody also specifically reacts with an Eimeria surface antigen (from a whole extract of Eimeria proteins) having an apparent molecular weight of about 28 kilodaltons in SDS gels. This antigen is present in the sporozoite developmental stage.
  • the nucleotide sequence of a cDNA molecule encoding this protein and the amino acid sequence predicted therefrom are shown in FIGS. 14, 15, and 26 .
  • 65 kd protein means a recombinant or synthetic protein having an apparent molecular weight of about 65 kilodaltons in SDS polyacrylamide gel electrophoresis which binds specifically to monoclonal antibodies 7D1, 7D4 and 20C6. These antibodies also specifically react with a surface antigen from Eimeria extracts having an apparent molecular weight of about 120 kilodaltons in SDS gels. This antigen is present in the sporozoite, schizont and merozoite developmental stages. The nucleotide sequence of a cDNA molecule encoding this protein and the amino acid sequence predicted therefrom are shown in FIGS. 16 and 17, 27 and 28 respectively.
  • 28 kd protein means a recombinant or synthetic protein having an apparent molecular weight of about 28 kilodaltons in SDS polyacrylamide gel electrophoresis which binds specifically to monoclonal antibody 8A2.
  • This antibody also specifically reacts with an Eimeria surface antigen having an apparent molecular weight of about 37 kilodaltons in SDS gels. This antigen is present in the sporozoite, schizont and merozoite developmental stages.
  • the nucleotide sequence of a cDNA molecule encoding this protein and the amino acid sequence predicted therefrom are shown in FIGS. 18 and 19, respectively. *
  • 45 kd protein means a recombinant or synthetic protein having an apparent molecular weight of about 45 kilodaltons in SDS polyacrylamide gel electrophoresis which binds specifically to monoclonal antibody 7B2.
  • This antibody also specifically reacts with an Eimeria surface antigen having an apparent molecular weight of greater than 200 kilodaltons in SDS gels. This antigen is present in the sporozoite developmental stage.
  • the nucleotide sequence of a cDNA molecule encoding this protein and the amino acid sequence predicted therefrom are shown in FIGS. 20 and 21, 33 and 34 respectively.
  • protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen means a protein having one or more regions or epitopes which are capable of eliciting an immune response in an, immunologically competent host organism and/or are capable of specifically binding to a complementary antibody.
  • nucleotide sequences of the DNA sequences and fragments of the invention inserted into vectors may include nucleotides which are not part of the actual structural genes, as long as the recombinant vectors containing such sequences and fragments are capable of directing the production in an appropriate host organism of a protein or fragment having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen.
  • amino acid substitutions in proteins which do not essentially alter biological and immunological activities have been known to occur and have been described, e.g., by Neurath et al. in “The Proteins”, Academic Press. New York (1979). in particular in FIG. 6 at page 14.
  • the most frequently observed amino acid substitutions are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly, and vice versa.
  • fragment means a DNA sequence or protein comprising a subsequence of one of the cDNA's or proteins of the invention.
  • Such fragments can be produced by enzymatic cleavage of the larger molecules, using restriction endonucleases for the DNA and proteases for the proteins.
  • the fragments of the invention are not limited to the products of any form of enzymatic cleavage but include subsequences, the termini of which do not correspond to any enzymatic cleavage points.
  • Such fragments can be made, e.g., by chemical synthesis, using the sequence data provided herein.
  • DNA fragments can be produced by incomplete complementary DNA (cDNA) synthesis from isolated messenger RNA (mRNA).
  • Protein fragments can also be produced by expressing DNA fragments encoding the protein fragments. Such protein fragments can be useful in this invention if they contain a sufficient number of amino acid residues to constitute an immunoreactive and/or antigenic determinant. Generally, at least about 7 or 8 residues are needed. As explained below, it may be necessary to couple such fragments to an immunogenic carrier molecule, to make them immunoreactive.
  • proteins of this invention can be made my methods known in the art such as by recombinant DNA methodology, chemical synthesis or isolation from Eimeria preparations.
  • DNA needed to make the proteins of this invention could be chemically synthesized, using the nucleotide sequence information provided in FIGS. 14, 16, 18 , 20 , 26 , 27 , 29 , 33 .
  • Such chemical synthesis could be carried out using any of the known methods, although the phosphoramidite solid support method of Matteucci et al. [J. Am. Chem. Soc. 103:3185 (1981)] is preferred.
  • cDNA can be made from Eimeria mRNA.
  • Messenger RNA can be isolated from Eimeria sporulating oocysts or merozoites using standard techniques. These mRNA samples can then be used to produce double-stranded cDNA as described by Maniatis et al., supra. This cDNA can then be inserted into an appropriate cloning vector which can be used to transform E. coli , to produce a cDNA library.
  • the cDNA library can then be screened using the cloned genes of this invention, or fragments thereof, as probes.
  • genes or fragments can be radiolabeled, e.g., by nick-translation using Pol I DNA polymerase in the presence of the four deoxyribonucleotides, one of which contains 32 P in the a position (Maniatis et al., supra, p. 109). for use as probes.
  • Eimeria tenella was used as an mRNA source in the Examples below, the cloned genes from this species can be used as probes to isolate genes from other species of Eimeria, due to DNA sequence homology among the various species.
  • the Eimeria genes of this invention are inserted into an appropriate expression vehicle which contains the elements necessary for transcription and translation of the inserted gene sequences.
  • Useful cloning vehicles may consist of segments of chromosomal, nonchromosomal and synthetic DNA sequences such as various known bacterial plasmids, phage DNA, combinations of plasmids and phage DNA such as plasmids which have been modified to employ phage DNA or other expression control sequences, or yeast plasmids.
  • Specific cloning vehicles which could be used include but are not limited to the pEV-vrf plasmids (pEV-vrf1, ⁇ 2 and ⁇ 3); SV40; adenovirus; yeast; lambda gt-WES-lambda B; Charon 4A and 28; lambda-gt-1-lambda B; M13-derived vectors such as pUC8, 9. 18 and 19, pBR313, 322 and 325; pAC105: pVA51; pACY177; pKH47; pACYC184; pUB110; pMB9; co1E1; pSC101; pML21; RSF2124; pCR1 or RP4.
  • pEV-vrf plasmids pEV-vrf1, ⁇ 2 and ⁇ 3
  • SV40 adenovirus
  • yeast lambda gt-WES-lambda B
  • Such linkers may comprise specific oligonucleotide sequences that encode restriction site recognition sequences.
  • the cleaved vector and the Eimeria genes may also be modified by homopolymeric tailing, as described by Morrow [Methods in Enzymology 68:3 (1979)].
  • Many of the cloning vehicles that may be used in this invention contain one or more marker activities that may be used to select for desired transformants, such as ampicillin and tetracycline resistance in pBR322, ampicillin resistance and ⁇ -galactosidase activity in pUC8, and ampicillin resistance in pEV-vrf2. Selection of host cells into which such vectors have been inserted is greatly simplified when the host cells otherwise lack the activities contributed by the vectors.
  • nucleotide sequences of the Eimeria genes inserted at a selected site in a cloning vehicle may include nucleotides which are not part of the actual structural genes.
  • the gene may contain only part of the complete wild-type gene. All that is required is that the gene fragments inserted into the cloning vehicle be capable of directing the production in an appropriate host organism of a polypeptide or protein having at least one immunoreactive and/or antigenic determinant of an Eimeria surface antigen.
  • Suitable host unicellular organisms which can be used in this invention include but are not limited to plant, mammalian or yeast cells and bacteria such as Escherichia coli, Bacillus subtilis. Bacillus stearothermophilus and Actinomyces. Especially preferred is Escherichia coli strain MC1061. which has been described by Casadaban et al. [J. Mol. Biol. 138:179 (1980)]. This strain can be used, or any other strain of E. coli K-12 containing the plasmid pRK248cIts. Plasmid pRK248cIts for use in other E. coli K-12 strains is available from the American Type Culture Collection and has accession No. ATCC 33766. E. coli strain MC1061 has also been deposited and has accession No. ATCC 53338.
  • Transfer of the recombinant cloning vector into the host cell may be carried out in a variety of ways. Depending upon the particular vector/host cell system chosen, such transfer may be effected by transformation, transduction or transfection. Once such a modified host cell is produced, the cell can be cultured and the protein expression product may be isolated from the culture.
  • Clones producing the Eimeria proteins of the invention can be identified using suitably labeled antibodies specific for the proteins.
  • Monoclonal antibodies which are preferred, can be prepared using standard methods as follows.
  • Antigenic proteins from Eimeria tenella are used to immunize animals such as mice, rats, horses, sheep, pigs, rabbits, etc., to obtain antibody producing somatic cells for fusion to myeloma cells.
  • Somatic cells with the potential for producing antibody are suitable for fusion with a myeloma cell line.
  • These somatic cells may be derived from the lymph nodes, spleens and peripheral blood of primed animals.
  • mouse spleen cells are used, in part because these cells produce a relatively high percentage of stable fusions with mouse myeloma lines. It would be possible, however, to use rat, rabbit, frog or other cells instead.
  • the purpose of using monoclonal techniques is to obtain fused hybrid cell lines with unlimited lifespans that produce the desired single antibody under the genetic control of the somatic cell component of the hybridoma.
  • myeloma cell lines incapable of producing light or heavy immunoglobulin chains or deficient in antibody secretion mechanisms are used.
  • a third reason for selection of these cell lines is for their suitability and efficiency for fusion.
  • Many myeloma cell lines may be used for the production of fused cell hybrids, including. e.g., P3/X63-Ag 8. P3/NSI/1-Ag 4-1, SP2/0-Ag-14 and S194/5.XXO.BU.1.
  • the P3/X63-Ag 8 and P3/NSI/1-Ag 4-1 cell lines have been described by Kohler and Milstein [Eur. J. Immunol. 6:511, (1976)].
  • Shulman et al. [Nature 276:269 (1978)] developed the Sp2/0-Ag14 myeloma line.
  • the S194/5.XXO.BU.1 line was reported by Trowbridge [J. Exp. Med. 148:313 (1979)].
  • the PAI-O mouse cell line (a non-Ig-producing subclone of P3/X63-Ag 8) was used.
  • Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually involve mixing somatic cells with myeloma cells in a 10:1 proportion (although the proportion may vary from about 20:1 to about 1:1), respectively, in the presence of an agent or agents (chemical, viral or electrical) that promote the fusion of cell membranes. It is preferred that the same species of animal serve as the source of the somatic add myeloma cells used in the fusion procedure. Fusion methods have been described by Kohler and Milstein [Nature 256:495 (1975) and Eur. J. Immunol. 6:511 (1976)], by Gefter et al. [Somatic Cell Genet.
  • the fusion-promoting agents used by those investigators were Sendai virus and polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • fusion procedures produce viable hybrids at very low frequency (e.g., when spleens are used as a source of somatic cells, only one hybrid is obtained for roughly every 1 ⁇ 10 5 spleen cells), it is essential to have a means of selecting the fused cell hybrids from the remaining unfused cells, particularly the unfused myeloma cells. A means of detecting the desired antibody-producing hybridomas among other resulting fused cell hybrids is also necessary.
  • the selection of fused cell hybrids is accomplished by culturing the cells in media that support the growth of hybridomas, but prevent the growth of the myeloma cells, which normally would go on dividing indefinitely.
  • the somatic cells used in the fusion do not maintain long-term viability in in vitro culture and hence do not pose a problem).
  • myeloma cells lacking hypoxanthine phosphoribosyl transferase HPRT-negative
  • Selection against these cells is made in hypoxanthine/aminopterin/thymidine (HAT) medium, a medium in which the fused cell hybrids survive due to the HPRT-positive genotype of the spleen cells.
  • HAT hypoxanthine/aminopterin/thymidine
  • the use of myeloma cells with different genetic deficiencies (drug sensitivities, etc.) that can be selected against in media supporting the growth of genotypically competent hybrids is also possible.
  • each cell line may be propagated in either of two standard ways.
  • a suspension of the hybridoma cells can be injected into a histocompatible animal. The injected animal will then develop tumors that secrete the specific monoclonal antibody produced by the fused cell hybrid.
  • the body fluids of the animal such as serum or ascites fluid, can be tapped to provide monoclonal antibodies in high concentration.
  • the individual cell lines may be propagated in vitro in laboratory culture vessels.
  • the culture medium containing high concentrations of a single specific monoclonal antibody can be harvested by decantation, filtration or centrifugation.
  • the Eimeria proteins remain in the cytoplasm, or in inclusion bodies. To free the proteins it is thus necessary to disrupt the outer membrane. This is preferably accomplished by sonication, or by other mechanically disruptive means, such as a French pressure cell or Gaulin homogenizer.
  • Cell disruption could also be accomplished by chemical or enzymatic means. Since divalent cations are often required for cell membrane integrity, treatment with appropriate chelating agents such as EDTA or EGTA might prove sufficiently disruptive to facilitate the leakage of the proteins from the cells. Similarly, enzymes such as lysozyme have been used to achieve the same result. That enzyme hydrolyzes the peptidoglycan backbone of the cell wall.
  • osmotic shock could also be employed. Briefly, this could be accomplished by first placing the cells in a hypertonic solution which would cause them to lose water and shrink. Subsequent placement in a hypotonic “shock” solution would then lead to a rapid influx of water into the cells with an expulsion of the desired proteins.
  • the Eimeria proteins may be concentrated by precipitation with salts such as sodium or ammonium sulfate, ultrafiltration or other methods well known to those skilled in the art. Further purification could be accomplished by conventional protein purification techniques including but not limited to gel filtration, ion-exchange chromatography, preparative disc-gel or curtain electrophoresis, isoelectric focusing, low temperature organic solvent fractionation, or countercurrent distribution. Purification is preferably carried out, however, by immunoaffinity chromatography as described below.
  • proteins of this invention or fragments thereof can also be chemically synthesized by a suitable method such as by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. Solid phase synthesis as described by Merrifield [J. Am. Chem. Soc. 85:2149 (1963)] is preferred.
  • Such synthesis is carried out with amino acids that are protected at the alpha-amino-terminus.
  • Trifunctional amino acids with labile side-chains are also protected with suitable groups which will prevent a chemical reaction from occurring at that site during the assemblage of the peptide.
  • the alpha-amino protecting group- is selectively removed to allow subsequent reaction to take place at the amino-terminus. The conditions for the removal of the alpha-amino protecting group do not cause deprotection of the side-chain protecting groups.
  • the alpha-amino protecting groups are those known to be useful in the art of stepwise synthesis of peptides. Included are acyl type protecting groups (e.g., formyl, trifluoroacetyl, acetyl), aromatic urethane type protecting groups (e.g., benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyl), aliphatic urethane protecting groups (e.g., t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl) and alkyl type protecting groups (e.g., benzyl, triphenylmethyl).
  • the preferred protecting group is Boc.
  • the side-chain protecting groups for Tyr include tetrahydropyranyl, tert.-butyl, triyl, benzyl, Cbz, 4-Br-Cbz and 2,6-dichlorobenzyl.
  • the preferred side-chain protecting group for Tyr is 2,6-dichlorobenzyl.
  • the side-chain protecting-groups for Asp include benzyl. 2,6-dichlorobenzyl, methyl, ethyl and cyclohexyl.
  • the preferred side-chain protecting group for Asp is cyclohexyl.
  • the side-chain protecting groups for Thr and Ser include acetyl, benzoyl, trityl, tetrahydropyranyl, benzyl, 2,6-dichlorobenzyl and Cbz.
  • the preferred protecting group for Thr and Ser is benzyl.
  • the side-chain protecting groups for Arg include nitro, Tos, Cbz, adamantyloxycarbonyl or Boc.
  • the preferred protecting group for Arg is Tos.
  • the side-chain amino group of Lys may be protected with Cbz, 2-ClCbz, Tos or Boc.
  • the 2-Cl-Cbz group is the preferred protecting group for Lys.
  • the selection of the side-chain protecting group is based on the following: The side-chain protecting group remains intact during coupling and is not split off during the deprotection of the amino-terminus protecting group or during coupling conditions. The side-chain protecting group must be removable upon the completion of the synthesis of the final peptide, using reaction conditions that will not alter the target peptide.
  • Solid phase synthesis is usually carried out from the carboxy-terminus by coupling the alpha-amino protected (side-chain protected,) amino acid toga suitable solid support.
  • An ester linkage is formed when the attachment is made to a chloromethylated or hydroxymethyl resin and the resultant target peptide will have a free carboxyl group at the C-terminus.
  • a benzhydrylamine or p-methylbenzhydrylamine resin is used in which case an amide bond is formed and the resultant target peptide will have a carboxamide group at the C-terminus.
  • These resins are commercially available and their preparation is described by Stewart et al., “Solid Phase Peptide Synthesis” (2nd Edition, Pierce Chemical Co., Rockford, Ill., 1984).
  • Various activating agents can be used for the coupling reactions including DDC, N,N′-diisopropylcarbodiimide, benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP) and DCC-hydroxybenzotriazole (HOBt).
  • BOP benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
  • HOBt DCC-hydroxybenzotriazole
  • the coupling reactions can be performed automatically on a Vega 250, Applied Biosystems synthesizer or other commercially available instrument.
  • the peptide-resin is deprotected with TFA/dithioethane and then cleaved with a reagen such as liquid HF for 1-2 hours at 0° C. which cleaves the peptide from the resin and removes all side-chain protecting groups.
  • Eimeria proteins can also be recovered from extracts of membrane proteins from E. tenella or other Eimeria species by immunoprecipitation or immunoaffinity chromatography. As already noted, such methods can produce the complete, wild-type proteins. In some cases, these proteins are larger than the proteins produced by recombinant DNA methodology. Monoclonal antibodies for this purpose can be produced as described above, using synthetic or natural Eimeria proteins as the antigen.
  • Other useful proteins which have the necessary immunoreactive and/or antigenic determinants are antibodies or fragments thereof which are anti-idiotypic toward the active determinant or determinants on the proteins of the invention.
  • anti-idiotypic antibodies can be raised against other antibodies which are specific for the determinants on the proteins of the invention (i.e., the anti-idiotypic antibodies are anti-antibodies).
  • monoclonal anti-idiotypic antibodies are used.
  • Such antibodies can be administered as a vaccine, in the same manner that the Eimeria proteins themselves can be used.
  • One or more of the Eimeria proteins and anti-idiotype antibodies of this invention can be formulated into vaccines comprising the proteins and a physiologically acceptable carrier.
  • suitable carriers include, e.g., 0.01 to 0.1 M phosphate buffer of neutral pH or physiological saline solution.
  • Enhanced immunity against coccidiosis can be produced in one of two ways.
  • an adjuvant or immunopotentiator can be added to the vaccine.
  • the proteins of the invention can be presented to an animal that is to be immunized in a larger form, either as a cross-linked complex or conjugated to a carrier molecule.
  • Suitable adjuvants for the vaccination of animals include but are not limited to Adjuvant 65 (containing peanut oil, mannide monooleate and aluminum monostearate); mineral gels such as aluminum hydroxide, aluminum phosphate and alum; surfactants such as hexadecylamine.
  • Adjuvant 65 containing peanut oil, mannide monooleate and aluminum monostearate
  • mineral gels such as aluminum hydroxide, aluminum phosphate and alum
  • surfactants such as hexadecylamine.
  • octadecylamine lysolecithin, dimethyldioctadecylammonium bromide, N,N-dioctadecyl-N′,N′-bis(2-hydroxymethyl) propanediamine, methoxyhexadecylglycerol and, pluronic polyols; polyanions such as pyran, dextran sulfate, poly IC, polyacrylic acid and carbopol; peptides such as muramyl dipeptide, dimethylglycine and tuftsin; and oil emulsions.
  • the proteins could also be administered following incorporation into liposomes or other microcarriers.
  • Incorporation into liposomes or other microcarriers provides a means by which the release of the vaccines can be sustained over a prolonged period of time.
  • a pump such as an Alza pump could be used for the same purpose.
  • the immunogenicity of the proteins of the invention can be enhanced by cross-linking or by coupling to an immunogenic carrier molecule (i.e., a macromolecule having the property of independently eliciting an immunological response in a host animal, to which the proteins and protein fragments of the invention can be covalently linked).
  • an immunogenic carrier molecule i.e., a macromolecule having the property of independently eliciting an immunological response in a host animal, to which the proteins and protein fragments of the invention can be covalently linked.
  • Cross-linking or conjugation to a carrier molecule may be required because small protein fragments sometimes act as haptens (molecules which are capable of specifically binding to an antibody but incapable of eliciting antibody production, i.e., they are not immunogenic). Conjugation of such fragments to an immunogenic carrier molecule renders the fragments immunogenic through what is commonly known as the “carrier effect”.
  • Suitable carrier molecules include, e.g., proteins and natural or synthetic polymeric compounds such as polypeptides, polysaccharides, lipopolysaccharides etc.
  • a useful carrier is a glycoside called Quil A, which has been described by Morein et al., Nature 308:457 (1984).
  • Proteins carrier molecules are especially preferred, including but not limited to mammalian serum proteins such as keyhole limpet hemocyanin, human or bovine gammaglobulin, human, bovine or rabbit serum albumin, or methylated or other derivatives of such proteins.
  • Other protein carriers will be apparent to those skilled in the art.
  • the protein carrier will be foreign to the host animal in which antibodies against the Eimeria proteins are to be elicited.
  • Covalent coupling to the carrier molecule can be carried out using methods well known in the art, the exact choice of which will be dictated by the nature of the carrier molecule used.
  • the immunogenic carrier molecule is a protein
  • the proteins or fragments of the invention can be coupled, e.g., using water soluble carbodiimides such as dicyclohexylcarbodiimide, or glutaraldehyde.
  • Coupling agents such as these can also be used to cross-link the proteins and fragments to themselves without the use of a separate carrier molecule. Such cross-linking into protein or protein fragment aggregates can also increase immunogenicity.
  • an effective amount of the vaccines of this invention can protect poultry against infection by E. tenella .
  • Monoclonal antibodies against the E. tenella antigens cross-react with E. acervulina and E. maxima in vitro, indicating that protection may also be conferred against these species.
  • An effective dose of the proteins or protein fragments ranges from about 10 to about 50 micrograms/kg of body weight of the vaccinated animal. A dose of about 25-50 ⁇ g/kg is preferred.
  • Initial vaccinations are preferably followed by booster vaccinations given from one to several weeks later. Multiple boosters may be administered.
  • the dosages of such boosters generally range from about 5 to 50 ⁇ g/kg, preferably about 20-50 ⁇ g/kg.
  • Standard routes of administration can be used such as subcutaneous, intradermal, intramuscular, oral, anal or in ovo administration.
  • the presentation of the coccidial antigens of the invention to the immune systems of fowl can be achieved by cloning genes coding for the antigens into bacteria (e.g., E. coli or Salmonella) or into viruses (e.g., poxviruses or herpesviruses) and administering the live vector systems to the birds orally, by injection or by other commonly used routes.
  • bacteria e.g., E. coli or Salmonella
  • viruses e.g., poxviruses or herpesviruses
  • vaccinia virus can be used to test the delivery of coccidial antigens in cell culture and in animals.
  • vaccinia virus has been found to be more efficient than fowlpox virus, another poxvirus carrier that can be used. This is because vaccinia virus multiplies more rapidly than the avian virus and has a host range that is not restricted to chicken cells.
  • Large amounts of heterologous DNA can be inserted into the vaccinia viral genome without inhibiting viral maturation and infectivity [Smith et al., Gene 25:21 (1983)].
  • the insertion and expression of multiple heterologous genes using the virus elicits antibody production against expressed antigens in infected animals [Perkus et al., Science 229:981 (1985)].
  • the techniques used to produce recombinant vaccinia viruses can be readily adapted by routine procedures to fowlpox or herpesvirus systems.
  • the use of such recombinant viruses as carriers in vaccines against coccidiosis is especially advantageous in that vaccinated fowl develop immunity against both the coccidial antigen and the viral carrier (i.e., such vaccines are bivalent).
  • the utility of such vaccines can be further enhanced by inserting additional genes into the carrier virus. For example, parts of the Newcastle disease viral genome can be inserted together with a coccidial antigen gene into a fowlpox virus, thereby conferring immunity against Newcastle disease, coccidiosis and fowlpox, all with a single vaccine.
  • the administration of the live vector vaccines of the invention can be carried out by numerous methods well known in the art.
  • the “stick” method commonly used to vaccinate poultry against fowlpox virus can be used. This method consists of sticking or pricking the skin of the wing web with a sharp needle dipped into the vaccine.
  • the needle usually has an eye near the tip like a sewing machine needle which carries a drop of vaccine.
  • the live vaccines can be injected subcutaneously or intradermally into the wing web or any other site.
  • the recombinant live vector vaccines can also be added to drinking water or even sprayed over chicks that are to be vaccinated. They can also be administered in feed, preferably after protective encapsulation [Balancou et al., Nature 322:373 (1986)], or in ovo. In the latter method, the viral vaccines are injected directly into chicken embryos [Sharma, Avian Dis. 25:1155 (1985)].
  • the sporozoites were then purified over a metrazimide gradient [Wisher et al., Parasitiology 88:515 (1984)). Briefly, the sporozoites were resuspended in 2 ml of PBS, pH 7.0, and 1 ml of the suspension was layered over a 15 ml metrizamide gradient. The gradient was composed of 5 ml of each of 12%, 18% and 24% metrazimide in PBS, pH 7.0. The sporozoites were sedimented by centrifugation at 900 ⁇ g for 40 minutes. Purified sporozoites were isolated from the interface between the 18% and 24% metrizamide by insertion of a 21 gauge needle through the side of the tube and aspirating the sporozoites into a syringe.
  • the purified sporozoites were washed 3 times with PBS, pH 7.0 and used immediately for immunizations, infection studies, surface labeling with 125 I, immunofluorescence assays or SDS-polyacrylamide gel electrophoresis (Laemmli. Nature 227:680 (1970)) and Western blotting studies.
  • mice Eight female Balb/c mice (Charles River, Wilmington, Mass.) were immunized with purified live sporozoites according to the following schedule.
  • the serum from each mouse was tested for anti-sporozoite antibodies by ELISA with purified sporozoite proteins, by Western blotting assays with solubilized sporozoite proteins, by immunoprecipitation of 125 I-labeled sporozoite surface proteins, and by immunofluorescence assays with purified sporozoites.
  • the mouse with the highest sporozoite antibody reactivity (mouse 107-2) was chosen for the pre-fusion immunization boosters (see FIG. 1 for ELISA analysis of this antiserum).
  • the mouse was killed and the spleen was removed for the preparation of splenocytes.
  • splenocyte feeder cells were prepared from naive mice in complete medium [Iscove's modified Dulbecco's medium (IMDM, Gibco) with 10% FBS, glutamine (2.0 mM), and 2-mercaptoethanol (100 ⁇ M)] plus HAT (100 ⁇ M hypoxanthine, 0.4 ⁇ M aminopterin and 16 ⁇ M thymidine).
  • IMDM Iscove's modified Dulbecco's medium
  • FBS FBS
  • glutamine 2.0 mM
  • 2-mercaptoethanol 100 ⁇ M
  • HAT 100 ⁇ M hypoxanthine, 0.4 ⁇ M aminopterin and 16 ⁇ M thymidine
  • 10 8 spleen cells were fused with 10 8 PAI-O mouse myeloma cells.
  • the cells were mixed, pelleted by centrifugation and resuspended under constant gentle agitation in 1.0 ml of 35% (vol/vol) polyethylene glycol in IMDM at 37° C. over 1 minute. After 3 minutes of incubation at 37° C., the cells were pelleted again and gently resuspended in 10 ml of IMDM+HAT. The cells were then diluted to 1 ⁇ 10 6 cells/ml in complete medium+HAT and dispersed into 24-well microtiter plates (1 ml/well) containing 5 ⁇ 10 5 splenocyte feeder cells in 1 ml of complete medium.
  • Hybridoma supernatants were assayed for anti-sporozoite antibodies by ELISA with purified sporozoites, by Western blotting with sporozoite proteins, by immunoprecipitation with 125 I-labeled sporozoite surface proteins and by immunofluorescence with purified sporozoites and with sporozoite-infected cells.
  • the hybridomas were cloned by limiting dilution.
  • the antibodies were further characterized by Western blot analysis using E. tenella merozoite and E. acervulina sporozoite proteins (FIG. 3).
  • the surface proteins of purified sporozoites were labeled with 125 I by the IODOGEN method (Pierce Chemical Co.) or by use of IODOBEADS (Pierce Chemical Co.). For the latter procedure. 4 IODOBEADS were washed 3 ⁇ with 0.2 M sodium phosphate, pH 7.5. and 1-3 mCi of 125 I-Na were added and incubated for 5 minutes at room temperature. Purified sporozoites (3 ⁇ 10 8 ) in 200 ⁇ l of PBS, pH 7.0, were added to the reaction vial, and the incubation was continued for 15 minutes. At the end of the incubation, phenylmethanesulfonyl fluoride (PMSF) was added to a final concentration of 0.5 mM.
  • PMSF phenylmethanesulfonyl fluoride
  • the sporozoites were recovered from the incubation mixture by centrifugation at 12.000 ⁇ g for 30 seconds and solubilized in 1 ml of either 2% sodium dodecysulfate (SDS) or 1% Triton X-100 in PBS, pH 7.0. Insoluble material was removed by centrifugation for 3 minutes at 12,000 ⁇ g.
  • the solubilized sporozoite proteins were dialyzed against 3 liters of PBS, pH 7.0. at 4° C. using a 3,500 molecular weight cutoff membrane to remove any residual free 125 -I.
  • the 125 I-labeled sporozoite proteins (typically 1.5 ⁇ 10 8 cpm incorporated into protein) were stored at 4° C. until used.
  • the TCA precipitable radioactivity was typically in excess of 95% of the total radioactivity.
  • SDS polyacrylamide gel electrophoretic analysis of the 125 I-labeled sporozite proteins is shown in FIG. 4, left panel. Immunoprecipitation was carried out by adding 300 ⁇ l of hybridoma supernatant or diluted antiserum to 250 ⁇ l of 125 I-labeled sporozoite proteins (1 ⁇ 10 5 cpm) in Buffer I (0.25% NP-40, 10 mM Tris-HCl, pH 7.5, 0.15 M NaCl).
  • the 125 I-labeled proteins bound to the solid phase antibodies were released and denatured by adding 60 ⁇ l of 2 ⁇ Laemmli sample buffer and heating for 3 minutes at 95° C.
  • the immunoprecipitated 125 I-labeled sporozoite proteins were separated by SDS-polyacrylamide gel electrophoresis in a 12.5% gel and visualized by autoradiography.
  • FIG. 4 The results of the immunoprecipitation assay with the immune mouse serum are shown in FIG. 4, right panel.
  • the hybridoma antibodies that were positive by sporozoite ELISA 74 were positive by immunoprecipitation assay.
  • the hybridoma antibodies fell into two categories, those which precipitated only single proteins (ea.. 3C4, 6A5, 7D4, 9A2, 1ID2 and 20C6), and those which precipitated two or more proteins (e.g., 12B2, 15A3, 15C4 and 19D6).
  • the cells were inoculated with 50,000 or 200,000 purified sporozoites. At 16 hours post-infection, the cell monolayers were washed several times to remove any sporozoites which had not penetrated the cells.
  • 7D4 identified a 120 kd membrane-antigen which was present on E. tenella sporozoites and merozoites. This antigen was not expressed during the schizont stage of parasite development until immature merozoites developed within the schizonts.
  • Antibody 14B1 showed a pattern of reactivity similar to that of antibody 7D4, staining the surface and tip of the intracellular sporozoites (FIG. 8. 14B1, 16 hrs) and showing diffuse staining of the cytoplasm in the immediate vicinity of the intracellular sporozoite.
  • the antigen recognized by 14B1 is present on the apical tip of the immature merozoite within the mature schizont (FIG. 8, 14B1, 100 hrs) and the apical tip of the mature released merozoites (FIG. 8, 14B1, 120 hrs).
  • the staining patterns exhibited by antibodies 7D4 and 14B1 are similar, but the proteins these antibodies recognize have very different molecular weights of about 120 and 6 kd, respectively.
  • antibodies 7D4 and 14B1 reacted with most stages of parasite development, other antibodies reacted only with surface antigens (FIG. 7, 15A3) or with the refractile body (FIG. 7, 7A2) of intracellular sporozoites and not with the schizont or merozoite stages of the parasite.
  • Antibody BA2 reacted with a 37 kd protein present on the surface of sporozoites (FIG. 7C, 8A2, 19 hrs). in all stages of the developing schizont (FIG. 7C. 8A2, 120 hrs) and on the surface of released merozoites (FIG. 7C, 8A2, 120 hrs). Unlike the proteins recognized by antibodies 7D4 and 14B1, the 37 kd protein was synthesized throughout the intracellular development of the parasite.
  • Antibody 19D6 reacted not only with a 180 kd sporozoite surface protein, but also with a protein in the cytoplasm of the sporozoite-infected cells (FIG. 8, 19D6 at 3 hours).
  • the cytoplasmic protein recognized by antibody 19D6 might have been shed by the sporozoite after cell infection, since the protein disappeared during immature schizont development and reappeared in the mature schizont and in the released merozoites (FIG. 8B, 19D6, 120 hrs).
  • the immunofluorescence studies with sporozoite-infected chicken kidney cells identified antigens which were (a) specific to the sporozoite (e.g., the greater than 200 and 28 kd proteins recognized by antibodies 7B2 and 6A5, respectively), (b) found in all stages of the intracellular parasite (e.g., the 37 kd protein recognized by 8A2) and (c) specific to sporozoites and merozoites but not to the schizont (e.g., the 120 and 6 kd proteins recognized by antibodies 7D4 and 14B1, respectively).
  • antigens which were (a) specific to the sporozoite (e.g., the greater than 200 and 28 kd proteins recognized by antibodies 7B2 and 6A5, respectively), (b) found in all stages of the intracellular parasite (e.g., the 37 kd protein recognized by 8A2) and (c) specific to sporozoites and merozoites but not to the schizont (e.g., the 120 and 6 k
  • MDBK cells were trypsinized and suspended in Minimal Essential Medium (Gibco) supplemented with 1% FBS at a density of 7.5 ⁇ 10 4 cells/ml.
  • Minimal Essential Medium Gibco
  • FBS FBS
  • To each well of a microtiter plate tissue culture treated 96-well, 1.5 ⁇ 10 4 cells were added and incubated for 48 hours at 40° C.
  • Purified sporozoites were either pretreated with antibody for 1 hour at 40° C. or left untreated prior to infecting the cell monolayers.
  • the antibodies either tissue culture supernatants, ascites fluid or antiserum
  • Ceca were removed from 3-week-old chicks (Hubbard Cross; Avian Services, Frenchtown, N.J.) 7 days after oral inoculation with 50.000 E. tenella (New Hampshire Strain; kindly supplied by Dr. R. Strout, University of New Hampshire) sporulated oocysts/bird and ground in a Waring blender with distilled water for 1 minute. The volume was adjusted to 1 liter with distilled water, and Pepsin (Sigma Chemical Co., St. Louis, Mo.) was added to 3 g/l. The pH was adjusted to 2.0 with concentrated HCl, and the mixture was incubated and stirred for 2 to 3 hours at 39° C. or until a single oocyst suspension was observed.
  • RNA preparation After digestion, the pH was adjusted to 8.0 with 10 N NaOH, and 3 liters of distilled water were added. The mixture was allowed to settle overnight. The supernatant was then removed and the sediment was washed with water until the supernatant was clear. The oocysts were sporulated by bubbling air through the suspension in distilled water at room temperature. Sporulation was stopped after 24 hours for RNA preparation.
  • Total RNA was prepared by a modification of the guanidinium/cesium chloride method described by Maniatis et al., supra, page 196.
  • the oocysts were washed with PBS (0.15 M NaCl, 20 mM sodium-phosphate, pH 7.9) and resuspended by gentle vortex mixing in 10 ml of a solution containing 5 M guanidinium isothiocyanante, 50 mM Tris-HCl, 10 mM ethylenediaminetetraacetic acid (EDTA), 0.5% Sarkosyl (sodium N-lauroyl sarcosine, Sigma Chemical Co.) and 0.1 M ⁇ -mercaptoethanol, pH 7.4, with 5 ⁇ l of Antifoam A (Union Carbide, Danbury, Conn.) or another antifoaming agent preferably added.
  • the cell suspension was homogenized until good oocyst breakage was observed microscopically.
  • Insoluble cellular debris was removed by low speed centrifugation, and the homogenate was divided into 4 aliquots and layered onto 1.2 ml of 5.7 M CsCl, 0.1 M EDTA, pH 7.5, in 12-ml polycarbonate tubes. The tubes were centrifuged at 40,000 rpm in a Beckman SW 50.1 rotor for 17 hours at 15° C.
  • the supernatant fluid was discarded, the walls of the tubes were dried, and the pellets were resuspended in 1.25 ml of 10 mM Tris-HCl, 1 mM EDTA, 1% sodium dodecyl sulfate (SDS), pH 7.5, with 200 ⁇ g/ml of Proteinase K (Boehringer-Mannheim). After incubation at 37° C. for 30 minutes, the solution was extracted 3 times with phenol. The RNA in the final aqueous phase was precipitated 3 times with ethanol and then dissolved in 1 ml of water.
  • Poly(A) + ] RNA was prepared by twice passing about 2 mg of total RNA over an oligo(dT)-cellulose column (Pharmacia Fine Chemicals) as described by Maniatis et al., supra, page 197.
  • the poly(A) + RNA was is precipitated twice with ethanol and dissolved in 200 ⁇ l of water. The yield was about 26 ⁇ g, as calculated from the optical density at 260 nm.
  • the pellet was resuspended in Lysing Buffer (8.29 g/l NH 4 Cl, 0.372 g/l Na 2 EDTA, 1.0 g/l KCO 3 , pH 7.6) and incubated on ice for 30 minutes.
  • Lysing Buffer 8.29 g/l NH 4 Cl, 0.372 g/l Na 2 EDTA, 1.0 g/l KCO 3 , pH 7.6
  • the merozoites were collected by centrifugation, washed once in PBS and passed over a column containing 1.0 g of spun nylon fiber (Scrub Nylon Fiber, Fenwall Laboratories, Deerfield, Ill.) in a separatory funnel.
  • the merozoites were collected by centrifugation as before and frozen on dry ice for RNA isolation, or further purified in diethylaminoethyl cellulose (DEAE, Whatman DE52) for Western blot analysis.
  • DEAE diethylaminoethyl
  • Frozen merozoite pellets containing 1 ⁇ 10 9 to 1 ⁇ 10 10 organisms were thawed into 10 ml of TEL/SDS buffer (0.2 M Tris HCl, 0.1 M LiCl, 25 mM EDTA, 1% (w/v) sodium dodecyl sulfate (SDS), pH 8.8) containing 1 mM dithiothreitol (DTT) and 300 units of RNasin (Promega Biotec, Madison, Wis.) and homogenized with 10-12 strokes in a teflon-coated tissue homogenizer. Insoluble debris was separated by centrifugation in the cold at 3,000 ⁇ g. The supernatant fluid was extracted twice with phenol:chloroform:isoamyl alcohol (24:24:1, v/v) which had been equilibrated with the TEL buffer.
  • TEL/SDS buffer 0.2 M Tris HCl, 0.1 M LiCl, 25 mM ED
  • the aqueous phase was digested with 100 ⁇ g/ml proteinase K at 37° C. for 30 minutes and reextracted with an equal volume of phenol:chloroform (1:1), and the nucleic acid was precipitated with two volumes of ethanol for 1 hour on dry ice, or overnight at ⁇ 20° C.
  • the pellet after centrifugation at 10.000 ⁇ g for one hour, was resuspended in TE (10 mM Tris, pH 7.5, 2 mM EDTA) and spun through a 4 ml CsCl cushion (5.7 M CsCl, 0.1 M EDTA) at 150,000 ⁇ g for 20 hours at 15° C.
  • RNA pellet was reprecipitated from 0.2 M potassium acetate with 2.5 volumes of ethanol. This total RNA was passed once over oligo-dT cellulose to enrich for poly(A) RNA, as described by Maniatis, supra, page 197. A typical yield of 1.9 mg of total RNA from 5 ⁇ 10 9 merozoites contained approximately 20 ⁇ g of poly(A) + RNA.
  • Double-stranded cDNA was synthesized from 6 ⁇ g of the sporulating oocyst poly (A) + RNA as described by Gubler et al., Gene 25:263 (1983), using reverse transcriptase (BRL) to elongate from an oligo(dT) primer and RNase H (BRL) and E. coli DNA polymerase I (New England Biolabs) to synthesize the complementary strand.
  • the double-stranded cDNA was then blunt-ended with T4 DNA polymerase (BRL), and Eco RI linkers (GGAATTCC, Collaborative Research) were added after treatment with EcoRI methylase (New England Biolabs), following the manufacturers' protocols.
  • the resulting library was amplified by plating on Y1088 host cells (ATCC No. 37195).
  • the percentage of recombinants was estimated from the ratio of blue to colorless plaques on X-gal plates (Maniatis, supra, page 24) in the presence of isopropyl thiogalactoside (IPTG, Sigma Chemical Co.) to be about 90%.
  • Double-stranded cDNA copies of the merozoite poly(A) + RNA were synthesized essentially as described above.
  • the double-stranded cDNA used in the construction of the library contained from about 200 to 4,500 base pairs (bp), as judged by migration in denaturing gels [Bailey et al., Anal. Biochem, 70:75 (1976)].
  • the merozoite cDNA was methylated and ligated to EcoRI linkers as described above, except that CCGAATTCGG linkers (Collaborative Research) were used. Following digestion with EcoRI, the cDNAs were fractionated in Biogel A-50M to remove excess linker molecules and cDNAs smaller than approximately 300 bp, as described by Huynh et al., supra.
  • the cDNAs were ligated to ⁇ gtll arms, and the DNA was packaged into phage as described above.
  • the resulting library which contained about 50,000 phage, was amplified by plating on Y1088 host cells. Plaque analysis on X-gal plates in the presence of IPTG showed about 90% recombinants.
  • the ⁇ gtll merozoite cDNA expression library was plated on Y1090 cells (ATCC No. 37197) at a density of about 10,000 plaques per 150 an plate. Six such plates were incubated for 3.5 hours at 42° C., overlayered with nitrocellulose filters previously soaked in 10 mM IPTG to induce the expression of the ⁇ -galactosidase fusion protein, and incubated for an additional 4-5 hours to overnight at 37° C. The filters were removed from the plates and subjected to several batchwise washes with TBS (20 mM Tris, pH 8.0, 0.15 M NaCl). Non-specific protein binding sites were blocked by incubation in 20% fetal calf serum (FCS) in TBS for 2-4 hours on a rotary shaker, at 4° C.
  • FCS fetal calf serum
  • Bound antibody was detected by incubating the filters with goat anti-mouse horseradish peroxidase (HPOD) conjugate (Boehringer-Mannheim), followed by color development using 3 mg/ml 4-chloro-1-naphthol (Bio Rad) and 0.018% H 2 O 2 , as described by Hawkes et al., Anal. Biochem, 119:142 (1982).
  • HPOD horseradish peroxidase
  • Positive plaques identified in the initial high density screen were plaque-purified in a secondary screen using the same monoclonal antibody pool. Each positive was assigned to an individual monoclonal from the pool by plating the positives in multiple grid arrays, each of which was induced with IPTG, transferred to nitrocellulose and incubated with one of the monoclonals from the pool. One positive phage designated ⁇ m2-4 was identified which was recognized by three of the eight antibodies in the pool, antibodies 7D1, 7D4 and 20C6.
  • plaques designated ⁇ S1-3, ⁇ S1-4 and ⁇ S1-7; ⁇ S2-1, ⁇ S2-4 and ⁇ 2-5; and ⁇ S3-1 which were recognized by monoclonal antibodies 6A5, 8A2 and 7B2, respectively, were identified in the oocyst cDNA library.
  • DNA made from the phage producing protein that reacted with the 6A5 antibody was analyzed by digestion with EcoRI and electrophoresis in agarose gels (Maniatis et al., supra, page 150). Three different inserts having sizes of approximately 1150, 890 and 615 bp were thus found.
  • the bacterial transformants were grown at 30° C. in M9 medium [Maniatis et al., supra, page 68] with 0.5% glucose and 0.5% Casamino acids and shifted to 42° C. at an O.D. (550 m ⁇ ) of 0.5 as described by Crowl et al., supra, to induce transcription at the ⁇ P L promoter. After incubating for 2-3 hours, 1-ml samples were taken, and the cells in the samples were collected by centrifugation.
  • the cell pellets were treated as described by Crowl et al., supra, and the lysates were subjected to sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis as described by Laemmli, Nature 227:680 (1970). Following electrophoresis, the proteins in the gels were either stained with Coomassie brilliant blue or transferred to nitrocellulose membranes for Western blot analysis (Towbin et al., Proc. Natl. Acad. Sci. USA 76:4350 (1979); Burnetti, Anal. Biochem. 112:195 (1981)], using the 6A5 monoclonal antibody and goat anti-mouse HPOD conjugate for detection.
  • SDS sodium dodecyl sulfate
  • the preferred medium contained per liter ( ⁇ 10%) 6.0 g KH 2 PO 4 , 4.0 g K 2 HPO 4 , 5.0 g (NH 4 ) 2 SO 4 , 3.5 g MgSO 4 -7H 2 O, 21.0 g Yeast Extract, 3.5 g Bacto Tryptone, 1.0 ml LB625 Antifoam, 25 g glucose, 70 mg Thiamine-HCl, 2.5 ml vitamin solution (GIBCO MEM (100 ⁇ ) Vitamin Solution] and 1.0 ml trace elements, LB625 Antifoam, a product of Union Carbide, is a linear polymer of ethylene and polypropylene-oxide having a viscosity of 625 Saybolt Universal Seconds at 37.9° C.
  • Vitamins per liter of fermentation broth included 0.25 mg each of D-Ca pantothenate, choline chloride, folic acid, nicotinimide, pyridoxal-HCl and additional thiamine-HCl; 0.50 mg of i-inositol: and 0.025 mg of riboflavin.
  • Trace elements per liter of broth included 2.7 mg of FeCl 3 -6H 2 O; 0.8 mg each of ZnS(O) 4 -7H 2 O and CuSO 4 -5H 2 O; 0.7 mg each of CoCl 2 -6H 2 O and Na 2 MoO 4 -2H 2 O; 0.2 mg of H 3 BO 3 ; and 0.5 mg of MnSO 4 -H 2 O.
  • the cells were harvested by centrifugation at 4° C. and lysed by boiling for 5 minutes in Laemmli sample buffer (0.125 M Tris, pH 6.8. 1% (w/v) SDS, 1.4 M ⁇ -mercaptoethanol, 001% Bromophenol Blue (w/v), 20% (v/v) glycerol).
  • Laemmli sample buffer (0.125 M Tris, pH 6.8. 1% (w/v) SDS, 1.4 M ⁇ -mercaptoethanol, 001% Bromophenol Blue (w/v), 20% (v/v) glycerol).
  • the phage ⁇ m2-4 DNA was digested with EcoRI to produce a 1.7 kb DNA molecule. This molecule was subcloned into an EcoRI-linearized plasmid pool containing plasmids pEV-VRF1, 2 and 3 [Crowl et al. supra] and transformed into E. coli strain MC1061 containing plasmid pRK248cIts, as described above. Transformants were screened for expression of an immunoreactive protein upon temperature induction, using the pool of three monoclonal antibodies shown to react with the fusion protein in the ⁇ m2-4 lysogen. The immunoreactive recombinant protein was further characterized by Western blot analysis of the E.
  • coli lysates employing one of the three monoclonal antibodies, 7D4, from the pool.
  • Each of the positive colonies was found to contain plasmid DNA with the expected 1.7 kb insert, and to direct the synthesis of a protein of approximately 65 kd upon induction, as determined by SDS-polyacrylamide gel electrophoretic analysis.
  • the expression plasmid containing the 1.7 kb insert was used in the subsequent production of recombinant protein and is shown schematically in FIG. 11.
  • This plasmid was propagated in MC1061 host cells lysogenic for ⁇ cIS857 (prepared using standard methods for the generation of ⁇ phage lysogens described by Arber et al., in Cold Spring Harbor Monograph, Lambda II, 1983, Hendrix et al., Eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, p. 450) at 30° C. to maintain the repressed state of the P L promoter in the plasmid.
  • the 1.1 kb EcoRI molecule from ⁇ S1-7 was transferred to plasmid pEV3-SEQ (FIG. 12), which has a polylinker next to the EcoRI site of pEV-vrf3.
  • This polylinker was used to linearize the plasmid at the BamHI and KpnI sites to generate unidirectional deletions with exonuclease III [Henikoff, Gene 28:351 (1984)].
  • the XbaI site in the polylinker was used for 3′-end labeling for Maxam-Gilbert sequencing of the deletions, and the primer CGGTCGACTCGAGCCA was used for Sanger sequencing.
  • This primer was 32 P labeled at its 5′ end using [ ⁇ - 32 P]ATP (ICN) and polynucleotide kinase as described by Maniatis et al., supra, page 122.
  • FIG. 13 shows the restriction sites in the 1.1 kb EcoRI molecule used for Maxam-Gilbert sequencing. The position of the EcoRI sites in the 0.9 kb molecule are also shown, since these were also used. The end points of deletions made with exoIII are also shown. These were sequenced either from the XbaI site in the pEV3-SEQ polylinker by the Maxam-Gilbert method or with a primer extension (FIG. 12) by the Sanger method. Both stands of the entire cDNA were sequenced by one or both of these methods. Due to a high G-C content in the DNA, the Maxam-Gilbert reactions were usually fractionated in both 8% and 15% polyacrylamide-urea gels.
  • Primer extension was carried out by incubating 1.5 ⁇ g of poly(A) + RNA with 2 pmoles of the 5′-end labeled synthetic oligonucleotide primer, GAGGTCTGCCATTTTGC, for 60 minutes at 42° C. in 50 mM Tris-HCl, pH 8.0, 8 mM MgSO 4 , 0.1 M NaCl, 2 mM dithiothreitol, 2 mM of each deoxynucleotide triphosphate (dNTP, Pharmacia Fine Chemicals), 20 units RNasin (Promega Biotec, Madison, Wis.) and 20 units AMV reverse transcriptase (Pharmacia, Piscataway. N.J., FPLCpure). The products were analyzed in the 8% polyacrylamide-urea gels used for sequence analysis, with 32 p-labeled HpaII digested PBR322 DNA as a molecular size marker.
  • the nucleotide sequence of the 1.1 kb cDNA molecule is shown in FIG. 14.
  • the sequence of the 0.9 kb molecule extends from base 188 to base 1082 within this larger molecule.
  • the amino acid sequence predicted from open reading frame analysis of this nucleotide sequence is shown in FIG. 15. The correctness of the predicted amino acid sequence shown in FIG. 15 was confirmed as follows.
  • Synthetic polypeptides were prepared having amino acid sequences corresponding to residues 41-54 and 145-164 of FIG. 15. Rabbit antisera raised against both of these polypeptides were used in Western blot analysis of both total sporozoite proteins and a lysate of the E. coli transformant expressing the 0.9 kb cDNA. The antibodies against both of the polypeptides bound to proteins in both of the Western blots.
  • nucleotide sequence of the 1.7 kb insect encoding the 65 kd protein in phage ⁇ 2-4 was determined, with the results shown in FIG. 16 and 27 .
  • the predicted amino acid sequence of the protein encoded by this DNA sequence is shown in FIG. 17 and 28 . This sequence was confirmed by amino acid sequence analysis performed on polypeptides produced by tryptic digestion of the expressed 65 kd protein, as described below. Regions in the overall amino acid sequence corresponding to some of these peptides are underlined in FIG. 17 and 28 .
  • the DNA sequence open reading frame for the 1.7 kb molecule would be expected to encode a protein of about 33.349 daltons. Yet, the expression product from this DNA fragment migrates in SDS gels with an apparent molecular weight of about 65 kd. The reason for this discrepancy between the predicted and observed protein size is unknown. This protein is referred to herein as the “65 kd” protein.
  • FIG. 29 and FIG. 30 The cDNA molecule encoding the 28 kD protein recognized by monoclonal antibody 8A2 has been resequenced using the standard sequencing techniques described above. The resulting sequence is provided in FIG. 29 and FIG. 30. The deduced amino acid sequence is provided in FIG. 31. Based on this amino acid sequence, the weight of the protein recognized by 8A2 is probably around 37 kD. The same sequence with the first three amino acids removed is provided in FIG. 32. These three amino acids were probably encoded by linker sequences described above and used in the cloning procedure described, and as such would therefore be artifacts and not part of the protein. Similarly, FIGS. 26, 27, 33 , 34 represent sequences from-which linker code has been removed.
  • nucleotide and predicted amino acid sequence of the 1.2 kb 7B2 cDNA were determined. Since a continuous open reading frame was found and the protein isolated from sporozoites by immunoprecipitation is larger than 200 kd, the library was screened for larger cDNAs, using the 1.2 kb cDNA as a probe. A 3.2 kb cDNA was thus obtained, having the nucleotide and predicted amino acid sequences shown in FIGS. 20 and 21, 33 and 34 .
  • a Pharmacia glass column (5 cm diameter ⁇ 10 cm length) was packed with NuGel P-DE 200® (200 Angstrom. 40-60 ⁇ m, weak anion exchange. Separation Industries, Metuchen, N.J.) silica support. The gel was equilibrated with 20 mM potassium phosphate, pH 6.8. The sample was loaded (10 ml/min), washed with equilibration buffer and eluted with 20 mM potassium phosphate containing 0.4 M NaCl, pH 6.8. The column fractions were analyzed by Western blotting with antibody 7D4 to detect the 65 kd protein.
  • An immunoaffinity column was used to further purify the 65 kd protein.
  • the adsorbent for this column was prepared by immobilizing monoclonal antibody 7D4 on NuGel P-polyaldehyde® (500 Angstrom, 40-60 ⁇ m, Separation Industries, Metuchen N.J.) silica support.
  • the immobilization procedure involved the following: 10 grams of polyaldehyde support were suspended and washed with 0.1 M potassium phosphate, 0.1 M NaCl, pH 6.8, and transferred quantitatively into an Ehrlenmeyer flask containing 20 ml of monoclonal antibody 7D4 at a protein concentration of 8 mg/ml. Sodium cyanoborohydride (4 mg) was then added to the suspension.
  • the mixture was shaken gently at 4° C. for 16 hours.
  • the gel was filtered and washed with 0.1 M potassium phosphate, 0.1 M NaCl, pH 6.8. Pooled filtrates were checked for unbound antibody. Binding density was 8 mg/g of support. Uncoupled activated sites were blocked by suspending the gel in 20 ml of 1 M ethanolamine, pH 7.5 Sodium cyanoborohydride (4 mg) was added to the suspension, which was then agitated at 4° C. for 16 hours. The gel was collected and washed thoroughly with cold coupling buffer.
  • the gel was stained with Coomassie blue dye to detect the protein bands.
  • the isoelectric point of the purified protein was then determined by measuring the position of the band within the pH gradient in relation to the positions of the protein standards. The isoelectric point of the protein thus determined was 4.6.
  • C-Terminal analysis was performed on 1200 picomoles of the 65 kd protein by time course carboxypeptidase Y digestion as described by Hayashi, Methods in Enzymology 47:84 (1977).
  • Carboxypeptidase Y (Boehringer Mannheim, Indianapolis, Ind.) was used at a concentration of 0.8 ⁇ g/350 ⁇ l in 0.05 M sodium acetate buffer, pH 5.9, and sample aliquots were taken after 0, 2, 5, 10, 20 and 30 minutes for analysis. The sample aliquots were acidified with HCl to stop further reaction and then subjected to amino acid analysis as described above. This analysis showed that the amino acid sequence at the C-terminus is probably (Met, Trp)-Ala-Ser.
  • Trp Tryptophan was observed to increase simultaneously with the methionine, but Trp is difficult to quantify in the fluorescamine analyzer because it has a low reactivity with fluorescamine. Therefore, the relative positions of Trp and Met could not be determined with certainty by this analysis.
  • each peak was first analyzed by amino acid analysis as described above to determine both the quantity and the composition of the peptides. Then, most of the peptide peaks from the HPLC column were sequenced by automated Edman degradation, using an Applied Biosystems Model 470A gas phase sequencer. Phenylthiohydantoin (PTH) amino acid derivatives were identified in a Waters HPLC system using an Altex ultrasphere C-18 column as described by Hawke et al. [Anal. Biochem. 120:302 (1982)], or in an Applied Biosystems Model 120A on-line PTH amino acid analyzer.
  • PTH Phenylthiohydantoin
  • Non-medicated broiler starter feed and water were supplied ad libitum throughout the experiments.
  • the birds were transferred to another building where they were kept until the end of the experiments.
  • the clinical-conditions of the animals were checked at least three times weekly before immunization and on a daily basis after immunization.
  • the birds were individually identified by means of wing bands at 3 or 4 weeks of age before random assignment into various test groups.
  • Bovine serum albumin (BSA, Pentex) was used as a control. Because pyrogenic activity was present in the immunogen used, approximately equal amounts of such activity were added to all BSA controls, to account for any nonspecific effects that might be due to this activity. This pyrogenic activity was added to the BSA in the form of an untransformed E. coli lysate which was prepared by disrupting E. coli by sonication and then filtering the material through a 0.45 ⁇ Millipore filter.
  • each bird was challenged with 25,000 sporulated oocysts of E. tenella by the oral route. Body weights were measured at the time of challenge and 7 days thereafter, at which time the birds were sacrificed and cecal lesions were scored. The results are shown in Table 5.
  • Subcutaneous injections were administered as described above. Intramuscular injections were made deeply into the exterior side of the left thigh. Intradermal injections were administered into the anterior side of the right wing. Oral administration was delivered using a 5 cm long 18 gauge ball-tipped needle, depositing the inoculum into the crop of the bird. Anal administration was made using a 5 cm long 18 gauge olive-tipped needle, introduced to its maximum length into the cloacal opening. After oral and anal administration, the birds were held in standing and inverted positions, respectively, for several minutes, to avoid possible expulsion of the inoculum.
  • the subcutaneous dosage form was as described above, with Freund's complete adjuvant used for the primary injection and Freund's incomplete adjuvant used for the booster injections.
  • Dosage forms for the other routes of administration contained protein at the indicated levels in 0.02 M K 2 HPO 4 buffer, pH 6.8.
  • Table 6 shows that the lowest cecal lesion scores were observed in birds immunized with 5 ⁇ g of antigen by the oral route and with 25 ⁇ g of antigen by the intradermal route. These results were statistically significant. Numerically lower lesion scores were seen for other routes of administration and other dosage levels, indicating a protective trend. The differences between these scores and those of the IUC birds, however, were not statistically significant.
  • TK viral thymidine kinase
  • VV HindIII J fragment was subcloned into pUCB (FIG. 24 a ). This construct was cleaved with HpaII. The fragments were treated with E. coli DNA polymerase Klenow fragment (Klenow) and recleaved with HindIII, and the piece containing the viral TK gene was isolated from low melting agarose. The isolated fragment was ligated into the HindIII and blunt ended (S1 treatment) EcoRI site of a pUC8 vector (FIG. 24 b , right). Subsequently, the HindIII site was eliminated by treating the HindIII digested DNA with Klenow and religating the vector fragment. For the insertion of the VV promoter (designated the 7.5K promoter), the vector was cleaved by ClaI and EcoRI.
  • the VV 7.5K promoter is located in one of the smallest SalI fragments of the virus [Venkatesan et al., Cell 25:805 (1981)].
  • the corresponding fragment was cloned into M13mp8.
  • a clone was selected in which the direction of transcription was toward the EcoRI site of M13mp8 (FIG. 24 a , left).
  • the DNA was cleaved with ScaI and SmaI, BqlII linkers were added and the DNA was religated (FIG. 24 b ).
  • the EcoRI-AccI fragment containing the viral promoter segment was isolated from the M13 construct and ligated into the pUC8-TK fragment described above. This new vector was digested with BqlII and EcoRI.
  • polylinker contained in the M13tg131 (Amersham) was chosen (FIG. 24 d ).
  • the polylinker fragment was isolated by digesting the phage DNA with BalII and EcoRI, and the fragment was inserted into the pUC8-TK-7.5K construct, resulting in the final basic vector for recombination of foreign antigens into VV (FIG. 24 c ).
  • an in-frame start codon was generated by deleting part of the polylinker in the recombination vector.
  • the vector was digested with EcoRV and SmaI, deleting part of the polylinker (FIG. 24 d ), and then religated.
  • the ATG codon contained in the SphI restriction site was placed in the correct reading frame for the coding region of the oocyst protein on the EcoRI fragment.
  • the successful manipulation was confirmed by sequencing the new polylinker fragment.
  • the EcoRI fragment was placed in the correct reading frame behind a leader sequence of a malarial antigen.
  • the malarial antigen used to isolate the leader sequence was the 190 kd protein described as Ro-33 [Certa et al., EMBO J. 6:4137 (1987)]. It must be noted, however, that other leader sequences such as coccidial leader sequences could be used for the same purpose.
  • the Ro-33 DNA was digested with DraI.
  • the fragment containing the recognition sites for the restriction enzymes PvuII and HindIII was isolated and digested with HindIII.
  • the original vector construct (FIG. 10 c ) was cleaved with SalI, treated with Klenow and then digested with HindIII.
  • the isolated DraI-HindIII malarial antigen leader fragment was cloned. This construct was used to express a fusion protein between the F. falciparum 190 kd protein and the E. tenella antigen recognized by antibody 8A2 and encoded by the EcoRI fragment.
  • CV1 monkey cells were grown in medium I [Eagle's Minimal Essential Medium (MEM), 5% fetal calf serum (FCS: from Amimed), Penicillin/Streptomycin (100 units/ml and 100 ⁇ g/ml, respectively) and 2 mM glutamine; all reagents from Gibco] in a cm culture plates to 80-90% confluency.
  • the medium was removed and replaced with 0.2 ml of a virus suspension containing the temperature sensitive vaccinia virus strain ts N7 (Drillen et al., Virology 131:385 (1983)] at 0.1 plaque forming units (pfu)/cell.
  • a DNA-containing calcium-phosphate precipitate was prepared. This contained HEBS buffer (280 mM NaCl, 1.5 mM sodium-hydrogen-phosphate, 50 mM HEPES], 200 ng of purified vaccinia strain WR virus DNA and 200 ng of purified coccidial antigen-gene containing plasmid DNA, in a total volume of 0.55 ml. Each DNA was added in 1 ⁇ l of TE-buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA). To this solution was added, drop-wise and with gentle swirling, 0.55 ml of a 250 mM calcium-chloride solution. This mixture was left at room temperature for 20 minutes.
  • the medium was removed after the above 2 hour incubation, and the cells were washed 3 times with 1 ml of PBS under gentle swirling. The final PBS solution was aspirated, and 2 ml of Medium I were added to each plate. Incubation at 39.5° C. in a CO 2 incubator was continued for 2 days.
  • CV1 cells infected with recombinant virus were sedimented in a table-top centrifuge (Hettich Mikrorapid K, 100% for 3 minutes at 20° C.), and the pellet was washed twice with PBS, recentrifuged and resuspended in PBS. The cell suspension was applied to a glass microscope slide (Flow) and allowed to dry.
  • a second method consisted of growing the CV1 cells directly on microscope slides (Miles Lab-Tek 4808), infecting the cells with virus and incubating for 1-2 days. The cells were then washed free of growth medium with PBS and allowed to dry on the slides at room temperature. To fix the cells, the slides were submerged in acetone for at least one hour at ⁇ 30° C. and allowed to dry at room temperature.
  • Mouse anti-coccidial antigen monoclonal antibodies diluted in PBS were layered onto the microscope slides so that the cells were evenly covered with liquid. The slides were placed in a humid chamber at 37° C. for one hour and subsequently washed several times with PBS. Without allowing the slides to dry, a second antibody (FITC labeled goat anti-mouse IgG. Nordic) also diluted in PBS was layered onto the slides, and the slides were placed in a humid chamber at 37° C. for one hour to allow the antibodies to react. After several washes with PBS, the slides were allowed to dry completely.
  • FITC labeled goat anti-mouse IgG. Nordic also diluted in PBS was layered onto the slides, and the slides were placed in a humid chamber at 37° C. for one hour to allow the antibodies to react. After several washes with PBS, the slides were allowed to dry completely.
  • the WR strain virus can multiply in almost all cell types [Drillen et al., J. Virology 28:843 (1978)], and its multiplication can be observed directly through the formation of plaques. In most cases, however, chicken embryo fibroblast (CEF) cells were used to prepare large stocks of the virus.
  • CEF chicken embryo fibroblast
  • the medium was removed from 80-90% confluent CEF cells growing in 175 cm culture flasks (Falcon 3028), and the cells were incubated in a PBS solution containing virus (0.1 pfu/cell, 0.01 ml/cm 2 ) for one hour at room temperature (20° C.) (PBS/Dulbecco, Amimed). Medium I was then added (0.2 ml/cm 2 ), and the flasks were incubated at 37° C. for 2-3 days until about 80% of the cells had lysed. The resulting stock solution was stored directly with cells and medium in the original culture flasks at ⁇ 30° C. before virus purification.
  • the purification steps for obtaining a virus preparation free of all host cell specific components were identical for both MVA and WR virus strains.
  • Infected cell cultures which had been stored at ⁇ 30° C. were thawed and the remaining cells were freed from the surface of the flask by shaking or scraping.
  • the cells and virus were centrifuged out of the medium (Sorvall centrifuge, GSA rotor, 1 hour at 5,000 rpm, 10° C.).
  • the pellet of cells and virus particles was resuspended in PBS (10-20 ⁇ the volume of the pellet) and recentrifuged as above. This pellet was then resuspended in a 10-fold volume of RSB buffer (10 mM Tris-HCl, pH 8.0, 10 mM KCl, 1 mM MgCl 2 ).
  • the second supernatant was combined with the first, layered onto a 10 ml 35% sucrose cushion (Fluka, in 10 mM Tirs-HCl, pH 8.0) and centrifuged for 90 minutes at 14,000 rpm in a Kontron TST 28.38/17 rotor (Beckman SW 27 analog) at 10° C.
  • the supernatant was decanted and the pellet of virus particles was resuspended in 10 ml of 10 mM Tris-HCl, pH 8.0. sonicated to homogenize the mixture (2 times for 10 seconds at room temperature as described above) and loaded onto a step gradient for further purification.
  • the step gradient consisted of 5 ml aliquots of sucrose in 10 mM Tris-HCl, pH 8.0, of the following concentrations: 20%, 25%, 30%, 35% and 40%. This gradient was centrifuged in a Kontron TST 28.38/17 rotor for 35 minutes at 14,000 rpm, 10° C. Several bands containing virus particles were visible in the 30%-40% sucrose region. This region of the gradient was removed (10 ml), the sucrose solution was diluted with PBS (20 ml) and the virus particles were sedimented (Kontron rotor, 90 minutes at 14,000 rpm, 10° C.). The pellet contained almost exclusively virus particles (as judged by comparison of OD measurement and plaque assay, see below). This pellet was resuspended in PBS so that the virus concentration was on the average 1-5 ⁇ 10 9 pfu/ml. This virus stock was used either directly or diluted with PBS.
  • the absolute concentration of virus particles was conveniently obtained by measuring the optical density (OD) of the stock solution in a spectrophotometer (Uvikon 860) at 260 nm (OD/260). where 1 OD/260 equals about 1.2 ⁇ 10 10 particles per ml [Joklik, Virology 18:9 (1962)]. Virus concentration was also obtained by titrating the virus on cells (plaque assay), assuming that only one out of 60 virus particles can infect a cell.
  • CEF cells were grown in Medium I on 8 cm 2 plastic culture plates (Falcon 3001). When the cells had reached 80-90% confluency, the medium was removed, replaced with 0.2 ml of a diluted virus solution in PBS, and left at room temperature for 1 hour. The virus stock solution was diluted in 10-fold steps. After the room temperature incubation, 2 ml of semi-solid Medium I (Medium I+1% agarose) were added to each plate, and the plates were placed for 16-24 hours in a CO 2 incubator.
  • semi-solid Medium I Medium I+1% agarose
  • Table 7 shows that compared to the wild-type control virus, both viruses containing DNA coding for the 28 kd protein conferred some protection against oocyst challenge, both in terms of a reduction of cecal lesion score and reduced oocyst excretion. The two viruses were equally effective, showing that the malarial leader sequence was not a factor.
  • Table 8 shows that, compared to the wild-type control virus, both viruses containing the coccidial DNA conferred some protection against the pathogenic oocyst challenge, in terms of weight gain, cecal lesion score and oocyst excretion. Both viruses were about equally effective. Administration of the booster 1 week after the primary injection produced somewhat better weight gain and lower oocyst excretion, but cecal lesion scores were about the same for both booster schedules.
  • Chicks were injected (right wing web) with two 50 ⁇ l aliquots (3 ⁇ 10 9 pfu/ml) of suspensions of wild-type vaccinia virus or virus containing DNA coding for the 20 kd protein which bound specifically to monoclonal antibody 6A5, at 21 days of age. All chicks were given same dose booster injections at day 28 into the left wing webs. Some chicks were given additional same-dose booster injections into the wing webs of both sides at day 35. Other chicks were maintained with no vaccinations, as further controls.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides DNA sequences coding for Eimeria surface antigens, recombinant vectors containing such DNA sequences, transformed microorganisms containing such vectors and methods for producing the antigens using the transformed microorganisms. Methods are also provided for protecting poultry against coccidiosis using the Eimeria surface antigens. The surface antigens can be administered for such protection either as purified proteins or in the form of DNA encoding the proteins in a suitable viral vector such as vaccinia virus.

Description

  • This application is a continuation-in-part of U.S. Ser. No. 07/202,721, filed Jun. 3, 1988, now pending.[0001]
    • TECHNICAL FIELD
  • This application relates to the use of recombinant DNA technology to produce antigens of Eimeria protozoan parasites. These recombinantly produced antigens can be used, through various routes of administration, to protect poultry against coccidiosis. [0002]
    • BACKGROUND OF THE INVENTION
  • Prevention of Coccidiosis [0003]
  • Coccidiosis is a costly disease of poultry caused by intracellular protozoan parasites of the genus Eimeria. The disease is endemic in the large, intensive poultry breeding establishments in this country, and the estimated cost of control of the disease through chemotherapy exceeds $100 million each year. Resistance to the anti-coccidial drugs develops, necessitating a continuing development of new agents, at a time when drug development is becoming increasingly expensive and consumer acceptance of drug residues in food animals is diminishing. [0004]
  • Protective immunity to natural coccidiosis infection has been well documented. Controlled, daily administration of small numbers of viable oocysts for several weeks has been shown to result in complete immunity to a challenge infection of a normally virulent dose [Rose et al., Parasitology 73:25 (1976): Rose et al., Parasitology 88:199 (1984)]. The demonstration of acquired resistance to infection suggests the possibility of constructing a vaccine to induce immunity in young chickens, circumventing the need for chemical coccidiostats. In fact, such a concept has been tested in the Coccivac® formulation of Sterwin Laboratories, Opelika, Ala. [0005]
  • With a view to producing a coccidiosis vaccine, Murray et al., European Patent Publication No. 167,443. prepared extracts from sporozoites or sporulated oocysts of [0006] Eimeria tenella which contain at least 15 polypeptides, many of which were associated with the surface of the sporozoite. Injection of these extracts into chickens reduced cecal lesions following oral inoculation with virulent E. tenella sporulated oocysts. More recently, Schenkel et al., U.S. Pat. No. 4,650,676. disclosed the production of monoclonal antibodies against E. tenella merozoites. Using these antibodies, Schenkel et al. identified a number of antigens against which the antibodies were directed. By pre-incubating E. tenella sporozoites with these antibodies and then introducing the treated sporozoites into the ceca of chickens, Schenkel et al. were able to show some reduction in cecal lesion scores, compared to untreated sporozoite controls.
  • Recombinant DNA Technology [0007]
  • Advances in recombinant DNA technology have made another approach available, a subunit vaccine. In the application of current recombinant DNA procedures, specific DNA sequences are inserted into an appropriate DNA vehicle, or vector, to form recombinant DNA molecules that can replicate in host cells. Circular double-stranded DNA molecules called plasmids are frequently used as vectors, and the preparation of such recombinant DNA forms entails the use of restriction endonuclease enzymes that can cleave DNA at specific base sequence sites. Once cuts have been made by a restriction enzyme in a plasmid and in the segment of foreign DNA that is to be inserted, the two DNA molecules may be covalently linked by an enzyme known as a ligase. General methods for the preparation of such recombinant DNA molecules have been described by Cohen et al. [U.S. Pat. No. 4,237,224], Collins et al. (U.S. Pat. No. 4,304,863 and Maniatis et al. [Molecular Cloning: A Laboratory Manual, 1982, Cold Spring Harbor Laboratory]. Because they illustrate much of the state of the art, these references are hereby incorporated by reference. [0008]
  • Once prepared, recombinant DNA molecules can be used to produce the product specified by the inserted gene sequence only if a number of conditions are met. Foremost is the requirement that the recombinant molecule be compatible with, and thus capable of autonomous replication in, the host cell. Much recent work has utilized [0009] Escherichia coli as a host organism, because it is compatible with a wide range of recombinant plasmids. Depending upon the vector/host cell system used, the recombinant DNA molecule is introduced into the host by transformation, transduction or transfection.
  • Detection of the presence of recombinant plasmids in host cells may be conveniently achieved through the use of plasmid marker activities, such as antibiotic resistance. Thus, a host bearing a plasmid coding for the production of an ampicillin-degrading enzyme could be selected from unaltered cells by growing the host in a medium containing ampicillin. Further advantage may be taken of antibiotic resistance markers where a plasmid codes for a second antibiotic-degrading activity at a site where the selected restriction endonuclease makes its cut and the foreign gene sequence is inserted. Host cells containing properly recombinant plasmids will then be characterized by resistance to the first antibiotic but sensitivity to the second. [0010]
  • The mere insertion of a recombinant plasmid into a host cell and the isolation of the modified host will not in itself assure that significant amounts of the desired gene product will be produced. For this to occur, the foreign gene sequence must be fused in proper relationship to a signal region in the plasmid for DNA transcription called a promoter. Alternatively, the foreign DNA may carry its own promoter, as long as it is recognized by the host. Whatever its origin, the promoter is a DNA sequence that directs the binding of RNA polymerase and therefore “promotes” the transcription of DNA to messenger RNA (mRNA). [0011]
  • Given strong promotion that can provide large quantities of mRNA, the ultimate production of the desired gene product will be dependent upon-the effectiveness of translation from mRNA to protein. This, in turn, is dependent upon the efficiency of ribosomal binding to the mRNA. In [0012] E. coli, the ribosome-binding site on mRNA includes an initiation codon (AUG) and an upstream Shine-Dalgarno (SD) sequence. This sequence, containing 3-9 nucleotides and located 3-11 nucleotides from the AUG codon, is complementary to the 3′ end of E. coli 16S ribosomal RNA (rRNA) [Shine and Dalgarno, Nature 254:34 (1975)]. Apparently, ribosomal binding to, mRNA is facilitated by base pairing between the SD sequence in the mRNA and the sequence at the 16S rRNA 3′ end. For a review on maximizing gene expression, see Roberts and Lauer, Methods in Enzymology 68:473 (1979).
  • An alternative expression system has been developed based on the lacZ operon in combination with lambda phage vectors. (Huynh et al., in [0013] DNA Cloning: Volume I, DM Glover, Ed.). In this system, the structural gene for β-galactosidase along with the inducible promoter controlling its expression have been engineered into the phage vector. A unique cloning site at the 3′ end of the gene for β-galactosidase results in a gene fusion upon the insertion of a cDNA copy of an mRNA or a genomic DNA fragment containing a protein-coding region.
  • Expression of the β-galactosidase gene results in the production of a fusion protein containing 114 kd of β-galactosidase and a carboxy terminal polypeptide encoded by the cDNA insert, provided that the insert contains an open reading frame in the same register as the reading frame for β-galactosidase. A phage containing a gene whose product is recognized by a monoclonal or a polyclonal antiserum can thus be identified by immunologic screening of the library following induction of expression of the fusion protein using β-D-thiogalactopyranoside (IPTG) to inactivate the lacZ repressor. This expression vector system combines the efficiency of the phage system in packaging DNA and introducing it into [0014] E. coli cells with an increased stability of polypeptide fusions with β-galactosidase.
  • Subunit Vaccines [0015]
  • In the vaccine subunit approach, a subunit of the whole infectious organism is delivered to the host animal in an immunologically relevant context. The subunit might be a protein purified from the parasite, a recombinant protein or protein fragment expressed in a heterologous system, a synthetic peptide comprising a single neutralizing determinant or a protein introduced by a viral vector such as vaccinia. The host immune system mounts a specific response to the subunit without ever being exposed to the whole parasite. Upon challenge with a virulent dose of the infectious organism, the host immune system mounts a successful defense, instructed only by the vaccine subunit to which it had been previously exposed. [0016]
  • Evidence can be found in the literature for the involvement of circulating antibodies, secretory IgA in the intestinal epithelium [Davis et al., Immunology 34:879 (1978)], and the cell-mediated immune system [Giambroni et al., Poultry Science 59:38 (1980)] in acquired resistance to coccidiosis. For a review, see P. S. Davis in Avian Immunology, M. E. Rose, Ed., British Poultry Science, Ltd., Edenberg, pp. 361-385 (1981). The probable involvement of various arms of the immune system means that complete and lasting protection may necessitate the ability to mimic specific aspects of the natural infectious process. These aspects include local exposure at the site where protection is desired, evocation of an inflammatory response to marshall antigen processing cells, presentation of an appropriate parasite antigen and possibly association with MHC determinants in a particular membrane configuration. [0017]
    • SUMMARY OF THE INVENTION
  • This invention provides purified proteins or fragments thereof having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen. [0018]
  • More particularly, this-invention provides proteins or fragments thereof having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28, 37, 120 or greater than 200 kilodaltons and specifically binds to one or more monoclonal antibodies deposited with the American Type Culture Collection and assigned accession Nos. HB 9707 through HB 9712. [0019]
  • This invention further provides the foregoing deposited monoclonal antibodies. [0020]
  • This invention still further provides DNA sequences or fragments thereof encoding proteins or fragments thereof having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28, 37, 120 or greater than 200 kilodaltons and specifically binds to one or more monoclonal antibodies deposited with the American Type Culture Collection and assigned accession Nos. HB 9707 through HB 9712: recombinant vectors containing and capable of directing the expression of such DNA sequences or fragments in compatible host organisms: and microorganisms containing such vectors which are capable of expressing the DNA sequences or fragments. [0021]
  • This invention still further provides a method for producing a protein or fragment thereof having one or more immunoreactive and/or antigenic determinants of an [0022] Eimeria tenella surface antigen, which method comprises:
  • (a) culturing a microorganism containing a recombinant vector and a DNA sequence or fragment thereof having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen hat an apparent molecular weight of 28, 37, 120 or greater than 200 kilodaltons and specifically binds to one or more monoclonal antibodies deposited with the American Type Culture Collection and assigned accession Nos. HB 9707 through HB 9712. under conditions in which the DNA sequence or fragment is expressed; and [0023]
  • (b) isolating the protein or fragment from the culture. [0024]
  • This invention still further provides vaccines for protecting poultry against coccidiosis comprising one or more of the proteins or fragments thereof of the invention and a physiologically acceptable carrier. [0025]
  • This invention still further provides vaccines for protecting poultry against coccidiosis comprising a viral vector containing a DNA sequence or fragment thereof coding for a protein or fragment thereof of the invention, which viral vector is capable of expressing the DNA sequence or fragment, and a physiologically acceptable carrier. [0026]
  • This invention still further provides a method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine of the invention to a young fowl which is susceptible to coccidiosis.[0027]
    • BRIEF DESCRIPTION OF THE FIGURES
  • The present invention can be more readily understood by reference to the following Description of the Invention and Examples, and to the following Figures in which: [0028]
  • FIG. 1 shows the results of an [0029] E. tenella sporozoite ELISA. Dilutions of immune mouse serum (MS 107-2; Δ) and control mouse serum (X) were incubated with 4×104 live purified sporozoites. Specific antibody bound to the sporozoites was detected with a peroxidase-conjugated anti-mouse IgG antibody and the peroxidase substrate o-phenylenediamine. The OD492 nm was read in a Titertek Multiscan® plate reader.
  • FIG. 2 shows the results of a Western blot assay performed with proteins solubilized from [0030] E. tenella sporozoites. Solubilized sporozoite proteins were separated by reducing SDS-polyacrylamide gel electrophoresis in 12.5% gels, transferred to nitrocellulose membranes and reacted with each antibody. The specific proteins recognized by each antibody were visualized with a peroxidase-conjugated anti-mouse IgG antibody and the peroxidase substrate 4-chloro-1-naphthol. The antibody which was reacted with each strip is noted at the top of the strip.
  • FIG. 3 shows the results-of a Western blot assay performed with proteins solubilized from sporozoites and merozoites of [0031] E. tenella, and from sporozoites of E. acervulina. Various monoclonal antibodies and sera were incubated with nitrocellulose bound Eimeria proteins and visualized as explained in the description of FIG. 2. The monoclonal antibodies used included 3A5 (1), 20C6 (2), 7D1 (3), 13A6 (4), 6A5 (5) and a control antibody that was unreactive to the Eimeria proteins. The sera used included mouse No. 107-2 immune serum (7) and control serum (8).
  • FIG. 4 shows in the left panel the results- of an immunoprecipitation assay with [0032] 125I-labeled surface proteins of E. tenella sporozoites. Sporozoite surface proteins were labeled by either the IODOGEN or IODOBEADS method, solubilized and visualized following SDS-polyacrylamide gel electrophoresis in 12.5% gels by autoradiography. The right panel shows the results of immunoprecipitation of 125 I-labeled sporozoite surface proteins by serum from mice immunized with live sporozoites. Immune mouse sera (105-1, 105-2, 105-3, 107-1, 107-2 and 107-3) and control mouse serum (Control) were incubated with 125I-sporozoite surface proteins, and the immune complexes were captured by an anti-mouse antibody coupled to agarose. The immune complexes were solubilized with Laemmli sample buffer, separated by SDS-gel electrophoresis in 12.5% gels and visualized by autoradiography. M represents the molecular weights of standard marker proteins in kilodaltons.
  • FIG. 5 shows the results of immunoprecipitation of [0033] 125I-sporozoite surface proteins by monoclonal antibodies. The procedure for identifying the 125I-proteins bound by each antibody is explained in the description of FIG. 4. Specific sporozoite monoclonal antibodies used and control antibody (control) are indicated at the top of each gel lane. Molecular weights of standard marker proteins are shown in kilodaltons.
  • FIG. 6 shows phase contrast micrographs and immunofluorescence staining pattern micrographs using various monoclonal antibodies, of air-dried [0034] E. tenella sporozoite slide preparations. The left sides of panels A, B. C and D are phase contrast micrographs showing intact elongated sporozoites with a large posterior refractile body (PRB), a small anterior refractile body (ARB) and the apical end (A) opposite the posterior refractile body. The right sides of panels A, B, C and D show slides which were treated with monoclonal antibodies 14C3 (specific for surface antigens). 6A5 (specific for surface and refractile body protein). 11D2 (specific for-sporozoite apical tip) and control antibody, respectively. The antibodies bound to the preparations were localized with rhodamine-conjugated anti-mouse antibodies, visualized by epifluorescence using a Leitz Dialux 22® microscope. All micrographs are 630×.
  • FIG. 7 shows antibody staining of intracellular sporozoites and the developing parasite in chicken kidney cells. Chicken kidney cells were infected with sporozoites, and at the indicated times after infection the cells were processed for antibody staining. The cultures were washed before fixation to remove any extracellular sporozoites. Phase contrast and corresponding immunofluorescence micrographs were made using antibodies 7D4, 8A2, 7B2 and 15A3 as indicated. The antibodies bound to the preparations were localized with rhodamine-conjugated anti-mouse antibodies, visualized by epifluorescence. All micrographs are 630×. [0035]
  • FIG. 8 shows antibody staining of intracellular sporozoites and the developing parasite in chicken kidney cells. Phase contrast micrographs and corresponding immunofluorescence micrographs were made using monoclonal antibodies 14B1 and 19D6, immune chick sera and fluorescent second antibodies, at the indicated times. [0036]
  • FIG. 9 shows the neutralization of intracellular sporozoite development by anti-sporozoite antibodies. Purified [0037] E. tenella sporozoites were preincubated for 1 hour at 40° C. with either control antibody (X) or anti-sporozoite antibodies 7D4 (□), 8A2 (∘), 14B1 () or 6A5 (▪) and-then allowed to infect MDBK cell cultures. Sporozoites were also preincubated with media (Δ) or with the anti-coccidial drug, lasalocid (*).
  • After infection, the development of the intracellular sporozoite was measured by the incorporation of [0038] 3H-uracil into the cell cultures. Since lasalocid prevents, intracellular development of the sporozoite, cultures pretreated with this drug showed minimal incorporation of 3H-uracil.
  • FIG. 10 shows the results of SDS-polyacrylamide gel electrophoretic/Western Blot analysis of 65 Kd-β-galactosidase fusion protein samples or other samples as noted. The Western Blot analysis was carried out using murine anti-β-galactosidase antibody (panel A) or pooled monoclonal antibodies 7D1, 7D4 and 20C6 (panel B) in conjunction with goat anti-mouse HPOD conjugate. The lanes in both panels represent (1) β-galactosidase, (m) prestained molecular weight markers, the sizes of which are indicated to the left of plate A in kd, (2) total cell pellet protein, (3) protein released from the cell pellet by sonication and (4) protein solubilized by guanidine-HCl from the pellet after sonication. [0039]
  • FIG. 11 is a schematic representation of plasmid pEV/2-4, a 65 kd protein expression plasmid containing a 1.7 kb EcoRI DNA insert from phage λ2-4. Positions of various restriction enzyme sites in the insert are shown relative to the EcoRI site, including PstI (P, at bp 53 and 776), KpnI (K, at bp 202), BstNI (B, at bp 584, 1303 and 1412) and Sau3A (S, at bp 1017 and 1439). [0040]
  • FIG. 12 is a map of pEV3-SEQ, containing a polylinker with the indicated sites inserted between the EcoRI and SalI sites of pEV-vrf3. The synthetic oligonucleotide CGGTCGACTCGAGCCA, indicated by the dashed arrow, was used as a primer for chain-termination DNA sequence analysis. [0041]
  • FIG. 13 is a restriction map of cDNA clones encoding proteins recognized by monoclonal antibody 6A5. Restriction endonuclease sites used for Maxam-Gilbert DNA sequence analysis of the 1.1 kb cDNA are shown. The EcoRI site in parentheses is at the end of the 0.9 kb cDNA. The bar above the map shows the open reading frame predicted from the DNA sequence, with the potential signal peptide filled in. The lines below the map indicate the exoIII deletions used for chain-termination sequence analysis. [0042]
  • FIG. 14 is the nucleotide sequence of the 1.1 kb cDNA molecule encoding the 20 kd protein recognized by monoclonal antibody 6A5. [0043]
  • FIG. 15 is the amino acid sequence of the protein of FIG. 14, predicted from the nucleotide sequence of that figure. [0044]
  • FIG. 16 is the nucleotide sequence of the 1.7 kb cDNA molecule encoding the 65 kd protein recognized by monoclonal antibodies 7D1, 7D4 and 20C6. [0045]
  • FIG. 17 is the amino acid sequence of the protein of FIG. 16, predicted from the nucleotide sequence of that figure and confirmed by sequence analysis of tryptic peptides produced from the expressed 65 kd protein. Regions in the overall amino acid sequence corresponding to some of these peptides are shown underlined. The determined sequences of these peptides are overlined. [0046]
  • FIG. 18 is the nucleotide sequence of the 1.1 kb cDNA molecule encoding the 28 kd protein recognized by monoclonal antibody 8A2. [0047]
  • FIG. 19 is the amino acid sequence of the protein of FIG. 18, predicted from the nucleotide sequence of that figure. [0048]
  • FIG. 20 is the nucleotide sequence of the 3.2 kb cDNA molecule encoding the protein recognized by monoclonal antibody 7B2. [0049]
  • FIG. 21 is the amino acid sequence of the protein of FIG. 20, predicted from the nucleotide sequence of that figure. [0050]
  • FIG. 22 is an SDS polyacrylamide gel electrophoretic analysis of the immunoaffinity-purified 65 kd protein. The gel was visualized by Coomassie blue stain and by Western blot analysis. [0051] Lanes 2 and 4 and 3 and 5 contain the purified protein from two preparations Lanes 1 and 6 contain a mixture of molecular weight marker proteins having the molecular weights shown to the left and right of the figure.
  • FIG. 23 is an HPLC elution profile of a β-mercaptoethanol reduced (panel A) and unreduced (panel B) tryptic digest of the 65 kd protein, showing absorbance at 215 mμ as a function of column retention time. [0052]
  • FIG. 24 shows restriction maps of four elements of the basic vector used for recombination of genes coding for coccidial antigens into vaccinia virus. These elements include the 7.5K promoter element (a and b, left), the TK locus (a and b, right), part of plasmid PUC8 (c) and the polycloning site from M13tg131 (d). The direction of transcription of the viral 7.5K and TK promoters is from left to right (i.e.. from the BglII to the EcoRI restriction site in the polylinker. [0053]
  • FIG. 25 shows the amino acid sequence of the N-terminus of the Eimeria antigen recognized by monoclonal antibody 8A2 (A) expressed from a construct containing the AUG translation start codon in the polylinker element of the vector of FIG. 24, and (B) fused to the malarial 190 kd leader segment (first 34 amino acids) and the polylinker of the cloning vector of FIG. 24 (next 13 amino acids). During the maturation process of the protein, the first 19 amino acids at the N-terminus may be cleaved at the position indicated by a colon. [0054]
  • In the figures, standard single letter abbreviations are used to represent nucleotides, and standard one or three letter abbreviations are used to represent amino acids. The meanings of these abbreviations can be found in standard biochemistry textbooks, such as Lehninger, Principles of Biochemistry, 1984, Worth Publishers. Inc., New York, pp. 96, 798. [0055]
  • FIG. 26 is the nucleotide sequence of the DNA molecule encoding the approximately 20 kD protein recognized by monoclonal antibody 6A5 (ATCC Accession No. HB9711). This sequence represents the coding sequence only and encodes the amino acid sequence of FIG. 15. FIG. 26 is the subsequence from about nucleotide 91 to about nucleotide 741 of the sequence of FIG. 14. The first seven and last seven nucleotides of the sequence of FIG. 14 are derived from linker sequences used in the cloning procedure. [0056]
  • FIG. 27 is the nucleotide sequence of the DNA molecule encoding the approximately 65 kD protein recognized by-monoclonal antibody 7D4 (ATCC Accession No. HB 9707). This sequence represents the coding sequence only and encodes the amino acid sequence of FIG. 17 from about [0057] residue 20,to about 325. FIG. 27 is the subsequence from about nucleotide 62 to about nucleotide 982 of the sequence of FIG. 16.
  • FIG. 28 is the amino acid sequence of the protein of FIG. 27 predicted from the nucleotide sequence of FIG. 27. This sequence is a subsequence of the sequence of FIG. 17 from about [0058] residue 20 to about 325. The 1st approximately 20 amino acids of FIG. 17 may result from an artifact during cDNA synthesis which caused “looping back” of a more internal sequence. Therefore, this sequence represents a more accurate sequence of the protein of FIG. 27.
  • FIG. 29 is the nucleotide sequence of the DNA molecule encoding the approximately 28 to approximately 37 kD protein recognized by monoclonal antibody 8A2 (ATCC Accession No. HB 9710). This sequence represents a resequencing of the DNA molecule from which the sequence of FIG. 18 was derived. [0059]
  • FIG. 30 is the nucleotide subsequence of the sequence of FIG. 29 which represents the coding sequence only as represented by FIG. 31. [0060]
  • FIG. 31 is the amino acid sequence of the protein of FIG. 29 deduced from the nucleotide sequence of FIG. 29. The resequencing suggests that the protein of FIG. 29 is approximately 37 kD. [0061]
  • FIG. 32 is the sequence of FIG. 31 from which the first three amino acids have been deleted. These three amino acids are encoded by nucleotides from linkers and are therefore artifacts of the cloning process. [0062]
  • FIG. 33 is the nucleotide sequence of the DNA molecule encoding the approximately 45 kD protein recognized by monoclonal antibody 7B2 (ATCC Accession No. HB 9712). This sequence represents the coding sequence only and encodes the amino acid sequence of FIG. 21 beginning at residue three. FIG. 33 is the subsequence from about nucleotide 9 to about nucleotide 3005 of the sequence of FIG. 20. The first seven and last seven nucleotides of the sequence of FIG. 20 are derived from linker sequences used in the cloning procedure. [0063]
  • FIG. 34 is the sequence of FIG. 21 from which the first two amino acids have been deleted. These two amino acids are encoded by nucleotides from linkers and are therefore artifacts of the cloning process. [0064]
    • DESCRIPTION OF THE INVENTION
  • Definitions [0065]
  • As used herein, the following terms shall have the following meanings: [0066]
  • “20 kd protein” means a recombinant or synthetic protein having an apparent molecular weight of about 20 kilodaltons in SDS polyacrylamide gel electrophoresis which binds specifically to monoclonal antibody 6A5. This antibody also specifically reacts with an Eimeria surface antigen (from a whole extract of Eimeria proteins) having an apparent molecular weight of about 28 kilodaltons in SDS gels. This antigen is present in the sporozoite developmental stage. The nucleotide sequence of a cDNA molecule encoding this protein and the amino acid sequence predicted therefrom are shown in FIGS. 14, 15, and [0067] 26.
  • “65 kd protein” means a recombinant or synthetic protein having an apparent molecular weight of about 65 kilodaltons in SDS polyacrylamide gel electrophoresis which binds specifically to monoclonal antibodies 7D1, 7D4 and 20C6. These antibodies also specifically react with a surface antigen from Eimeria extracts having an apparent molecular weight of about 120 kilodaltons in SDS gels. This antigen is present in the sporozoite, schizont and merozoite developmental stages. The nucleotide sequence of a cDNA molecule encoding this protein and the amino acid sequence predicted therefrom are shown in FIGS. 16 and 17, [0068] 27 and 28 respectively.
  • “28 kd protein” means a recombinant or synthetic protein having an apparent molecular weight of about 28 kilodaltons in SDS polyacrylamide gel electrophoresis which binds specifically to monoclonal antibody 8A2. This antibody also specifically reacts with an Eimeria surface antigen having an apparent molecular weight of about 37 kilodaltons in SDS gels. This antigen is present in the sporozoite, schizont and merozoite developmental stages. The nucleotide sequence of a cDNA molecule encoding this protein and the amino acid sequence predicted therefrom are shown in FIGS. 18 and 19, respectively. * [0069]
  • “45 kd protein” means a recombinant or synthetic protein having an apparent molecular weight of about 45 kilodaltons in SDS polyacrylamide gel electrophoresis which binds specifically to monoclonal antibody 7B2. This antibody also specifically reacts with an Eimeria surface antigen having an apparent molecular weight of greater than 200 kilodaltons in SDS gels. This antigen is present in the sporozoite developmental stage. The nucleotide sequence of a cDNA molecule encoding this protein and the amino acid sequence predicted therefrom are shown in FIGS. 20 and 21, [0070] 33 and 34 respectively.
  • The term “protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen” means a protein having one or more regions or epitopes which are capable of eliciting an immune response in an, immunologically competent host organism and/or are capable of specifically binding to a complementary antibody. [0071]
  • Because of the degeneracy of the genetic code, it will be understood that there are many potential nucleotide sequences (functional equivalents) that could code for the amino acid sequences shown in FIGS. 15, 17, [0072] 19, 21, 28, 31, 32, 34 it should also be understood that the nucleotide sequences of the DNA sequences and fragments of the invention inserted into vectors may include nucleotides which are not part of the actual structural genes, as long as the recombinant vectors containing such sequences and fragments are capable of directing the production in an appropriate host organism of a protein or fragment having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen.
  • Moreover, amino acid substitutions in proteins which do not essentially alter biological and immunological activities have been known to occur and have been described, e.g., by Neurath et al. in “The Proteins”, Academic Press. New York (1979). in particular in FIG. 6 at [0073] page 14. The most frequently observed amino acid substitutions are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly, and vice versa.
  • Such functionally equivalent nucleotide sequence variations and amino acid substitutions of the exemplary embodiments of this invention are within the scope of the invention as long as the resulting proteins retain one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen. [0074]
  • The term “fragment” means a DNA sequence or protein comprising a subsequence of one of the cDNA's or proteins of the invention. Such fragments can be produced by enzymatic cleavage of the larger molecules, using restriction endonucleases for the DNA and proteases for the proteins. The fragments of the invention, however, are not limited to the products of any form of enzymatic cleavage but include subsequences, the termini of which do not correspond to any enzymatic cleavage points. Such fragments can be made, e.g., by chemical synthesis, using the sequence data provided herein. DNA fragments can be produced by incomplete complementary DNA (cDNA) synthesis from isolated messenger RNA (mRNA). Protein fragments can also be produced by expressing DNA fragments encoding the protein fragments. Such protein fragments can be useful in this invention if they contain a sufficient number of amino acid residues to constitute an immunoreactive and/or antigenic determinant. Generally, at least about 7 or 8 residues are needed. As explained below, it may be necessary to couple such fragments to an immunogenic carrier molecule, to make them immunoreactive. [0075]
  • Preparation of Coccidial Proteins [0076]
  • The proteins of this invention can be made my methods known in the art such as by recombinant DNA methodology, chemical synthesis or isolation from Eimeria preparations. [0077]
  • Recombinant DNA [0078]
  • DNA needed to make the proteins of this invention could be chemically synthesized, using the nucleotide sequence information provided in FIGS. 14, 16, [0079] 18, 20, 26, 27, 29, 33. Such chemical synthesis could be carried out using any of the known methods, although the phosphoramidite solid support method of Matteucci et al. [J. Am. Chem. Soc. 103:3185 (1981)] is preferred.
  • Alternatively, cDNA can be made from Eimeria mRNA. Messenger RNA can be isolated from Eimeria sporulating oocysts or merozoites using standard techniques. These mRNA samples can then be used to produce double-stranded cDNA as described by Maniatis et al., supra. This cDNA can then be inserted into an appropriate cloning vector which can be used to transform [0080] E. coli, to produce a cDNA library.
  • The cDNA library can then be screened using the cloned genes of this invention, or fragments thereof, as probes. Such genes or fragments can be radiolabeled, e.g., by nick-translation using Pol I DNA polymerase in the presence of the four deoxyribonucleotides, one of which contains [0081] 32P in the a position (Maniatis et al., supra, p. 109). for use as probes.
  • Although [0082] Eimeria tenella was used as an mRNA source in the Examples below, the cloned genes from this species can be used as probes to isolate genes from other species of Eimeria, due to DNA sequence homology among the various species.
  • Once identified and isolated, the Eimeria genes of this invention are inserted into an appropriate expression vehicle which contains the elements necessary for transcription and translation of the inserted gene sequences. Useful cloning vehicles may consist of segments of chromosomal, nonchromosomal and synthetic DNA sequences such as various known bacterial plasmids, phage DNA, combinations of plasmids and phage DNA such as plasmids which have been modified to employ phage DNA or other expression control sequences, or yeast plasmids. Specific cloning vehicles which could be used include but are not limited to the pEV-vrf plasmids (pEV-vrf1, −2 and −3); SV40; adenovirus; yeast; lambda gt-WES-lambda B; Charon 4A and 28; lambda-gt-1-lambda B; M13-derived vectors such as pUC8, 9. 18 and 19, pBR313, 322 and 325; pAC105: pVA51; pACY177; pKH47; pACYC184; pUB110; pMB9; co1E1; pSC101; pML21; RSF2124; pCR1 or RP4. [0083]
  • The insertion of the Eimeria genes into a cloning vector is easily accomplished when both the genes and the desired cloning vehicle have been cut with the same restriction enzyme or enzymes, since complementary DNA termini are thereby produced. If this cannot be accomplished, it may be necessary to modify the cut ends that are produced by digesting back single-stranded DNA to produce blunt ends, or by achieving the same result by filling in the single-stranded termini with an appropriate DNA polymerase. In this way, blunt-end ligation with an enzyme such as T4 DNA ligase may be carried out. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini. Such linkers may comprise specific oligonucleotide sequences that encode restriction site recognition sequences. The cleaved vector and the Eimeria genes may also be modified by homopolymeric tailing, as described by Morrow [Methods in Enzymology 68:3 (1979)]. [0084]
  • Many of the cloning vehicles that may be used in this invention contain one or more marker activities that may be used to select for desired transformants, such as ampicillin and tetracycline resistance in pBR322, ampicillin resistance and β-galactosidase activity in pUC8, and ampicillin resistance in pEV-vrf2. Selection of host cells into which such vectors have been inserted is greatly simplified when the host cells otherwise lack the activities contributed by the vectors. [0085]
  • It should be understood that the nucleotide sequences of the Eimeria genes inserted at a selected site in a cloning vehicle may include nucleotides which are not part of the actual structural genes. Alternatively, the gene may contain only part of the complete wild-type gene. All that is required is that the gene fragments inserted into the cloning vehicle be capable of directing the production in an appropriate host organism of a polypeptide or protein having at least one immunoreactive and/or antigenic determinant of an Eimeria surface antigen. [0086]
  • The selection of an appropriate host organism is affected by a number of factors known in the art. These factors include, for example, compatibility with the chosen vector, toxicity of proteins encoded by the hybrid plasmid, ease of recovery of the desired protein, expression characteristics, biosafety and costs. A balance of these factors must be struck, and it must be understood that not all hosts will be equally effective for expression of a particular recombinant DNA molecule. [0087]
  • Suitable host unicellular organisms which can be used in this invention include but are not limited to plant, mammalian or yeast cells and bacteria such as [0088] Escherichia coli, Bacillus subtilis. Bacillus stearothermophilus and Actinomyces. Especially preferred is Escherichia coli strain MC1061. which has been described by Casadaban et al. [J. Mol. Biol. 138:179 (1980)]. This strain can be used, or any other strain of E. coli K-12 containing the plasmid pRK248cIts. Plasmid pRK248cIts for use in other E. coli K-12 strains is available from the American Type Culture Collection and has accession No. ATCC 33766. E. coli strain MC1061 has also been deposited and has accession No. ATCC 53338.
  • Transfer of the recombinant cloning vector into the host cell may be carried out in a variety of ways. Depending upon the particular vector/host cell system chosen, such transfer may be effected by transformation, transduction or transfection. Once such a modified host cell is produced, the cell can be cultured and the protein expression product may be isolated from the culture. [0089]
  • Identification of Clones [0090]
  • Clones producing the Eimeria proteins of the invention can be identified using suitably labeled antibodies specific for the proteins. Monoclonal antibodies, which are preferred, can be prepared using standard methods as follows. [0091]
  • Antigenic proteins from [0092] Eimeria tenella are used to immunize animals such as mice, rats, horses, sheep, pigs, rabbits, etc., to obtain antibody producing somatic cells for fusion to myeloma cells.
  • Somatic cells with the potential for producing antibody, particularly B cells, are suitable for fusion with a myeloma cell line. These somatic cells may be derived from the lymph nodes, spleens and peripheral blood of primed animals. In the preferred embodiment of this invention mouse spleen cells are used, in part because these cells produce a relatively high percentage of stable fusions with mouse myeloma lines. It would be possible, however, to use rat, rabbit, frog or other cells instead. [0093]
  • Specialized myeloma cell lines have been developed from lymphocytic tumors for use in hyridoma-producing fusion procedures [Kohler and Milstein, Eur. J. Immunol. 6:511 (1976); Shulman et al., Nature 276:269 (1978); Volk et al., J. Virol. 42:220 (1982)]. These cell lines have been developed for at least three reasons. The first is to facilitate the selection of fused hybridomas among unfused and similarity indefinitely self-propogating myeloma cells. Usually, this is accomplished by using myelomas with enzyme deficiencies that render them incapable of growing in certain selective media that support the growth of hybridomas. The second reason arises from the inherent ability of lymphocytic tumor cells to produce their own antibodies. The purpose of using monoclonal techniques is to obtain fused hybrid cell lines with unlimited lifespans that produce the desired single antibody under the genetic control of the somatic cell component of the hybridoma. To eliminate the production of tumor cell antibodies by the hybridomas, myeloma cell lines incapable of producing light or heavy immunoglobulin chains or deficient in antibody secretion mechanisms are used. A third reason for selection of these cell lines is for their suitability and efficiency for fusion. [0094]
  • Many myeloma cell lines may be used for the production of fused cell hybrids, including. e.g., P3/X63-[0095] Ag 8. P3/NSI/1-Ag 4-1, SP2/0-Ag-14 and S194/5.XXO.BU.1. The P3/X63-Ag 8 and P3/NSI/1-Ag 4-1 cell lines have been described by Kohler and Milstein [Eur. J. Immunol. 6:511, (1976)]. Shulman et al. [Nature 276:269 (1978)] developed the Sp2/0-Ag14 myeloma line. The S194/5.XXO.BU.1 line was reported by Trowbridge [J. Exp. Med. 148:313 (1979)]. In the example of the present invention, the PAI-O mouse cell line (a non-Ig-producing subclone of P3/X63-Ag 8) was used.
  • Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually involve mixing somatic cells with myeloma cells in a 10:1 proportion (although the proportion may vary from about 20:1 to about 1:1), respectively, in the presence of an agent or agents (chemical, viral or electrical) that promote the fusion of cell membranes. It is preferred that the same species of animal serve as the source of the somatic add myeloma cells used in the fusion procedure. Fusion methods have been described by Kohler and Milstein [Nature 256:495 (1975) and Eur. J. Immunol. 6:511 (1976)], by Gefter et al. [Somatic Cell Genet. 3:231 (1977)], and by Volk et al. [J. Virol. 42:220 (1982)]. The fusion-promoting agents used by those investigators were Sendai virus and polyethylene glycol (PEG). The fusion procedure for the example of the present invention uses PEG. [0096]
  • Because fusion procedures produce viable hybrids at very low frequency (e.g., when spleens are used as a source of somatic cells, only one hybrid is obtained for roughly every 1×10[0097] 5 spleen cells), it is essential to have a means of selecting the fused cell hybrids from the remaining unfused cells, particularly the unfused myeloma cells. A means of detecting the desired antibody-producing hybridomas among other resulting fused cell hybrids is also necessary.
  • Generally, the selection of fused cell hybrids is accomplished by culturing the cells in media that support the growth of hybridomas, but prevent the growth of the myeloma cells, which normally would go on dividing indefinitely. (The somatic cells used in the fusion do not maintain long-term viability in in vitro culture and hence do not pose a problem). In the example of the present invention, myeloma cells lacking hypoxanthine phosphoribosyl transferase (HPRT-negative) were used. Selection against these cells is made in hypoxanthine/aminopterin/thymidine (HAT) medium, a medium in which the fused cell hybrids survive due to the HPRT-positive genotype of the spleen cells. The use of myeloma cells with different genetic deficiencies (drug sensitivities, etc.) that can be selected against in media supporting the growth of genotypically competent hybrids is also possible. [0098]
  • Several weeks are required to selectively culture the fused cell hybrids. Early in this time period, it is necessary to identify those hybrids which produce the desired antibody so that they may subsequently be cloned and propagated. Generally, around 10% of hybrids obtained produce the desired antibody, although a range of from 1 to 30% is not uncommon. The detection of antibody-producing hybrids can be achieved by any one of several standard assay methods, including enzyme-linked immunoassay and radioimmunoassay techniques which have been described in the literature [see. e.g., Kennet et al. (editors), Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses, pp. 376-384, Plenum Press, New York (1980)]. Several detection methods were used in the example of the present invention. [0099]
  • Once the desired fused cell hybrids have been selected and cloned into individual antibody-producing-cell lines, each cell line may be propagated in either of two standard ways. A suspension of the hybridoma cells can be injected into a histocompatible animal. The injected animal will then develop tumors that secrete the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can be tapped to provide monoclonal antibodies in high concentration. Alternatively, the individual cell lines may be propagated in vitro in laboratory culture vessels. The culture medium containing high concentrations of a single specific monoclonal antibody can be harvested by decantation, filtration or centrifugation. [0100]
  • Cell Disruption [0101]
  • As produced in [0102] E. coli, the Eimeria proteins remain in the cytoplasm, or in inclusion bodies. To free the proteins it is thus necessary to disrupt the outer membrane. This is preferably accomplished by sonication, or by other mechanically disruptive means, such as a French pressure cell or Gaulin homogenizer.
  • Cell disruption could also be accomplished by chemical or enzymatic means. Since divalent cations are often required for cell membrane integrity, treatment with appropriate chelating agents such as EDTA or EGTA might prove sufficiently disruptive to facilitate the leakage of the proteins from the cells. Similarly, enzymes such as lysozyme have been used to achieve the same result. That enzyme hydrolyzes the peptidoglycan backbone of the cell wall. [0103]
  • The application of osmotic shock could also be employed. Briefly, this could be accomplished by first placing the cells in a hypertonic solution which would cause them to lose water and shrink. Subsequent placement in a hypotonic “shock” solution would then lead to a rapid influx of water into the cells with an expulsion of the desired proteins. [0104]
  • Once freed from the cells, the Eimeria proteins may be concentrated by precipitation with salts such as sodium or ammonium sulfate, ultrafiltration or other methods well known to those skilled in the art. Further purification could be accomplished by conventional protein purification techniques including but not limited to gel filtration, ion-exchange chromatography, preparative disc-gel or curtain electrophoresis, isoelectric focusing, low temperature organic solvent fractionation, or countercurrent distribution. Purification is preferably carried out, however, by immunoaffinity chromatography as described below. [0105]
  • Chemical Systhesis [0106]
  • The proteins of this invention or fragments thereof can also be chemically synthesized by a suitable method such as by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. Solid phase synthesis as described by Merrifield [J. Am. Chem. Soc. 85:2149 (1963)] is preferred. [0107]
  • Such synthesis is carried out with amino acids that are protected at the alpha-amino-terminus. Trifunctional amino acids with labile side-chains are also protected with suitable groups which will prevent a chemical reaction from occurring at that site during the assemblage of the peptide. The alpha-amino protecting group-is selectively removed to allow subsequent reaction to take place at the amino-terminus. The conditions for the removal of the alpha-amino protecting group do not cause deprotection of the side-chain protecting groups. [0108]
  • The alpha-amino protecting groups are those known to be useful in the art of stepwise synthesis of peptides. Included are acyl type protecting groups (e.g., formyl, trifluoroacetyl, acetyl), aromatic urethane type protecting groups (e.g., benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyl), aliphatic urethane protecting groups (e.g., t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl) and alkyl type protecting groups (e.g., benzyl, triphenylmethyl). The preferred protecting group is Boc. The side-chain protecting groups for Tyr include tetrahydropyranyl, tert.-butyl, triyl, benzyl, Cbz, 4-Br-Cbz and 2,6-dichlorobenzyl. The preferred side-chain protecting group for Tyr is 2,6-dichlorobenzyl. The side-chain protecting-groups for Asp include benzyl. 2,6-dichlorobenzyl, methyl, ethyl and cyclohexyl. The preferred side-chain protecting group for Asp is cyclohexyl. The side-chain protecting groups for Thr and Ser include acetyl, benzoyl, trityl, tetrahydropyranyl, benzyl, 2,6-dichlorobenzyl and Cbz. The preferred protecting group for Thr and Ser is benzyl. The side-chain protecting groups for Arg include nitro, Tos, Cbz, adamantyloxycarbonyl or Boc. The preferred protecting group for Arg is Tos. The side-chain amino group of Lys may be protected with Cbz, 2-ClCbz, Tos or Boc. The 2-Cl-Cbz group is the preferred protecting group for Lys. The selection of the side-chain protecting group is based on the following: The side-chain protecting group remains intact during coupling and is not split off during the deprotection of the amino-terminus protecting group or during coupling conditions. The side-chain protecting group must be removable upon the completion of the synthesis of the final peptide, using reaction conditions that will not alter the target peptide. [0109]
  • Solid phase synthesis is usually carried out from the carboxy-terminus by coupling the alpha-amino protected (side-chain protected,) amino acid toga suitable solid support. An ester linkage is formed when the attachment is made to a chloromethylated or hydroxymethyl resin and the resultant target peptide will have a free carboxyl group at the C-terminus. Alternatively, a benzhydrylamine or p-methylbenzhydrylamine resin is used in which case an amide bond is formed and the resultant target peptide will have a carboxamide group at the C-terminus. These resins are commercially available and their preparation is described by Stewart et al., “Solid Phase Peptide Synthesis” (2nd Edition, Pierce Chemical Co., Rockford, Ill., 1984). [0110]
  • The C-terminal amino acid, Arg, protected at the side-chain with Tos and at the alpha-amino function with Boc is coupled to the benzhydrylamine resin using various activating agents including dicyclohexylcarbodiimide (DCC). N,N′-diisopropylcarbodiimide and carbonyldiimidazole. Following the attachment to the resin support the alpha-amino protecting group is removed by using trifluoroacetic acid (TFA) or HCl in dioxane at a temperature between 0° and 25° C. Dimethylsulfide is added to the TFA after the introduction of methionine (Met) to suppress possible S-alkylation. After removal of the alpha-amino protecting group, the remaining protected amino acids are coupled stepwise in the required order to obtain the desired peptide sequence. [0111]
  • Various activating agents can be used for the coupling reactions including DDC, N,N′-diisopropylcarbodiimide, benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP) and DCC-hydroxybenzotriazole (HOBt). Each protected amino acid is used in excess (>2.5 equivalents), and the couplings are usually carried out in DMF, CH[0112] 2Cl2 or mixtures thereof. The extent of completion of the coupling reaction is monitored at each stage by the ninhydrin reaction as described by Kaiser et al., Anal. Biochem. 34:595 (1970). In cases where incomplete coupling is determined the coupling reaction is repeated. The coupling reactions can be performed automatically on a Vega 250, Applied Biosystems synthesizer or other commercially available instrument. After the entire assemblage of the target peptide, the peptide-resin is deprotected with TFA/dithioethane and then cleaved with a reagen such as liquid HF for 1-2 hours at 0° C. which cleaves the peptide from the resin and removes all side-chain protecting groups.
  • Side-chain to side-chain cyclization on the solid support requires the use of an orthogonal protection scheme which enables selective cleavage of the side-chain functions of the acidic amino acids (e.g., Asp) and the basic amino acids (e.g., Lys). The 9-fluorenylmethyl (OFm) protecting group for the side-chain of Asp and the 9-fluorenylmethoxycarbonyl (Fmoc) protecting group for the side-chain of Lys can be used for this purpose. In these cases the side-chain protecting groups of the Boc-protected peptide-resin are selectively removed with piperidine in DMF. Cyclization is achieved on the solid support using various activating agents including DCC, DCC/HOBt or BOP. The HF reaction is carried out on the cyclized peptide-resin as described above. [0113]
  • Purification of the synthetic proteins can be carried out as described above for the recombinantly produced proteins. [0114]
  • Immunoprecipitation and Immunoaffinity Chromatography [0115]
  • Eimeria proteins can also be recovered from extracts of membrane proteins from [0116] E. tenella or other Eimeria species by immunoprecipitation or immunoaffinity chromatography. As already noted, such methods can produce the complete, wild-type proteins. In some cases, these proteins are larger than the proteins produced by recombinant DNA methodology. Monoclonal antibodies for this purpose can be produced as described above, using synthetic or natural Eimeria proteins as the antigen.
  • Anti-Idiotype Antibodies [0117]
  • Other useful proteins which have the necessary immunoreactive and/or antigenic determinants are antibodies or fragments thereof which are anti-idiotypic toward the active determinant or determinants on the proteins of the invention. Such anti-idiotypic antibodies can be raised against other antibodies which are specific for the determinants on the proteins of the invention (i.e., the anti-idiotypic antibodies are anti-antibodies). Preferably. monoclonal anti-idiotypic antibodies are used. Such antibodies can be administered as a vaccine, in the same manner that the Eimeria proteins themselves can be used. [0118]
  • Poultry Vaccination [0119]
  • Use of Eimeria Proteins and Anti-Idiotype Antibodies [0120]
  • One or more of the Eimeria proteins and anti-idiotype antibodies of this invention can be formulated into vaccines comprising the proteins and a physiologically acceptable carrier. Suitable carriers include, e.g., 0.01 to 0.1 M phosphate buffer of neutral pH or physiological saline solution. [0121]
  • Enhanced immunity against coccidiosis can be produced in one of two ways. First, an adjuvant or immunopotentiator can be added to the vaccine. Secondly, the proteins of the invention can be presented to an animal that is to be immunized in a larger form, either as a cross-linked complex or conjugated to a carrier molecule. [0122]
  • Suitable adjuvants for the vaccination of animals include but are not limited to Adjuvant 65 (containing peanut oil, mannide monooleate and aluminum monostearate); mineral gels such as aluminum hydroxide, aluminum phosphate and alum; surfactants such as hexadecylamine. octadecylamine, lysolecithin, dimethyldioctadecylammonium bromide, N,N-dioctadecyl-N′,N′-bis(2-hydroxymethyl) propanediamine, methoxyhexadecylglycerol and, pluronic polyols; polyanions such as pyran, dextran sulfate, poly IC, polyacrylic acid and carbopol; peptides such as muramyl dipeptide, dimethylglycine and tuftsin; and oil emulsions. The proteins could also be administered following incorporation into liposomes or other microcarriers. [0123]
  • Incorporation into liposomes or other microcarriers provides a means by which the release of the vaccines can be sustained over a prolonged period of time. A pump such as an Alza pump could be used for the same purpose. [0124]
  • The immunogenicity of the proteins of the invention, especially the smaller fragments, can be enhanced by cross-linking or by coupling to an immunogenic carrier molecule (i.e., a macromolecule having the property of independently eliciting an immunological response in a host animal, to which the proteins and protein fragments of the invention can be covalently linked). Cross-linking or conjugation to a carrier molecule may be required because small protein fragments sometimes act as haptens (molecules which are capable of specifically binding to an antibody but incapable of eliciting antibody production, i.e., they are not immunogenic). Conjugation of such fragments to an immunogenic carrier molecule renders the fragments immunogenic through what is commonly known as the “carrier effect”. [0125]
  • Suitable carrier molecules include, e.g., proteins and natural or synthetic polymeric compounds such as polypeptides, polysaccharides, lipopolysaccharides etc. A useful carrier is a glycoside called Quil A, which has been described by Morein et al., Nature 308:457 (1984). Proteins carrier molecules are especially preferred, including but not limited to mammalian serum proteins such as keyhole limpet hemocyanin, human or bovine gammaglobulin, human, bovine or rabbit serum albumin, or methylated or other derivatives of such proteins. Other protein carriers will be apparent to those skilled in the art. Preferably, but not necessarily, the protein carrier will be foreign to the host animal in which antibodies against the Eimeria proteins are to be elicited. [0126]
  • Covalent coupling to the carrier molecule can be carried out using methods well known in the art, the exact choice of which will be dictated by the nature of the carrier molecule used. When the immunogenic carrier molecule is a protein, the proteins or fragments of the invention can be coupled, e.g., using water soluble carbodiimides such as dicyclohexylcarbodiimide, or glutaraldehyde. [0127]
  • Coupling agents such as these can also be used to cross-link the proteins and fragments to themselves without the use of a separate carrier molecule. Such cross-linking into protein or protein fragment aggregates can also increase immunogenicity. [0128]
  • Administration of an effective amount of the vaccines of this invention can protect poultry against infection by [0129] E. tenella. Monoclonal antibodies against the E. tenella antigens cross-react with E. acervulina and E. maxima in vitro, indicating that protection may also be conferred against these species. An effective dose of the proteins or protein fragments ranges from about 10 to about 50 micrograms/kg of body weight of the vaccinated animal. A dose of about 25-50 μg/kg is preferred. Initial vaccinations are preferably followed by booster vaccinations given from one to several weeks later. Multiple boosters may be administered. The dosages of such boosters generally range from about 5 to 50 μg/kg, preferably about 20-50 μg/kg. Standard routes of administration can be used such as subcutaneous, intradermal, intramuscular, oral, anal or in ovo administration.
  • Vector Systems [0130]
  • The presentation of the coccidial antigens of the invention to the immune systems of fowl can be achieved by cloning genes coding for the antigens into bacteria (e.g., [0131] E. coli or Salmonella) or into viruses (e.g., poxviruses or herpesviruses) and administering the live vector systems to the birds orally, by injection or by other commonly used routes. Carbit et al. (in: Vaccines, 1987, Cold Spring Harbor Laboratory, pp. 68-711 have described the use of E. Coli, while Clements [Pathol. Immunopathol. Res. 6:137 (1987)] has described the use of Salmonella. Moss et al. [Ann. Rev. Immunol. 5:305 (1987)] have reviewed the use of viral vector systems employing recombinant poxviruses.
  • One kind of poxvirus, vaccinia virus, can be used to test the delivery of coccidial antigens in cell culture and in animals. For analytical studies, vaccinia virus has been found to be more efficient than fowlpox virus, another poxvirus carrier that can be used. This is because vaccinia virus multiplies more rapidly than the avian virus and has a host range that is not restricted to chicken cells. Large amounts of heterologous DNA can be inserted into the vaccinia viral genome without inhibiting viral maturation and infectivity [Smith et al., Gene 25:21 (1983)]. The insertion and expression of multiple heterologous genes using the virus elicits antibody production against expressed antigens in infected animals [Perkus et al., Science 229:981 (1985)]. [0132]
  • The techniques used to produce recombinant vaccinia viruses can be readily adapted by routine procedures to fowlpox or herpesvirus systems. The use of such recombinant viruses as carriers in vaccines against coccidiosis is especially advantageous in that vaccinated fowl develop immunity against both the coccidial antigen and the viral carrier (i.e., such vaccines are bivalent). The utility of such vaccines can be further enhanced by inserting additional genes into the carrier virus. For example, parts of the Newcastle disease viral genome can be inserted together with a coccidial antigen gene into a fowlpox virus, thereby conferring immunity against Newcastle disease, coccidiosis and fowlpox, all with a single vaccine. [0133]
  • The administration of the live vector vaccines of the invention can be carried out by numerous methods well known in the art. For example, the “stick” method commonly used to vaccinate poultry against fowlpox virus can be used. This method consists of sticking or pricking the skin of the wing web with a sharp needle dipped into the vaccine. The needle usually has an eye near the tip like a sewing machine needle which carries a drop of vaccine. Alternatively, the live vaccines can be injected subcutaneously or intradermally into the wing web or any other site. [0134]
  • The recombinant live vector vaccines can also be added to drinking water or even sprayed over chicks that are to be vaccinated. They can also be administered in feed, preferably after protective encapsulation [Balancou et al., Nature 322:373 (1986)], or in ovo. In the latter method, the viral vaccines are injected directly into chicken embryos [Sharma, Avian Dis. 25:1155 (1985)]. [0135]
    • EXAMPLES
  • Unless otherwise specified, percentages given below for solids in solid mixtures, liquids in liquids, and solids in liquids are on a wt/wt, vol/vol and wt/vol basis, respectively. [0136]
  • Preparation of Monoclonal Antibodies against Eimeria Antigens [0137]
  • Parasite Preparation [0138]
  • Sporozoites of [0139] E. tenella, E. acervulina, E. brunetti, and E. maxima were isolated from sporulated oocysts by standard procedures. Briefly, sporulated oocysts were washed with distilled water and 20% bleach and then with distilled water. The oocysts were disrupted in a tissue homogenizer and insoluble material, including sporocysts, was recovered by centrifugation. The released sporocysts and other material in the pellet were resuspended in 0.25% trypsin and chicken bile in Hank's salt solution, pH 8, and incubated for 2 hours at 40° C. The excising solution was removed by two washes with RPMI-1640 medium containing 10% fetal bovine serum (FBS). followed by two washes with PBS at pH 7.4.
  • The sporozoites were then purified over a metrazimide gradient [Wisher et al., Parasitiology 88:515 (1984)). Briefly, the sporozoites were resuspended in 2 ml of PBS, pH 7.0, and 1 ml of the suspension was layered over a 15 ml metrizamide gradient. The gradient was composed of 5 ml of each of 12%, 18% and 24% metrazimide in PBS, pH 7.0. The sporozoites were sedimented by centrifugation at 900×g for 40 minutes. Purified sporozoites were isolated from the interface between the 18% and 24% metrizamide by insertion of a 21 gauge needle through the side of the tube and aspirating the sporozoites into a syringe. [0140]
  • The purified sporozoites were washed 3 times with PBS, pH 7.0 and used immediately for immunizations, infection studies, surface labeling with [0141] 125I, immunofluorescence assays or SDS-polyacrylamide gel electrophoresis (Laemmli. Nature 227:680 (1970)) and Western blotting studies.
  • Merozoites of [0142] E. tenella were isolated as described below in Section 6.2.3. The purified merozoites were used for immunizations and were solubilized with Laemmli sample buffer for SDS-polyacrylamide gel electrophoresis and Western blotting studies.
  • Immunizations [0143]
  • Eight female Balb/c mice (Charles River, Wilmington, Mass.) were immunized with purified live sporozoites according to the following schedule. [0144]
  • [0145] Day 1 1×107 sporozoites intravenously (i.v.)
  • Day 7 6×10[0146] 6 sporozoites intraperitoneally (i.p.)
  • Day 85 6×10[0147] 6 sporozoites i.p.
  • [0148] Day 120 3×107 sporozoites i.p.
  • Day 244 Pre-fusion immunization boosters [0149]
  • [0150] Day 1 5×106 sporozoites i.v.; 5×106 sporozoites i.p.
  • [0151] Day 2 same as Day 1
  • [0152] Day 5 fusion of hyperimmune splenocytes and myeloma cells
  • The serum from each mouse was tested for anti-sporozoite antibodies by ELISA with purified sporozoite proteins, by Western blotting assays with solubilized sporozoite proteins, by immunoprecipitation of [0153] 125I-labeled sporozoite surface proteins, and by immunofluorescence assays with purified sporozoites. The mouse with the highest sporozoite antibody reactivity (mouse 107-2) was chosen for the pre-fusion immunization boosters (see FIG. 1 for ELISA analysis of this antiserum). On the fifth day, the mouse was killed and the spleen was removed for the preparation of splenocytes.
  • Cell Culture and Cell Fusions [0154]
  • Two days before-fusion, splenocyte feeder cells were prepared from naive mice in complete medium [Iscove's modified Dulbecco's medium (IMDM, Gibco) with 10% FBS, glutamine (2.0 mM), and 2-mercaptoethanol (100 μM)] plus HAT (100 μM hypoxanthine, 0.4 μM aminopterin and 16 μM thymidine). Using a modification of the procedure of de St. Groth et al. [J. Immunol. Methods 35:1 (1980)], 10[0155] 8 spleen cells were fused with 108 PAI-O mouse myeloma cells.
  • The cells were mixed, pelleted by centrifugation and resuspended under constant gentle agitation in 1.0 ml of 35% (vol/vol) polyethylene glycol in IMDM at 37° C. over 1 minute. After 3 minutes of incubation at 37° C., the cells were pelleted again and gently resuspended in 10 ml of IMDM+HAT. The cells were then diluted to 1×10[0156] 6 cells/ml in complete medium+HAT and dispersed into 24-well microtiter plates (1 ml/well) containing 5×105 splenocyte feeder cells in 1 ml of complete medium.
  • Hybridoma supernatants were assayed for anti-sporozoite antibodies by ELISA with purified sporozoites, by Western blotting with sporozoite proteins, by immunoprecipitation with [0157] 125I-labeled sporozoite surface proteins and by immunofluorescence with purified sporozoites and with sporozoite-infected cells. The hybridomas were cloned by limiting dilution.
  • Sporozoite Elisa [0158]
  • Purified sporozoites (4×10[0159] 4) were added to each well of a 96-well U-bottom PVC plate which had previously been blocked with 1% BSA in PBS, pH 7.0. The sporozoites were sedimented to the bottom of the wells by centrifugation at 1000×g for 5 minutes. The sporozoites were resuspended in 100 μl of diluted antiserum or hybridoma supernatants and incubated for 2 hours at room temperature with constant agitation. The sporozoites were then washed with 1% BSA in PBS, pH 7.0. to remove unbound antibody.
  • To detect specific antibody bound to the sporozoites, 100 μl of peroxidase-conjugated goat anti-mouse IgG were added to the resuspended sporozoites, and the suspension was incubated for 2 hours at room temperature. The sporozoites were washed, and bound antibody was visualized by adding substrate solution (o-phenylenediamine, 0.4 mg/ml in 0.1 M citrate buffer, pH 4.5., 0.12% hydrogen peroxide) for 30 minutes at room temperature. The reaction was stopped by the addition of 2.5 M H[0160] 2SO4 containing 50 mM sodium metabisulfite. The amount of bound antibody was determined by reading the OD488 of the substrate color.
  • From a total of 480 wells plated from the cell fusion, 432 were positive for hybridoma growth. Of these, 358 hybridomas tested positive for antibody production in the primary sporozoite ELISA. During expansion and passage of these original parental hybridoma cells, 104 died or stopped producing antibody and thus were negative in subsequent screenings with the sporozoite ELISA and Western blot assays. The sporozoite ELISA identified 205 hybridomas which were producing antibody at 10X background levels. [0161]
  • Western Blotting of Sporozoite Proteins [0162]
  • Purified sporozoites (approximately 5×10[0163] 7 sporozoites per ml per gel) were solubilized in Laemmli sample buffer, separated by SDS-polyacrylamide gel electrophoresis in either a 12.5% gel or a 7.5 to 20% gradient gel (Laemmli, supra) and electrophoretically transferred to nitrocellulose sheets. The sheets were blocked in 3% gelatin buffer (3% gelatin. Tris-HCl, pH 7.5, 0.15 M NaCl) and cut into strips, and the strips were allowed to react with diluted antiserum or hybridoma supernatant for 12 hours at 4° C. in 1% BSA buffer (1% BSA, 50 mM sodium phosphate, pH 6.5, 0.5 M NaCl, 0.05% Tween-20). The strips were washed in PBS, pH 7.4, 0.05% Tween-20 and the specifically bound antibody was detected with a peroxidase-conjugated anti-mouse antibody. The bound antibodies were visualized by adding substrate solution [4-chloro-1-naphthol (30 mg dissolved in 10 ml of ice cold methanol and 50 ml of Tris-HCl, pH 7.5), 0.15 M NaCl, 0.015% final concentration H2O2] for 30 minutes at room temperature. The reaction was terminated by extensive washing with distilled water.
  • Of the antibodies that were positive in the sporozoite ELISA, 160 were also positive by Western blotting analysis using solubilized sporozoite proteins. [0164]
  • Western blot analysis (see FIG. 2) showed that the monoclonal antibodies fell into one of three reactivity patterns: (a) those which bind single Eimeria proteins (e.g., 11A1 and 11D1), (b) those which bind to 2 or 3 proteins (e.g., 6A5 and 20C6) and (c) those which bind to multiple proteins (e.g., 11A5, 13A6 and 14B5). [0165]
  • The antibodies were further characterized by Western blot analysis using [0166] E. tenella merozoite and E. acervulina sporozoite proteins (FIG. 3). A number of antibodies, including 3A5, 13A6, 7D1 and 20C6, recognized proteins isolated from sporozoites of E. tenella and E. acervulina and from merozoites of E. tenella. Other antibodies, such as 6A5, were shown to be species and stage specific and to bind only to proteins from E. tenella sporozoites.
  • A summary of results obtained on some of the antibodies is shown in Table 1. in which the specificity of the antibodies is shown both in terms of (a) the origin and size of the protein(s) in the gels to which the antibodies bound and (b) the size of [0167] 125I-labeled Eimeria tenella proteins precipitated by the antibodies (right column). The antibodies are further characterized in the Table by isotype.
    TABLE 1
    WESTERN BLOT ANALYSIS
    Eimeria Protein (gel size in kd) Size of
    Tenella Acervulina Maxima Protein Ppt.
    Antibody Isotype spz Mrz Spz spz (kd)
    7B2 G2a >200 — — — —
    7D4 G 1 120 120 120 — 110
    7D1 G 1 120 120 120 N.D. 110
    20C6 G 1 120 120 120 N.D. 110
    3A5 M 120 120 120 17 120
    19D6 G 3 180 180 — — 120
    8A2 G2a 37 37 — — 37
    6A5 G2b 28/26 — — — 25
    14B5 N.D. >150 N.D. N.D.
    15B3 N.D. >150 N.D. N.D.
    14B1 G 3 6 6 — — 24/17
    12B2 G3 28/26 — — — 24/17
    15A3 G1 28/6  — — —  17/15/6
    15C4 M 28/26 — — — 105/15/6
    12C3 G3 28 — N.D. N.D. 25
    5B6 G3 — N.D. 6
    3C4 M m m m — 70
    16D2 M m m m — 70/85
    13A6 M m m m — 110
    11B6 G3 m m m — 105
    12A3 G3 m m m — 24/17
    12D4 G1 m N.D. N.D.
  • Immunoprecipitation of [0168] 125I-Labeled Sporozoite Surface Protein
  • The surface proteins of purified sporozoites were labeled with [0169] 125I by the IODOGEN method (Pierce Chemical Co.) or by use of IODOBEADS (Pierce Chemical Co.). For the latter procedure. 4 IODOBEADS were washed 3× with 0.2 M sodium phosphate, pH 7.5. and 1-3 mCi of 125I-Na were added and incubated for 5 minutes at room temperature. Purified sporozoites (3×108) in 200 μl of PBS, pH 7.0, were added to the reaction vial, and the incubation was continued for 15 minutes. At the end of the incubation, phenylmethanesulfonyl fluoride (PMSF) was added to a final concentration of 0.5 mM.
  • The sporozoites were recovered from the incubation mixture by centrifugation at 12.000×g for 30 seconds and solubilized in 1 ml of either 2% sodium dodecysulfate (SDS) or 1% Triton X-100 in PBS, pH 7.0. Insoluble material was removed by centrifugation for 3 minutes at 12,000×g. The solubilized sporozoite proteins were dialyzed against 3 liters of PBS, pH 7.0. at 4° C. using a 3,500 molecular weight cutoff membrane to remove any residual free [0170] 125-I. The 125I-labeled sporozoite proteins (typically 1.5×108 cpm incorporated into protein) were stored at 4° C. until used. The TCA precipitable radioactivity was typically in excess of 95% of the total radioactivity. SDS polyacrylamide gel electrophoretic analysis of the 125I-labeled sporozite proteins is shown in FIG. 4, left panel. Immunoprecipitation was carried out by adding 300 μl of hybridoma supernatant or diluted antiserum to 250 μl of 125I-labeled sporozoite proteins (1×105 cpm) in Buffer I (0.25% NP-40, 10 mM Tris-HCl, pH 7.5, 0.15 M NaCl). Following incubation for 16 hours at 4° C., 100-200 μl of a 50% suspension of goat anti-mouse IgG coupled to agarose (Sigma Chemical Co.) were added, and the mixture was incubated on a rotating mixer for 2 hours at room temperature. The beads were pelleted by centrifugation for 1 minute at 12,000×g and washed 3× in Wash Buffer (0.1% SDS. 0.5% NP-40, 0.2% sodium deoxycholate, 10 mM PMSF. 10 mM Tris-HCl, pH 8.5, 0.15 M NaCl).
  • The [0171] 125I-labeled proteins bound to the solid phase antibodies were released and denatured by adding 60 μl of 2×Laemmli sample buffer and heating for 3 minutes at 95° C. The immunoprecipitated 125I-labeled sporozoite proteins were separated by SDS-polyacrylamide gel electrophoresis in a 12.5% gel and visualized by autoradiography.
  • The results of the immunoprecipitation assay with the immune mouse serum are shown in FIG. 4, right panel. Of the hybridoma antibodies that were positive by sporozoite ELISA, 74 were positive by immunoprecipitation assay. As shown in FIG. 5, the hybridoma antibodies fell into two categories, those which precipitated only single proteins (ea.. 3C4, 6A5, 7D4, 9A2, 1ID2 and 20C6), and those which precipitated two or more proteins (e.g., 12B2, 15A3, 15C4 and 19D6). [0172]
  • Immunofluorescence Assays with Purified Sporozoites [0173]
  • Sporozoites (1×10[0174] 5) were added to 8-chambered slides (Lab Tek) in PBS, pH 7.0. and air dried at 37° C. for 12 hours. The slides were blocked with 10% normal goat serum for 2 hours at 37° C. Diluted antiserum or hybridoma supernatant were added to each chamber and incubated for 2 hours at room temperature. The slides were washed, and a rhodamine-conjugated anti-mouse antibody (diluted in PBS, pH 7.0, 0.3% Triton X-100) was added for 1 hour at room temperature. After washing the slides, the bound antibody was visualized by fluorescence.
  • Most of the antibodies showed specific immunofluorescence either to the surface membrane and/or to the refractile body of air-dried sporozoites (FIG. 6, panels A and B). Some antibodies intensely stained the apical tip of the sporozoite and only lightly stained the remaining sporozoite surface (FIG. 6, panel C). A representation of the air-dried purified sporozoites can be seen in FIG. 6, left hand slides of panels A, B, C and D. The purified sporozoites were intact and elongated and showed the prominant large posterior refractile body (PRB) and the smaller anterior retractile body (ARB). The apical end (A) is of the sporozoite was opposite the posterior refractile body. There was also slight contamination of the preparations by intact sporocysts (panel B, left slide) and broken sporocyst membranes. [0175]
  • Summary of Elisa, Western Blot, Immunoprecipitation and Immunofluorescence Results [0176]
  • A summary of results from the above analyses of 55 monoclonal antibodies is shown in Table 2. [0177]
    TABLE 2
    SUMMARY OF MONOCLONAL ANTIBODY ANALYSES WESTERN BLOT
    E.
    E. tenella Low acervulina E. tenella Immuno-
    Antibody Spz.a Spz.b Spz.c Mz.d IFAe ppt.f
    3C4 M1 — 60-80
    11B6 M1 + + + 1, 2, 4 105
    12A5 M1 − − − 1 —
    14D4 M1 + + + 1, 3, 4 66
    15B6 M1 1, 4, 7 20-24
    17A5 M1 + + 1 150/83 
    18B6 M1 + + + — 25/20, 66/60
    19C6 M1 + + + 1, 2 25/20
    20A2 M1 + + + 5 66/60
    20B4 M1 + + + 1, 4 86/60
    11C4 M2 + − 1, 6 —
    12A3 M2 − − − 1, 4, 7 22/24
    13A6 M2 + + + 1, 5 110
    14B6 M2 1, 4, 7 105-120
    14D1 M2 — 120
    9B2 M3 + + + 5 66/45
    12B1 M3 + − − 6 26-28
    14C6 M3 − − − 105
    15C4 M3 + − − 6 105
    16D2 M3 — 60-80
    20C3 M3 + + + 3 14-17
    3A5 120 + + + 3 —
    6A4 120 — —
    7D1 120 + + 1, 2, 4 110
    7D4 120 + + 5, 1 110
    10A6 120 + − − 1, 2, 6 105
    11D2 120 − − − 4, 1, 2 105
    14A1 120 − − − 6, 1 110
    17B6 120 − − − 1, 6, 7 120
    17C6 120 − − 8, 1 105
    19D6 120 + − − 3 120
    20C6 120 + + + 1, 2 110
    10A5 >150 − − 7, 5 105
    11A6 >150 − − − 3 —
    7B2 >200 + — >200
    11B1  >150, 200 − − − 1, 7, 6 27
    11D4 120/24 + − − 1 27
    11D6 120/24 + − − 2 —
    12C3 120/24 + − − 1, 8, 2 25
    15B2 120/24 + + + 3 —
    15A3    90/10-14 + − − 1, 6   28/14-17
    14C3 60 − − − 1, 4 6
    14A5 120/6  − − − 1, 3, 6 6
    8A2 37 + + − 1, 4 37
    6A5 28, 10-14 + − − 1, 6 25-28
    11A1 24 + − − 1, 6 —
    11C1 24 + − − — —
    12B2 24 + − − 1, 5  24/120
    12C6 24 + − − — —
    16B1 24 + − − 1, 4   6/14-17
    18D5 24 + − − 1, 6   48/25/6
    20C4 24 1, 3   5/14-17
    14B1 <6 + − − 1, 6 20-24
    10A2 — − 1, 2, 4  6/105
    5B6 — 1, 6    6/17/15
  • Monoclonal antibodies 7D4, 7D1, 20C6, 8A2, 6A5 and 7B2, which are preferred, have been deposited with the American Type Culture Collection under the provisions of the Budapest Treaty and assigned accession Nos. HS 9707, HB 9708, HB 9709, HB 9710, HE 9711 and-HB-9712, respectively. [0178]
  • In Vitro Infection Assays [0179]
  • Primary chicken kidney epithelial cells were established according to the method of Doran et al., J. Protozool. 25:544 (1978) and grown to 40-50% confluency in 4-chambered Lab-Tek slides. MDBK (Hadin-Darby bovine kidney) cells (ATTC-CCL 22) were also used in place of the chicken kidney epithelial cells. [0180]
  • The cells were inoculated with 50,000 or 200,000 purified sporozoites. At 16 hours post-infection, the cell monolayers were washed several times to remove any sporozoites which had not penetrated the cells. [0181]
  • Representative inoculated cell cultures were fixed in 100% methanol (room temperature for 5 minutes) at 3, 16, 24, 48, 64, 96 and 120 hours post-infection Fixed slides were stored in 1% BSA in PBS. pH 7.0, at 4° C. until processed for immunofluorescence as described above. Staining patterns obtained with various antibodies are shown in FIG. 7. [0182]
  • Between 3 and 24 hours after infection, the fixed cultures revealed intracellular sporozoites (FIG. 7, 7D4 at 3 hours and 8A2 at 19 hours). At later times, the sporozoites degenerated to refractile bodies only (7D4, 60 hrs). The surface and apical tip of the intracellular sporozoites stained brightly with antibody 7D4 (FIG. 7, 7D4 at 3 hours). but this antibody did not stain the surface of the infected cells. [0183]
  • After 24 hours, the sporozoites began to degenerate and develop into schizonts that matured during the following 48 hours. Antibody 7D4 continued to react with the degenerating sporozoites but did not react with the immature schizonts (FIG. 7, 7D4, 60 hrs). As the schizonts matured, however. 7D4 began to react with structures within the schizonts (FIG. 7, 7D4, 100 hrs). These structures were the developing merozoites, and antibody 7D4 continued to react with a surface antigen of the mature and released merozoites (FIG. 7, 7D4. 120 hrs). [0184]
  • Thus, 7D4 identified a 120 kd membrane-antigen which was present on [0185] E. tenella sporozoites and merozoites. This antigen was not expressed during the schizont stage of parasite development until immature merozoites developed within the schizonts.
  • Antibody 14B1 showed a pattern of reactivity similar to that of antibody 7D4, staining the surface and tip of the intracellular sporozoites (FIG. 8. 14B1, 16 hrs) and showing diffuse staining of the cytoplasm in the immediate vicinity of the intracellular sporozoite. The antigen recognized by 14B1 is present on the apical tip of the immature merozoite within the mature schizont (FIG. 8, 14B1, 100 hrs) and the apical tip of the mature released merozoites (FIG. 8, 14B1, 120 hrs). The staining patterns exhibited by antibodies 7D4 and 14B1 are similar, but the proteins these antibodies recognize have very different molecular weights of about 120 and 6 kd, respectively. [0186]
  • Although antibodies 7D4 and 14B1 reacted with most stages of parasite development, other antibodies reacted only with surface antigens (FIG. 7, 15A3) or with the refractile body (FIG. 7, 7A2) of intracellular sporozoites and not with the schizont or merozoite stages of the parasite. [0187]
  • Two unique antibodies, 8A2 and 19D6, were identified by the infection assay. Antibody BA2 reacted with a 37 kd protein present on the surface of sporozoites (FIG. 7C, 8A2, 19 hrs). in all stages of the developing schizont (FIG. 7C. 8A2, 120 hrs) and on the surface of released merozoites (FIG. 7C, 8A2, 120 hrs). Unlike the proteins recognized by antibodies 7D4 and 14B1, the 37 kd protein was synthesized throughout the intracellular development of the parasite. [0188]
  • Antibody 19D6 reacted not only with a 180 kd sporozoite surface protein, but also with a protein in the cytoplasm of the sporozoite-infected cells (FIG. 8, 19D6 at 3 hours). The cytoplasmic protein recognized by antibody 19D6 might have been shed by the sporozoite after cell infection, since the protein disappeared during immature schizont development and reappeared in the mature schizont and in the released merozoites (FIG. 8B, 19D6, 120 hrs). [0189]
  • Serum antibodies from chickens which have survived an [0190] E. tenella infection stain the apical tip and surface of intracellular sporozoites (FIG. 8B, Immune Chick Sera, 3 hrs) in a pattern similar to the staining pattern of antibody 7D4, but not the refractile bodies of the intracellular sporozoite.
  • The immunofluorescence studies with sporozoite-infected chicken kidney cells identified antigens which were (a) specific to the sporozoite (e.g., the greater than 200 and 28 kd proteins recognized by antibodies 7B2 and 6A5, respectively), (b) found in all stages of the intracellular parasite (e.g., the 37 kd protein recognized by 8A2) and (c) specific to sporozoites and merozoites but not to the schizont (e.g., the 120 and 6 kd proteins recognized by antibodies 7D4 and 14B1, respectively). [0191]
  • In Vitro Sporozoite Neutralization Assays [0192]
  • In a modification of the method of Schmatz et al., J. Protozool. 33:109 (1986). MDBK cells were trypsinized and suspended in Minimal Essential Medium (Gibco) supplemented with 1% FBS at a density of 7.5×10[0193] 4 cells/ml. To each well of a microtiter plate (tissue culture treated 96-well), 1.5×104 cells were added and incubated for 48 hours at 40° C. Purified sporozoites were either pretreated with antibody for 1 hour at 40° C. or left untreated prior to infecting the cell monolayers. The antibodies (either tissue culture supernatants, ascites fluid or antiserum) were extensively dialyzed against PBS, pH 7.0, heat inactivated at 56° C. for 30 minutes and sterile filtered before use.
  • Immediately after infection, [5,6]-[0194] 3H-uracil was added to all wells to give a final level of 5 μCi/ml. At 19 hours post-infection, the medium was removed and the cultures were washed once with PBS. The cells are released with trypsin-EDTA for 15 minutes at 40° C. and harvested onto glass fiber filters. The filters were dried, placed in scintillation fluid (READY-SOLV®, New England Nuclear) and counted for bound radioactivity. The ability of the antibodies to inhibit sporozoite penetration and/or development was determined by the radioactivity incorporated into cells infected with untreated sporozoites, compared to cells infected with antibody-treated sporozoites.
  • Sporozoites were also preincubated with control antibodies, buffer or lasalocid, a coccidiostatic drug. Lasalo, i completely blocks sporozoite development within the MDBK cells and greatly reduces the incorporation of [0195] 3H-uracil.
  • The results are shown in FIG. 9, where it can be seen that antibodies 7D4 (□), 8A2 (∘) and 14B1 () significantly inhibited [0196] 3H-uridine incorporation into the infected MDBK cultures. Antibody 6A5 (▪) was less effective but showed some inhibition. Treatment with buffer (Δ) and control antibody (X) produced no inhibition, while lasalocid (*) produced essentially complete inhibition.
  • Construction of cDNA Expression Libraries [0197]
  • Preparation of Sporulating Oocysts [0198]
  • Ceca were removed from 3-week-old chicks (Hubbard Cross; Avian Services, Frenchtown, N.J.) 7 days after oral inoculation with 50.000 [0199] E. tenella (New Hampshire Strain; kindly supplied by Dr. R. Strout, University of New Hampshire) sporulated oocysts/bird and ground in a Waring blender with distilled water for 1 minute. The volume was adjusted to 1 liter with distilled water, and Pepsin (Sigma Chemical Co., St. Louis, Mo.) was added to 3 g/l. The pH was adjusted to 2.0 with concentrated HCl, and the mixture was incubated and stirred for 2 to 3 hours at 39° C. or until a single oocyst suspension was observed. After digestion, the pH was adjusted to 8.0 with 10 N NaOH, and 3 liters of distilled water were added. The mixture was allowed to settle overnight. The supernatant was then removed and the sediment was washed with water until the supernatant was clear. The oocysts were sporulated by bubbling air through the suspension in distilled water at room temperature. Sporulation was stopped after 24 hours for RNA preparation.
  • Isolation of Sporulating Oocyst mRNA [0200]
  • Total RNA was prepared by a modification of the guanidinium/cesium chloride method described by Maniatis et al., supra, page 196. The oocysts were washed with PBS (0.15 M NaCl, 20 mM sodium-phosphate, pH 7.9) and resuspended by gentle vortex mixing in 10 ml of a solution containing 5 M guanidinium isothiocyanante, 50 mM Tris-HCl, 10 mM ethylenediaminetetraacetic acid (EDTA), 0.5% Sarkosyl (sodium N-lauroyl sarcosine, Sigma Chemical Co.) and 0.1 M β-mercaptoethanol, pH 7.4, with 5 μl of Antifoam A (Union Carbide, Danbury, Conn.) or another antifoaming agent preferably added. The cell suspension was homogenized until good oocyst breakage was observed microscopically. [0201]
  • Insoluble cellular debris was removed by low speed centrifugation, and the homogenate was divided into 4 aliquots and layered onto 1.2 ml of 5.7 M CsCl, 0.1 M EDTA, pH 7.5, in 12-ml polycarbonate tubes. The tubes were centrifuged at 40,000 rpm in a Beckman SW 50.1 rotor for 17 hours at 15° C. The supernatant fluid was discarded, the walls of the tubes were dried, and the pellets were resuspended in 1.25 ml of 10 mM Tris-HCl, 1 mM EDTA, 1% sodium dodecyl sulfate (SDS), pH 7.5, with 200 μg/ml of Proteinase K (Boehringer-Mannheim). After incubation at 37° C. for 30 minutes, the solution was extracted 3 times with phenol. The RNA in the final aqueous phase was precipitated 3 times with ethanol and then dissolved in 1 ml of water. [0202]
  • Polyadenylated (poly(A)[0203] +] RNA was prepared by twice passing about 2 mg of total RNA over an oligo(dT)-cellulose column (Pharmacia Fine Chemicals) as described by Maniatis et al., supra, page 197. The poly(A)+ RNA was is precipitated twice with ethanol and dissolved in 200 μl of water. The yield was about 26 μg, as calculated from the optical density at 260 nm.
  • Preparation of Merozoites [0204]
  • Merozoites of [0205] E. tenella were harvested from the ceca of 50 infected chickens (3 week old Hubbard Cross; Avian Services, Frenchtown, N.J.) 5 days after infection with 50,000 of the above sporulated oocysts/bird. The ceca were removed and washed with phosphate buffered saline (PBS) for 15 minutes on a magnetic stirrer. The epithelial debris was partially removed by low speed centrifugation (50×g), and the crude merozoites were recovered by centrifugation at 2,000×g at 4° C. for 10 minutes. The pellet was resuspended in Lysing Buffer (8.29 g/l NH4Cl, 0.372 g/l Na2EDTA, 1.0 g/l KCO3, pH 7.6) and incubated on ice for 30 minutes. The merozoites were collected by centrifugation, washed once in PBS and passed over a column containing 1.0 g of spun nylon fiber (Scrub Nylon Fiber, Fenwall Laboratories, Deerfield, Ill.) in a separatory funnel. The merozoites were collected by centrifugation as before and frozen on dry ice for RNA isolation, or further purified in diethylaminoethyl cellulose (DEAE, Whatman DE52) for Western blot analysis.
  • For purification in DEAE cellulose, approximately 1×10[0206] 9 merozoites were applied in PBS to a 10-ml bed volumn column and eluted with PBS. The merozoites were recovered in the first 100 ml of flow-through, essentially free of red blood cells and other cellular debris.
  • Isolation of Merozoite mRNA [0207]
  • Frozen merozoite pellets containing 1×10[0208] 9 to 1×1010 organisms were thawed into 10 ml of TEL/SDS buffer (0.2 M Tris HCl, 0.1 M LiCl, 25 mM EDTA, 1% (w/v) sodium dodecyl sulfate (SDS), pH 8.8) containing 1 mM dithiothreitol (DTT) and 300 units of RNasin (Promega Biotec, Madison, Wis.) and homogenized with 10-12 strokes in a teflon-coated tissue homogenizer. Insoluble debris was separated by centrifugation in the cold at 3,000×g. The supernatant fluid was extracted twice with phenol:chloroform:isoamyl alcohol (24:24:1, v/v) which had been equilibrated with the TEL buffer.
  • The aqueous phase was digested with 100 μg/ml proteinase K at 37° C. for 30 minutes and reextracted with an equal volume of phenol:chloroform (1:1), and the nucleic acid was precipitated with two volumes of ethanol for 1 hour on dry ice, or overnight at −20° C. The pellet, after centrifugation at 10.000×g for one hour, was resuspended in TE (10 mM Tris, pH 7.5, 2 mM EDTA) and spun through a 4 ml CsCl cushion (5.7 M CsCl, 0.1 M EDTA) at 150,000×g for 20 hours at 15° C. The RNA pellet was reprecipitated from 0.2 M potassium acetate with 2.5 volumes of ethanol. This total RNA was passed once over oligo-dT cellulose to enrich for poly(A) RNA, as described by Maniatis, supra, page 197. A typical yield of 1.9 mg of total RNA from 5×10[0209] 9 merozoites contained approximately 20 μg of poly(A)+ RNA.
  • Synthesis of Oocyst and Merozoite cDNAs, and Insertion into Phage Vectors [0210]
  • Double-stranded cDNA was synthesized from 6 μg of the sporulating oocyst poly (A)[0211] +RNA as described by Gubler et al., Gene 25:263 (1983), using reverse transcriptase (BRL) to elongate from an oligo(dT) primer and RNase H (BRL) and E. coli DNA polymerase I (New England Biolabs) to synthesize the complementary strand. The double-stranded cDNA was then blunt-ended with T4 DNA polymerase (BRL), and Eco RI linkers (GGAATTCC, Collaborative Research) were added after treatment with EcoRI methylase (New England Biolabs), following the manufacturers' protocols.
  • After digesting the thus prepared cDNA with EcoRI, a library was prepared in λgtll (Stratagene Cloning Systems, San Diego, Calif.) as described by Huynh et al., in D. Glover (ed.), DNA Cloning Vol. I: A Practical Approach, 1985, IRL Press, Washington, D.C., pp. 49-78. The EcoRI cDNA fragments were ligated to EcoRI digested, dephosphorylated λgtll arms (Stratagene Cloning Systems), and the resulting DNA was packaged into phage with the Gigapack® kit (Stratagene Cloning Systems), following the manufacturer's protocol. [0212]
  • The resulting library was amplified by plating on Y1088 host cells (ATCC No. 37195). The percentage of recombinants was estimated from the ratio of blue to colorless plaques on X-gal plates (Maniatis, supra, page 24) in the presence of isopropyl thiogalactoside (IPTG, Sigma Chemical Co.) to be about 90%. [0213]
  • Double-stranded cDNA copies of the merozoite poly(A)[0214] +RNA were synthesized essentially as described above. The double-stranded cDNA used in the construction of the library contained from about 200 to 4,500 base pairs (bp), as judged by migration in denaturing gels [Bailey et al., Anal. Biochem, 70:75 (1976)].
  • The merozoite cDNA was methylated and ligated to EcoRI linkers as described above, except that CCGAATTCGG linkers (Collaborative Research) were used. Following digestion with EcoRI, the cDNAs were fractionated in Biogel A-50M to remove excess linker molecules and cDNAs smaller than approximately 300 bp, as described by Huynh et al., supra. [0215]
  • The cDNAs were ligated to λgtll arms, and the DNA was packaged into phage as described above. The resulting library, which contained about 50,000 phage, was amplified by plating on Y1088 host cells. Plaque analysis on X-gal plates in the presence of IPTG showed about 90% recombinants. [0216]
  • Immunological Screening of cDNA Libraries [0217]
  • The λgtll merozoite cDNA expression library was plated on Y1090 cells (ATCC No. 37197) at a density of about 10,000 plaques per 150 an plate. Six such plates were incubated for 3.5 hours at 42° C., overlayered with nitrocellulose filters previously soaked in 10 mM IPTG to induce the expression of the β-galactosidase fusion protein, and incubated for an additional 4-5 hours to overnight at 37° C. The filters were removed from the plates and subjected to several batchwise washes with TBS (20 mM Tris, pH 8.0, 0.15 M NaCl). Non-specific protein binding sites were blocked by incubation in 20% fetal calf serum (FCS) in TBS for 2-4 hours on a rotary shaker, at 4° C. [0218]
  • Ascites fluid for nine monoclonal antibodies known to react with merozoite antigens (designated 7D4, 7D1, 20C6, 13A6, 20C1, 11B6, 3A5, 13A1 and 15B2) was pooled, adjusted to 20% FCS and 0.15 M NaCl in a final volume of 100 ml and applied to each of the filters in petri dishes, two filters per dish. The filters were incubated with the primary monoclonal antibody pool at 4° C. overnight on a rotary shaker. Unbound antibody was removed by washing the filters 5-6 times with TBS at room temperature. Bound antibody was detected by incubating the filters with goat anti-mouse horseradish peroxidase (HPOD) conjugate (Boehringer-Mannheim), followed by color development using 3 mg/ml 4-chloro-1-naphthol (Bio Rad) and 0.018% H[0219] 2O2, as described by Hawkes et al., Anal. Biochem, 119:142 (1982).
  • Positive plaques identified in the initial high density screen were plaque-purified in a secondary screen using the same monoclonal antibody pool. Each positive was assigned to an individual monoclonal from the pool by plating the positives in multiple grid arrays, each of which was induced with IPTG, transferred to nitrocellulose and incubated with one of the monoclonals from the pool. One positive phage designated λm2-4 was identified which was recognized by three of the eight antibodies in the pool, antibodies 7D1, 7D4 and 20C6. [0220]
  • Similar methods were used to screen the sporulating oocyst cDNA library, except that a pool of monoclonal antibodies containing antibodies 6A5, 7B2, 15A3 and 20C6 was used for the initial screening; 7B2 15A3, 20C6 and 8A2 were used in a second screening; and 15A3, 7B2 and 20C6 were used in a third screening: and the incubation buffer contained in addition 0.05% Tween-20 [polyoxyethylene(20) sorbitan monolaurate]. In this way, plaques designated λS1-3, λS1-4 and λS1-7; λS2-1, λS2-4 and λ2-5; and λS3-1 which were recognized by monoclonal antibodies 6A5, 8A2 and 7B2, respectively, were identified in the oocyst cDNA library. DNA made from the phage producing protein that reacted with the 6A5 antibody was analyzed by digestion with EcoRI and electrophoresis in agarose gels (Maniatis et al., supra, page 150). Three different inserts having sizes of approximately 1150, 890 and 615 bp were thus found. [0221]
  • Expression of Eimeria Genes in [0222] E. coli
  • The 1.1 kb and 0.9 kb EcoRI DNA molecules from phages λS1-7 and λS1-3. respectively, were isolated and inserted into the EcoRI site of each of three variable reading frame expression vectors, pEV-vrf1, pEV-vrf2 and pEV-vrf3, constructed as described by Crowl et al., Gene 38:31 (1985). Plasmids containing the inserts in both possible orientations were transformed as described by Handel et al. [J. Mol. Biol. 53:159 (1970)] into [0223] E. coli strain MC1061 carrying the compatible plasmid pRK248cIts described by Bernard et al. [Methods in Enzymology 68:482 (1979)]. Strain MC1061 and plasmid pRK248cIts have been deposited with the American Type culture Collection and assigned accession Nos. ATCC 33766 and 53338, respectively.
  • The bacterial transformants were grown at 30° C. in M9 medium [Maniatis et al., supra, page 68] with 0.5% glucose and 0.5% Casamino acids and shifted to 42° C. at an O.D. (550 mμ) of 0.5 as described by Crowl et al., supra, to induce transcription at the λP[0224] L promoter. After incubating for 2-3 hours, 1-ml samples were taken, and the cells in the samples were collected by centrifugation. The cell pellets were treated as described by Crowl et al., supra, and the lysates were subjected to sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis as described by Laemmli, Nature 227:680 (1970). Following electrophoresis, the proteins in the gels were either stained with Coomassie brilliant blue or transferred to nitrocellulose membranes for Western blot analysis (Towbin et al., Proc. Natl. Acad. Sci. USA 76:4350 (1979); Burnetti, Anal. Biochem. 112:195 (1981)], using the 6A5 monoclonal antibody and goat anti-mouse HPOD conjugate for detection.
  • This analysis showed that the 0.9 kb cDNA molecule in one orientation in vector pEV-vrf1 produced a 20 kd protein that reacted with the 6A5 antibody. No expression was observed with the 1.1 kb molecule, probably because it contained 5′ noncoding sequences. To optimize the yield of this protein, various expression media were examined. It was found that the preferred medium contained per liter (±10%) 6.0 g KH[0225] 2PO4, 4.0 g K2HPO4, 5.0 g (NH4)2SO4, 3.5 g MgSO4-7H2O, 21.0 g Yeast Extract, 3.5 g Bacto Tryptone, 1.0 ml LB625 Antifoam, 25 g glucose, 70 mg Thiamine-HCl, 2.5 ml vitamin solution (GIBCO MEM (100×) Vitamin Solution] and 1.0 ml trace elements, LB625 Antifoam, a product of Union Carbide, is a linear polymer of ethylene and polypropylene-oxide having a viscosity of 625 Saybolt Universal Seconds at 37.9° C.
  • Vitamins per liter of fermentation broth included 0.25 mg each of D-Ca pantothenate, choline chloride, folic acid, nicotinimide, pyridoxal-HCl and additional thiamine-HCl; 0.50 mg of i-inositol: and 0.025 mg of riboflavin. Trace elements per liter of broth included 2.7 mg of FeCl[0226] 3-6H2O; 0.8 mg each of ZnS(O)4-7H2O and CuSO4-5H2O; 0.7 mg each of CoCl2-6H2O and Na2MoO4-2H2O; 0.2 mg of H3BO3; and 0.5 mg of MnSO4-H2O.
  • The nature of the immunoreactive protein expressed by phage λm2-4 was investigated first in a lysogen isolated from an infection of Y1090 cells by differential growth at the permissive (30° C.) and non-permissive (42° C.) temperatures. For Western blot analysis of the proteins synthesized by this lysogen, a 50 ml culture was grown at 30° C. in LB medium (Maniatis et al., supra, page 69] to an O.D. (550 mμ) of 0.5, and shifted to 42° C. to induce replication of the phage. After 15 minutes at 42° C., IPTG was added to 10 mM, and incubation was continued at 37° C. for 30 minutes. The cells were harvested by centrifugation at 4° C. and lysed by boiling for 5 minutes in Laemmli sample buffer (0.125 M Tris, pH 6.8. 1% (w/v) SDS, 1.4 M β-mercaptoethanol, 001% Bromophenol Blue (w/v), 20% (v/v) glycerol). [0227]
  • The equivalent of 1.0 ml of culture was resolved by electrophoresis in a 12.5% SDS-polyacrylanide gel, transferred electrophoretically to nitrocellulose and probed as described above with a pool of the three monoclonal antibodies (7D1, 7D4 and 20C6) which identified the λm2-4 phage. Development of the Western blot revealed a fusion protein of greater than 150 kd size which was present in the induced lysogen (FIG. 10, panel B, Lane 2). Antibody specific for β-galactosidase also reacted with this high molecular weight protein, and to a protein of approximately 114 kd, the expected size of β-galactosidase alone (see FIG. 10, panel A, lane 2). [0228]
  • The phage λm2-4 DNA was digested with EcoRI to produce a 1.7 kb DNA molecule. This molecule was subcloned into an EcoRI-linearized plasmid pool containing plasmids pEV-VRF1, 2 and 3 [Crowl et al. supra] and transformed into [0229] E. coli strain MC1061 containing plasmid pRK248cIts, as described above. Transformants were screened for expression of an immunoreactive protein upon temperature induction, using the pool of three monoclonal antibodies shown to react with the fusion protein in the λm2-4 lysogen. The immunoreactive recombinant protein was further characterized by Western blot analysis of the E. coli lysates, employing one of the three monoclonal antibodies, 7D4, from the pool. Each of the positive colonies was found to contain plasmid DNA with the expected 1.7 kb insert, and to direct the synthesis of a protein of approximately 65 kd upon induction, as determined by SDS-polyacrylamide gel electrophoretic analysis.
  • The expression of this 65 kd protein was found to be relatively insensitive to variations in growth medium and induction protocol. The protein was recovered quantitatively in the supernatant following sonic disruption of the cell pellet. [0230]
  • The expression plasmid containing the 1.7 kb insert was used in the subsequent production of recombinant protein and is shown schematically in FIG. 11. This plasmid was propagated in MC1061 host cells lysogenic for λcIS857 (prepared using standard methods for the generation of λ phage lysogens described by Arber et al., in Cold Spring Harbor Monograph, Lambda II, 1983, Hendrix et al., Eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, p. 450) at 30° C. to maintain the repressed state of the P[0231] L promoter in the plasmid.
  • Using similar methods, expression of a 28 kd protein encoded by a sporulating oocyst cDNA segment having about 1.1 kb was carried out. This protein bound specifically to monoclonal antibody 8A2. Expression of a 45 kd protein encoded by a sporulating oocyst cDNA of about 1.2 kb was also carried out. This protein bound specifically to monoclonal antibody 7B2. [0232]
  • DNA Sequence Analysis [0233]
  • In general, small scale isolation of plasmid DNA from 1 ml of saturated overnight cultures was carried out using the procedure of Birnboim et al. [Nucleic Acids Research 7:1513 (1979)]. This procedure allows the isolation of a small quantity of DNA from a bacterial colony for analytical purposes. Larger amounts of plasmid DNA were prepared using 1-liter cultures following a standard protocol with cesium chloride centrifugation. [Maniatis et al., supra, page 93]. [0234]
  • The DNA sequences of the cDNAs from the sporulating oocyst library were determined by the chemical cleavage method of Maxam et al., Methods in Enzymology 65:499 (1980) and by the chain-termination method of Sanger et al., Proc. Natl. Acad. Sci. USA 74:5463 (1977), as modified for double-stranded plasmid DNA by Smith et al., Cell 16:753 (1979) and Wallace et al., Gene 16:21 (1981). In the chain termination protocol, 7-deaza-dGTP [Barr et al., BioTechniques 4:428 (1986)] was substituted for dGTP to eliminate G-C compression artifacts. [0235]
  • To facilitate sequence analysis, the 1.1 kb EcoRI molecule from λS1-7 was transferred to plasmid pEV3-SEQ (FIG. 12), which has a polylinker next to the EcoRI site of pEV-vrf3. This polylinker was used to linearize the plasmid at the BamHI and KpnI sites to generate unidirectional deletions with exonuclease III [Henikoff, Gene 28:351 (1984)]. The XbaI site in the polylinker was used for 3′-end labeling for Maxam-Gilbert sequencing of the deletions, and the primer CGGTCGACTCGAGCCA was used for Sanger sequencing. This primer was [0236] 32P labeled at its 5′ end using [γ-32P]ATP (ICN) and polynucleotide kinase as described by Maniatis et al., supra, page 122.
  • FIG. 13 shows the restriction sites in the 1.1 kb EcoRI molecule used for Maxam-Gilbert sequencing. The position of the EcoRI sites in the 0.9 kb molecule are also shown, since these were also used. The end points of deletions made with exoIII are also shown. These were sequenced either from the XbaI site in the pEV3-SEQ polylinker by the Maxam-Gilbert method or with a primer extension (FIG. 12) by the Sanger method. Both stands of the entire cDNA were sequenced by one or both of these methods. Due to a high G-C content in the DNA, the Maxam-Gilbert reactions were usually fractionated in both 8% and 15% polyacrylamide-urea gels. [0237]
  • Primer extension was carried out by incubating 1.5 μg of poly(A)[0238] +RNA with 2 pmoles of the 5′-end labeled synthetic oligonucleotide primer, GAGGTCTGCCATTTTGC, for 60 minutes at 42° C. in 50 mM Tris-HCl, pH 8.0, 8 mM MgSO4, 0.1 M NaCl, 2 mM dithiothreitol, 2 mM of each deoxynucleotide triphosphate (dNTP, Pharmacia Fine Chemicals), 20 units RNasin (Promega Biotec, Madison, Wis.) and 20 units AMV reverse transcriptase (Pharmacia, Piscataway. N.J., FPLCpure). The products were analyzed in the 8% polyacrylamide-urea gels used for sequence analysis, with 32p-labeled HpaII digested PBR322 DNA as a molecular size marker.
  • For sequence analysis, the primary products were eluted from the gel and analyzed by the chemical cleavage method of Maxam et al., supra, or ddNTPs were used in the extension reaction [Tolan et al., J. Biol. Chem. 259:1127 (1984); Graves et al., J. Biol. Chem. 261:11409 (1986)]. The reactions were analyzed in 8% polyacrylamide-urea gels. [0239]
  • The nucleotide sequence of the 1.1 kb cDNA molecule is shown in FIG. 14. The sequence of the 0.9 kb molecule extends from base 188 to base 1082 within this larger molecule. The amino acid sequence predicted from open reading frame analysis of this nucleotide sequence is shown in FIG. 15. The correctness of the predicted amino acid sequence shown in FIG. 15 was confirmed as follows. [0240]
  • Synthetic polypeptides were prepared having amino acid sequences corresponding to residues 41-54 and 145-164 of FIG. 15. Rabbit antisera raised against both of these polypeptides were used in Western blot analysis of both total sporozoite proteins and a lysate of the [0241] E. coli transformant expressing the 0.9 kb cDNA. The antibodies against both of the polypeptides bound to proteins in both of the Western blots.
  • Using similar methods, the nucleotide sequence of the 1.7 kb insect encoding the 65 kd protein in phage λ2-4 was determined, with the results shown in FIG. 16 and [0242] 27. The predicted amino acid sequence of the protein encoded by this DNA sequence is shown in FIG. 17 and 28. This sequence was confirmed by amino acid sequence analysis performed on polypeptides produced by tryptic digestion of the expressed 65 kd protein, as described below. Regions in the overall amino acid sequence corresponding to some of these peptides are underlined in FIG. 17 and 28.
  • Curiously, the DNA sequence open reading frame for the 1.7 kb molecule would be expected to encode a protein of about 33.349 daltons. Yet, the expression product from this DNA fragment migrates in SDS gels with an apparent molecular weight of about 65 kd. The reason for this discrepancy between the predicted and observed protein size is unknown. This protein is referred to herein as the “65 kd” protein. [0243]
  • In a similar fashion, the nucleotide and predicted amino acid sequences of the cDNA molecule encoding the 28 kd protein recognized by monoclonal antibody [0244] 8A2 were determined, with the results shown in FIGS. 18 and 19, respectively.
  • The cDNA molecule encoding the 28 kD protein recognized by monoclonal antibody 8A2 has been resequenced using the standard sequencing techniques described above. The resulting sequence is provided in FIG. 29 and FIG. 30. The deduced amino acid sequence is provided in FIG. 31. Based on this amino acid sequence, the weight of the protein recognized by 8A2 is probably around 37 kD. The same sequence with the first three amino acids removed is provided in FIG. 32. These three amino acids were probably encoded by linker sequences described above and used in the cloning procedure described, and as such would therefore be artifacts and not part of the protein. Similarly, FIGS. 26, 27, [0245] 33, 34 represent sequences from-which linker code has been removed.
  • Similarly, the nucleotide and predicted amino acid sequence of the 1.2 kb 7B2 cDNA were determined. Since a continuous open reading frame was found and the protein isolated from sporozoites by immunoprecipitation is larger than 200 kd, the library was screened for larger cDNAs, using the 1.2 kb cDNA as a probe. A 3.2 kb cDNA was thus obtained, having the nucleotide and predicted amino acid sequences shown in FIGS. 20 and 21, [0246] 33 and 34.
  • Purification and Characterization of the 65 kd[0247]
  • PROTEIN [0248]
  • Protein Purification [0249]
  • High cell density fermentation of [0250] E. coli MC1061 (pRK248cIts) containing the pEV/2-4 expression plasmid was carried out in 10-liter fermenters in 1.5×M-9 medium, using standard protocols of temperature induction as described above after approximately 4 hours of growth at the permissive temperature. The cell mass was harvested 5 hours after induction, yielding 500 grams of cell paste.
  • Fifty grams of the [0251] E. coli cell paste were uniformly suspended in 500 ml of 10 mM Tris-HCl, 5 MM EDTA. pH 8.0, and stirred at 2°-8° C. for two hours. The suspension was passed through a Gaulin homogenizer (APV Gaulin, Everett, Mass.) two to three times at 7,000 psi. The cell lyeate was centrifuged at 24,000×g for one hour in a Sorvall RC-5 centrifuge, and the pellet was discarded. Solid ammonium sulfate was added to the supernatant (final concentration 80%). This was kept at 4° C. for two hours, and then centrifuged at 24,000×g for one hour. The pellet was dissolved in 20 mM potassium phosphate, pH 6.8. After centrifugation, the supernatant was dialyzed against 20 mM potassium phosphate, pH 6.8.
  • A Pharmacia glass column (5 cm diameter×10 cm length) was packed with NuGel P-[0252] DE 200® (200 Angstrom. 40-60 μm, weak anion exchange. Separation Industries, Metuchen, N.J.) silica support. The gel was equilibrated with 20 mM potassium phosphate, pH 6.8. The sample was loaded (10 ml/min), washed with equilibration buffer and eluted with 20 mM potassium phosphate containing 0.4 M NaCl, pH 6.8. The column fractions were analyzed by Western blotting with antibody 7D4 to detect the 65 kd protein.
  • An immunoaffinity column was used to further purify the 65 kd protein. The adsorbent for this column was prepared by immobilizing monoclonal antibody 7D4 on NuGel P-polyaldehyde® (500 Angstrom, 40-60 μm, Separation Industries, Metuchen N.J.) silica support. The immobilization procedure involved the following: 10 grams of polyaldehyde support were suspended and washed with 0.1 M potassium phosphate, 0.1 M NaCl, pH 6.8, and transferred quantitatively into an Ehrlenmeyer flask containing 20 ml of monoclonal antibody 7D4 at a protein concentration of 8 mg/ml. Sodium cyanoborohydride (4 mg) was then added to the suspension. The mixture was shaken gently at 4° C. for 16 hours. The gel was filtered and washed with 0.1 M potassium phosphate, 0.1 M NaCl, pH 6.8. Pooled filtrates were checked for unbound antibody. Binding density was 8 mg/g of support. Uncoupled activated sites were blocked by suspending the gel in 20 ml of 1 M ethanolamine, pH 7.5 Sodium cyanoborohydride (4 mg) was added to the suspension, which was then agitated at 4° C. for 16 hours. The gel was collected and washed thoroughly with cold coupling buffer. [0253]
  • To carry out the immunoaffinity chromatography, a column (1 cm×10 cm) was packed with the immobilized 7D4 antibody and equilibrated with cold phosphate buffered saline (PBS) containing 0.1% Triton x-100. A pool of fractions from the NuGel P-[0254] DE 200® column containing the 65 kd protein was diluted 2× with PBS containing 0.1% Triton X-100 and loaded onto the column at a flow rate of 10 ml/min. After loading, the gel was washed with PBS to remove unadsorbed material. The adsorbed immunoreactive material was eluted with 0.3 M acetic acid. 0.1 M NaCl, pH 2.7. buffer. The protein was then concentrated in an Amicon Stircella® apparatus using a YM 10 membrane.
  • The purity of the protein was determined by SDS polyacrylamide gel electrophoresis as described by Laemmli [Nature 227:680 (1970)]. The gel was stained with Coomassie blue. Western blot analysis was also carried out, using the 7D4 monoclonal antibody with goat anti-mouse horseradish peroxidase conjugate. The results are shown in FIG. 22. [0255] Lanes 2, 3, 4 and 5 contain purified protein from two preparations. Lanes 1 and-6 contain a mixture of molecular weight marker proteins having the molecular weights shown to the left and right of the figure. Ten micrograms of protein were run in each lane.
  • In FIG. 22, it can be seen that the purified protein migrated in the SDS gel as a major band having an apparent molecular weight of about 65 kd, with minor bands having higher and lower mobility. [0256]
  • Isoelectric Point Determination [0257]
  • Ten micrograms of the purified 65 kd protein were subjected to isoelectric focusing in a preformed isoelectric focusing gel obtained from LKB Instruments, Gaithersburg. Md. A mixture of standard proteins having known isoelectric points was run at the same time. The gel was run for about 2 hours at 50 mA, 1.500 V according to the manufacturer's instructions, using a 3.5-9.5 pH gradient. [0258]
  • Upon completion of electrofocusing, the gel was stained with Coomassie blue dye to detect the protein bands. The isoelectric point of the purified protein was then determined by measuring the position of the band within the pH gradient in relation to the positions of the protein standards. The isoelectric point of the protein thus determined was 4.6. [0259]
  • Amine Acid Composition Analysis [0260]
  • Amino acid composition analysis was carried out using post column reaction with fluorescamine as described by Pan et al., in Methods of Protein Microcharacterization, 1986, Shively, ed., The Humana Press, pp. 105-119. Samples containing 3 μg of the 65 kd protein were hydrolyzed in 6 N HCl containing 4% thioglycolic acid at 110° C. for 20 to 24 hours in vacuo, and 10% of the hydrolysate was used for analysis. Cysteine values were determined after performic acid oxidation. The results are shown in Table 3. [0261]
    TABLE 3
    AMINO ACID COMPOSITION ANALYSIS
    OF THE 65 KD PROTEIN
    AMINO ACID MOLE PERCENT
    Asp 6.06
    Thr 6.07
    Ser 7.27
    Glu 18.24
    Pro 5.35
    Gly 16.76
    Ala 11.71
    Cys 4.45
    Val 4.88
    Met 2.08
    Ile 2.17
    Leu 3.22
    Tyr 2.20
    Phe 2.13
    His 1.07
    Lys 2.72
    Arg 3.61
    Trp ND
  • N- and C-Terminal Sequence Analysis [0262]
  • Two hundred picomoles of the protein (as determined by amino acid composition analysis) were subjected to N-terminal analysis, using the method of Hewick et al.; J. Biol. Chem. 256:7990 (1981) and an Applied Biosystems model 470A sequencer (Applied Biosystems, Inc., Foster City, Calif.). The N-Terminal sequence thus determined was M-N-K-N-S-?-L-G-G-F-?-S-M-Q-E-S-P-P-P-. The identities of the amino acid residues at positions indicated by question marks are uncertain because the recovery of PTH-Cys was low, and cysteine residues might be involved in disulfide linkages [Hewick et al., J. Biol. Chem. 256:7990 (1981)]. [0263]
  • C-Terminal analysis was performed on 1200 picomoles of the 65 kd protein by time course carboxypeptidase Y digestion as described by Hayashi, Methods in Enzymology 47:84 (1977). Carboxypeptidase Y (Boehringer Mannheim, Indianapolis, Ind.) was used at a concentration of 0.8 μg/350 μl in 0.05 M sodium acetate buffer, pH 5.9, and sample aliquots were taken after 0, 2, 5, 10, 20 and 30 minutes for analysis. The sample aliquots were acidified with HCl to stop further reaction and then subjected to amino acid analysis as described above. This analysis showed that the amino acid sequence at the C-terminus is probably (Met, Trp)-Ala-Ser. Tryptophan was observed to increase simultaneously with the methionine, but Trp is difficult to quantify in the fluorescamine analyzer because it has a low reactivity with fluorescamine. Therefore, the relative positions of Trp and Met could not be determined with certainty by this analysis. [0264]
  • Tryptic Peptide Analysis [0265]
  • In part to verify the amino acid sequence predicted from the nucleotide sequence of the cDNA encoding the 65 kd protein, some of the protein was digested with trypsin (Cooper Biomedical, Philadelphia, Pa.) and the resulting peptides were sequenced as described below. [0266]
  • Tryptic digestions were carried out overnight at 37° C. on 148 μg of protein in 0.2 M ammonium bicarbonate, [0267] pH 8, using an enzyme-to-substrate ratio of 1:30 (weight or molar basis?). Peptides thus generated were separated in a Waters HPLC system using an Altex ultrasphere 250×4.6 mm C-18 column (Beckman Instruments, Fullerton, Calif.) with a 0 to 55% gradient of increasing acetonitrile in 0.1% (basis) trifluoroacetic acid. Prior to the HPLC separation, the digest was reduced with β-mercaptoethanol for 30 minutes at 37° C. to break any disulfide bonds in the peptides. Column effluent was monitored at 215 mμ using a laboratory Data Control detector (Laboratory Data Control, Rivera Beach, Fla.). The HPLC column resolved 8 major peaks, as shown in FIG. 23A.
  • Each peak was first analyzed by amino acid analysis as described above to determine both the quantity and the composition of the peptides. Then, most of the peptide peaks from the HPLC column were sequenced by automated Edman degradation, using an Applied Biosystems Model 470A gas phase sequencer. Phenylthiohydantoin (PTH) amino acid derivatives were identified in a Waters HPLC system using an Altex ultrasphere C-18 column as described by Hawke et al. [Anal. Biochem. 120:302 (1982)], or in an Applied Biosystems Model 120A on-line PTH amino acid analyzer. [0268]
  • The amino acid sequences of some of these peptides are shown under the underlined regions of FIG. 17. The number of each of these peptides (corresponding to the HPLC peak numbers) is shown circled beside the corresponding sequence. Uncertainly in the identity of some of the residues in the peptide sequences is indicated by a question mark at those positions, although the amino acid composition analyses of the peptides showed that the amino acids indicated in the corresponding positions of the predicted sequence were present in the peptides. The uncertainly in the identity of some of the peptide residues was due to the low reactivity of tryptophan with fluorescamine. [0269]
  • [0270] Peptide 6, which corresponds to the N-terminus of the complete 65 kd protein, contains 4 residues at its N-terminus which are encoded by nucleotides in the expression plasmid. Analysis of peptide 8 produced an amino acid sequence similar to that of peptide 3 but lacking the 4 C-terminal residues, suggesting that it was probably the result of incomplete tryptic digestion. Peptide 5 was not sequenced, because amino acid composition analysis of this peptide showed that it was the same as peptide 6, less the first 3 amino acid residues at the N-terminus.
  • HPLC analysis of the tryptic digest carried out as described above but without prior mercaptoethanol reduction produced an elution profile in which peaks 4, 7 and 8 were absent (FIG. 23 B). This observation suggests that these cysteine-containing peptides were probably involved in disulfide bond formation in the unreduced protein. [0271]
  • Poultry Immunization [0272]
  • Use of the 65 Kd Antigen [0273]
  • To determine whether administration of the purified recombinant 65 kd protein could protect chickens against challenge by [0274] Eimeria tenella sporulated oocysts, a series of immunization experiments was performed. In these experiments, one day to three week old Leghorn chickens (Avian Services, Frenchtown, N.J.) were maintained in a clean room and cared for by attendants who did not have contact with other birds up to the time of challenge. The birds were kept in electrically heated brooder cages until they were 3 or 4 weeks old, after which they were transferred to grow-out cages.
  • Non-medicated broiler starter feed and water were supplied ad libitum throughout the experiments. At the time of challenge with oocysts, the birds were transferred to another building where they were kept until the end of the experiments. The clinical-conditions of the animals were checked at least three times weekly before immunization and on a daily basis after immunization. The birds were individually identified by means of wing bands at 3 or 4 weeks of age before random assignment into various test groups. [0275]
  • Various lots of the 65 kd protein purified by immunoaffinity chromatography as described above were used as the immunogen. These lots of immunogen contained bacterial endotoxin activity ranging from about 0.3 to about 50 endotoxin units per μg of protein, with activity determined and defined as described in the United States Pharmacopeia, 21st Revision, 1985, United States Pharmacopeial Convention. Inc., Rockville, Md., pp. 1165-1167. The protein was dissolved in 0.02 M K[0276] 2HPO4 buffer, pH 6.8, before use and diluted with the same buffer as required.
  • Bovine serum albumin (BSA, Pentex) was used as a control. Because pyrogenic activity was present in the immunogen used, approximately equal amounts of such activity were added to all BSA controls, to account for any nonspecific effects that might be due to this activity. This pyrogenic activity was added to the BSA in the form of an untransformed [0277] E. coli lysate which was prepared by disrupting E. coli by sonication and then filtering the material through a 0.45μ Millipore filter.
  • Diluted samples of control BSA or the Eimeria antigen were combined with an equal volume of adjuvants and mixed thoroughly in glass syringes fitted with 18 gauge needles prior to administration. Freund's complete and incomplete adjuvant were used for primary and booster immunizations, respectively. Both adjuvants were obtained from GIBCO, Grand Island, N.Y. [0278]
  • Primary immunizations were made subcutaneously on the posterior portion of the body at the base of the neck, when the birds were 4 weeks old. Some birds also received booster immunizations at 6 weeks of age. The volume of injected material ranged from about 0.4 to 2.4 ml. For the larger volumes, the dose was divided between 2 injections. Two or three weeks after the last vaccination, birds were challenged with 25,000 or 50,000 sporulated oocysts of [0279] E. tenella, administered orally. Seven days post infection, the surviving birds were sacrificed, necropsied and scored for gross lesions. All birds that died during the experiments were also necropsied. Diagnoses were made, and the intestinal lesions were scored as 0=normal, 1=slight infestation, 2=moderate infestation, 3=severe infestation and 4=death. The readings obtained were summarized as the average degree of infection for each group of birds. The birds were also weighed at the time of infection and 7 days post infection. Some birds were not vaccinated with BSA or coccidial antigen but were treated as infected or uninfected, unvaccinated controls.
  • The results of two such experiments are shown in Table 4. [0280]
    TABLE 4
    EFFECT OF SUBCUTANEOUS IMMUNIZATION OF
    CHICKS GIVEN ONE OR TWO VACCINATIONS WITH
    PURIFIED RECOMBINANT 65 KD ANTIGEN
    Weight
    Dose (μg) at Age Lesion Gain/Lossc
    No. Birds Treatment a 4 Weeks 6 Weeks Scoreb (grams)
    Experiment 1
    10 IUC — — 2.8 −25
    8 Antigen 3.15 — 2.4 −44
    10 Antigen 12.25 — 2.5 −10
    6 BSA 17.5 — 3.0 +40
    10 UUC — — 0 +107
    10 IUC — — 2.9 −40
    8 Antigen 3.15 1.6 2.0e −15
    10 Antigen 17.5 13.2 1.8e +5
    8 BSA 12.25 13.2 2.5 −13
    10 UUC — — 0 +87
    Experiment 2
    8d IUC — — 2.6 −11
    10 Antigen 4 — 2.2 +65
    10 Antigen 20 — 2.0 +19
    9 Antigen 100 — 2.9 +14
    10 BSA 100 — 2.4 −7
    10 IUC — — 2.5 +15
    10 Antigen 4 4 2.1 +35
    10 Antigen 20 20 2.0 +74
    8 Antigen 100 100 2.1 +81
    10 BSA 100 100 2.4 +69
    4 UUC — — 0 −3
    # birds. Infected unimmunized controls were maintained for each experiment and given identical numbers of sporulated oocysts at the same age, seven days prior to sacrifice. Results are based on a score of 0-4, as described in the text.
  • The data of Table 4 show that vaccination with the 65 kd protein generally produced numerically lower lesion scores, compared to infected but unimmunized controls. Two groups of birds given booster vaccinations in Experiment 1 (denoted by superscript e in the Table) showed reduced lesion scores that were statistically significant. In other cases, the degree of reduction in lesion scores was not as great, but weight gain was nevertheless generally improved in the vaccinated birds. [0281]
  • To determine whether a third vaccination would further enhance protection, an experiment was carried out in which groups of 8 birds were treated as infected or uninfected, unvaccinated controls or vaccinated with BSA or the merozoite protein at 3 and 5 weeks of age or at 3, 5 and 7 weeks of age. The first two vaccinations were made with Freund's complete adjuvant. Where a third vaccination was given, it was given with Freund's incomplete adjuvant. Inoculations were given subcutaneously as described above. [0282]
  • Two weeks after the last vaccination, each bird was challenged with 25,000 sporulated oocysts of [0283] E. tenella by the oral route. Body weights were measured at the time of challenge and 7 days thereafter, at which time the birds were sacrificed and cecal lesions were scored. The results are shown in Table 5.
    TABLE 5
    EFFECT OF SUBCUTANEOUS IMMUNIZATION OF
    CHICKS GIVEN TWO OR THREE VACCINATIONS
    WITH PURIFIED RECOMBINANT 65 KD ANTIGEN
    Weight
    Gain/
    Treat- Dose (mg) at Age Lesion Lossc
    menta 3 Weeks 5 Weeks 7 Weeks Scoreb (grams)
    IUC — — — 2.13 +59
    Antigen 4 4 — 1.75 +122
    Antigen 4 4 — 2.88 +128
    Antigen 20 20 — 1.88 +87
    Antigen 20 20 — 1.88 +69
    BSA 20 20 — 3.13 +106
    BSA 20 20 — 2.38 +131
    UUC — — — 0 +131
    IUC — — — 2.25 +23
    Antigen 4 4 4 2.25 +91
    Antigen 20 20 20 2.25 +86
    BSA 20 20 20 1.75 +78
  • The data in Table 5 show that immunity was not improved by administering a third vaccination. Greater protection, as shown by reduced cecal lesion scores, was conferred by the antigen, compared to untreated infected controls or birds vaccinated with BSA. [0284]
  • To determine whether routes of administration other than subcutaneous injection might produce better results, two dosage levels of the 65 kd protein were administered three times, two weeks apart, to groups of 8 3-week-old Leghorn chicks, using intradermal, subcutaneous, intramuscular, oral and anal routes of administration. Two weeks after the last immunogen administration, the birds were challenged with 25,000 sporulated oocysts of [0285] Eimeria tenella given orally. The birds were sacrificed one week after challenge, and cecal lesion scores were determined.
  • Subcutaneous injections were administered as described above. Intramuscular injections were made deeply into the exterior side of the left thigh. Intradermal injections were administered into the anterior side of the right wing. Oral administration was delivered using a 5 cm long 18 gauge ball-tipped needle, depositing the inoculum into the crop of the bird. Anal administration was made using a 5 cm long 18 gauge olive-tipped needle, introduced to its maximum length into the cloacal opening. After oral and anal administration, the birds were held in standing and inverted positions, respectively, for several minutes, to avoid possible expulsion of the inoculum. [0286]
  • The subcutaneous dosage form was as described above, with Freund's complete adjuvant used for the primary injection and Freund's incomplete adjuvant used for the booster injections. Dosage forms for the other routes of administration contained protein at the indicated levels in 0.02 M K[0287] 2HPO4 buffer, pH 6.8.
  • The results of this experiment are shown in Table 6. [0288]
    TABLE 6
    EFFECT OF VARIOUS ROUTES OF ADMINISTRATION
    ON CHICK VACCINATION WITH THE 65 KD ANTIGEN
    Weight
    Gain/
    Treatment/ Dose (μg) at Age Lesion Lossc
    Routea 3 weeks 5 Weeks 7 Weeks Scoreb (grams)
    IUC — — — 2.9 +58
    Antigen/SC 5 5 5 2.3 +66
    Antigen/SC 25 25 25 2.8 +68
    BSA/SC 25 25 25 2.8 +47
    Antigen/IM 5 5 5 2.3 +33
    Antigen/IM 25 25 25 2.3 +72
    Antigen/A 5 5 5 2.5 +53
    Antigen/A 25 25 25 2.6 +50
    Antigen/O 5 5 5 1.8d +67
    Antigen/O 25 25 25 2.5 +87
    Antigen/ID 5 5 5 2.1 +26
    Antigen/ID 25 25 25 1.9d +114
    UUC — — — 0 +114
  • Table 6 shows that the lowest cecal lesion scores were observed in birds immunized with 5 μg of antigen by the oral route and with 25 μg of antigen by the intradermal route. These results were statistically significant. Numerically lower lesion scores were seen for other routes of administration and other dosage levels, indicating a protective trend. The differences between these scores and those of the IUC birds, however, were not statistically significant. [0289]
  • Failure to observe linear dose responses in the foregoing experiments may have been due to differences in trace contaminants and/or pyrogenic content in the 65 kd antigen preparations, or to other factors. [0290]
  • Vaccinia Vector Vaccination [0291]
  • To produce a more effective means of immunizing chicks with the [0292] E. tenella antigens of this invention, the 1.1 kb cDNA encoding the 20 kd protein recognized by monoclonal antibody 6A5 (FIG. 14) and the 1.1 kb cDNA molecule encoding the 28 kd protein recognized by monoclonal antibody 8A2 (FIG. 29) were cloned into vaccinia virus and used to vaccinate chicks, as described below.
  • Vector Preparation [0293]
  • All recombinants made were based on homologous recombination into the viral thymidine kinase (TK) locus as described by Mackett et al. [Proc. Natl. Acad. Sci. USA 79:7415 (1982)]. The TK locus has been mapped to the vaccinia virus (VV) HindIII J fragment [Hruby et al., J. Virol. 43:403 (1982)], and part of this fragment has been sequenced [Weir et al., J. Virol. 46:530 (1983)]. [0294]
  • To construct a vector for recombination, the VV HindIII J fragment was subcloned into pUCB (FIG. 24[0295] a). This construct was cleaved with HpaII. The fragments were treated with E. coli DNA polymerase Klenow fragment (Klenow) and recleaved with HindIII, and the piece containing the viral TK gene was isolated from low melting agarose. The isolated fragment was ligated into the HindIII and blunt ended (S1 treatment) EcoRI site of a pUC8 vector (FIG. 24b, right). Subsequently, the HindIII site was eliminated by treating the HindIII digested DNA with Klenow and religating the vector fragment. For the insertion of the VV promoter (designated the 7.5K promoter), the vector was cleaved by ClaI and EcoRI.
  • The VV 7.5K promoter is located in one of the smallest SalI fragments of the virus [Venkatesan et al., Cell 25:805 (1981)]. The corresponding fragment was cloned into M13mp8. A clone was selected in which the direction of transcription was toward the EcoRI site of M13mp8 (FIG. 24[0296] a, left). The DNA was cleaved with ScaI and SmaI, BqlII linkers were added and the DNA was religated (FIG. 24b). The EcoRI-AccI fragment containing the viral promoter segment was isolated from the M13 construct and ligated into the pUC8-TK fragment described above. This new vector was digested with BqlII and EcoRI.
  • To create a vector with multiple cloning sites, an appropriate polylinker was included in the above construct. For this purpose the polylinker contained in the M13tg131 (Amersham) was chosen (FIG. 24[0297] d). The polylinker fragment was isolated by digesting the phage DNA with BalII and EcoRI, and the fragment was inserted into the pUC8-TK-7.5K construct, resulting in the final basic vector for recombination of foreign antigens into VV (FIG. 24c).
  • The EcoRI fragment coding for the 28 kd protein which binds to monoclonal antibody 8A2 does not contain the sequence for the N-terminal part of the protein. The original start codon and the leader sequence for the protein are missing. [0298]
  • To compensate for these missing regions, two different constructs were made and tested for expression. In the first construct, an in-frame start codon was generated by deleting part of the polylinker in the recombination vector. The vector was digested with EcoRV and SmaI, deleting part of the polylinker (FIG. 24[0299] d), and then religated. By this manipulation, the ATG codon contained in the SphI restriction site was placed in the correct reading frame for the coding region of the oocyst protein on the EcoRI fragment. The successful manipulation was confirmed by sequencing the new polylinker fragment.
  • To compensate in the DNA sequence not only for the start codon but also for the missing leader sequence, the EcoRI fragment was placed in the correct reading frame behind a leader sequence of a malarial antigen. The malarial antigen used to isolate the leader sequence was the 190 kd protein described as Ro-33 [Certa et al., EMBO J. 6:4137 (1987)]. It must be noted, however, that other leader sequences such as coccidial leader sequences could be used for the same purpose. [0300]
  • To isolate the DNA fragment containing the leader sequence, the Ro-33 DNA was digested with DraI. The fragment containing the recognition sites for the restriction enzymes PvuII and HindIII was isolated and digested with HindIII. The original vector construct (FIG. 10[0301] c) was cleaved with SalI, treated with Klenow and then digested with HindIII. In this vector fragment, the isolated DraI-HindIII malarial antigen leader fragment was cloned. This construct was used to express a fusion protein between the F. falciparum 190 kd protein and the E. tenella antigen recognized by antibody 8A2 and encoded by the EcoRI fragment.
  • The EcoRI fragment encoding the 28 kd protein was cloned into the EcoRI site of the polylinker contained in the basic vector (FIG. 24[0302] c). Constructs containing the fragment in the correct orientation were propagated and used for recombination into the vaccinia virus.
  • Because of the way that the initiation site for translation of the fragment was engineered into the basic vector (see above), two different N-terminal sequences were expected for the gene to be expressed by the recombinant vaccinia virus (FIG. 25). While only 3 additional amino acids (Met, Arg, and Trp) are added to the original sequence in the first construct (FIG. 25A), in the second a total of 47 amino acids are fused to the N-terminus of the polypeptide (FIG. 25B). By processing at the potential cleavage site of the leader sequence, 19 of the additional amino acids are removed, leading to a maturated protein starting with Val, Thr, His. [0303]
  • The EcoRI fragment coding for the 20 kd protein recognized by monoclonal antibody 6A5 contains the entire sequence. This fragment, without further manipulation, was cloned into the EcoRI site of the VV vector as described above. [0304]
  • Recombination of the above genes coding for coccidial antigens into a strain WR vaccinia virus was carried out using a two-step procedure for selection of the recombinant virus. [0305]
  • In the first step, CV1 monkey cells were grown in medium I [Eagle's Minimal Essential Medium (MEM), 5% fetal calf serum (FCS: from Amimed), Penicillin/Streptomycin (100 units/ml and 100 μg/ml, respectively) and 2 mM glutamine; all reagents from Gibco] in a cm culture plates to 80-90% confluency. The medium was removed and replaced with 0.2 ml of a virus suspension containing the temperature sensitive vaccinia virus strain ts N7 (Drillen et al., Virology 131:385 (1983)] at 0.1 plaque forming units (pfu)/cell. The plates were left at room temperature for 1 hour, after which 2 ml of Medium I were added to each plate and the plates were incubated for 2 hours at 33° C. (the growth permissive temperature for this virus) in a CO[0306] 2 incubator (Kieny et al., Nature 312:163 (1984)].
  • One half hour before the end of the above incubation period, a DNA-containing calcium-phosphate precipitate was prepared. This contained HEBS buffer (280 mM NaCl, 1.5 mM sodium-hydrogen-phosphate, 50 mM HEPES], 200 ng of purified vaccinia strain WR virus DNA and 200 ng of purified coccidial antigen-gene containing plasmid DNA, in a total volume of 0.55 ml. Each DNA was added in 1 μl of TE-buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA). To this solution was added, drop-wise and with gentle swirling, 0.55 ml of a 250 mM calcium-chloride solution. This mixture was left at room temperature for 20 minutes. [0307]
  • After the 2 hour incubation, the medium from the culture plates was aspirated and replaced with 0.25 ml of the above DNA-containing calcium precipitate and left at room temperature for one hour. Subsequently, 2 ml of Medium I was added to each plate, and the plates were incubated for 2 hours at 39.5° C. in a 5% CO[0308] 2 incubator (Kieny et al., supra). At this temperature, the ts N7 virus cannot replicate, resulting in a selection for viruses which have recombined at least in the ts7 locus. Because the calcium-phosphate is eventually inhibitory to cell growth, the medium was removed after the above 2 hour incubation, and the cells were washed 3 times with 1 ml of PBS under gentle swirling. The final PBS solution was aspirated, and 2 ml of Medium I were added to each plate. Incubation at 39.5° C. in a CO2 incubator was continued for 2 days.
  • After the two-day incubation, the culture plates with the medium and cells were placed at −30° C. for a short time and then thawed, the still attached cells were scraped from the bottom of the plate and the suspension was sonicated as described above. This homogenate was used for the second selection step. [0309]
  • In this step, medium from a nearly confluent lawn of human 143B TK cells (ATCC CRL 8303) growing in 8 cm[0310] 2 culture plates was removed and replaced with 0.2 ml of undiluted homogenate or homogenate diluted 1:5 or 1.30 (vol/vol) with PBS. Infection of the TK− cells was allowed to proceed at room temperature for 1 hour.
  • After the incubation, 2 ml of semi-solid Medium II (Medium I with NEAA, vitamins (explain) and 1% agarose) containing 0.1 mg/ml bromodeoxyuridine (BUdR, Sigman Chemical Co. were added to the cells. The plates were then incubated for 16-24 hours at 37° C. in a CO[0311] 2 incubator. A second layer of semi-solid Medium II, containing 0.2% neutral red in addition to the above components, was placed over-the cells and the plates were incubated for another 16-24 hours. Colorless plaques appeared which were clearly visible, and the virus was recovered as individual clones by piercing the plaque region with a Pasteur pipette (plaque purification). Virus recovered in this way was grown on Cv1 cells as described above and subjected to a second and third round of plaque purification on 143B TK− cells. These plaque-purified viruses were grown and purified as described above.
  • To test for the expression of the coccidial antigen by the recombinant virus, CV1 cells infected with recombinant virus were sedimented in a table-top centrifuge (Hettich Mikrorapid K, 100% for 3 minutes at 20° C.), and the pellet was washed twice with PBS, recentrifuged and resuspended in PBS. The cell suspension was applied to a glass microscope slide (Flow) and allowed to dry. A second method consisted of growing the CV1 cells directly on microscope slides (Miles Lab-Tek 4808), infecting the cells with virus and incubating for 1-2 days. The cells were then washed free of growth medium with PBS and allowed to dry on the slides at room temperature. To fix the cells, the slides were submerged in acetone for at least one hour at −30° C. and allowed to dry at room temperature. [0312]
  • Mouse anti-coccidial antigen monoclonal antibodies diluted in PBS were layered onto the microscope slides so that the cells were evenly covered with liquid. The slides were placed in a humid chamber at 37° C. for one hour and subsequently washed several times with PBS. Without allowing the slides to dry, a second antibody (FITC labeled goat anti-mouse IgG. Nordic) also diluted in PBS was layered onto the slides, and the slides were placed in a humid chamber at 37° C. for one hour to allow the antibodies to react. After several washes with PBS, the slides were allowed to dry completely. A few drops of 20% (vol/vol) glycerine in water were pipetted onto the slide, and a cover glass (Menzel 24×60) was placed on top. The fluorescence of the cell preparation was then monitored under UV light in a microscope (Zeiss ICM 405, F10 or Planapo 63 objective). [0313]
  • The WR strain virus can multiply in almost all cell types [Drillen et al., J. Virology 28:843 (1978)], and its multiplication can be observed directly through the formation of plaques. In most cases, however, chicken embryo fibroblast (CEF) cells were used to prepare large stocks of the virus. [0314]
  • To obtain CEF cells, 11-day old embryos were isolated from eggs, freed from their extremities, cut into small pieces and resuspended in a 0.25% trypsin solution (Difco) for 2 hours at room temperature. This suspension was diluted with one volume of Medium I and filtered through a cell sieve (Bellco, 150 mesh), and the cells were sedimented (Hermie table-top centrifuge, 5 minutes, 2,000 rpm, room temperature). The cell pellet was resuspended in ¼ of the original volume of Medium I and this CEF cell suspension inoculated into cell culture plates. Depending on the starting cell density, the cultures were allowed to grow 1-2 days and used for infection directly or after 1-2 further passages. A synopsis for the establishment of such primary cultures can be found in Frehney, Culture of Animal Cells, Alan R. Liss Verlag, New York 1983, [0315] Chapter 11, p. 99.
  • For infection, the medium was removed from 80-90% confluent CEF cells growing in 175 cm culture flasks (Falcon 3028), and the cells were incubated in a PBS solution containing virus (0.1 pfu/cell, 0.01 ml/cm [0316] 2) for one hour at room temperature (20° C.) (PBS/Dulbecco, Amimed). Medium I was then added (0.2 ml/cm2), and the flasks were incubated at 37° C. for 2-3 days until about 80% of the cells had lysed. The resulting stock solution was stored directly with cells and medium in the original culture flasks at −30° C. before virus purification. The purification steps for obtaining a virus preparation free of all host cell specific components were identical for both MVA and WR virus strains. Infected cell cultures which had been stored at −30° C. were thawed and the remaining cells were freed from the surface of the flask by shaking or scraping. The cells and virus were centrifuged out of the medium (Sorvall centrifuge, GSA rotor, 1 hour at 5,000 rpm, 10° C.). The pellet of cells and virus particles was resuspended in PBS (10-20×the volume of the pellet) and recentrifuged as above. This pellet was then resuspended in a 10-fold volume of RSB buffer (10 mM Tris-HCl, pH 8.0, 10 mM KCl, 1 mM MgCl2).
  • To lyse the remaining intact cells and free the virus from the cell membranes, the above suspension was subjected to sonification (twice, 10 seconds at 60 watts, room temperature, [0317] Labsonic 1510 with 4 mm probe). The mixture was then centrifuged in a Sorval GSA rotor for 3 minutes at 3,000 rpm, 10° C. A virus suspension free from cell nuclei and large cell debris was thus produced. The supernatant was carefully removed, and the pellet was resuspended in RSB buffer, resonicated and centrifuged as above.
  • The second supernatant was combined with the first, layered onto a 10 ml 35% sucrose cushion (Fluka, in 10 mM Tirs-HCl, pH 8.0) and centrifuged for 90 minutes at 14,000 rpm in a Kontron TST 28.38/17 rotor (Beckman SW 27 analog) at 10° C. The supernatant was decanted and the pellet of virus particles was resuspended in 10 ml of 10 mM Tris-HCl, pH 8.0. sonicated to homogenize the mixture (2 times for 10 seconds at room temperature as described above) and loaded onto a step gradient for further purification. [0318]
  • The step gradient consisted of 5 ml aliquots of sucrose in 10 mM Tris-HCl, pH 8.0, of the following concentrations: 20%, 25%, 30%, 35% and 40%. This gradient was centrifuged in a Kontron TST 28.38/17 rotor for 35 minutes at 14,000 rpm, 10° C. Several bands containing virus particles were visible in the 30%-40% sucrose region. This region of the gradient was removed (10 ml), the sucrose solution was diluted with PBS (20 ml) and the virus particles were sedimented (Kontron rotor, 90 minutes at 14,000 rpm, 10° C.). The pellet contained almost exclusively virus particles (as judged by comparison of OD measurement and plaque assay, see below). This pellet was resuspended in PBS so that the virus concentration was on the average 1-5×10[0319] 9 pfu/ml. This virus stock was used either directly or diluted with PBS.
  • To determine the virus concentration and the purity of the virus stock, two methods were used. The absolute concentration of virus particles was conveniently obtained by measuring the optical density (OD) of the stock solution in a spectrophotometer (Uvikon 860) at 260 nm (OD/260). where 1 OD/260 equals about 1.2×10[0320] 10 particles per ml [Joklik, Virology 18:9 (1962)]. Virus concentration was also obtained by titrating the virus on cells (plaque assay), assuming that only one out of 60 virus particles can infect a cell.
  • To titer the virus concentration on cultured cells. CEF cells were grown in Medium I on 8 cm[0321] 2 plastic culture plates (Falcon 3001). When the cells had reached 80-90% confluency, the medium was removed, replaced with 0.2 ml of a diluted virus solution in PBS, and left at room temperature for 1 hour. The virus stock solution was diluted in 10-fold steps. After the room temperature incubation, 2 ml of semi-solid Medium I (Medium I+1% agarose) were added to each plate, and the plates were placed for 16-24 hours in a CO2 incubator. Subsequently, 2 ml of semi-solid Medium I containing 0.2% neutral red (Fluka 72210) was layered on to stain the living cells, and the plates were incubated for an additional 16-24 hours. The colorless plaques were then counted under a microscope.
  • Chick Immunization [0322]
  • To determine whether vaccinia viral vectors harboring genes coding for the [0323] E. tenella proteins which specifically bound to monoclonal antibodies 8A2 and 6A5 could protect chicks against challenge by sporulated oocysts of a pathogenic strain of E. tenella (strains T2-750/7, T7-776/1 or T6-771), the following tests were carried out.
  • All tests were conducted using cockerels of a layer breed (Warren) supplied by the hatchery E. Wuthrich, Belp, Switzerland. Day-old chicks were reared in heated battery-brooders until the indicated ages, after which they were divided into various test groups and maintained coccidiosis-free in wire-floored cages. Throughout the tests, a commercial broiler-grower diet, based on maize, wheat and soybean meal (crude protein 21.7%) was fed. [0324]
  • In the first test, on day 42 chicks of equivalent weight were randomly divided into three groups of six birds each. Three days later, the chicks were immunized with either recombinant or wild type Vaccinia virus by means of two injections of 50 μl each of the respective virus suspension (10[0325] 10 pfu/ml in PBS) given subcutaneously into the right wing web. Two recombinant vaccinia viruses were used, both of which contained DNA coding for the E. tenella protein which specifically bound to antibody 8A2. One of the viruses (designated 37K M3) contained the leader sequence of the 190 kd malarial antigen; the other virus (designated 37K K3) lacked this leader sequence. The wild type vaccinia strain WR served as a negative control.
  • One week after the first injection, a booster injection was made into the left wing web of the chicks under identical conditions, using the same type of vaccinia virus used previously. [0326]
  • Four weeks after the first injection (day 73) the chicks were challenged with 50,000 of the sporulated oocysts. The inoculum of coccidial, which was suspended in 1 ml of physiological saline, was administered orally into the crop of the chicks by means of a blunt needle on a calibrated syringe. On [0327] day 80, all of the chicks were sacrificed, necropsied and scored for gross lesions in the ceca (score 0=normal, 1=slight infestation, 2=medium infestation, 3=severe lesions, 4=chick died from coccidiosis). The droppings were collected quantitatively over the last two days of the infectious cycle, and the number of excreted oocysts was determined in a representative sample of feces. The results are shown in Table 7.
    TABLE 7
    VACCINATION OF 45 DAY OLD CHICKS WITH VACCINIA
    VIRUSES EXPRESSING THE 28 KD PROTEIN
    Daily Oocyst
    Number of Cecal Lesion Excretion/Chick
    Virusa Chicks Score (×10−6)
    37 K3 6 1.33 149
    37 M3  4b 1.50 107
    wild-Type 6 2.67 271
  • Table 7 shows that compared to the wild-type control virus, both viruses containing DNA coding for the 28 kd protein conferred some protection against oocyst challenge, both in terms of a reduction of cecal lesion score and reduced oocyst excretion. The two viruses were equally effective, showing that the malarial leader sequence was not a factor. [0328]
  • In the second test, cockerels were reared and immunized as described above but beginning at day 22. A viral dose of 2×10[0329] 8 pfu in 100 μl of PBS was administered at that time. The viruses used were from different preparations of vaccinia virus containing DNA coding for the 28 kd protein without (designated 37 K5) or with (designated 37 M19) the malarial leader sequence. The same wild-type strain WR virus was used as a control. Booster injections into the right wing webs at the same doses were given either one or 2 weeks after the first injections.
  • On day 57 (5 weeks after the first injection), all of the chicks were challenged with 50,000 of the sporulated oocysts. One week later, the chicks were sacrificed, necropsied and scored as described above. Daily weight gain following infection and oocyst excretion during the final two days were also determined. The results are shown in Table 8. [0330]
    TABLE 8
    VACCINATION OF 22 DAY OLD CHICKS WITH VACCINIA
    VIRUSES EXPRESSING THE 28 KD PROTEIN
    Daily Oocyst
    Time to Daily Cecal Excretion/
    Booster Number of Weight Lesion Chick
    Virusa (Weeks) Chicks Gain (g) Score (×10−6)
    37 K5 1 8 11.45 2.38 21.0
    37 M19 1 8 15.61 2.13 24.0
    Wild-Type 1 8 8.77 2.50 33.1
    37 K5 2 8 5.14 2.25 22.3
    37 M19 2 8 11.79 2.13 32.7
    Wild-Type 2 8 8.34 2.63 37.0
  • Table 8 shows that, compared to the wild-type control virus, both viruses containing the coccidial DNA conferred some protection against the pathogenic oocyst challenge, in terms of weight gain, cecal lesion score and oocyst excretion. Both viruses were about equally effective. Administration of the [0331] booster 1 week after the primary injection produced somewhat better weight gain and lower oocyst excretion, but cecal lesion scores were about the same for both booster schedules.
  • In the third test, the effect of three vaccinations was examined. Chicks were injected (right wing web) with two 50 μl aliquots (3×10[0332] 9 pfu/ml) of suspensions of wild-type vaccinia virus or virus containing DNA coding for the 20 kd protein which bound specifically to monoclonal antibody 6A5, at 21 days of age. All chicks were given same dose booster injections at day 28 into the left wing webs. Some chicks were given additional same-dose booster injections into the wing webs of both sides at day 35. Other chicks were maintained with no vaccinations, as further controls.
  • On day 49 (4 weeks after the first injections), all of the chicks were challenged with 50,000 of the sporulated oocysts. One week later, the chicks were sacrificed, necropsied and scored for gross cecal lesions as described above. Body weight was recorded weekly for calculation of daily weight gain, and the droppings were collected over the last two days of the infectious cycle to determine oocyst excretion. The results are shown in Table 9. [0333]
    TABLE 9
    VACCINATION OF 21 DAY OLD CHICKS WITH VACCINIA
    VIRUS EXPRESSING THE 20 KD PROTEIN
    Cecal Oocyst
    No. of Number Daily Weight Lesion Excretion/g
    Virus Injections of Chicks Gain (g) Score Feces (×10−1
    With Coccidial DNA 2 6 2.9 2.33 1.69
    With Coccidial DNA 3 6 4.2 1.67 1.32
    Wild-Type 3 6 −4.1 2.67 2.09
    None — 6 −3.8 2.83 1.75
  • The data of Table 9 show that the virus producing the coccidual antigen provided some protection against oocyst infection in terms of enhanced weight gain, reduced cecal lesion score and lowered oocyst excretion. Comparison of the results obtained with unvaccinated controls shows that vaccination with the wild-type vaccinia virus did not confer protection. Therefore, the protection conferred by the virus harboring the coccidial DNA was specific and not due to a generalized immune stimulation caused by exposure to the vaccinia virus itself. Three vaccinations were more effective than two. [0334]
  • Many modifications and variations of this invention may be made without departing from its spirit and scope, as will become apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims. [0335]
  • 1 23 1 1089 DNA Unknown Description of Unknown Organism 1.1 kb cDNA coding 20 kd protein recognized by mab 6A5. 1 gaattccctc caactcttcg cgactctctc tctctcgccc caactttttc ccccgcgccc 60 cgcagcagca gcagcagcag cagcagcaaa atggcagacc tcttcagcgg actcgtgggc 120 ggcgtcgtcg gcgctgttgc tgcagcagat ttgcctgcgg agggcgagag ggccccccgc 180 cccgcccccg gcactgcctg gacttgctgc tgcagcaaac tgcaagaagg ggcccgcgag 240 ctggagggtt ttgtgcagca gctgagtttt gttgcaggga agctggcctg ctgcctgcgg 300 gtgggggcgg agcagctggc gcgctgcgct gcggaggggc ggctgcccag cagcagcagc 360 agcagcagct gctgcgcgct gctgcagctc gagaagcagg acctcgagca gagcctcgag 420 gccggcaagc agggcgcgga gtgcctcttg aggagcagca aactggccct cgaggccctc 480 ctcgaggggg cccgcgttgc agcaacgcgg ggtttgctgc tggtcgagag cagcaaagac 540 acggtgctgc gcagcattcc ccacacccag gagaagctgg ctcaggccta cagttctttc 600 ctgcggggct accagggggc agcagcgggg aggtctctgg gctacggggc ccctgctgct 660 gcttacggcc agcagcagca gcccagcagc tacggggcgc cccccgcctc cagccagcag 720 ccctccggct tcttctggta gccctgcagc agcagcagca gcagcagcag cagcagcagc 780 ggcggcggca gccgcggcgg ggccggggcg ccgctgcagc aacagcagca gccgcggcgg 840 ctagcgnnnn gagcactcgc agggaactcc acaggcagcg ggagagcagc agggacgaga 900 agcaggtcta tgtagcgcag gcagcagcgc cagctgcagc agcagcagca gcagcagcag 960 cagcagcagc agctcctgca ccgcagcgtt gtgtcattta ttacgttggc agctctgagg 1020 cctcggcgca gccaacgcgc ctcaggtatc tttcagactc ttttctctaa ggtcttccag 1080 acggaattc 1089 2 216 PRT Unknown Description of Unknown Organism AA sequence of nucleotide seq in 14. 2 Met Ala Asp Leu Phe Ser Gly Leu Val Gly Gly Val Val Gly Ala Val 1 5 10 15 Ala Ala Ala Asp Leu Pro Ala Glu Gly Glu Arg Ala Pro Arg Pro Ala 20 25 30 Pro Gly Thr Ala Trp Thr Cys Cys Cys Ser Lys Leu Gln Glu Gly Ala 35 40 45 Arg Glu Leu Glu Gly Phe Val Gln Gln Leu Ser Phe Val Ala Gly Lys 50 55 60 Leu Ala Cys Cys Leu Arg Val Gly Ala Glu Gln Leu Ala Arg Cys Ala 65 70 75 80 Ala Glu Gly Arg Leu Pro Ser Ser Ser Ser Ser Ser Ser Cys Cys Ala 85 90 95 Leu Leu Gln Leu Glu Lys Gln Asp Leu Glu Gln Ser Leu Glu Ala Gly 100 105 110 Lys Gln Gly Ala Glu Cys Leu Leu Arg Ser Ser Lys Leu Ala Leu Glu 115 120 125 Ala Leu Leu Glu Gly Ala Arg Val Ala Ala Thr Arg Gly Leu Leu Leu 130 135 140 Val Glu Ser Ser Lys Asp Thr Val Leu Arg Ser Ile Pro His Thr Gln 145 150 155 160 Glu Lys Leu Ala Gln Ala Tyr Ser Ser Phe Leu Arg Gly Tyr Gln Gly 165 170 175 Ala Ala Ala Gly Arg Ser Leu Gly Tyr Gly Ala Pro Ala Ala Ala Tyr 180 185 190 Gly Gln Gln Gln Gln Pro Ser Ser Tyr Gly Ala Pro Pro Ala Ser Ser 195 200 205 Gln Gln Pro Ser Gly Phe Phe Trp 210 215 3 1637 DNA Unknown Description of Unknown Organism 1.7 kb cDNA coding 65 kd protein recognized by mabs 7D1, 7D4 and 20C6. 3 gaattcatgt ttaggcggat tttgttccat gcaagaaagc ccaccaccgg ctgcaggtgg 60 actgtacggg ggacagactt tggaacaaca aggcattgct gtgagggaaa ctgcttcgtg 120 cagcgagaac ccgtgcccta tcgacgcaac gtgcggagaa tggacagagt acagtgcgtg 180 ctccagaact tgcggaggcg gtacccaaga gaggaagagg gagccgtggt tggataatgc 240 gcaacacggg gggcgcacct gcatggaaca gtatcctgat gggcccatat cggtcaggga 300 gtgcaacacc cagccgtgcc ctgtggacga agtagttggt gattgggaag actgggggca 360 atgcagcgaa cagtgtggtg gcggcaagcg gactcgtaat cgcggcccaa gcaagcaaga 420 ggccatgttc ggaggcaaga cagttgctca acagaacgca gagctccctg aaggcgagaa 480 gattgaggtg gttcaggaag aaggatgcaa tgaagttcca tgcggacctt gcacgctccc 540 cttcagtgag tggaccgaat gcgagtcgtg ctccgggcat agaaccaggg aatccgcagt 600 agcatttgat tacactgaca gaatgtgcag tggtgacaca cacgaggtac aaagctgtga 660 ggaatactgt tcccaaaatg ctggaggggg tgctggagga gatgggggcg caggaggagg 720 gactggaggc tctggagagg aggaaggaaa ggaggaatcg agtggatttc caactgcagc 780 tgtagccggt ggcgtggctg ggggagtcct cgcgattgct gcgggagctg gagcgtttta 840 tggattgagt ggtgggagcg cggctgctgc cactgaagca ggtgctgaag tgatgacaga 900 agctggtaca tccaatgctg ctgaggtaga aaaggagagc ctcatcagtg caggtgaaca 960 atcagagatg tgggcatcct aaatggaaac gtcgccgccg cgggtttcga aaaggtgcgg 1020 atcttgcata tctgtgaacg aattatttac taacatcgag ctccttgacc tcccgttggc 1080 aaatcattta ccaagcatct ctggcgcata gcttcttgaa caagacaacg gaatgtccaa 1140 ctggggaaca gctatattgc gaagtgtggt gttcaaacca gaagagagca cagcgtcatg 1200 tgtatgttac ggttgggcgc ctcctttccc ttatttatcc catttcctcc gccttcatct 1260 ttccgccttc tctctgtgcg ccgtattttg ggtgttattg gtgcctggcg gacagtaaag 1320 agagattggc gttatttgca gcgtgcgcag gccatggtag ggttggataa cactcattgg 1380 tgaagcgcaa gccaacaggg ccacctttac ctcctggtgg tcaatggggc agcttgcttc 1440 tgatcattgg ttggttctgt ttcaaggggc cggtaatggg cagcagaagc ttctgccagc 1500 caccacacaa tcgaagcaac aaataaggga ggttctgcta acaattgtgc gtagtcatga 1560 ttgtaggtag gctccgtttc gaagatgaat gaccgggagc agcctgaatg aaacttgact 1620 ctcaaagaag ggaattc 1637 4 325 PRT Unknown Description of Unknown Organism AA seq of nucleotide seq in Fig. 16. 4 Ser Cys Leu Gly Gly Phe Cys Ser Met Gln Glu Ser Pro Pro Pro Ala 1 5 10 15 Ala Gly Gly Leu Tyr Gly Gly Gln Thr Leu Glu Gln Gln Gly Ile Ala 20 25 30 Val Arg Glu Thr Ala Ser Cys Ser Glu Asn Pro Cys Pro Ile Asp Ala 35 40 45 Thr Cys Gly Glu Trp Thr Glu Tyr Ser Ala Cys Ser Arg Thr Cys Gly 50 55 60 Gly Gly Thr Gln Glu Arg Lys Arg Glu Pro Trp Leu Asp Asn Ala Gln 65 70 75 80 His Gly Gly Arg Thr Cys Met Glu Gln Tyr Pro Asp Gly Pro Ile Ser 85 90 95 Val Arg Glu Cys Asn Thr Gln Pro Cys Pro Val Asp Glu Val Val Gly 100 105 110 Asp Trp Glu Asp Trp Gly Gln Cys Ser Glu Gln Cys Gly Gly Gly Lys 115 120 125 Arg Thr Arg Asn Arg Gly Pro Ser Lys Gln Glu Ala Met Phe Gly Gly 130 135 140 Lys Thr Val Ala Gln Gln Asn Ala Glu Leu Pro Glu Gly Glu Lys Ile 145 150 155 160 Glu Val Val Gln Glu Glu Gly Cys Asn Glu Val Pro Cys Gly Pro Cys 165 170 175 Thr Leu Pro Phe Ser Glu Trp Thr Glu Cys Glu Ser Cys Ser Gly His 180 185 190 Arg Thr Arg Glu Ser Ala Val Ala Phe Asp Tyr Thr Asp Arg Met Cys 195 200 205 Ser Gly Asp Thr His Glu Val Gln Ser Cys Glu Glu Tyr Cys Ser Gln 210 215 220 Asn Ala Gly Gly Gly Ala Gly Gly Asp Gly Gly Ala Gly Gly Gly Thr 225 230 235 240 Gly Gly Ser Gly Glu Glu Glu Gly Lys Glu Glu Ser Ser Gly Phe Pro 245 250 255 Thr Ala Ala Val Ala Gly Gly Val Ala Gly Gly Val Leu Ala Ile Ala 260 265 270 Ala Gly Ala Gly Ala Phe Tyr Gly Leu Ser Gly Gly Ser Ala Ala Ala 275 280 285 Ala Thr Glu Ala Gly Ala Glu Val Met Thr Glu Ala Gly Thr Ser Asn 290 295 300 Ala Ala Glu Val Glu Lys Glu Ser Leu Ile Ser Ala Gly Glu Gln Ser 305 310 315 320 Glu Met Trp Ala Ser 325 5 1001 DNA Unknown Description of Unknown Organism 1.1 kb cDNA coding 28 kd protein recognized by mab 8AZ. 5 gaattcccga cttcgaggga ggccccgggg gcctccccgc ctgcgaagcg gcggcggacg 60 tcgctggggg cccctgcagc aggggagggc cccctgcggc ggtgggagca gcctgctgct 120 gggactgcag cagcaatccg gcagcaggct ggaggagcgg gagcagcagc ggcagcgcga 180 gcggcagctg cagcacgtgc gcgcaccccc gggcgcgcag cagcagtgca ggcgcggcta 240 aacgcgtggg tggcggaggg caacaaactg ccagagtccg agagaagaag aaggatgtta 300 gaacaatata tgaacttgga aaaagtcaaa aagttgagga aaaaactcga cgaagaagca 360 gaagccaggg ccaattacat cgaaggcgga gttcaaaaag aacccccact gggggcccct 420 caaggccgaa aaccctttgc tgccttttgc ccagagagag gccgacgagg cctacaggcg 480 gttcggcagg ggcgctccct ctgcggggcc cctcagggag aagatgctgc aggcccgcag 540 gaagtaaagc agcagcagca gcagcagcag cagcggcagc ggcagcggca ggggaggcgg 600 aggaggcagg gaggcttttg tttcgaattg tttagggaga gggcggaggg ctcgcggggt 660 gtatgtacag cgcgcgaacg cggcggctca tgtttgggtg ttggatttcg tctgcagaaa 720 acacgaagca aattaaactg gcagaagttc catttttcca ctttaaaatg ccacttttgc 780 tctttatatt gattaaaact aatgccatgc tgctggcatt catataaatg catttccgcg 840 catttatgtg catgcatggc tgggcgcggg tgtctgtaca ccccaagagc cttgctgctc 900 cgccggcgcg aatttatatt tatatttcat ttatgtaaat ataaaagcct tcaaaaacac 960 aaatggacat taatttatca agaaaaaaga ttaaggaatt c 1001 6 263 PRT Unknown Description of Unknown Organism AA seq of nucleotide seq in Fig. 18. 6 Glu Phe Pro Thr Ser Arg Glu Ala Pro Gly Ala Ser Pro Pro Ala Lys 1 5 10 15 Arg Arg Arg Thr Ser Leu Gly Ala Pro Ala Ala Gly Glu Gly Pro Leu 20 25 30 Arg Arg Trp Glu Gln Pro Ala Ala Gly Thr Ala Ala Ala Ile Arg Gln 35 40 45 Gln Ala Gly Gly Ala Gly Ala Ala Ala Ala Ala Arg Ala Ala Ala Ala 50 55 60 Ala Arg Ala Arg Thr Pro Gly Arg Ala Ala Ala Val Gln Ala Arg Leu 65 70 75 80 Asn Ala Trp Val Ala Glu Gly Asn Lys Leu Pro Glu Ser Glu Arg Arg 85 90 95 Arg Arg Met Leu Glu Gln Tyr Met Asn Leu Glu Lys Val Lys Lys Leu 100 105 110 Arg Lys Lys Leu Asp Glu Glu Ala Glu Ala Arg Ala Lys Tyr Ile Glu 115 120 125 Gly Gly Val Gln Lys Glu Pro Pro Leu Gly Ala Pro Gln Gly Arg Lys 130 135 140 Pro Phe Ala Ala Phe Cys Pro Glu Arg Gly Arg Arg Gly Leu Gln Ala 145 150 155 160 Val Arg Gln Gly Arg Ser Leu Cys Gly Ala Pro Gln Gly Glu Asp Ala 165 170 175 Ala Gly Pro Gln Glu Val Lys Gln Gln Gln Gln Gln Gln Gln Gln Arg 180 185 190 Gln Arg Gln Arg Gln Gly Arg Arg Arg Arg Gln Gly Gly Phe Cys Phe 195 200 205 Glu Leu Phe Arg Glu Arg Ala Glu Gly Ser Arg Gly Val Cys Thr Ala 210 215 220 Arg Glu Arg Gly Gly Ser Cys Leu Gly Val Gly Phe Arg Leu Gln Lys 225 230 235 240 Thr Arg Ser Lys Leu Asn Trp Gln Lys Phe His Phe Ser Thr Leu Lys 245 250 255 Cys His Phe Cys Ser Leu Tyr 260 7 3094 DNA Unknown Description of Unknown Organism 3.2 kb cDNA coding 20 kd protein recognized by mab 7B2. 7 gaattccgcc ccagacagct aagcgtggca acattcttgg tcttgtgggc atggtagccg 60 ctgtcgtcgt gaccttcacg gaggcagggt ttggacagca ttacttgctg tttttcgcca 120 ctgctgcacc ggcccttggc ctggggctgt acattgcgca gtctgtcaac atgactgaga 180 tgcctcaact cgtggctctt ttccacagtt tcgtcggtct tgccgccgta atggttgggt 240 tcgcgaactt ccactcccct gctggcgtgg agcgcgcttc ctcacttcta cgtctgttgg 300 aggtctacgc cggcgttttc gtcgccggta tcaccttcac cggatcagtg gtcgctgcgg 360 caaagctcca tggatcgatg gagagccgct cattgagggt tcccggacgc catgcgttga 420 atactgccac tattgctgcc attggcgtac ttggcgctct tttttgcgtc tcttctggcc 480 actttacacg catgctttgc ctttatgtga atgctggctt gagcatgtgg cttggttttc 540 acctggtcgc cgctattggt ggagctgaca tgcccgtcgt gatcagcttg ctgaactcgt 600 attccggagt ggcgttggct gccagtggct tcatgttgga caacaacttg ctgatcattg 660 ctggtgctct catcgcgtca tctggtgcca ttctgtctta catcatgtgc aaaggcatga 720 accggagtct gtggaatgtc gttcttggtg gcttcgagga ggccgaggac gttggcgcag 780 ccagccctca gggggctgtg cagcaggcca cggctgatca ggtcgccgac gagttgctgg 840 ctgcccgcaa agttttgatc gtgcctggat acggaatggc cgttgcaagg tgccagagcg 900 agcttgcaga cattgccaag aacttgatga actgcggtat caccgtcgat ttcggcatcc 960 atccagttgc tggtcgcatg ccaggccaca tgaacgtcct cctcgctgag gctgatgttc 1020 cgtacaagat tgtcaaggag atgtctgaag tcaacccgga aatgagctcc tacgacgtcg 1080 tcctggttgt tggagccaac gacaccgtca atcctgcagc ccttgagcca ggatcaaaga 1140 tctcaggaat gcccgttata gaggcctgga aagctagacg cgtttttgtg ctgaagcggt 1200 ccatggctgc tggatatgcc agcattgaaa atccactttt ccatctggag aacacacgca 1260 tgctcttcgg aaacgcaaag aacaccactt ctgcagtctt cgcccgtgtc aatgccagag 1320 ccgagcaaat gccaccatct gctgcccgtg atgacctcga agctggacta cttgagttcg 1380 atagggaaga acgtgttgat ccctcttctt ggccatatcc caggatggct gttggtgttc 1440 tgagagactc caatggctct gttatggtgc cagtagctcc gaagtttgtg cccaagctga 1500 ggaagttggc attccgtgtc aatgtcgagt ctggtgctgg cgccgatgcc ggctttactg 1560 acgaagagta caggagggct ggagcagaag tcctgtcggg ccccgatgca gtcattaacc 1620 agtctcaagt cctgctccgc gtttcagcgc cgtcgccaga tctggtttcg cgcattccta 1680 gggacaaggt ccttatcagt tacctattcc ccagcatcaa ccaacaagct cttgacatgc 1740 tagcacgcca aggcgtcacc gcacttgctg tggatgaggt tcctcgcgtc acaagagcac 1800 agaagctaga cgtgaagtct gctatgcaag gtctccaggg ataccgcgcc gttatcgaag 1860 cgttcaacgc tcttccgaag ctcagcaaag catctatcag tgctgcaggc cgtgtagaag 1920 ccgctaaagt tttcgtcatc ggtgccggtg ttgctggact acaggcaatt tctaccgccc 1980 atggtttggg tgcacaagta nttggccacg atgtgcgctc tgcaactcgt gaggaagtcg 2040 aatcttgcgg tggaaagttc attggtttga gaatgggaga ggagggtgaa gtcctcggag 2100 gatatgcacg cgagatgggt gatgcatatc agagagcgca acgcgagatg attgccaaca 2160 caatcaagca ctgcgatgtc gtcatctgta ccgctgctat tcacggcaga ccttcaccaa 2220 agctcatatc acgcgacatg ttgcgttcaa tgaagcctgg ctccgtcgtc gtagatcttg 2280 caacagagtt cggtgatgtg cgctccggct ggggtggaaa cgtcgaggtt tcgcctaagg 2340 acgaccagat tgtcgttgat ggcgtcactg tcattggtcg cagacgcatt gagactcgca 2400 tgcccattca ggcgtctgag ctgttctcca tgaacatatg caacctcctt gaggatcttg 2460 gtggtggcag caacttccgc atcaacatgg acgacgaagt catcagagga ttggtcgcag 2520 tctaccaagg tcgcaacgtg tggcagccat cgcagcccac tcctgtttcc aggacacctc 2580 cgcgcggcca gatgccgccc ccgtctgcac ctggtgcacc agctcctgag aagcctggtg 2640 cctttgctca agcacttgct tcggatgcat tcttcgcaat gtgtcttgtt gttgctgccg 2700 ctgttgtcgg gctccttggc attgtccttg accctgtgga gctcaagcat ttgactctcc 2760 tcggcttgtc tctcatcgtc ggctactact gcgtgtgggc cgttacgcct tcgcttcaca 2820 caccattgat gtctgtgacg aatgcccttt cgggagtcat tgtcatcggc tgcatgctcg 2880 agtacggaac cgccatgata tccggattca ctcttctcgc actcattgga accttcttgg 2940 cttccgtcaa cgttgctggt ggattcttcg taactcaccg catgctgaag atgtttcaga 3000 tataagggga gaaccccctt gagttaatct taactcagaa taactctttt tcaattgtat 3060 aaacctgtac tcgttgcaaa aaaaaaagga attc 3094 8 998 PRT Unknown Description of Unknown Organism AA seq of nucleotide seq of Fig. 20. 8 Pro Gln Thr Ala Lys Arg Gly Asn Ile Leu Gly Leu Val Gly Met Val 1 5 10 15 Ala Ala Val Val Val Thr Phe Thr Glu Ala Gly Phe Gly Gln His Tyr 20 25 30 Leu Leu Phe Phe Ala Thr Ala Ala Pro Ala Leu Gly Leu Gly Leu Tyr 35 40 45 Ile Ala Gln Ser Val Asn Met Thr Glu Met Pro Gln Leu Val Ala Leu 50 55 60 Phe His Ser Phe Val Gly Leu Ala Ala Val Met Val Gly Phe Ala Asn 65 70 75 80 Phe His Ser Pro Ala Gly Val Glu Arg Ala Ser Ser Leu Leu Arg Leu 85 90 95 Leu Glu Val Tyr Ala Gly Val Phe Val Ala Gly Ile Thr Phe Thr Gly 100 105 110 Ser Val Val Ala Ala Ala Lys Leu His Gly Ser Met Glu Ser Arg Ser 115 120 125 Leu Arg Val Pro Gly Arg His Ala Leu Asn Thr Ala Thr Ile Ala Ala 130 135 140 Ile Gly Val Leu Gly Ala Leu Phe Cys Val Ser Ser Gly His Phe Thr 145 150 155 160 Arg Met Leu Cys Leu Tyr Val Asn Ala Gly Leu Ser Met Trp Leu Gly 165 170 175 Phe His Leu Val Ala Ala Ile Gly Gly Ala Asp Met Pro Val Val Ile 180 185 190 Ser Leu Leu Asn Ser Tyr Ser Gly Val Ala Leu Ala Ala Ser Gly Phe 195 200 205 Met Leu Asp Asn Asn Leu Leu Ile Ile Ala Gly Ala Leu Ile Ala Ser 210 215 220 Ser Gly Ala Ile Leu Ser Tyr Ile Met Cys Lys Gly Met Asn Arg Ser 225 230 235 240 Leu Trp Asn Val Val Leu Gly Gly Phe Glu Glu Ala Glu Asp Val Gly 245 250 255 Ala Ala Ser Pro Gln Gly Ala Val Gln Gln Ala Thr Ala Asp Gln Val 260 265 270 Ala Asp Glu Leu Leu Ala Ala Arg Lys Val Leu Ile Val Pro Gly Tyr 275 280 285 Gly Met Ala Val Ala Arg Cys Gln Ser Glu Leu Ala Asp Ile Ala Lys 290 295 300 Asn Leu Met Asn Cys Gly Ile Thr Val Asp Phe Gly Ile His Pro Val 305 310 315 320 Ala Gly Arg Met Pro Gly His Met Asn Val Leu Leu Ala Glu Ala Asp 325 330 335 Val Pro Tyr Lys Ile Val Lys Glu Met Ser Glu Val Asn Pro Glu Met 340 345 350 Ser Ser Tyr Asp Val Val Leu Val Val Gly Ala Asn Asp Thr Val Asn 355 360 365 Pro Ala Ala Leu Glu Pro Gly Ser Lys Ile Ser Gly Met Pro Val Ile 370 375 380 Glu Ala Trp Lys Ala Arg Arg Val Phe Val Leu Lys Arg Ser Met Ala 385 390 395 400 Ala Gly Tyr Ala Ser Ile Glu Asn Pro Leu Phe His Leu Glu Asn Thr 405 410 415 Arg Met Leu Phe Gly Asn Ala Lys Asn Thr Thr Ser Ala Val Phe Ala 420 425 430 Arg Val Asn Ala Arg Ala Glu Gln Met Pro Pro Ser Ala Ala Arg Asp 435 440 445 Asp Leu Glu Ala Gly Leu Leu Glu Phe Asp Arg Glu Glu Arg Val Asp 450 455 460 Pro Ser Ser Trp Pro Tyr Pro Arg Met Ala Val Gly Val Leu Arg Asp 465 470 475 480 Ser Asn Gly Ser Val Met Val Pro Val Ala Pro Lys Phe Val Pro Lys 485 490 495 Leu Arg Lys Leu Ala Phe Arg Val Asn Val Glu Ser Gly Ala Gly Ala 500 505 510 Asp Ala Gly Phe Thr Asp Glu Glu Tyr Arg Arg Ala Gly Ala Glu Val 515 520 525 Leu Ser Gly Pro Asp Ala Val Ile Asn Gln Ser Gln Val Leu Leu Arg 530 535 540 Val Ser Ala Pro Ser Pro Asp Leu Val Ser Arg Ile Pro Arg Asp Lys 545 550 555 560 Val Leu Ile Ser Tyr Leu Phe Pro Ser Ile Asn Gln Gln Ala Leu Asp 565 570 575 Met Leu Ala Arg Gln Gly Val Thr Ala Leu Ala Val Asp Glu Val Pro 580 585 590 Arg Val Thr Arg Ala Gln Lys Leu Asp Val Lys Ser Ala Met Gln Gly 595 600 605 Leu Gln Gly Tyr Arg Ala Val Ile Glu Ala Phe Asn Ala Leu Pro Lys 610 615 620 Leu Ser Lys Ala Ser Ile Ser Ala Ala Gly Arg Val Glu Ala Ala Lys 625 630 635 640 Val Phe Val Ile Gly Ala Gly Val Ala Gly Leu Gln Ala Ile Ser Thr 645 650 655 Ala His Gly Leu Gly Ala Gln Val Xaa Gly His Asp Val Arg Ser Ala 660 665 670 Thr Arg Glu Glu Val Glu Ser Cys Gly Gly Lys Phe Ile Gly Leu Arg 675 680 685 Met Gly Glu Glu Gly Glu Val Leu Gly Gly Tyr Ala Arg Glu Met Gly 690 695 700 Asp Ala Tyr Gln Arg Ala Gln Arg Glu Met Ile Ala Asn Thr Ile Lys 705 710 715 720 His Cys Asp Val Val Ile Cys Thr Ala Ala Ile His Gly Arg Pro Ser 725 730 735 Pro Lys Leu Ile Ser Arg Asp Met Leu Arg Ser Met Lys Pro Gly Ser 740 745 750 Val Val Val Asp Leu Ala Thr Glu Phe Gly Asp Val Arg Ser Gly Trp 755 760 765 Gly Gly Asn Val Glu Val Ser Pro Lys Asp Asp Gln Ile Val Val Asp 770 775 780 Gly Val Thr Val Ile Gly Arg Arg Arg Ile Glu Thr Arg Met Pro Ile 785 790 795 800 Gln Ala Ser Glu Leu Phe Ser Met Asn Ile Cys Asn Leu Leu Glu Asp 805 810 815 Leu Gly Gly Gly Ser Asn Phe Arg Ile Asn Met Asp Asp Glu Val Ile 820 825 830 Arg Gly Leu Val Ala Val Tyr Gln Gly Arg Asn Val Trp Gln Pro Ser 835 840 845 Gln Pro Thr Pro Val Ser Arg Thr Pro Pro Arg Gly Gln Met Pro Pro 850 855 860 Pro Ser Ala Pro Gly Ala Pro Ala Pro Glu Lys Pro Gly Ala Phe Ala 865 870 875 880 Gln Ala Leu Ala Ser Asp Ala Phe Phe Ala Met Cys Leu Val Val Ala 885 890 895 Ala Ala Val Val Gly Leu Leu Gly Ile Val Leu Asp Pro Val Glu Leu 900 905 910 Lys His Leu Thr Leu Leu Gly Leu Ser Leu Ile Val Gly Tyr Tyr Cys 915 920 925 Val Trp Ala Val Thr Pro Ser Leu His Thr Pro Leu Met Ser Val Thr 930 935 940 Asn Ala Leu Ser Gly Val Ile Val Ile Gly Cys Met Leu Glu Tyr Gly 945 950 955 960 Thr Ala Met Ile Ser Gly Phe Thr Leu Leu Ala Leu Ile Gly Thr Phe 965 970 975 Leu Ala Ser Val Asn Val Ala Gly Gly Phe Phe Val Thr His Arg Met 980 985 990 Leu Lys Met Phe Gln Ile 995 9 15 PRT Eimeria tenella 9 Met Arg Trp Glu Phe Pro Thr Ser Arg Glu Ala Pro Gly Ala Ser 1 5 10 15 10 59 PRT Unknown Description of Unknown Organism AA seq of Fig. 25a fused to malarial 190 kd leader segment. 10 Met Lys Ile Ile Phe Phe Leu Cys Ser Phe Leu Phe Phe Ile Ile Asn 1 5 10 15 Thr Gln Cys Val Thr His Glu Ser Tyr Gln Glu Leu Val Lys Lys Leu 20 25 30 Glu Ala Ser Ser Arg Gly Thr Ala Cys Asp Ile Glu Leu Ser Arg Glu 35 40 45 Phe Pro Thr Ser Arg Glu Ala Pro Gly Ala Ser 50 55 11 651 DNA Unknown Description of Unknown Organism DNA coding 20 kd protein recognized by mab 6A5. 11 atggcagacc tcttcagcgg actcgtgggc ggcgtcgtcg gcgctgttgc tgcagcagat 60 ttgcctgcgg agggcgagag ggccccccgc cccgcccccg gcactgcctg gacttgctgc 120 tgcagcaaac tgcaagaagg ggcccgcgag ctggagggtt ttgtgcagca gctgagtttt 180 gttgcaggga agctggcctg ctgcctgcgg gtgggggcgg agcagctggc gcgctgcgct 240 gcggaggggc ggctgcccag cagcagcagc agcagcagct gctgcgcgct gctgcagctc 300 gagaagcagg acctcgagca gagcctcgag gccggcaagc agggcgcgga gtgcctcttg 360 aggagcagca aactggccct cgaggccctc ctcgaggggg cccgcgttgc agcaacgcgg 420 ggtttgctgc tggtcgagag cagcaaagac acggtgctgc gcagcattcc ccacacccag 480 gagaagctgg ctcaggccta cagttctttc ctgcggggct accagggggc agcagcgggg 540 aggtctctgg gctacggggc ccctgctgct gcttacggcc agcagcagca gcccagcagc 600 tacggggcgc cccccgcctc cagccagcag ccctccggct tcttctggta g 651 12 921 DNA Unknown Description of Unknown Organism DNA coding 65 kd protein recognized by mab 7D4. 12 ctgtacgggg gacagacttt ggaacaacaa ggcattgctg tgagggaaac tgcttcgtgc 60 agcgagaacc cgtgccctat cgacgcaacg tgcggagaat ggacagagta cagtgcgtgc 120 tccagaactt gcggaggcgg tacccaagag aggaagaggg agccgtggtt ggataatgcg 180 caacacgggg ggcgcacctg catggaacag tatcctgatg ggcccatatc ggtcagggag 240 tgcaacaccc agccgtgccc tgtggacgaa gtagttggtg attgggaaga ctgggggcaa 300 tgcagcgaac agtgtggtgg cggcaagcgg actcgtaatc gcggcccaag caagcaagag 360 gccatgttcg gaggcaagac agttgctcaa cagaacgcag agctccctga aggcgagaag 420 attgaggtgg ttcaggaaga aggatgcaat gaagttccat gcggaccttg cacgctcccc 480 ttcagtgagt ggaccgaatg cgagtcgtgc tccgggcata gaaccaggga atccgcagta 540 gcatttgatt acactgacag aatgtgcagt ggtgacacac acgaggtaca aagctgtgag 600 gaatactgtt cccaaaatgc tggagggggt gctggaggag atgggggcgc aggaggaggg 660 actggaggct ctggagagga ggaaggaaag gaggaatcga gtggatttcc aactgcagct 720 gtagccggtg gcgtggctgg gggagtcctc gccattgctg cgggagctgg agcgttttat 780 ggattgagtg gtgggagcgc ggctgctgcc actgaagcag gtgctgaagt gatgacagaa 840 gctggtacat ccaatgctgc tgaggtagaa aaggagagcc tcatcagtgc aggtgaacaa 900 tcagagatgt gggcatccta a 921 13 306 PRT Unknown Description of Unknown Organism AA seq. of the nucleotide seq. of Fig. 27. 13 Leu Tyr Gly Gly Gln Thr Leu Glu Gln Gln Gly Ile Ala Val Arg Glu 1 5 10 15 Thr Ala Ser Cys Ser Glu Asn Pro Cys Pro Ile Asp Ala Thr Cys Gly 20 25 30 Glu Trp Thr Glu Tyr Ser Ala Cys Ser Arg Thr Cys Gly Gly Gly Thr 35 40 45 Gln Glu Arg Lys Arg Glu Pro Trp Leu Asp Asn Ala Gln His Gly Gly 50 55 60 Arg Thr Cys Met Glu Gln Tyr Pro Asp Gly Pro Ile Ser Val Arg Glu 65 70 75 80 Cys Asn Thr Gln Pro Cys Pro Val Asp Glu Val Val Gly Asp Trp Glu 85 90 95 Asp Trp Gly Gln Cys Ser Glu Gln Cys Gly Gly Gly Lys Arg Thr Arg 100 105 110 Asn Arg Gly Pro Ser Lys Gln Glu Ala Met Phe Gly Gly Lys Thr Val 115 120 125 Ala Gln Gln Asn Ala Glu Leu Pro Glu Gly Glu Lys Ile Glu Val Val 130 135 140 Gln Glu Glu Gly Cys Asn Glu Val Pro Cys Gly Pro Cys Thr Leu Pro 145 150 155 160 Phe Ser Glu Trp Thr Glu Cys Glu Ser Cys Ser Gly His Arg Thr Arg 165 170 175 Glu Ser Ala Val Ala Phe Asp Tyr Thr Asp Arg Met Cys Ser Gly Asp 180 185 190 Thr His Glu Val Gln Ser Cys Glu Glu Tyr Cys Ser Gln Asn Ala Gly 195 200 205 Gly Gly Ala Gly Gly Asp Gly Gly Ala Gly Gly Gly Thr Gly Gly Ser 210 215 220 Gly Glu Glu Glu Gly Lys Glu Glu Ser Ser Gly Phe Pro Thr Ala Ala 225 230 235 240 Val Ala Gly Gly Val Ala Gly Gly Val Leu Ala Ile Ala Ala Gly Ala 245 250 255 Gly Ala Phe Tyr Gly Leu Ser Gly Gly Ser Ala Ala Ala Ala Thr Glu 260 265 270 Ala Gly Ala Glu Val Met Thr Glu Ala Gly Thr Ser Asn Ala Ala Glu 275 280 285 Val Glu Lys Glu Ser Leu Ile Ser Ala Gly Glu Gln Ser Glu Met Trp 290 295 300 Ala Ser 305 14 999 DNA Unknown Description of Unknown Organism DNA coding 28 to 37 kd protein recognized by mab 8A2. 14 gaattcccga cttcgaggga ggccccgggg gcctccccgc ctgcgaagcg gcggcggacg 60 tcgctggggg cccctgcagc aggggagggc cccctgcggc ggtgggagca gcctgctgct 120 gggactgcag cagcaatccg gcagcagctg gaggagcggg agcagcagcg gcagcgcgag 180 cagcagctgc agcacgtgca gcgcaccccc gggcgcgcag cagcagtgca ggcgcggcta 240 aacgcgtggg tggcggaggg caacaaactg ccagagtccg agagaagaag aaggatgtta 300 gaacaatata tgaacttgga aaaagtcaaa aagttgagga aaaaactcga cgaagaagca 360 gaagccaggg ccaaatacat cgaaggcgag ttcaaaaaga acccccactg ggggcccctc 420 aaggccgaaa accctttgct gccttttgcc cagagagagg ccgacgaggc ctacaggcgg 480 ttcggcaggg gcgctccctc tgcggggccc ctcagggaga agatgctgca ggcccgcagg 540 aagtaaagca gcagcagcag cagcagcagc agcggcagcg gcagcggcag gggaggcgga 600 ggaggcaggg aggcttttgt ttgaattgtt tagggagagg gcggagggct cgcggggtgt 660 atgtacagcg cgcgaacgcg cgggctcatg tttgggtgtt ggatttcgtc tgcagaaaac 720 acgaagcaaa ttaaactggc agaagttcca tttttccact ttaaaatgcc acttttgctc 780 tttatattga ttaaaactaa tgccatgctg ctggcattca tataaatgca tttccgcgca 840 tttatgtgca tgcatggctg ggcgcgggtg tctgtacacc ccaagagcct tgctgctccg 900 ccggcgcgaa tttatattta tatttcattt atgtaaatat aaaagccttc aaaaacacaa 960 atggacatta atttatcaag aaaaaagatt aaggaattc 999 15 539 DNA Unknown Description of Unknown Organism Nucleotide subsequence of the seq. of Fig. 29, which represents the coding seq. only as represented by Fig. 31. 15 cgacttcgag ggaggccccg ggggcctccc cgcctgcgaa gcggcggcgg acgtcgctgg 60 gggcccctgc agcaggggag ggccccctgc ggcggtggga gcagcctgct gctgggactg 120 cagcagcaat ccggcagcag ctggaggagc gggagcagca gcggcagcgc gagcagcagc 180 tgcagcacgt gcagcgcacc cccgggcgcg cagcagcagt gcaggcgcgg ctaaacgcgt 240 gggtggcgga gggcaacaaa ctgccagagt ccgagagaag aagaaggatg ttagaacaat 300 atatgaactt ggaaaaagtc aaaaagttga ggaaaaaact cgacgaagaa gcagaagcca 360 gggccaaata catcgaaggc gagttcaaaa agaaccccca ctgggggccc ctcaaggccg 420 aaaacccttt gctgcctttt gcccagagag aggccgacga ggcctacagg cggttcggca 480 ggggcgctcc ctctgcgggg cccctcaggg agaagatgct gcaggcccgc aggaagtaa 539 16 181 PRT Unknown Description of Unknown Organism AA sequence of the nucleotide seq of Fig. 29. 16 Glu Phe Pro Thr Ser Arg Glu Ala Pro Gly Ala Ser Pro Pro Ala Lys 1 5 10 15 Arg Arg Arg Thr Ser Leu Gly Ala Pro Ala Ala Gly Glu Gly Pro Leu 20 25 30 Arg Arg Trp Glu Gln Pro Ala Ala Gly Thr Ala Ala Ala Ile Arg Gln 35 40 45 Gln Leu Glu Glu Arg Glu Gln Gln Arg Gln Arg Glu Gln Gln Leu Gln 50 55 60 His Val Arg Ser Thr Pro Gly Arg Ala Ala Ala Val Gln Ala Arg Leu 65 70 75 80 Asn Ala Trp Val Ala Glu Gly Asn Lys Leu Pro Glu Ser Glu Arg Arg 85 90 95 Arg Arg Met Leu Glu Gln Tyr Met Asn Leu Glu Lys Val Lys Lys Leu 100 105 110 Arg Lys Lys Leu Asp Glu Glu Ala Glu Ala Arg Ala Lys Tyr Ile Glu 115 120 125 Gly Glu Phe Lys Lys Asn Pro His Trp Gly Pro Leu Lys Ala Glu Asn 130 135 140 Pro Leu Leu Pro Phe Ala Gln Arg Glu Ala Asp Glu Ala Tyr Arg Arg 145 150 155 160 Phe Gly Arg Gly Ala Pro Ser Ala Gly Pro Leu Arg Glu Lys Met Leu 165 170 175 Gln Ala Arg Arg Lys 180 17 178 PRT Unknown Description of Unknown Organism The seq. of Fig.31 less the first three AAs, which are artifacts from cloning process. 17 Thr Ser Arg Glu Ala Pro Gly Ala Ser Pro Pro Ala Lys Arg Arg Arg 1 5 10 15 Thr Ser Leu Gly Ala Pro Ala Ala Gly Glu Gly Pro Leu Arg Arg Trp 20 25 30 Glu Gln Pro Ala Ala Gly Thr Ala Ala Ala Ile Arg Gln Gln Leu Glu 35 40 45 Glu Arg Glu Gln Gln Arg Gln Arg Glu Gln Gln Leu Gln His Val Arg 50 55 60 Ser Thr Pro Gly Arg Ala Ala Ala Val Gln Ala Arg Leu Asn Ala Trp 65 70 75 80 Val Ala Glu Gly Asn Lys Leu Pro Glu Ser Glu Arg Arg Arg Arg Met 85 90 95 Leu Glu Gln Tyr Met Asn Leu Glu Lys Val Lys Lys Leu Arg Lys Lys 100 105 110 Leu Asp Glu Glu Ala Glu Ala Arg Ala Lys Tyr Ile Glu Gly Glu Phe 115 120 125 Lys Lys Asn Pro His Trp Gly Pro Leu Lys Ala Glu Asn Pro Leu Leu 130 135 140 Pro Phe Ala Gln Arg Glu Ala Asp Glu Ala Tyr Arg Arg Phe Gly Arg 145 150 155 160 Gly Ala Pro Ser Ala Gly Pro Leu Arg Glu Lys Met Leu Gln Ala Arg 165 170 175 Arg Lys 18 2997 DNA Unknown Description of Unknown Organism Nucleotide seq. of DNA encoding 45 kd protein recognized by mab 7B2. 18 ccccagacag ctaagcgtgg caacattctt ggtcttgtgg gcatggtagc cgctgtcgtc 60 gtgaccttca cggaggcagg gtttggacag cattacttgc tgtttttcgc cactgctgca 120 ccggcccttg gcctggggct gtacattgcg cagtctgtca acatgactga gatgcctcaa 180 ctcgtggctc ttttccacag tttcgtcggt cttgccgccg taatggttgg gttcgcgaac 240 ttccactccc ctgctggcgt ggagcgcgct tcctcacttc tacgtctgtt ggaggtctac 300 gccggcgttt tcgtcgccgg tatcaccttc accggatcag tggtcgctgc ggcaaagctc 360 catggatcga tggagagccg ctcattgagg gttcccggac gccatgcgtt gaatactgcc 420 actattgctg ccattggcgt acttggcgct cttttttgcg tctcttctgg ccactttaca 480 cgcatgcttt gcctttatgt gaatgctggc ttgagcatgt ggcttggttt tcacctggtc 540 gccgctattg gtggagctga catgcccgtc gtgatcagct tgctgaactc gtattccgga 600 gtggcgttgg ctgccagtgg cttcatgttg gacaacaact tgctgatcat tgctggtgct 660 ctcatcgcgt catctggtgc cattctgtct tacatcatgt gcaaaggcat gaaccggagt 720 ctgtggaatg tcgttcttgg tggcttcgag gaggccgagg acgttggcgc agccagccct 780 cagggggctg tgcagcaggc cacggctgat caggtcgccg acgagttgct ggctgcccgc 840 aaagttttga tcgtgcctgg atacggaatg gccgttgcaa ggtgccagag cgagcttgca 900 gacattgcca agaacttgat gaactgcggt atcaccgtcg atttcggcat ccatccagtt 960 gctggtcgca tgccaggcca catgaacgtc ctcctcgctg aggctgatgt tccgtacaag 1020 attgtcaagg agatgtctga agtcaacccg gaaatgagct cctacgacgt cgtcctggtt 1080 gttggagcca acgacaccgt caatcctgca gcccttgagc caggatcaaa gatctcagga 1140 atgcccgtta tagaggcctg gaaagctaga cgcgtttttg tgctgaagcg gtccatggct 1200 gctggatatg ccagcattga aaatccactt ttccatctgg agaacacacg catgctcttc 1260 ggaaacgcaa agaacaccac ttctgcagtc ttcgcccgtg tcaatgccag agccgagcaa 1320 atgccaccat ctgctgcccg tgatgacctc gaagctggac tacttgagtt cgatagggaa 1380 gaacgtgttg atccctcttc ttggccatat cccaggatgg ctgttggtgt tctgagagac 1440 tccaatggct ctgttatggt gccagtagct ccgaagtttg tgcccaagct gaggaagttg 1500 gcattccgtg tcaatgtcga gtctggtgct ggcgccgatg ccggctttac tgacgaagag 1560 tacaggaggg ctggagcaga agtcctgtcg ggccccgatg cagtcattaa ccagtctcaa 1620 gtcctgctcc gcgtttcagc gccgtcgcca gatctggttt cgcgcattcc tagggacaag 1680 gtccttatca gttacctatt ccccagcatc aaccaacaag ctcttgacat gctagcacgc 1740 caaggcgtca ccgcacttgc tgtggatgag gttcctcgcg tcacaagagc acagaagcta 1800 gacgtgaagt ctgctatgca aggtctccag ggataccgcg ccgttatcga agcgttcaac 1860 gctcttccga agctcagcaa agcatctatc agtgctgcag gccgtgtaga agccgctaaa 1920 gttttcgtca tcggtgccgg tgttgctgga ctacaggcaa tttctaccgc ccatggtttg 1980 ggtgcacaag tatttggcca cgatgtgcgc tctgcaactc gtgaggaagt cgaatcttgc 2040 ggtggaaagt tcattggttt gagaatggga gaggagggtg aagtcctcgg aggatatgca 2100 cgcgagatgg gtgatgcata tcagagagcg caacgcgaga tgattgccaa cacaatcaag 2160 cactgcgatg tcgtcatctg taccgctgct attcacggca gaccttcacc aaagctcata 2220 tcacgcgaca tgttgcgttc aatgaagcct ggctccgtcg tcgtagatct tgcaacagag 2280 ttcggtgatg tgcgctccgg ctggggtgga aacgtcgagg tttcgcctaa ggacgaccag 2340 attgtcgttg atggcgtcac tgtcattggt cgcagacgca ttgagactcg catgcccatt 2400 caggcgtctg agctgttctc catgaacata tgcaacctcc ttgaggatct tggtggtggc 2460 agcaacttcc gcatcaacat ggacgacgaa gtcatcagag gattggtcgc agtctaccaa 2520 ggtcgcaacg tgtggcagcc atcgcagccc actcctgttt ccaggacacc tccgcgcggc 2580 cagatgccgc ccccgtctgc acctggtgca ccagctcctg agaagcctgg tgcctttgct 2640 caagcacttg cttcggatgc attcttcgca atgtgtcttg ttgttgctgc cgctgttgtc 2700 gggctccttg gcattgtcct tgaccctgtg gagctcaagc atttgactct cctcggcttg 2760 tctctcatcg tcggctacta ctgcgtgtgg gccgttacgc cttcgcttca cacaccattg 2820 atgtctgtga cgaatgccct ttcgggagtc attgtcatcg gctgcatgct cgagtacgga 2880 accgccatga tatccggatt cactcttctc gcactcattg gaaccttctt ggcttccgtc 2940 aacgttgctg gtggattctt cgtaactcac cgcatgctga agatgtttca gatataa 2997 19 996 PRT Unknown Description of Unknown Organism The seq of Fig.21 less the first two AAs, which are artifacts from cloning process. 19 Thr Ala Lys Arg Gly Asn Ile Leu Gly Leu Val Gly Met Val Ala Ala 1 5 10 15 Val Val Val Thr Phe Thr Glu Ala Gly Phe Gly Gln His Tyr Leu Leu 20 25 30 Phe Phe Ala Thr Ala Ala Pro Ala Leu Gly Leu Gly Leu Tyr Ile Ala 35 40 45 Gln Ser Val Asn Met Thr Glu Met Pro Gln Leu Val Ala Leu Phe His 50 55 60 Ser Phe Val Gly Leu Ala Ala Val Met Val Gly Phe Ala Asn Phe His 65 70 75 80 Ser Pro Ala Gly Val Glu Arg Ala Ser Ser Leu Leu Arg Leu Leu Glu 85 90 95 Val Tyr Ala Gly Val Phe Val Ala Gly Ile Thr Phe Thr Gly Ser Val 100 105 110 Val Ala Ala Ala Lys Leu His Gly Ser Met Glu Ser Arg Ser Leu Arg 115 120 125 Val Pro Gly Arg His Ala Leu Asn Thr Ala Thr Ile Ala Ala Ile Gly 130 135 140 Val Leu Gly Ala Leu Phe Cys Val Ser Ser Gly His Phe Thr Arg Met 145 150 155 160 Leu Cys Leu Tyr Val Asn Ala Gly Leu Ser Met Trp Leu Gly Phe His 165 170 175 Leu Val Ala Ala Ile Gly Gly Ala Asp Met Pro Val Val Ile Ser Leu 180 185 190 Leu Asn Ser Tyr Ser Gly Val Ala Leu Ala Ala Ser Gly Phe Met Leu 195 200 205 Asp Asn Asn Leu Leu Ile Ile Ala Gly Ala Leu Ile Ala Ser Ser Gly 210 215 220 Ala Ile Leu Ser Tyr Ile Met Cys Lys Gly Met Asn Arg Ser Leu Trp 225 230 235 240 Asn Val Val Leu Gly Gly Phe Glu Glu Ala Glu Asp Val Gly Ala Ala 245 250 255 Ser Pro Gln Gly Ala Val Gln Gln Ala Thr Ala Asp Gln Val Ala Asp 260 265 270 Glu Leu Leu Ala Ala Arg Lys Val Leu Ile Val Pro Gly Tyr Gly Met 275 280 285 Ala Val Ala Arg Cys Gln Ser Glu Leu Ala Asp Ile Ala Lys Asn Leu 290 295 300 Met Asn Cys Gly Ile Thr Val Asp Phe Gly Ile His Pro Val Ala Gly 305 310 315 320 Arg Met Pro Gly His Met Asn Val Leu Leu Ala Glu Ala Asp Val Pro 325 330 335 Tyr Lys Ile Val Lys Glu Met Ser Glu Val Asn Pro Glu Met Ser Ser 340 345 350 Tyr Asp Val Val Leu Val Val Gly Ala Asn Asp Thr Val Asn Pro Ala 355 360 365 Ala Leu Glu Pro Gly Ser Lys Ile Ser Gly Met Pro Val Ile Glu Ala 370 375 380 Trp Lys Ala Arg Arg Val Phe Val Leu Lys Arg Ser Met Ala Ala Gly 385 390 395 400 Tyr Ala Ser Ile Glu Asn Pro Leu Phe His Leu Glu Asn Thr Arg Met 405 410 415 Leu Phe Gly Asn Ala Lys Asn Thr Thr Ser Ala Val Phe Ala Arg Val 420 425 430 Asn Ala Arg Ala Glu Gln Met Pro Pro Ser Ala Ala Arg Asp Asp Leu 435 440 445 Glu Ala Gly Leu Leu Glu Phe Asp Arg Glu Glu Arg Val Asp Pro Ser 450 455 460 Ser Trp Pro Tyr Pro Arg Met Ala Val Gly Val Leu Arg Asp Ser Asn 465 470 475 480 Gly Ser Val Met Val Pro Val Ala Pro Lys Phe Val Pro Lys Leu Arg 485 490 495 Lys Leu Ala Phe Arg Val Asn Val Glu Ser Gly Ala Gly Ala Asp Ala 500 505 510 Gly Phe Thr Asp Glu Glu Tyr Arg Arg Ala Gly Ala Glu Val Leu Ser 515 520 525 Gly Pro Asp Ala Val Ile Asn Gln Ser Gln Val Leu Leu Arg Val Ser 530 535 540 Ala Pro Ser Pro Asp Leu Val Ser Arg Ile Pro Arg Asp Lys Val Leu 545 550 555 560 Ile Ser Tyr Leu Phe Pro Ser Ile Asn Gln Gln Ala Leu Asp Met Leu 565 570 575 Ala Arg Gln Gly Val Thr Ala Leu Ala Val Asp Glu Val Pro Arg Val 580 585 590 Thr Arg Ala Gln Lys Leu Asp Val Lys Ser Ala Met Gln Gly Leu Gln 595 600 605 Gly Tyr Arg Ala Val Ile Glu Ala Phe Asn Ala Leu Pro Lys Leu Ser 610 615 620 Lys Ala Ser Ile Ser Ala Ala Gly Arg Val Glu Ala Ala Lys Val Phe 625 630 635 640 Val Ile Gly Ala Gly Val Ala Gly Leu Gln Ala Ile Ser Thr Ala His 645 650 655 Gly Leu Gly Ala Gln Val Phe Gly His Asp Val Arg Ser Ala Thr Arg 660 665 670 Glu Glu Val Glu Ser Cys Gly Gly Lys Phe Ile Gly Leu Arg Met Gly 675 680 685 Glu Glu Gly Glu Val Leu Gly Gly Tyr Ala Arg Glu Met Gly Asp Ala 690 695 700 Tyr Gln Arg Ala Gln Arg Glu Met Ile Ala Asn Thr Ile Lys His Cys 705 710 715 720 Asp Val Val Ile Cys Thr Ala Ala Ile His Gly Arg Pro Ser Pro Lys 725 730 735 Leu Ile Ser Arg Asp Met Leu Arg Ser Met Lys Pro Gly Ser Val Val 740 745 750 Val Asp Leu Ala Thr Glu Phe Gly Asp Val Arg Ser Gly Trp Gly Gly 755 760 765 Asn Val Glu Val Ser Pro Lys Asp Asp Gln Ile Val Val Asp Gly Val 770 775 780 Thr Val Ile Gly Arg Arg Arg Ile Glu Thr Arg Met Pro Ile Gln Ala 785 790 795 800 Ser Glu Leu Phe Ser Met Asn Ile Cys Asn Leu Leu Glu Asp Leu Gly 805 810 815 Gly Gly Ser Asn Phe Arg Ile Asn Met Asp Asp Glu Val Ile Arg Gly 820 825 830 Leu Val Ala Val Tyr Gln Gly Arg Asn Val Trp Gln Pro Ser Gln Pro 835 840 845 Thr Pro Val Ser Arg Thr Pro Pro Arg Gly Gln Met Pro Pro Pro Ser 850 855 860 Ala Pro Gly Ala Pro Ala Pro Glu Lys Pro Gly Ala Phe Ala Gln Ala 865 870 875 880 Leu Ala Ser Asp Ala Phe Phe Ala Met Cys Leu Val Val Ala Ala Ala 885 890 895 Val Val Gly Leu Leu Gly Ile Val Leu Asp Pro Val Glu Leu Lys His 900 905 910 Leu Thr Leu Leu Gly Leu Ser Leu Ile Val Gly Tyr Tyr Cys Val Trp 915 920 925 Ala Val Thr Pro Ser Leu His Thr Pro Leu Met Ser Val Thr Asn Ala 930 935 940 Leu Ser Gly Val Ile Val Ile Gly Cys Met Leu Glu Tyr Gly Thr Ala 945 950 955 960 Met Ile Ser Gly Phe Thr Leu Leu Ala Leu Ile Gly Thr Phe Leu Ala 965 970 975 Ser Val Asn Val Ala Gly Gly Phe Phe Val Thr His Arg Met Leu Lys 980 985 990 Met Phe Gln Ile 995 20 10 DNA Unknown Description of Unknown Organism linkers (Collaborative Research) 20 ccgaattcgg 10 21 16 DNA Unknown Description of Unknown Organism primer for Sanger Sequencing. 21 cggtcgactc gagcca 16 22 17 DNA Unknown Description of Unknown Organism Primer 22 gaggtctgcc attttgc 17 23 19 PRT Unknown UNSURE (6) UNSURE (11) Description of Unknown Organism N-terminus sequence. 23 Met Asn Lys Asn Ser Xaa Leu Gly Gly Phe Xaa Ser Met Gln Glu Ser 1 5 10 15 Pro Pro Pro

Claims (97)

What is claimed is:
1. A protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711.
2. The protein of claim 1 encoded by the nucleic acid sequence
ATGGCAGACC TCTTCAGCGG ACTCGTGGGC GGCGTCGTCG GCGCTGTTGC TGCAGCAGAT TTGCCTGCGG AGGGCGAGAG GGCCCCCCGC CCCGCCCCCG GCACTGCCTG GACTTGCTGC TGCAGCAAAC TGCAAGAAGG GGCCCGCGAG CTGGAGGGTT TTGTGCAGCA GCTGAGTTTT GTTGCAGGGA AGCTGGCCTG CTGCCTGCGG GTGGGGGCGG AGCAGCTGGC GCGCTGCGCT GCGGAGGGGC GGCTGCCCAG CAGCAGCAGC AGCAGCAGCT GCTGCGCGCT GCTGCAGCTC GAGAAGCAGG ACCTCGAGCA GAGCCTCGAG GCCGGCAAGC AGGGCGCGGA GTGCCTCTTG AGGAGCAGCA AAGTGGCCCT CGAGGCCCTC CTCGAGGGGG CCCGCGTTGC AGCAACGCGG GGTTTGCTGC TGGTCGAGAG CAGCAAAGAC ACGGTGCTGC GCAGCATTCC CCACACCCAG GAGAAGCTGG CTCAGGCCTA CAGTTCTTTC CTGCGGGGCT ACCAGGGGGC AGCAGCGGGG AGGTCTCTGG GCTACGGGGC CCCTGCTGCT GCTTACGGCC AGCAGCAGCA GCCCAGCAGC TACGGGGCGC CCCCCGCCTC CAGCCAGCAG CCCTCCGGCT TCTTCTGGTA G
or by a functional equivalent or partial sequence thereof.
3. The protein of claim 1 having the amino acid sequence
MetAlaAspLeuPheSerGlyLeuValGlyGlyValValGlyAlaValAlaAlaAlaAsp LeuProAlaGluGlyGluArgAlaProArgProAlaProGlyThrAlaTrpThrCysCys CysSerLysLeuGlnGluGlyAlaArgGluLeuGluGlyPheValGlnGlnLeuSerPhe ValAlaGlyLysLeuAlaCysCysLeuArgValGlyAlaGluGlnLeuAlaArgCysAla AlaGluGlyArgLeuProSerSerSerSerserSerserCysCysAlaLeuLeuGlnLeu GluLysGlnAspLeuGluGlnserLeuGluAlaGlyLysGlnGlyAlaGluCysLeuLeu ArgSerSerLysLeuAlaLeuGluAlaLeuLeuGluGlyAlaArgValAlaAlaThrArg GlyLeuLeuLeuValGluSerSerLysAspThrValLeuArgSerIleProHisThrGln GluLysLeuAlaGlnAlaTyrSerSerPheLeuArgGlyTyrGlnGlyAlaAlaAlaGly ArgSerLeuGlyTyrGlyAlaProAlaAlaAlaTyrGlyGlnGlnGlnGlnProSerSer TyrGlyAlaProProAlaSerSerGlnGlnProSerGlyPhePheTrp
or a functional equivalent or partial sequence thereof.
4. A DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711.
5. The DNA sequence of claim 4 encoding a protein having the amino acid sequence
MetAlaAspLeuPheSerGlyLeuValGlyGlyValValGlyAlaValAlaAlaAlaAsp LeuProAlaGluGlyGluArgAlaProArgProAlaProGlyThrAlaTrpThrCysCys CysSerLysLeuGlnGluGlyAlaArgGluLeuGluGlyPheValGlnGlnLeuSerPhe ValAlaGlyLysLeuAlaCysCysLeuArgValGlyAlaGluGlnLeuAlaArgCysAla AlaGluGlyArgLeuProSerSerSerSerSerSerSerCysCysAlaLeuLeuGlnLeu GluLysGlnAspLeuGluGlnSerLeuGluAlaGlyLysGlnGlyAlaGluCysLeuLeu ArgSerSerLysLeuAlaLeuGluAlaLeuLeuGluGlyAlaArgValAlaAlaThrArg GlyLeuLeuLeuValGluSerSerLysAspThrValLeuArgSerIleProHisThrGln GluLysLeuAlaGlnAlaTyrSerSerPheLeuArgGlyTyrGlnGlyAlaAlaAlaGly ArgSerLeuGlyTyrGlyAlaProAlaAlaAlaTyrGlyGlnGlnGlnGlnProSerSer TyrGlyAlaProProAlaSerSerGlnGlnProSerGlyPhePheTrp
or a functional equivalent or partial sequence thereof.
6. The DNA sequence of claim 4 comprising all or part of the nucleotide sequence
ATGGCAGACC TCTTCAGCGG ACTCGTGGGC GGCGTCGTCG GCGCTGTTGC TGCAGCAGAT TTGCCTGCGG AGGGCGAGAG GGCCCCCCGC CCCGCCCCCG GCACTGCCTG GACTTGCTGC TGCAGCAAAC TGCAAGAAGG GGCCCGCGAG CTGGAGGGTT TTGTGCAGCA GCTGAGTTTT GTTGCAGGGA AGCTGGCCTG CTGCCTGCGG GTGGGGGCGG AGCAGCTGGC GCGCTGCGCT GCGGAGGGGC GGCTGCCCAG CAGCAGCAGC AGCAGCAGCT GCTGCGCGCT GCTGCAGCTC GAGAAGCAGG ACCTCGAGCA GAGCCTCGAG GCCGGCAAGC AGGGCGCGGA GTGCCTCTTG AGGAGCAGCA AACTGGCCCT CGAGGCCCTC CTCGAGGGGG CCCGCGTTGC AGCAACGCGG GGTTTGCTGC TGGTCGAGAG CAGCAAAGAC ACGGTGCTGC GCAGCATTCC CCACACCCAG GAGAAGCTGG CTCAGGCCTA CAGTTCTTTC CTGCGGGGCT ACCAGGGGGC AGCAGCGGGG AGGTCTCTGG GCTACGGGGC CCCTGCTGCT GCTTACGGCC AGCAGCAGCA GCCCAGCAGC TACGGGGCGC CCCCCGCCTC CAGCCAGCAG CCCTCCGGCT TCTTCTGGTA G.
7. A recombinant vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711.
8. The recombinant vector of claim 7 comprising a DNA sequence encoding a protein having the amino acid sequence
MetAlaAspLeuPheSerGlyLeuValGlyGlyValValGlyAlaValAlaAlaAlaAsp LeuProAlaGluGlyGluArgAlaProArgProAlaProGlyThrAlaTrpThrCysCys CysSerLysLeuGlnGluGlyAlaArgGluLeuGluGlyPheValGlnGlnLeuSerPhe ValAlaGlyLysLeuAlaCysCysLeuArgValGlyAlaGluGlnLeuAlaArgCysAla AlaGluGlyArgLeuProSerSerSerSerSerSerSerCysCysAlaLeuLeuGlnLeu GluLysGlnAspLeuGluGlnSerLeuGluAlaGlyLysGlnGlyAlaGluCysLeuLeu ArgserSerLysLeuAlaLeuGluAlaLeuLeuGluGlyAlaArgValAlaAlaThrArg GlyLeuLeuLeuValGluSerSerLysAspThrValLeuArgSerIleProHisThrGln GluLysLeuAlaGlnAlaTyrSerSerPheLeuArgGlyTyrGlnGlyAlaAlaAlaGly ArgSrLeuGlyTyrGlyAlaProAlaAlaAlaTyrGlyGlnGlnGlnGlnProSerSer TyrGlyAlaProProAlaSerSerGlnGlnProSerGlyPhePheTrp
or a functional equivalent or partial sequence thereof.
9. The recombinant vector of claim 7 comprising all or part of the nucleotide sequence
ATGGCAGACC TCTTCAGCGG ACTCGTGGGC GGCGTCGTCG GCGCTGTTGC TGCAGCAGAT TTGCCTGCGG AGGGCGAGAG GGCCCCCCGC CCCGCCCCCG GCACTGCCTG GACTTGCTGC TGCAGCAAAC TGCAAGAAGG GGCCCGCGAG CTGGAGGGTT TTGTGCAGCA GCTGAGTTTT GTTGCAGGGA AGCTGGCCTG CTGCCTGCGG GTGGGGGCGG AGCAGCTGGC GCGCTGCGCT GCGGAGGGGC GGCTGCCCAG CAGCAGCAGC AGCAGCAGCT GCTGCGCGCT GCTGCAGCTC GAGAAGCAGG ACCTCGAGCA GAGCCTCGAG GCCGGCAAGC AGGGCGCGGA GTGCCTCTTG AGGAGCAGCA AACTGGCCCT CGAGGCCCTC CTCGAGGGGG CCCGCGTTGC AGCAACGCGG GGTTTGCTGC TGGTCGAGAG CAGCAAAGAC ACGGTGCTGC GCAGCATTCC CCACACCCAG GAGAAGCTGG CTCAGGCCTA CAGTTCTTTC CTGCGGGGCT ACCAGGGGGC AGCAGCGGGG AGGTCTCTGG GCTACGGGGC CCCTGCTGCT GCTTACGGCC AGCAGCAGCA GCCCAGCAGC TACGGGGCGC CCCCCGCCTC CAGCCAGCAG CCCTCCGGCT TCTTCTGGTA G.
10. The recombinant vector of claim 7 which recombinant vector is an E. coli vector.
11. The recombinant vector of claim 7 which is a pox virus vector.
12. A microorganism transformed with a recombinant vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711.
13. A method for producing a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711, which process comprises:
(a) culturing a microorganism transformed with a recombinant vector comprising a DNA sequence encoding the said protein in a culture medium under conditions in which the DNA sequence is expressed;
(b) isolating the said protein from the culture.
14. A vaccine for protecting poultry against coccidiosis comprising a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711 and a physiologically acceptable carrier.
15. A vaccine for protecting poultry against coccidiosis containing a recombinant poxvirus vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711 and a physiologically acceptable carrier.
16. A method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine comprising a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711 and a physiologically acceptable carrier to a young fowl that is susceptible to coccidiosis.
17. A method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine containing a recombinant poxvirus vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711 and a physiologically acceptable carrier to a young fowl that is susceptible to coccidiosis.
18. An isolated antibody which is directed against an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 28 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711.
19. The antibody of claim 18 which is a monoclonal antibody, such as the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9711.
20. A protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707.
21. The protein of claim 20 encoded by the nucleic acid sequence
GAATTCATGT TTAGGCGGAT TTTGTTCCAT GCAAGAAAGC CCACCACCGG CTGCAGGTGG ACTGTACGGG GGACAGACTT TGGAACAACA AGGCATTGCT GTGAGGGAAA CTGCTTCGTG CAGCGAGAAC CCGTGCCCTA TCGACGCAAC GTGCGGAGAA TGGACAGAGT ACAGTGCGTG CTCCAGAACT TGCGGAGGCG GTACCCAAGA GAGGAAGAGG GAGCCGTGGT TGGATAATGC GCAACACGGG GGGCGCACCT GCATGGAACA GTATCCTGAT GGGCCCATAT CGGTCAGGGA GTGCAACACC CAGCCGTGCC CTGTGGACGA AGTAGTTGGT GATTGGGAAG ACTGGGGGCA ATGCAGCGAA CAGTGTGGTG GCGGCAAGCG GACTCGTAAT CGCGGCCCAA GCAAGCAAGA GGCCATGTTC GGAGGCAAGA CAGTTGCTCA ACAGAACGCA GAGCTCCCTG AAGGCGAGAA GATTGAGGTG GTTCAGGAAG AAGGATGCAA TGAAGTTCCA TGCGGACCTT GCACGCTCCC CTTCAGTGAG TGGACCGAAT GCGAGTCGTG CTCCGGGCAT AGAACCAGGG AATCCGCAGT AGCATTTGAT TACACTGACA GAATGTGCAG TGGTGACACA CACGAGGTAC AAAGCTGTGA GGAATACTGT TCCCAAAATG CTGGAGGGGG TGCTGGAGGA GATGGGGGCG CAGGAGGAGG GACTGGAGGC TCTGGAGAGG AGGAAGGAAA GGAGGAATCG AGTGGATTTC CAACTGCAGC TGTAGCCGGT GGCGTGGCTG GGGGAGTCCT CGCGATTGCT GCGGGAGCTG GAGCGTTTTA TGGATTGAGT GGTGGGAGCG CGGCTGCTGC CACTGAAGCA GGTGCTGAAG TGATGACAGA AGCTGGTACA TCCAATGCTG CTGAGGTAGA AAAGGAGAGC CTCATCAGTG CAGGTGAACA ATCAGAGATG TGGGCATCCT AAATGGAAAC GTCGCCGCCG CGGGTTTCGA AAAGGTGCGG ATCTTGCATA TCTGTGAACG AATTATTTAC TAACATCGAG CTCCTTGACC TCCCGTTGGC AAATCATTTA CCAAGCATCT CTGGCGCATA GCTTCTTGAA CAAGACAACG GAATGTCCAA CTGGGGAACA GCTATATTGC GAAGTGTGGT GTTCAAACCA GAAGAGAGCA CAGCGTCATG TGTATGTTAG GGTTGGGCGC CTCCTTTCCC TTATTTATCC CATTTCCTCC GCCTTCATCT TTCCGCCTTC TCTCTGTGCG CCGTATTTTG GGTGTTATTG GTGCCTGGCG GACAGTAAAG AGAGATTGGC GTTATTTGCA GCGTGCGCAG GCCATGGTAG GGTTGGATAA CACTCATTGG TGAAGCGCAA GCCAACAGGG CCACCTTTAC CTCCTGGTGG TCAATGGGGC AGCTTGCTTC TGATCATTGG TTGGTTCTGT TTCAAGGGGC CGGTAATGGG CAGCAGAAGC TTCTGCCAGC CACCACACAA TCGAAGCAAC AAATAAGGGA GGTTCTGCTA ACAATTGTGC GTAGTCATGA TTGTAGGTAG GCTCCGTTTC GAAGATGAAT GACCGGGAGC AGCCTGAATG AAACTTGACT CTCAAAGAAG GGAATTC
or by a functional equivalent or partial sequence thereof.
22. The protein of claim 20 encoded by the nucleic acid sequence
CTGTACGGG GGACAGACTT TGGAACAACA AGGCATTGCT GTGAGGGAAA CTGCTTCGTG CAGCGAGAAC CCGTGCCCTA TCGACGCAAC GTGCGGAGAA TGGACAGAGT ACAGTGCGTG CTCCAGAACT TGCGGAGGCG GTACCCAAGA GAGGAAGAGG GAGCCGTGGT TGGATAATGC GCAACACGGG GGGCGCACCT GCATGGAACA GTATCCTGAT GGGCCCATAT CGGTCAGGGA GTGCAACACC CAGCCGTGCC CTGTGGACGA AGTAGTTGGT GATTGGGAAG ACTGGGGGCA ATGCAGCGAA CAGTGTGGTG GCGGCAAGCG GACTCGTAAT CGCGGCCCAA GCAAGCAAGA GGCCATGTTC GGAGGCAAGA CAGTTGCTCA ACAGAACGCA GAGCTCCCTG AAGGCGAGAA GATTGAGGTG GTTCAGGAAG AAGGATGCAA TGAAGTTCCA TGCGGACCTT GCACGCTCCC CTTCAGTGAG TGGACCGAAT GCGAGTCGTG CTCCGGGCAT AGAACCAGGG AATCCGCAGT AGCATTTGAT TACACTGACA GAATGTGCAG TGGTGACACA CACGAGGTAC AAAGCTGTGA GGAATACTGT TCCCAAAATG CTGGAGGGGG TGCTGGAGGA GATGGGGGCG CAGGAGGAGG GACTGGAGGC TCTGGAGAGG AGGAAGGAAA GGAGGAATCG AGTGGATTTC CAACTGCAGC TGTAGCCGGT GGCGTGGCTG GGGGAGTCCT CGCCATTGCT GCGGGAGCTG GAGCGTTTTA TGGATTGAGT GGTGGGAGCG CGGCTGCTGC CACTGAAGCA GGTGCTGAAG TGATGACAGA AGCTGGTACA TCCAATGCTG CTGAGGTAGA AAAGGAGAGC CTCATCAGTG CAGGTGAACA ATCAGAGATG TGGGCATCCT AA
or by a functional equivalent or partial sequence thereof.
23. The protein of claim 20 having the amino acid sequence
SerCysLeuGlyGlyPheCysSerMetGlnGluSerProProProAlaAlaGlyGlyLeu TyrGlyGlyGlnThrLeuGluGlnGlnGlyIleAlaValArgGluThrAlaSerCysSer GluAsnProCysProlleAspAlaThrCysGlyGluTrpThrGluTyrSerAlaCysSer ArgThrCysGlyGlyGlyThrGlnGluArgLysArgGluProTrpLeuAspAsnAlaGln HisGlyGlyArgThrCysMetGluGlnTyrProAspGlyProIleSerValArgGluCys AsnThrGlnProCysProValAspGluValValGlyAspTrpGluAspTrpGlyGlnCys SerGluGlnCysGlyGlyGlyLysArgThrArgAsnArgGlyProSerLysGlnGluAla MetPheGlyGlyLysThrValAlaGlnGlnAsnAlaGluLeuProGluGlyGluLysIle GluValValGlnGluGluGlyCysAsnGluValProCysGlyProCysThrLeuProPhe SerGluTrpThrGluCysGluSerCysSerGlyHisArgThrArgGluSerAlaValAla PheAspTyrThrAspArgMetCysSerGlyAspThrHisGluValGlnSerCysGluGlu TyrCysSerGlnAsnAlaGlyGlyGlyAlaGlyGlyAspGlyGlyAlaGlyGlyGlyThr GlyGlySerGlyGluGluGluGlyLysGluGluSerSerGlyPheProThrAlaAlaVal AlaGlyGlyValAlaGlyGlyValLeuAlaIleAlaAlaGlyAlaGlyAlaPheTyrGly LeuSerGlyGlySerAlaAlaAlaAlaThrGluAlaGlyAlaGluValMetThrGluAla GlyThrSerAsnAlaAlaGluValGluLysGluSerLeuIleSerAlaGlyGluGlnSer GluMetTrpAlaSer
or a functional equivalent or partial sequence thereof.
24. The protein of claim 20 having the amino acid sequence
LeuTyrGlyGlyGlnThrLeuGluGlnGlnGlyIleAlaValArgGluThrAlaSerCys SerGluAsnProCysProIleAspAlaThrCysGlyGluTrpThrGluTyrSerAlaCys SerArgThrCysGlyGlyGlyThrGlnGluArgLysArgGluProTrpLeuAspAsnAla GlnHisGlyGlyArgThrCysMetGluGlnTyrProAspGlyProIleSerValArgGlu CysAsnThrGlnProCysProValAspGluValValGlyAspTrpGluAspTrpGlyGln CysSerGluGlnCysGlyGlyGlyLysArgThrArgAsnArgGlyProSerLysGlnGlu AlaMetPheGlyGlyLysThrValAlaGlnGlnAsnAlaGluLeuProGluGlyGluLys IleGluValValGlnGluGluGlyCysAsnGluValProCysGlyProCysThrLeuPro PheSerGluTrpThrGluCysGluSerCysSerGlyHisArgThrArgGluSerAlaVal AlaPheAspTyrThrAspArgMetCysSerGlyAspThrHisGluValGlnSerCysGlu GluTyrCysSerGlnAsnAlaGlyGlyGlyAlaGlyGlyAspGlyGlyAlaGlyGlyGly ThrGlyGlySerGlyGluGluGluGlyLysGluGluSerSerGlyPheProThrAlaAla ValAlaGlyGlyValAlaGlyGlyValLeuAlaIleAlaAlaGlyAlaGlyAlaPheTyr GlyLeuSerGlyGlySerAlaAlaAlaAlaThrGluAlaGlyAlaGluValMetThrGlu AlaGlyThrSerAsnAlaAlaGluValGluLysGluSerLeuIleSerAlaGlyGluGln SerGluMetTrpAlaSer
or a functional equivalent or partial sequence thereof.
25. A DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707.
26. The DNA sequence of claim 25 encoding a protein having the amino acid sequence
SerCysLeuGlyGlyPheCysSerMetGlnGluSerProProProAlaAlaGlyGlyLeu TyrGlyGlyGlnThrLeuGluGlnGlnGlyIleAlaValArgGluThrAlaSerCysSer GluAsnProCysProIleAspAlaThrCysGlyGluTrpThrGluTyrSerAlaCysSer ArgThrCysGlyGlyGlyThrGlnGluArgLysArgGluProTrpLeuAspAsnAlaGln HisGlyGlyArgThrCysMetGluGlnTyrProAspGlyProIleSerValArgGluCys AsnThrGlnProCysProValAspGluValValGlyAspTrpGluAspTrpGlyGlnCys SerGluGlnCysGlyGlyGlyLysArgThrArgAsnArgGlyProSerLysGlnGluAla MetPheGlyGlyLysThrValAlaGlnGlnAsnAlaGluLeuProGluGlyGluLysIle GluValValGlnGluGluGlyCysAsnGluValProCysGlyProCysThrLeuProPhe SerGluTrpThrGluCysGluSerCysSerGlyHisArgThrArgGluSerAlaValAla PheAspTyrThrAspArgMetCysSerGlyAspThrHisGluValGlnSerCysGluGlu TyrCysSerGlnAsnAlaGlyGlyGlyAlaGlyGlyAspGlyGlyAlaGlyGlyGlyThr GlyGlySerGlyGluGluGluGlyLysGluGluSerSerGlyPheProThrAlaAlaVal AlaGlyGlyValAlaGlyGlyValLeuAlaIleAlaAlaGlyAlaGlyAlaPheTyrGly LeuSerGlyGlySerAlaAlaAlaAlaThrGluAlaGlyAlaGluValMetThrGluAla GlyThrSerAsnAlaAlaGluValGluLysGluSerLeuIleSerAlaGlyGluGlnSer GluMetTrpAlaSer
or a functional equivalent or par wal sequence thereof.
27. The DNA sequence of claim 25 encoding a protein having the amino acid sequence
LeuTyrGlyGlyGlnThrLeuGluGlnGlnGlyIleAlaValArgGluThrAlaSerCys SerGluAsnProCysProIleAspAlaThrCysGlyGluTrpThrGluTyrSerAlaCys SerArgThrCysGlyGlyGlyThrGlnGluArgLysArgGluProTrpLeuAspAsnAla GlnHisGlyGlyArgThrCysMetGluGlnTyrProAspGlyProIleSerValArgGlu CysAsnThrGlnProCysProValAspGluValValGlyAspTrpGluAspTrpGlyGln CysSerGluGlnCysGlyGlyGlyLysArgThrArgAsnArgGlyProSerLysGlnGlu AlaMetPheGlyGlyLysThrValAlaGlnGlnAsnAlaGluLeuProGluGlyGluLys IleGluValValGlnGluGluGlyCysAsnGluValProCysGlyProCysThrLeuPro PheSerGluTrpThrGluCysGluSerCysSerGlyHisArgThrArgGluSerAlaVal AlaPheAspTyrThrAspArgMetCysSerGlyAspThrHisGluValGlnSerCysGlu GluTyrCysSerGlnAsnAlaGlyGlyGlyAlaGlyGlyAspGlyGlyAlaGlyGlyGly ThrGlyGlySerGlyGluGluGluGlyLysGluGluSerSerGlyPheProThrAlaAla ValAlaGlyGlyValAlaGlyGlyValLeuAlaIleAlaAlaGlyAlaGlyAlaPheTyr GlyLeuSerGlyGlySerAlaAlaAlaAlaThrGluAlaGlyAlaGluValMetThrGlu AlaGlyThrSerAsnAlaAlaGluValGluLysGluSerLeuIleSerAlaGlyGluGln SerGluMetTrpAlaSer
or a functional equivalent or partial sequence thereof.
28. The DNA sequence of claim 25 comprising all or part of the nucleotide sequence
GAATTCATGT TTAGGCGGAT TTTGTTCCAT GCAAGAAAGC CCACCACCGG CTGCAGGTGG ACTGTACGGG GGACAGACTT TGGAACAACA AGGCATTGCT GTGAGGGAAA CTGCTTCGTG CAGCGAGAAC CCGTGCCCTA TCGACGCAAC GTGCGGAGAA TGGACAGAGT ACAGTGCGTG CTCCAGAACT TGCGGAGGCG GTACCCAAGA GAGGAAGAGG GAGCCGTGGT TGGATAATGC GCAACACGGG GGGCGCACCT GCATGGAACA GTATCCTGAT GGGCCCATAT CGGTCAGGGA GTGCAACACC CAGCCGTGCC CTGTGGACGA AGTAGTTGGT GATTGGGAAG ACTGGGGGCA ATGCAGCGAA CAGTGTGGTG GCGGCAAGCG GACTCGTAAT CGCGGCCCAA GCAAGCAAGA GGCCATGTTC GGAGGCAAGA CAGTTGCTCA ACAGAACGCA GAGCTCCCTG AAGGCGAGAA GATTGAGGTG GTTCAGGAAG AAGGATGCAA TGAAGTTCCA TGCGGACCTT GCACGCTCCC CTTCAGTGAG TGGACCGAAT GCGAGTCGTG CTCCGGGCAT AGAACCAGGG AATCCGCAGT AGCATTTGAT TACACTGACA GAATGTGCAG TGGTGACACA CACGAGGTAC AAAGCTGTGA GGAATACTGT TCCCAAAATG CTGGAGGGGG TGCTGGAGGA GATGGGGGCG CAGGAGGAGG GACTGGAGGC TCTGGAGAGG AGGAAGGAAA GGAGGAATCG AGTGGATTTC CAACTGCAGC TGTAGCCGGT GGCGTGGCTG GGGGAGTCCT CGCGATTGCT GCGGGAGCTG GAGCGTTTTA TGGATTGAGT GGTGGGAGCG CGGCTGCTGC CACTGAAGCA GGTGCTGAAG TGATGACAGA AGCTGGTACA TCCAATGCTG CTGAGGTAGA AAAGGAGAGC CTCATCAGTG CAGGTGAACA ATCAGAGATG TGGGCATCCT AAATGGAAAC GTCGCCGCCG CGGGTTTCGA AAAGGTGCGG ATCTTGCATA TCTGTGAACG AATTATTTAC TAACATCGAG CTCCTTGACC TCCCGTTGGC AAATCATTTA CCAAGCATCT CTGGCGCATA GCTTCTTGAA CAAGACAACG GAATGTCCAA CTGGGGAACA GCTATATTGC GAAGTGTGGT GTTCAAACCA GAAGAGAGCA CAGCGTCATG TGTATGTTAG GGTTGGGCGC CTCCTTTCCC TTATTTATCC CATTTCCTCC GCCTTCATCT TTCCGCCTTC TCTCTGTGCG CCGTATTTTG GGTGTTATTG GTGCCTGGCG GACAGTAAAG AGAGATTGGC GTTATTTGCA GCGTGCGCAG GCCATGGTAG GGTTGGATAA CACTCATTGG TGAAGCGCAA GCCAACAGGG CCACCTTTAC CTCCTGGTGG TCAATGGGGC AGCTTGCTTC TGATCATTGG TTGGTTCTGT TTCAAGGGGC CGGTAATGGG CAGCAGAAGC TTCTGCCAGC CACCACACAA TCGAAGCAAC AAATAAGGGA GGTTCTGCTA ACAATTGTGC GTAGTCATGA TTGTAGGTAG GCTCCGTTTC GAAGATGAAT GACCGGGAGC AGCCTGAATG AAACTTGACT CTCAAAGAAG GGAATTC.
29. The DNA sequence of claim 25 comprising all or part of the nucleotide sequence
CTGTACGGG GGACAGACTT TGGAACAACA AGGCATTGCT GTGAGGGAAA CTGCTTCGTG CAGCGAGAAC CCGTGCCCTA TCGACGCAAC GTGCGGAGAA TGGACAGAGT ACAGTGCGTG CTCCAGAACT TGCGGAGGCG GTACCCAAGA GAGGAAGAGG GAGCCGTGGT TGGATAATGC GCAACACGGG GGGCGCACCT GCATGGAACA GTATCCTGAT GGGCCCATAT CGGTCAGGGA GTGCAACACC CAGCCGTGCC CTGTGGACGA AGTAGTTGGT GATTGGGAAG ACTGGGGGCA ATGCAGCGAA CAGTGTGGTG GCGGCAAGCG GACTCGTAAT CGCGGCCCAA GCAAGCAAGA GGCCATGTTC GGAGGCAAGA CAGTTGCTCA ACAGAACGCA GAGCTCCCTG AAGGCGAGAA GATTGAGGTG GTTCAGGAAG AAGGATGCAA TGAAGTTCCA TGCGGACCTT GCACGCTCCC CTTCAGTGAG TGGACCGAAT GCGAGTCGTG CTCCGGGCAT AGAACCAGGG AATCCGCAGT AGCATTTGAT TACACTGACA GAATGTGCAG TGGTGACACA CACGAGGTAC AAAGCTGTGA GGAATACTGT TCCCAAAATG CTGGAGGGGG TGCTGGAGGA GATGGGGGCG CAGGAGGAGG GACTGGAGGC TCTGGAGAGG AGGAAGGAAA GGAGGAATCG AGTGGATTTC CAACTGCAGC TGTAGCCGGT GGCGTGGCTG GGGGAGTCCT CGCCATTGCT GCGGGAGCTG GAGCGTTTTA TGGATTGAGT GGTGGGAGCG CGGCTGCTGC CACTGAAGCA GGTGCTGAAG TGATGACAGA AGCTGGTACA TCCAATGCTG CTGAGGTAGA AAAGGAGAGC CTCATCAGTG CAGGTGAACA ATCAGAGATG TGGGCATCCT AA.
30. A recombinant vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigen c determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707.
31. The recombinant vector of claim 30 comprising a DNA sequence encoding a protein having the amino acid sequence
SerCysLeuGlyGlyPheCysSerMetGlnGluSerProProProAlaAlaGlyGlyLeu TyrGlyGlyGlnThrLeuGluGlnGlnGlyIleAlaValArgGluThrAlaSerCysSer GluAsnProCysProIleAspAlaThrCysGlyGluTrpThrGluTyrSerAlaCysSer ArgThrCysGlyGlyGlyThrGlnGluArgLysArgGluProTrpLeuAspAsnAlaGln HisGlyGlyArgThrCysMetGluGlnTyrProAspGlyProIleSerValArgGluCys AsnThrGlnProCysProValAspGluValValGlyAspTrpGluAspTrpGlyGlnCys SerGluGlnCysGlyGlyGlyLysArgThrArgAsnArgGlyProSerLysGlnGluAla MetPheGlyGlyLysThrValAlaGlnGlnAsnAlaGluLeuProGluGlyGluLysIle GluValValGlnGluGluGlyCysAsnGluValProCysGlyProCysThrLeuProPhe SerGluTrpThrGluCysGluSerCysSerGlyHisArgThrArgGluSerAlaValAla PheAspTyrThrAspArgMetCysSerGlyAspThrHisGluValGlnSerCysGluGlu TyrCysSerGlnAsnAlaGlyGlyGlyAlaGlyGlyAspGlyGlyAlaGlyGlyGlyThr GlyGlySerGlyGluGluGluGlyLysGluGluSerSerGlyPheProThrAlaAlaVal AlaGlyGlyValAlaGlyGlyValLeuAlaIleAlaAlaGlyAlaGlyAlaPheTyrGly LeuSerGlyGlySerAlaAlaAlaAlaThrGluAlaGlyAlaGluValMetThrGluAla GlyThrSerAsnAlaAlaGluValGluLysGluSerLeuIleSerAlaGlyGluGlnSer GluMetTrpAlaSer
or a functional equivalent or partial sequence thereof.
32. The recombinant vector of claim 30 comprising a DNA sequence encoding a protein having the amino acid sequence
LeuTyrGlyGlyGlnThrLeuGluGlnGlnGlyIleAlaValArgGluThrAlaSerCys SerGluAsnProCysProIleAspAlaThrCysGlyGluTrpThrGluTyrSerAlaCys SerArgThrCysGlyGlyGlyThrGlnGluArgLysArgGluProTrpLeuAspAsnAla GlnHisGlyGlyArgThrCysMetGluGlnTyrProAspGlyProIleSerValArgGlu CysAsnThrGlnProCysProValAspGluValValGlyAspTrpGluAspTrpGlyGln CysSerGluGlnCysGlyGlyGlyLysArgThrArgAsnArgGlyProSerLysGlnGlu AlaMetPheGlyGlyLysThrValAlaGlnGlnAsnAlaGluLeuProGluGlyGluLys IleGluValValGlnGluGluGlyCysAsnGluValProCysGlyProCysThrLeuPro PheSerGluTrpThrGluCysGluSerCysSerGlyHisArgThrArgGluSerAlaVal AlaPheAspTyrThrAspArgMetCysSerGlyAspThrHisGluValGlnSerCysGlu GluTyrCysSerGlnAsnAlaGlyGlyGlyAlaGlyGlyAspGlyGlyAlaGlyGlyGly ThrGlyGlySerGlyGluGluGluGlyLysGluGluSerSerGlyPheProThrAlaAla ValAlaGlyGlyValAlaGlyGlyValLeuAlaIleAlaAlaGlyAlaGlyAlaPheTyr GlyLeuSerGlyGlySerAlaAlaAlaAlaThrGluAlaGlyAlaGluValMetThrGlu AlaGlyThrSerAsnAlaAlaGluValGluLysGluSerLeuIleSerAlaGlyGluGln SerGluMetTrpAlaSer
or a functional equivalent or partial sequence thereof.
33. The recombinant vector of claim 30 comprising all or part of the nucleotide sequence
GAATTCATGT TTAGGCGGAT TTTGTTCCAT GCAAGAAAGC CCACCACCGG CTGCAGGTGG ACTGTACGGG GGACAGACTT TGGAACAACA AGGCATTGCT GTGAGGGAAA CTGCTTCGTG CAGCGAGAAC CCGTGCCCTA TCGACGCAAC GTGCGGAGAA TGGACAGAGT ACAGTGCGTG CTCCAGAACT TGCGGAGGCG GTACCCAAGA GAGGAAGAGG GAGCCGTGGT TGGATAATGC GCAACACGGG GGGCGCACCT GCATGGAACA GTATCCTGAT GGGCCCATAT CGGTCAGGGA GTGCAACACC CAGCCGTGCC CTGTGGACGA AGTAGTTGGT GATTGGGAAG ACTGGGGGCA ATGCAGCGAA CAGTGTGGTG GCGGCAAGCG GACTCGTAAT CGCGGCCCAA GCAAGCAAGA GGCCATGTTC GGAGGCAAGA CAGTTGCTCA ACAGAACGCA GAGCTCCCTG AAGGCGAGAA GATTGAGGTG GTTCAGGAAG AAGGATGCAA TGAAGTTCCA TGCGGACCTT GCACGCTCCC CTTCAGTGAG TGGACCGAAT GCGAGTCGTG CTCCGGGCAT AGAACCAGGG AATCCGCAGT AGCATTTGAT TACACTGACA GAATGTGCAG TGGTGACACA CACGAGGTAC AAAGCTGTGA GGAATACTGT TCCCAAAATG CTGGAGGGGG TGCTGGAGGA GATGGGGGCG CAGGAGGAGG GACTGGAGGC TCTGGAGAGG AGGAAGGAAA GGAGGAATCG AGTGGATTTC CAACTGCAGC TGTAGCCGGT GGCGTGGCTG GGGGAGTCCT CGCGATTGCT GCGGGAGCTG GAGCGTTTTA TGGATTGAGT GGTGGGAGCG CGGCTGCTGC CACTGAAGCA GGTGCTGAAG TGATGACAGA AGCTGGTACA TCCAATGCTG CTGAGGTAGA AAAGGAGAGC CTCATCAGTG CAGGTGAACA ATCAGAGATG TGGGCATCCT AAATGGAAAC GTCGCCGCCG CGGGTTTCGA AAAGGTGCGG ATCTTGCATA TCTGTGAACG AATTATTTAC TAACATCGAG CTCCTTGACC TCCCGTTGGC AAATCATTTA CCAAGCATCT CTGGCGCATA GCTTCTTGAA CAAGACAACG GAATGTCCAA CTGGGGAACA GCTATATTGC GAAGTGTGGT GTTCAAACCA GAAGAGAGCA CAGCGTCATG TGTATGTTAG GGTTGGGCGC CTCCTTTCCC TTATTTATCC CATTTCCTCC GCCTTCATCT TTCCGCCTTC TCTCTGTGCG CCGTATTTTG GGTGTTATTG GTGCCTGGCG GACAGTAAAG AGAGATTGGC GTTATTTGCA GCGTGCGCAG GCCATGGTAG GGTTGGATAA CACTCATTGG TGAAGCGCAA GCCAACAGGG CCACCTTTAC CTCCTGGTGG TCAATGGGGC AGCTTGCTTC TGATCATTGG TTGGTTCTGT TTCAAGGGGC CGGTAATGGG CAGCAGAAGC TTCTGCCAGC CACCACACAA TCGAAGCAAC AAATAAGGGA GGTTCTGCTA ACAATTGTGC GTAGTCATGA TTGTAGGTAG GCTCCGTTTC GAAGATGAAT GACCGGGAGC AGCCTGAATG AAACTTGACT CTCAAAGAAG GGAATTC.
34. The recombinant vector of claim 30 comprising all or part of the nucleotide sequence
CTGTACGGG GGACAGACTT TGGAACAACA AGGCATTGCT GTGAGGGAAA CTGCTTCGTG CAGCGAGAAC CCGTGCCCTA TCGACGCAAC GTGCGGAGAA TGGACAGAGT ACAGTGCGTG CTCCAGAACT TGCGGAGGCG GTACCCAAGA GAGGAAGAGG GAGCCGTGGT TGGATAATGC GCAACACGGG GGGCGCACCT GCATGGAACA GTATCCTGAT GGGCCCATAT CGGTCAGGGA GTGCAACACC CAGCCGTGCC CTGTGGACGA AGTAGTTGGT GATTGGGAAG ACTGGGGGCA ATGCAGCGAA CAGTGTGGTG GCGGCAAGCG GACTCGTAAT CGCGGCCCAA GCAAGCAAGA GGCCATGTTC GGAGGCAAGA CAGTTGCTCA ACAGAACGCA GAGCTCCCTG AAGGCGAGAA GATTGAGGTG GTTCAGGAAG AAGGATGCAA TGAAGTTCCA TGCGGACCTT GCACGCTCCC CTTCAGTGAG TGGACCGAAT GCGAGTCGTG CTCCGGGCAT AGAACCAGGG AATCCGCAGT AGCATTTGAT TACACTGACA GAATGTGCAG TGGTGACACA CACGAGGTAC AAAGCTGTGA GGAATACTGT TCCCAAAATG CTGGAGGGGG TGCTGGAGGA GATGGGGGCG CAGGAGGAGG GACTGGAGGC TCTGGAGAGG AGGAAGGAAGGAGGAATCG AGTGGATTTC CAACTGCAGC TGTAGCCGGT GGCGTGGCTG GGGGAGTCCT CGCCATTGCT GCGGGAGCTG GAGCGTTTTA TGGATTGAGT GGTGGGAGCG CGGCTGCTGC CACTGAAGCA GGTGCTGAAG TGATGACAGA AGCTGGTACA TCCAATGCTG CTGAGGTAGA AAAGGAGAGC CTCATCAGTG CAGGTGAACA ATCAGAGATG TGGGCATCCT AA.
35. The recombinant vector of claim 30 which recombinant vector is an E. coli vector such as pEV/2-4.
36. The recombinant vector of claim 30 which is a pox virus vector.
37. A microorganism transformed with a recombinant vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707.
38. A method for producing a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707, which process comprises:
(a) culturing a microorganism transformed with a recombinant vector comprising a DNA sequence encoding the said protein in a culture medium under conditions in which the DNA sequence is expressed;
(b) isolating the said protein from the culture.
39. A vaccine for protecting poultry against coccidiosis comprising a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707 and a physiologically acceptable carrier.
40. A vaccine for protecting poultry against coccidiosis containing a recombinant poxvirus vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707 and a physiologically acceptable carrier.
41. A method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine comprising a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707 and a physiologically acceptable carrier to a young fowl that is susceptible to coccidiosis.
42. A method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine containing a recombinant poxvirus vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707 and a physiologically acceptable carrier to a young fowl that is susceptible to coccidiosis.
43. An isolated antibody which is directed against an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 120 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707.
44. The antibody of claim 43 which is a monoclonal antibody, such as the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9707.
45. A protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710.
46. The protein of claim 45 encoded by the nucleic acid sequence
GAATTCCCGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGGCT GGAGGAGCGG GAGCAGCAGC GGCAGCGCGA GCGGCAGCTG CAGCACGTGC GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGGA GTTCAAAAAG AACCCCCACT GGGGGCCCCT CAAGGCCGAA AACCCTTTGC TGCCTTTTGC CCAGAGAGAG GCCGACGAGG CCTACAGGCG GTTCGGCAGG GGCGCTCCCT CTGCGGGGCC CCTCAGGGAG AAGATGCTGC AGGCCCGCAG GAAGTAAAGC AGCAGCAGCA GCAGCAGCAG CAGCGGCAGC GGCAGCGGCA GGGGAGGCGG AGGAGGCAGG GAGGCTTTTG TTTCGAATTG TTTAGGGAGA GGGCGGAGGG CTCGCGGGGT GTATGTACAG CGCGCGAACG CGGCGGCTCA TGTTTGGGTG TTGGATTTCG TCTGCAGAAA ACACGAAGCA AATTAAACTG GCAGAAGTTC CATTTTTCCA CTTTAAAATG CCACTTTTGC TCTTTATATT GATTAAAACT AATGCCATGC TGCTGGCATT CATATAAATG CATTTCCGCG CATTTATGTG CATGCATGGC TGGGCGCGGG TGTCTGTACA CCCCAAGAGC CTTGCTGCTC CGCCGGCGCG AATTTATATT TATATTTCAT TTATGTAAAT ATAAAAGCCT TCAAAAACAC AAATGGACAT TAATTTATCA AGAAAAAAGA TTAAGGAATT C
or by a functional equivalent or partial sequence thereof.
47. The protein of claim 45 encoded by the nucleic acid sequence
GAATTCCCGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGCTG GAGGAGCGGG AGCAGCAGCG GCAGCGCGAG CAGCAGCTGC AGCACGTGCA GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGAG TTCAAAAAGA ACCCCCACTG GGGGCCCCTC AAGGCCGAAA ACCCTTTGCT GCCTTTTGCC CAGAGAGAGG CCGACGAGGC CTACAGGCGG TTCGGCAGGG GCGCTCCCTC TGCGGGGCCC CTCAGGGAGA AGATGCTGCA GGCCCGCAGG AAGTAAAGCA GCAGCAGCAG CAGCAGCAGC AGCGGCAGCG GCAGCGGCAG GGGAGGCGGA GGAGGCAGGG AGGCTTTTGT TTGAATTGT TTAGGGAGAGG GCGGAGGGCT CGCGGGGTGT ATGTACAGCG CGCGAACGCG CGGGCTCATG TTTGGGTGTT GGATTTCGTC TGCAGAAAAC ACGAAGCAAA TTAAACTGGC AGAAGTTCCA TTTTTCCACT TTAAAATGCC ACTTTTGCTC TTTATATTGA TTAAAACTAA TGCCATGCTG CTGGCATTCA TATAAATGCA TTTCCGCGCA TTTATGTGCA TGCATGGCTG GGCGCGGGTG TCTGTACACC CCAAGAGCCT TGCTGCTCCG CCGGCGCGAA TTTATATTTA TATTTCATTT ATGTAAATAT AAAAGCCTTC AAAAACACAA ATGGACATTA ATTTATCAAG AAAAAAGATT AAGGAATTC
or by a functional equivalent or partial sequence thereof.
48. The protein of claim 45 encoded by the nucleic acid sequence
CGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGCTG GAGGAGCGGG AGCAGCAGCG GCAGCGCGAG CAGCAGCTGC AGCACGTGCA GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGAG TTCAAAAAGA ACCCCCACTG GGGGCCCCTC AAGGCCGAAA ACCCTTTGCT GCCTTTTGCC CAGAGAGAGG CCGACGAGGC CTACAGGCGG TTCGGCAGGG GCGCTCCCTC TGCGGGGCCC CTCAGGGAGA AGATGCTGCA GGCCCGCAGG AAGTAA
or by a functional equivalent or partial sequence thereof.
49. The protein of claim 45 having the amino acid sequence
GluPheProThrSerArgGluAlaProGlyAlaSerProProAlaLysArgArgArgThr SerLeuGlyAlaProAlaAlaGlyGluGlyProLeuArgArgTrpGluGlnProAlaAla GlyThrAlAlaAlaIleArgGlnGlnLeuGluGluArgGluGlnGlnArgGlnArgGlu GlnGlnLeuGlnHisValArgSerThrProGlyArgAlaAlaAlaValGlnAlaArgLeu AsnAlaTrpValAlaGluGlyAsnLysLeuProGluSerGluArgArgArgArgMetLeu GluGlnTyrMetAsnLeuGluLysValLysLysLeuArgLysLysLeuAspGluGluAla GluAlaArgAlaLysTyrIleGluGlyGluPheLysLysAsnProHisTrpGlyProLeu LysAlaGluAsnProLeuLeuProPheAlaGlnArgGluAlaAspGluAlaTyrArgArg PheGlyArgGlyAlaProSerAlaGlyProLeuArgGluLysMetLeuGlnAlaArgArg Lys
or a functional equivalent or partial sequence thereof.
50. The protein of claim 45 having the amino acid sequence
ThrSerArgGluAlaProGlyAlaSerProProAlaLysArgArgArgThrSerLeuGly AlaProAlaAlaGlyGluGlyProLeuArgArgTrpGluGlnProAlaAlaGlyThrAla AlaAlaIleArgGlnGlnLeuGluGluArgGluGlnGlnArgGlnArgGluGlnGlnLeu GlnHisValArgSerThrProGlyArgAlaAlaAlaValGlnAlaArgLeuAsnAlaTrp ValAlaGluGlyAsnLysLeuProGluSerGluArgArgArgArgMetLeuGluGlnTyr MetAsnLeuGluLysValLysLysLeuArgLysLysLeuAspGluGluAlaGluAlaArg AlaLysTyrIleGluGlyGluPheLysLysAsnProHisTrpGlyProLeuLysAlaGlu AsnProLeuLeuProPheAlaGlnArgGluAlaAspGluAlaTyrArgArgPheGlyArg GlyAlaProSerAlaGlyProLeuArgGluLysMetLeuGlnAlaArgArgLys
or a functional equivalent or partial sequence thereof.
51. A DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710.
52. The DNA sequence of claim 51 encoding a protein having the amino acid sequence
GluPheProThrSerArgGluAlaProGlyAlaSerProProAlaLysArgArgArgThr SerLeuGlyAlaProAlaAlaGlyGluGlyProLeuArgArgTrpGluGlnProAlaAla GlyThrAlaAlaAlaIleArgGlnGlnLeuGluGluArgGluGlnGlnArgGlnArgGlu GlnGlnLeuGlnHisValArgSerThrProGlyArgAlaAlaAlaValGlnAlaArgLeu AsnAlaTrpValAlaGluGlyAsnLysLeuProGluSerGluArgArgArgArgMetLeu GluGlnTyrMetAsnLeuGluLysValLysLysLeuArgLysLysLeuAspGluGluAla GluAlaArgAlaLysTyrIleGluGlyGluPheLysLysAsnProHisTrpGlyProLeu LysAlaGluAsnProLeuLeuProPheAlaGlnArgGluAlaAspGluAlaTyrArgArg PheGlyArgGlyAlaProSerAlaGlyProLeuArgGluLysMetLeuGlnAlaArgArg Lys
or a functional equivalent or partial sequence thereof.
53. The DNA sequence of claim 51 encoding a protein having the amino acid sequence
ThrSerArgGluAlaProGlyAlaSerProProAlaLysArgArgArgThrSerLeuGly AlaProAlaAlaGlyGluGlyProLeuArgArgTrpGluGlnProAlaAlaGlyThrAla AlaAlaIleArgGlnGlnLeuGluGluArgGluGlnGlnArgGlnArgGluGlnGlnLeu GlnHisValArgSerThrProGlyArgAlaAlaAlaValGlnAlaArgLeuAsnAlaTrp ValAlaGluGlyAsnLysLeuProGluSerGluArgArgArgArgMetLeuGluGlnTyr MetAsnLeuGluLysValLysLysLeuArgLysLysLeuAspGluGluAlaGluAlaArg AlaLysTyrIleGluGlyGluPheLysLysAsnProHisTrpGlyProLeuLysAlaGlu AsnProLeuLeuProPheAlaGlnArgGluAlaAspGluAlaTyrArgArgPheGlyArg GlyAlaProSerAlaGlyProLeuArgGluLysMetLeuGlnAlaArgArgLys
or a functional equivalent or partial sequence thereof.
54. The DNA sequence of claim 51 comprising all or part of the nucleotide sequence
GAATTCCCGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGGCT GGAGGAGCGG GAGCAGCAGC GGCAGCGCGA GCGGCAGCTG CAGCACGTGC GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGGA GTTCAAAAAG AACCCCCACT GGGGGCCCCT CAAGGCCGAA AACCCTTTGC TGCCTTTTGC CCAGAGAGAG GCCGACGAGG CCTACAGGCG GTTCGGCAGG GGCGCTCCCT CTGCGGGGCC CCTCAGGGAG AAGATGCTGC AGGCCCGCAG GAAGTAAAGC AGCAGCAGCA GCAGCAGCAG CAGCGGCAGC GGCAGCGGCA GGGGAGGCGG AGGAGGCAGG GAGGCTTTTG TTTCGAATTG TTTAGGGAGA GGGCGGAGGG CTCGCGGGGT GTATGTACAG CGCGCGAACG CGGCGGCTCA TGTTTGGGTG TTGGATTTCG TCTGCAGAAA ACACGAAGCA AATTAAACTG GCAGAAGTTC CATTTTTCCA CTTTAAAATG CCACTTTTGC TCTTTATATT GATTAAAACT AATGCCATGC TGCTGGCATT CATATAAATG CATTTCCGCG CATTTATGTG CATGCATGGC TGGGCGCGGG TGTCTGTACA CCCCAAGAGC CTTGCTGCTC CGCCGGCGCG AATTTATATT TATATTTCAT TTATGTAAAT ATAAAAGCCT TCAAAAACAC AAATGGACAT TAATTTATCA AGAAAAAAGA TTAAGGAATT C.
55. The DNA sequence of claim 51 comprising all or part of the nucleotide sequence
GAATTCCCGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGCTG GAGGAGCGGG AGCAGCAGCG GCAGCGCGAG CAGCAGCTGC AGCACGTGCA GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGAG TTCAAAAAGA ACCCCCACTG GGGGCCCCTC AAGGCCGAAA ACCCTTTGCT GCCTTTTGCC CAGAGAGAGG CCGACGAGGC CTACAGGCGG TTCGGCAGGG GCGCTCCCTC TGCGGGGCCC CTCAGGGAGA AGATGCTGCA GGCCCGCAGG AAGTAAAGCA GCAGCAGCAG CAGCAGCAGC AGCGGCAGCG GCAGCGGCAG GGGAGGCGGA GGAGGCAGGG AGGCTTTTGT TTGAATTGT TTAGGGAGAGG GCGGAGGGCT CGCGGGGTGT ATGTACAGCG CGCGAACGCG CGGGCTCATG TTTGGGTGTT GGATTTCGTC TGCAGAAAAC ACGAAGCAAA TTAAACTGGC AGAAGTTCCA TTTTTCCACT TTAAAATGCC ACTTTTGCTC TTTATATTGA TTAAAACTAA TGCCATGCTG CTGGCATTCA TATAAATGCA TTTCCGCGCA TTTATGTGCA TGCATGGCTG GGCGCGGGTG TCTGTACACC CCAAGAGCCT TGCTGCTCCG CCGGCGCGAA TTTATATTTA TATTTCATTT ATGTAAATAT AAAAGCCTTC AAAAACACAA ATGGACATTA ATTTATCAAG AAAAAAGATT AAGGAATTC.
56. The DNA sequence of claim 51 comprising all or part of the nucleotide sequence
CGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGCTG GAGGAGCGGG AGCAGCAGCG GCAGCGCGAG CAGCAGCTGC AGCACGTGCA GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGAG TTCAAAAAGA ACCCCCACTG GGGGCCCCTC AAGGCCGAAA ACCCTTTGCT GCCTTTTGCC CAGAGAGAGG CCGACGAGGC CTACAGGCGG TTCGGCAGGG GCGCTCCCTC TGCGGGGCCC CTCAGGGAGA AGATGCTGCA GGCCCGCAGG AAGTAA.
57. A recombinant vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710.
58. The recombinant vector of claim 57 comprising a DNA sequence encoding a protein having the amino acid sequence
GluPheProThrSerArgGluAlaProGlyAlaSerProProAlaLysArgArgArgThr SerLeuGlyAlaProAlaAlaGlyGluGlyProLeuArgArgTrpGluGlnProAlaAla GlyThrAlaAlaAlaIleArgGlnGlnLeuGluGluArgGluGlnGlnArgGlnArgGlu GlnGlnLeuGlnHisValArgSerThrProGlyArgAlaAlaAlaValGlnAlaArgLeu AsnAlaTrpValAlaGluGlyAsnLysLeuProGluSerGluArgArgArgArgMetLeu GluGlnTyrMetAsnLeuGluLysValLysLysLeuArgLysLysLeuAspGluGluAla GluAlaArgAlaLysTyrIleGluGlyGluPheLysLysAsnProHisTrpGlyProLeu LysAlaGluAsnProLeuLeuProPheAlaGlnArgGluAlaAspGluAlaTyrArgArg PheGlyArgGlyAlaProSerAlaGlyProLeuArgGluLysMetLeuGlnA,aArgArg Lys
or a functional equivalent or partial sequence thereof.
59. The recombinant vector of claim 57 comprising a DNA sequence encoding a protein having the amino acid sequence
ThrSerArgGluAlaProGlyAlaSerProProAlaLysArgArgArgThrSerLeuGly AlaProAlaAlaGlyGluGlyProLeuArgArgTrpGluGlnProAlaAlaGlyThrAla AlaAlaIleArgGlnGlnLeuGluGluArgGluGlnGlnArgGlnArgGluGlnGlnLeu GlnHisValArgserThrproGlyArgAlaAlaAlaValGlnAlaArgLeuAsnAlaTrp ValAlaGluGlyAsnLysLeuProGluSerGluArgArgArgArgMetLeuGluGlnTyr MetAsnLeuGluLysValLysLysLeuArgLysLysLeuAspGluGluAlaGluAlaArg AlaLysTyrIleGluGlyGluPheLysLysAsnProHisTrpGlyProLeuLysAlaGlu AsnProLeuLeuProPheAlaGlnArgGluAlaAspGluAlaTyrArgArgPheGlyArg GlyAlaProSerAlaGlyProLeuArgGluLysMetLeuGlnAlaArgArgLys
or a functional equivalent or partial sequence thereof.
60. The recombinant vector of claim 57 comprising all or part of the nucleotide sequence
GAATTCCCGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGGCT GGAGGAGCGG GAGCAGCAGC GGCAGCGCGA GCGGCAGCTG CAGCACGTGC GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGGA GTTCAAAAAG AACCCCCACT GGGGGCCCCT CAAGGCCGAA AACCCTTTGC TGCCTTTTGC CCAGAGAGAG GCCGACGAGG CCTACAGGCG GTTCGGCAGG GGCGCTCCCT CTGCGGGGCC CCTCAGGGAG AAGATGCTGC AGGCCCGCAG GAAGTAAAGC AGCAGCAGCA GCAGCAGCAG CAGCGGCAGC GGCAGCGGCA GGGGAGGCGG AGGAGGCAGG GAGGCTTTTG TTTCGAATTG TTTAGGGAGA GGGCGGAGGG CTCGCGGGGT GTATGTACAG CGCGCGAACG CGGCGGCTCA TGTTTGGGTG TTGGATTTCG TCTGCAGAAA ACACGAAGCA AATTAAACTG GCAGAAGTTC CATTTTTCCA CTTTAAAATG CCACTTTTGC TCTTTATATT GATTAAAACT AATGCCATGC TGCTGGCATT CATATAAATG CATTTCCGCG CATTTATGTG CATGCATGGC TGGGCGCGGG TGTCTGTACA CCCCAAGAGC CTTGCTGCTC CGCCGGCGCG AATTTATATT TATATTTCAT TTATGTAAAT ATAAAAGCCT TCAAAAACAC AAATGGACAT TAATTTATCA AGAAAAAAGA TTAAGGAATT C.
61. The recombinant vector of claim 57 comprising all or part of the nucleotide sequence
GAATTCCCGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGCTG GAGGAGCGGG AGCAGCAGCG GCAGCGCGAG CAGCAGCTGC AGCACGTGCA GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGAG TTCAAAAAGA ACCCCCACTG GGGGCCCCTC AAGGCCGAAA ACCCTTTGCT GCCTTTTGCC CAGAGAGAGG CCGACGAGGC CTACAGGCGG TTCGGCAGGG GCGCTCCCTC TGCGGGGCCC CTCAGGGAGA AGATGCTGCA GGCCCGCAGG AAGTAAAGCA GCAGCAGCAG CAGCAGCAGC AGCGGCAGCG GCAGCGGCAG GGGAGGCGGA GGAGGCAGGG AGGCTTTTGT TTGAATTGT TTAGGGAGAGG GCGGAGGGCT CGCGGGGTGT ATGTACAGCG CGCGAACGCG CGGGCTCATG TTTGGGTGTT GGATTTCGTC TGCAGAAAAC ACGAAGCAAA TTAAACTGGC AGAAGTTCCA TTTTTCCACT TTAAAATGCC ACTTTTGCTC TTTATATTGA TTAAAACTAA TGCCATGCTG CTGGCATTCA TATAAATGCA TTTCCGCGCA TTTATGTGCA TGCATGGCTG GGCGCGGGTG TCTGTACACC CCAAGAGCCT TGCTGCTCCG CCGGCGCGAA TTTATATTTA TATTTCATTT ATGTAAATAT AAAAGCCTTC AAAAACACAA ATGGACATTA ATTTATCAAG AAAAAAGATT AAGGAATTC.
62. The recombinant vector of claim 57 comprising all or part of the nucleotide sequence
CGA CTTCGAGGGA GGCCCCGGGG GCCTCCCCGC CTGCGAAGCG GCGGCGGACG TCGCTGGGGG CCCCTGCAGC AGGGGAGGGC CCCCTGCGGC GGTGGGAGCA GCCTGCTGCT GGGACTGCAG CAGCAATCCG GCAGCAGCTG GAGGAGCGGG AGCAGCAGCG GCAGCGCGAG CAGCAGCTGC AGCACGTGCA GCGCACCCCC GGGCGCGCAG CAGCAGTGCA GGCGCGGCTA AACGCGTGGG TGGCGGAGGG CAACAAACTG CCAGAGTCCG AGAGAAGAAG AAGGATGTTA GAACAATATA TGAACTTGGA AAAAGTCAAA AAGTTGAGGA AAAAACTCGA CGAAGAAGCA GAAGCCAGGG CCAAATACAT CGAAGGCGAG TTCAAAAAGA ACCCCCACTG GGGGCCCCTC AAGGCCGAAA ACCCTTTGCT GCCTTTTGCC CAGAGAGAGG CCGACGAGGC CTACAGGCGG TTCGGCAGGG GCGCTCCCTC TGCGGGGCCC CTCAGGGAGA AGATGCTGCA GGCCCGCAGG AAGTAA.
63. The recombinant vector of claim 57 which recombinant vector is an E. coli vector.
64. The recombinant vector of claim 57 which is a pox virus vector.
65. A microorganism transformed with a recombinant vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710.
66. A method for producing a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710, which process comprises:
(a) culturing a microorganism transformed with a recombinant vector comprising a DNA sequence encoding the said protein in a culture medium under conditions in which the DNA sequence is expressed;
(b) isolating the said protein from the culture.
67. A vaccine for protecting poultry against coccidiosis comprising a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710 and a physiologically acceptable carrier.
68. A vaccine for protecting poultry against coccidiosis containing a recombinant poxvirus vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710 and a physiologically acceptable carrier.
69. A method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine comprising a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710 and a physiologically acceptable carrier to a young-fowl that is susceptible to coccidiosis.
70. A method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine containing a recombinant poxvirus vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710 and a physiologically acceptable carrier to a young fowl that is susceptible to coccidiosis.
71. An isolated antibody which is directed against an Eimeria surface antigen, which surface antigen has an apparent molecular weight of about 37 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710.
72. The antibody of claim 71 which is a monoclonal antibody, such as the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9710.
73. A protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712.
74. The protein of claim 73 encoded by the nucleic acid sequence
GAATTCCGCC CCAGACAGCT AAGCGTGGCA ACATTCTTGG TCTTGTGGGC ATGGTAGCCG CTGTCGTCGT GACCTTCACG GAGGCAGGGT TTGGACAGCA TTACTTGCTG TTTTTCGCCA CTGCTGCACC GGCCCTTGGC CTGGGGCTGT ACATTGCGCA GTCTGTCAAC ATGACTGAGA TGCCTCAACT CGTGGCTCTT TTCCACAGTT TCGTCGGTCT TGCCGCCGTA ATGGTTGGGT TCGCGAACTT CCACTCCCCT GCTGGCGTGG AGCGCGCTTC CTCACTTCTA CGTCTGTTGG AGGTCTACGC CGGCGTTTTC GTCGCCGGTA TCACCTTCAC CGGATCAGTG GTCGCTGCGG CAAAGCTCCA TGGATCGATG GAGAGCCGCT CATTGAGGGT TCCCGGACGC CATGCGTTGA ATACTGCCAC TATTGCTGCC ATTGGCGTAC TTGGCGCTCT TTTTTGCGTC TCTTCTGGCC ACTTTACACG CATGCTTTGC CTTTATGTGA ATGCTGGCTT GAGCATGTGG CTTGGTTTTC ACCTGGTCGC CGCTATTGGT GGAGCTGACA TGCCCGTCGT GATCAGCTTG CTGAACTCGT ATTCCGGAGT GGCGTTGGCT GCCAGTGGCT TCATGTTGGA CAACAACTTG CTGATCATTG CTGGTGCTCT CATCGCGTCA TCTGGTGCCA TTCTGTCTTA CATCATGTGC AAAGGCATGA ACCGGAGTCT GTGGAATGTC GTTCTTGGTG GCTTCGAGGA GGCCGAGGAC GTTGGCGCAG CCAGCCCTCA GGGGGCTGTG CAGCAGGCCA CGGCTGATCA GGTCGCCGAC GAGTTGCTGG CTGCCCGCAA AGTTTTGATC GTGCCTGGAT ACGGAATGGC CGTTGCAAGG TGCCAGAGCG AGCTTGCAGA CATTGCCAAG AACTTGATGA ACTGCGGTAT CACCGTCGAT TTCGGCATCC ATCCAGTTGC TGGTCGCATG CCAGGCCACA TGAACGTCCT CCTCGCTGAG GCTGATGTTC CGTACAAGAT TGTCAAGGAG ATGTCTGAAG TCAACCCGGA AATGAGCTCC TACGACGTCG TCCTGGTTGT TGGAGCCAAC GACACCGTCA ATCCTGCAGC CCTTGAGCCA GGATCAAAGA TCTCAGGAAT GCCCGTTATA GAGGCCTGGA AAGCTAGACG CGTTTTTGTG CTGAAGCGGT CCATGGCTGC TGGATATGCC AGCATTGAAA ATCCACTTTT CCATCTGGAG AACACACGCA TGCTCTTCGG AAACGCAAAG AACACCACTT CTGCAGTCTT CGCCCGTGTC AATGCCAGAG CCGAGCAAAT GCCACCATCT GCTGCCCGTG ATGACCTCGA AGCTGGACTA CTTGAGTTCG ATAGGGAAGA ACGTGTTGAT CCCTCTTCTT GGCCATATCC CAGGATGGCT GTTGGTGTTC TGAGAGACTC CAATGGCTCT GTTATGGTGC CAGTAGCTCC GAAGTTTGTG CCCAAGCTGA GGAAGTTGGC ATTCCGTGTC AATGTCGAGT CTGGTGCTGG CGCCGATGCC GGCTTTACTG ACGAAGAGTA CAGGAGGGCT GGAGCAGAAG TCCTGTCGGG CCCCGATGCA GTCATTAACC AGTCTCAAGT CCTGCTCCGC GTTTCAGCGC CGTCGCCAGA TCTGGTTTCG CGCATTCCTA GGGACAAGGT CCTTATCAGT TACCTATTCC CCAGCATCAA CCAACAAGCT CTTGACATGC TAGCACGCCA AGGCGTCACC GCACTTGCTG TGGATGAGGT TCCTCGCGTC ACAAGAGCAC AGAAGCTAGA CGTGAAGTCT GCTATGCAAG GTCTCCAGGG ATACCGCGCC GTTATCGAAG CGTTCAACGC TCTTCCGAAG CTCAGCAAAG CATCTATCAG TGCTGCAGGC CGTGTAGAAG CCGCTAAAGT TTTCGTCATC GGTGCCGGTG TTGCTGGACT ACAGGCAATT TCTACCGCCC ATGGTTTGGG TGCACAAGTA 8TTGGCCACG ATGTGCGCTC TGCAACTCGT GAGGAAGTCG AATCTTGCGG TGGAAAGTTC ATTGGTTTGA GAATGGGAGA GGAGGGTGAA GTCCTCGGAG GATATGCACG CGAGATGGGT GATGCATATC AGAGAGCGCA ACGCGAGATG ATTGCCAACA CAATCAAGCA CTGCGATGTC GTCATCTGTA CCGCTGCTAT TCACGGCAGA CCTTCACCAA AGCTCATATC ACGCGACATG TTGCGTTCAA TGAAGCCTGG CTCCGTCGTC GTAGATCTTG CAACAGAGTT CGGTGATGTG CGCTCCGGCT GGGGTGGAAA CGTCGAGGTT TCGCCTAAGG ACGACCAGAT TGTCGTTGAT GGCGTCACTG TCATTGGTCG CAGACGCATT GAGACTCGCA TGCCCATTCA GGCGTCTGAG CTGTTCTCCA TGAACATATG CAACCTCCTT GAGGATCTTG GTGGTGGCAG CAACTTCCGC ATCAACATGG ACGACGAAGT CATCAGAGGA TTGGTCGCAG TCTACCAAGG TCGCAACGTG TGGCAGCCAT CGCAGCCCAC TCCTGTTTCC AGGACACCTC CGCGCGGCCA GATGCCGCCC CCGTCTGCAC CTGGTGCACC AGCTCCTGAG AAGCCTGGTG CCTTTGCTCA AGCACTTGCT TCGGATGCAT TCTTCGCAAT GTGTCTTGTT GTTGCTGCCG CTGTTGTCGG GCTCCTTGGC ATTGTCCTTG ACCCTGTGGA GCTCAAGCAT TTGACTCTCC TCGGCTTGTC TCTCATCGTC GGCTACTACT GCGTGTGGGC CGTTACGCCT TCGCTTCACA CACCATTGAT GTCTGTGACG AATGCCCTTT CGGGAGTCAT TGTCATCGGC TGCATGCTCG AGTACGGAAC CGCCATGATA TCCGGATTCA CTCTTCTCGC ACTCATTGGA ACCTTCTTGG CTTCCGTCAA CGTTGCTGGT GGATTCTTCG TAACTCACCG CATGCTGAAG ATGTTTCAGA TATAAGGGGA GAACCCCCTT GAGTTAATCT TAACTCAGAA TAACTCTTTT TCAATTGTAT AAACCTGTAC TCGTTGCAAA AAAAAAAGGA ATTC
or by a functional equivalent or partial sequence thereof.
75. The protein of claim 73 encoded by the nucleic acid sequence
CC CCAGACAGCT AAGCGTGGCA ACATTCTTGG TCTTGTGGGC ATGGTAGCCG CTGTCGTCGT GACCTTCACG GAGGCAGGGT TTGGACAGCA TTACTTGCTG TTTTTCGCCA CTGCTGCACC GGCCCTTGGC CTGGGGCTGT ACATTGCGCA GTCTGTCAAC ATGACTGAGA TGCCTCAACT CGTGGCTCTT TTCCACAGTT TCGTCGGTCT TGCCGCCGTA ATGGTTGGGT TCGCGAACTT CCACTCCCCT GCTGGCGTGG AGCGCGCTTC CTCACTTCTA CGTCTGTTGG AGGTCTACGC CGGCGTTTTC GTCGCCGGTA TCACCTTCAC CGGATCAGTG GTCGCTGCGG CAAAGCTCCA TGGATCGATG GAGAGCCGCT CATTGAGGGT TCCCGGACGC CATGCGTTGA ATACTGCCAC TATTGCTGCC ATTGGCGTAC TTGGCGCTCT TTTTTGCGTC TCTTCTGGCC ACTTTACACG CATGCTTTGC CTTTATGTGA ATGCTGGCTT GAGCATGTGG CTTGGTTTTC ACCTGGTCGC CGCTATTGGT GGAGCTGACA TGCCCGTCGT GATCAGCTTG CTGAACTCGT ATTCCGGAGT GGCGTTGGCT GCCAGTGGCT TCATGTTGGA CAACAACTTG CTGATCATTG CTGGTGCTCT CATCGCGTCA TCTGGTGCCA TTCTGTCTTA CATCATGTGC AAAGGCATGA ACCGGAGTCT GTGGAATGTC GTTCTTGGTG GCTTCGAGGA GGCCGAGGAC GTTGGCGCAG CCAGCCCTCA GGGGGCTGTG CAGCAGGCCA CGGCTGATCA GGTCGCCGAC GAGTTGCTGG CTGCCCGCAA AGTTTTGATC GTGCCTGGAT ACGGAATGGC CGTTGCAAGG TGCCAGAGCG AGCTTGCAGA CATTGCCAAG AACTTGATGA ACTGCGGTAT CACCGTCGAT TTCGGCATCC ATCCAGTTGC TGGTCGCATG CCAGGCCACA TGAACGTCCT CCTCGCTGAG GCTGATGTTC CGTACAAGAT TGTCAAGGAG ATGTCTGAAG TCAACCCGGA AATGAGCTCC TACGACGTCG TCCTGGTTGT TGGAGCCAAC GACACCGTCA ATCCTGCAGC CCTTGAGCCA GGATCAAAGA TCTCAGGAAT GCCCGTTATA GAGGCCTGGA AAGCTAGACG CGTTTTTGTG CTGAAGCGGT CCATGGCTGC TGGATATGCC AGCATTGAAA ATCCACTTTT CCATCTGGAG AACACACGCA TGCTCTTCGG AAACGCAAAG AACACCACTT CTGCAGTCTT CGCCCGTGTC AATGCCAGAG CCGAGCAAAT GCCACCATCT GCTGCCCGTG ATGACCTCGA AGCTGGACTA CTTGAGTTCG ATAGGGAAGA ACGTGTTGAT CCCTCTTCTT GGCCATATCC CAGGATGGCT GTTGGTGTTC TGAGAGACTC CAATGGCTCT GTTATGGTGC CAGTAGCTCC GAAGTTTGTG CCCAAGCTGA GGAAGTTGGC ATTCCGTGTC AATGTCGAGT CTGGTGCTGG CGCCGATGCC GGCTTTACTG ACGAAGAGTA CAGGAGGGCT GGAGCAGAAG TCCTGTCGGG CCCCGATGCA GTCATTAACC AGTCTCAAGT CCTGCTCCGC GTTTCAGCGC CGTCGCCAGA TCTGGTTTCG CGCATTCCTA GGGACAAGGT CCTTATCAGT TACCTATTCC CCAGCATCAA CCAACAAGCT CTTGACATGC TAGCACGCCA AGGCGTCACC GCACTTGCTG TGGATGAGGT TCCTCGCGTC ACAAGAGCAC AGAAGCTAGA CGTGAAGTCT GCTATGCAAG GTCTCCAGGG ATACCGCGCC GTTATCGAAG CGTTCAACGC TCTTCCGAAG CTCAGCAAAG CATCTATCAG TGCTGCAGGC CGTGTAGAAG CCGCTAAAGT TTTCGTCATC GGTGCCGGTG TTGCTGGACT ACAGGCAATT TCTACCGCCC ATGGTTTGGG TGCACAAGTA TTTGGCCACG ATGTGCGCTC TGCAACTCGT GAGGAAGTCG AATCTTGCGG TGGAAAGTTC ATTGGTTTGA GAATGGGAGA GGAGGGTGAA GTCCTCGGAG GATATGCACG CGAGATGGGT GATGCATATC AGAGAGCGCA ACGCGAGATG ATTGCCAACA CAATCAAGCA CTGCGATGTC GTCATCTGTA CCGCTGCTAT TCACGGCAGA CCTTCACCAA AGCTCATATC ACGCGACATG TTGCGTTCAA TGAAGCCTGG CTCCGTCGTC GTAGATCTTG CAACAGAGTT CGGTGATGTG CGCTCCGGCT GGGGTGGAAA CGTCGAGGTT TCGCCTAAGG ACGACCAGAT TGTCGTTGAT GGCGTCACTG TCATTGGTCG CAGACGCATT GAGACTCGCA TGCCCATTCA GGCGTCTGAG CTGTTCTCCA TGAACATATG CAACCTCCTT GAGGATCTTG GTGGTGGCAG CAACTTCCGC ATCAACATGG ACGACGAAGT CATCAGAGGA TTGGTCGCAG TCTACCAAGG TCGCAACGTG TGGCAGCCAT CGCAGCCCAC TCCTGTTTCC AGGACACCTC CGCGCGGCCA GATGCCGCCC CCGTCTGCAC CTGGTGCACC AGCTCCTGAG AAGCCTGGTG CCTTTGCTCA AGCACTTGCT TCGGATGCAT TCTTCGCAAT GTGTCTTGTT GTTGCTGCCG CTGTTGTCGG GCTCCTTGGC ATTGTCCTTG ACCCTGTGGA GCTCAAGCAT TTGACTCTCC TCGGCTTGTC TCTCATCGTC GGCTACTACT GCGTGTGGGC CGTTACGCCT TCGCTTCACA CACCATTGAT GTCTGTGACG AATGCCCTTT CGGGAGTCAT TGTCATCGGC TGCATGCTCG AGTACGGAAC CGCCATGATA TCCGGATTCA CTCTTCTCGC ACTCATTGGA ACCTTCTTGG CTTCCGTCAA CGTTGCTGGT GGATTCTTCG TAACTCACCG CATGCTGAAG ATGTTTCAGA TATAA
or by a functional equivalent or partial sequence thereof.
76. The protein of claim 73 having the amino acid sequence
ProGlnThrAlaLysArgGlyAsnIleLeuGlyLeuValGlyMetValAlaAlaValVal ValThrPheThrGluAlaGlyPheGlyGlnHisTyrLeuLeuPhePheAlaThrAlaAla ProAlaLeuGlyLeuGlyLeuTyrIleAlaGlnSerValAsnMetThrGluMetProGln LeuValAlaLeuPheHisSerPheValGlyLeuAlaAlaValMetValGlyPheAlaAsn PheHisSerProAlaGlyValGluArgAlaSerSerLeuLeuArgLeuLeuGluValTyr AlaGlyValPheValAlaGlyIleThrPheThrGlySerValValAlaAlaAlaLysLeu HisGlySerMetGluSerArgSerLeuArgValProGlyArgHisAlaLeuAsnThrAla ThrIleAlaAlaIleGlyValLeuGlyAlaLeuPheCysValSerSerGlyHisPheThr ArgMetLeuCysLeuTyrValAsnAlaGlyLeuSerMetTrpLeuGlyPheHisLeuVal AlaAlaIleGlyGlyAlaAspMetProValValIleSerLeuLeuAsnSerTyrSerGly ValAlaLeuAlaAlaSerGlyPheMetLeuAspAsnAsnLeuLeuIleIleAlaGlyAla LeuIleAlaSerSerGlyAlaIleLeuSerTyrIleMetCysLysGlyMetAsnArgSer LeuTrpAsnValValLeuGlyGlyPheGluGluAlaGluAspValGlyAlaAlaSerPro GlnGlyAlaValGlnGlnAlaThrAlaAspGlnValAlaAspGluLeuLeuAlaAlaArg LysValLeuIleValProGlyTyrGlyMetAlaValAlaArgCysGlnSerGluLeuAla AspIleAlaLysAsnLeuMetAsnCysGlyIleThrValAspPheGlyIleHisProVal AlaGlyArgMetProGlyHisMetAsnValLeuLeuAlaGluAlaAspValProTyrLys IleValLysGluMetSerGluValAsnProGluMetSerSerTyrAspValValLeuVal ValGlyAlaAsnAspThrValAsnProAlaAlaLeuGluProGlySerLysIleSerGly MetProValIleGluAlaTrpLysAlaArgArgValPheValLeuLysArgSerMetAla AlaGlyTyrAlaSerIleGluAsnProLeuPheHisLeuGluAsnThrArgMetLeuPhe GlyAsnAlaLysAsnThrThrSerAlaValPheAlaArgValAsnAlaArgAlaGluGln MetProProSerAlaAlaArgAspAspLeuGluAlaGlyLeuLeuGluPheAspArgGlu GluArgValAspProSerSerTrpProTyrProArgMetAlaValGlyValLeuArgAsp SerAsnGlySerValMetValProValAlaProLysPheValProLysLeuArgLysLeu AlaPheArgValAsnValGluSerGlyAlaGlyAlaAspAlaGlyPheThrAspGluGlu TyrArgArgAlaGlyAlaGluValLeuSerGlyProAspAlaValIleAsnGlnSerGln ValLeuLeuArgValSerAlaProSerProAspLeuValSerArgIleProArgAspLys ValLeuIleSerTyrLeuPheProSerIleAsnGlnGlnAlaLeuAspMetLeuAlaArg GlnGlyValThrAlaLeuAlaValAspGluValProArgValThrArgAlaGlnLysLeu AspValLysSerAlaMetGlnGlyLeuGlnGlyTyrArgAlaValIleGluAlaPheAsn AlaLeuProLysLeuSerLysAlaSerIleSerAlaAlaGlyArgValGluAlaAlaLys ValPheValIleGlyAlaGlyValAlaGlyLeuGlnAlaIleSerThrAlaHisGlyLeu GlyAlaGlnVal???GlyHisAspValArgSerAlaThrArgGluGluValGluSerCys GlyGlyLysPheIleGlyLeuArgMetGlyGluGluGlyGluValLeuGlyGlyTyrAla ArgGluMetGlyAspAlaTyrGlnArgAlaGlnArgGluMetIleAlaAsnThrIleLys HisCysAspValValIleCysThrAlaAlaIleHisGlyArgProSerProLysLeuIle SerArgAspMetLeuArgSerMetLysProGlySerValValValAspLeuAlaThrGlu PheGlyAspValArgSerGlyTrpGlyGlyAsnValGluValSerProLysAspAspGln IleValValAspGlyValThrValIleGlyArgArgArgIleGluThrArgMetProIle GlnAlaSerGluLeuPheSerMetAsnIleCysAsnLeuLeuGluAspLeuGlyGlyGly SerAsnPheArgIleAsnMetAspAspGluValIleArgGlyLeuValAlaValTyrGln GlyArgAsnValTrpGlnProSerGlnProThrProValSerArgThrProProArgGly GlnMetProProProSerAlaProGlyAlaProAlaProGluLysProGlyAlaPheAla GlnAlaLeuAlaSerAspAlaPhePheAlaMetCysLeuValValAlaAlaAlaValVal GlyLeuLeuGlyIleValLeuAspProValGluLeuLysHisLeuThrLeuLeuGlyLeu SerLeuIleValGlyTyrTyrCysValTrpAlaValThrProSerLeuHisThrProLeu MetSerValThrAsnAlaLeuSerGlyValIleValIleGlyCysMetLeuGluTyrGly ThrAlaMetIleSerGlyPheThrLeuLeuAlaLeuIleGlyThrPheLeuAlaSerVal AsnValAlaGlyGlyPhePheValThrHisArgMetLeuLysMetPheGlnIle
or a functional equivalent or partial sequence thereof.
77. The protein of claim 73 having the amino acid sequence
ThrAlaLysArgGlyAsnIleLeuGlyLeuValGlyMetValAlaAlaValVal ValThrPheThrGluAlaGlyPheGlyGlnHisTyrLeuLeuPhePheAlaThrAlaAla ProAlaLeuGlyLeuGlyLeuTyrIleAlaGlnSerValAsnMetThrGluMetProGln LeuValAlaLeuPheHisSerPheValGlyLeuAlaAlaValMetValGlyPheAlaAsn PheHisSerProAlaGlyValGluArgAlaSerSerLeuLeuArgLeuLeuGluValTyr AlaGlyValPheValAlaGlyIleThrPheThrGlySerValValAlaAlaAlaLysLeu HisGlySerMetGluSerArgSerLeuArgValProGlyArgHisAlaLeuAsnThrAla ThrIleAlaAlaIleGlyValLeuGlyAlaLeuPheCysValSerSerGlyHisPheThr ArgMetLeuCysLeuTyrValAsnAlaGlyLeuSerMetTrpLeuGlyPheHisLeuVal AlaAlaIleGlyGlyAlaAspMetProValValIleSerLeuLeuAsnSerTyrSerGly ValAlaLeuAlaAlaSerGlyPheMetLeuAspAsnAsnLeuLeuIleIleAlaGlyAla LeuIleAlaSerSerGlyAlaIleLeuSerTyrIleMetCysLysGlyMetAsnArgSer LeuTrpAsnValValLeuGlyGlyPheGluGluAlaGluAspValGlyAlaAlaSerPro GlnGlyAlaValGlnGlnAlaThrAlaAspGlnValAlaAspGluLeuLeuAlaAlaArg LysValLeuIleValProGlyTyrGlyMetAlaValAlaArgCysGlnSerGluLeuAla AspIleAlaLysAsnLeuMetAsnCysGlyIleThrValAspPheGlyIleHisProVal AlaGlyArgMetProGlyHisMetAsnValLeuLeuAlaGluAlaAspValProTyrLys IleValLysGluMetSerGluValAsnProGluMetSerSerTyrAspValValLeuVal ValGlyAlaAsnAspThrValAsnProAlaAlaLeuGluProGlySerLysIleSerGly MetProValIleGluAlaTrpLysAlaArgArgValPheValLeuLysArgserMetAla AlaGlyTyrAlaSerIleGluAsnProLeuPheHisLeuGluAsnThrArgMetLeuPhe GlyAsnAlaLysAsnThrThrSerAlaValPheAlaArgValAsnAlaArgAlaGluGln MetProProSerAlaAlaArgAspAspLeuGluAlaGlyLeuLeuGluPheAspArgGlu GluArgValAspProSerSerTrpProTyrProArgMetAlaValGlyValLeuArgAsp SerAsnGlySerValMetValProValAlaProLysPheValProLysLeuArgLysLeu AlaPheArgValAsnValGluSerGlyAlaGlyAlaAspAlaGlyPheThrAspGluGlu TyrArgArgAlaGlyAlaGluValLeuSerGlyProAspAlaValIleAsnGlnSerGln ValLeuLeuArgValSerAlaProSerProAspLeuValSerArgIleProArgAspLys ValLeuIleSerTyrLeuPheProSerIleAsnGlnGlnAlaLeuAspMetLeuAlaArg GlnGlyValThrAlaLeuAlaValAspGluValProArgValThrArgAlaGlnLysLeu AspValLysSerAlaMetGlnGlyLeuGlnGlyTyrArgAlaValIleGluAlaPheAsn AlaLeuProLysLeuSerLysAlaSerIleSerAlaAlaGlyArgValGluAlaAlaLys ValPheValIleGlyAlaGlyValAlaGlyLeuGlnAlaIleSerThrAlaHisGlyLeu GlyAlaGlnValPheGlyHisAspValArgSerAlaThrArgGluGluValGluSerCys GlyGlyLysPheIleGlyLeuArgMetGlyGluGluGlyGluValLeuGlyGlyTyrAla ArgGluMetGlyAspAlaTyrGlnArgAlaGlnArgGluMetIleAlaAsnThrIleLys HisCysAspValValIleCysThrAlaAlaIleHisGlyArgProSerProLysLeuIle SerArgAspMetLeuArgSerMetLysProGlySerValValValAspLeuAlaThrGlu PheGlyAspValArgSerGlyTrpGlyGlyAsnValGluValSerProLysAspAspGln IleValValAspGlyValThrValIleGlyArgArgArgIleGluThrArgMetProIle GlnAlaSerGluLeuPheSerMetAsnIleCysAsnLeuLeuGluAspLeuGlyGlyGly SerAsnPheArgIleAsnMetAspAspGluValIleArgGlyLeuValAlaValTyrGln GlyArgAsnValTrpGlnProSerGlnProThrProValSerArgThrProProArgGly GlnMetProProProSerAlaProGlyAlaProAlaProGluLysProGlyAlaPheAla GlnAlaLeuAlaSerAspAlaPhePheAlaMetCysLeuValValAlaAlaAlaValVal GlyLeuLeuGlyIleValLeuAspProValGluLeuLysHisLeuThrLeuLeuGlyLeu SerLeuIleValGlyTyrTyrCysValTrpAlaValThrProSerLeuHisThrProLeu MetSerValThrAsnAlaLeuSerGlyValIleValIleGlyCysMetLeuGluTyrGly ThrAlaMetIleSerGlyPheThrLeuLeuAlaLeuIleGlyThrPheLeuAlaSerVal AsnValAlaGlyGlyPhePheValThrHisArgMetLeuLysMetPheGlnIle
or a functional equivalent or partial sequence thereof.
78. A DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712.
79. The DNA sequence of claim 78 encoding a protein having the amino acid sequence
ProGlnThrAlaLysArgGlyAsnIleLeuGlyLeuValGlyMetValAlaAlaValVal ValThrPheThrGluAlaGlyPheGlyGlnHisTyrLeuLeuPhePheAlaThrAlaAla ProAlaLeuGlyLeuGlyLeuTyrIleAlaGlnSerValAsnMetThrGluMetProGln LeuValAlaLeuPheHisSerPheValGlyLeuAlaAlaValMetValGlyPheAlaAsn PheHisSerProAlaGlyValGluArgAlaSerSerLeuLeuArgLeuLeuGluValTyr AlaGlyValPheValAlaGlyIleThrPheThrGlySerValValAlaAlaAlaLysLeu HisGlySerMetGluSerArgSerLeuArgValProGlyArgHisAlaLeuAsnThrAla ThrIleAlaAlaIleGlyValLeuGlyAlaLeuPheCysValSerSerGlyHisPheThr ArgMetLeuCysLeuTyrValAsnAlaGlyLeuSerMetTrpLeuGlyPheHisLeuVal AlaAlaIleGlyGlyAlaAspMetProValValIleSerLeuLeuAsnSerTyrSerGly ValAlaLeuAlaAlaSerGlyPheMetLeuAspAsnAsnLeuLeuIleIleAlaGlyAla LeuIleAlaSerSerGlyAlaIleLeuSerTyrIleMetCysLysGlyMetAsnArgser LeuTrpAsnValValLeuGlyGlyPheGluGluAlaGluAspValGlyAlaAlaSerPro GlnGlyAlaValGlnGlnAlaThrAlaAspGlnValAlaAspGluLeuLeuAlaAlaArg LysValLeuIleValProGlyTyrGlyMetAlaValAlaArgCysGlnSerGluLeuAla AspIleAlaLysAsnLeuMetAsnCysGlyIleThrValAspPheGlyIleHisProVal AlaGlyArgMetProGlyHisMetAsnValLeuLeuAlaGluAlaAspValProTyrLys IleValLysGluMetSerGluValAsnProGluMetSerSerTyrAspValValLeuVal ValGlyAlaAsnAspThrValAsnProAlaAlaLeuGluProGlySerLysIleSerGly MetProValIleGluAlaTrpLysAlaArgArgValPheValLeuLysArgserMetAla AlaGlyTyrAlaSerIleGluAsnProLeuPheHisLeuGluAsnThrArgMetLeuPhe GlyAsnAlaLysAsnThrThrSerAlaValPheAlaArgValAsnAlaArgAlaGluGln MetProProSerAlaAlaArgAspAspLeuGluAlaGlyLeuLeuGluPheAspArgGlu GluArgValAspProSerSerTrpProTyrProArgMetAlaValGlyValLeuArgAsp SerAsnGlySerValMetValProValAlaProLysPheValProLysLeuArgLysLeu AlaPheArgValAsnValGluSerGlyAlaGlyAlaAspAlaGlyPheThrAspGluGlu TyrArgArgAlaGlyAlaGluValLeuSerGlyProAspAlaValIleAsnGlnSerGln ValLeuLeuArgValSerAlaProSerProAspLeuValSerArgIleProArgAspLys ValLeuIleSerTyrLeuPheProSerIleAsnGlnGlnAlaLeuAspMetLeuAlaArg GlnGlyValThrAlaLeuAlaValAspGluValProArgValThrArgAlaGlnLysLeu AspValLysSerAlaMetGlnGlyLeuGlnGlyTyrArgAlaValIleGluAlaPheAsn AlaLeuProLysLeuSerLysAlaSerIleSerAlaAlaGlyArgValGluAlaAlaLys ValPheValIleGlyAlaGlyValAlaGlyLeuGlnAlaIleSerThrAlaHisGlyLeu GlyAlaGlnVal???GlyHisAspValArgSerAlaThrArgGluGluValGluSerCys GlyGlyLysPheIleGlyLeuArgMetGlyGluGluGlyGluValLeuGlyGlyTyrAla ArgGluMetGlyAspAlaTyrGlnArgAlaGlnArgGluMetIleAlaAsnThrIleLys HisCysAspValValIleCysThrAlaAlaIleHisGlyArgProSerProLysLeuIle SerArgAspMetLeuArgSerMetLysProGlySerValValValAspLeuAlaThrGlu PheGlyAspValArgSerGlyTrpGlyGlyAsnValGluValSerProLysAspAspGln IleValValAspGlyValThrValIleGlyArgArgArgIleGluThrArgMetProIle GlnAlaSerGluLeuPheSerMetAsnIleCysAsnLeuLeuGluAspLeuGlyGlyGly SerAsnPheArgIleAsnMetAspAspGluValIleArgGlyLeuValAlaValTyrGln GlyArgAsnValTrpGlnProSerGlnProThrProValSerArgThrProProArgGly GlnMetProProProSerAlaProGlyAlaProAlaProGluLysProGlyAlaPheAla GlnAlaLeuAlaSerAspAlaPhePheAlaMetCysLeuValValAlaAlaAlaValVal GlyLeuLeuGlyIleValLeuAspProValGluLeuLysHisLeuThrLeuLeuGlyLeu SerLeuIleValGlyTyrTyrCysValTrpAlaValThrProSerLeuHisThrProLeu MetSerValThrAsnAlaLeuSerGlyValIleValIleGlyCysMetLeuGluTyrGly ThrAlaMetIleSerGlyPheThrLeuLeuAlaLeuIleGlyThrPheLeuAlaSerVal AsnValAlaGlyGlyphepheValThrHisArgMetLeuLysMetPheGlnIle
or a functional equivalent or partial sequence thereof.
80. The DNA sequence of claim 78 encoding a protein having the amino acid sequence
ThrAlaLysArgGlyAsnIleLeuGlyLeuValGlyMetValAlaAlaValVal ValThrPheThrGluAlaGlyPheGlyGlnHisTyrLeuLeuPhePheAlaThrAlaAla ProAlaLeuGlyLeuGlyLeuTyrIleAlaGlnSerValAsnMetThrGluMetProGln LeuValAlaLeupheHisSerpheValGlyLeuAlaAlaValMetValGlyPheAlaAsn PheHisSerProAlaGlyValGluArgAlaSerSerLeuLeuArgLeuLeuGluValTyr AlaGlyValPheValAlaGlyIleThrPheThrGlySerValValAlaAlaAlaLysLeu HisGlySerMetGluSerArgSerLeuArgValProGlyArgHisAlaLeuAsnThrAla ThrIleAlaAlaIleGlyValLeuGlyAlaLeuPheCysValSerSerGlyHisPheThr ArgMetLeuCysLeuTyrValAsnAlaGlyLeuSerMetTrpLeuGlyPheHisLeuVal AlaAlaIleGlyGlyAlaAspMetProValValIleSerLeuLeuAsnSerTyrSerGly ValAlaLeuAlaAlaSerGlyPheMetLeuAspAsnAsnLeuLeuIleIleAlaGlyAla LeuIleAlaSerSerGlyAlaIleLeuSerTyrIleMetCysLysGlyMetAsnArgSer LeuTrpAsnValValLeuGlyGlyPheGluGluAlaGluAspValGlyAlaAlaSerPro GlnGlyAlaValGlnGlnAlaThrAlaAspGlnValAlaAspGluLeuLeuAlaAlaArg LysValLeuIleValProGlyTyrGlyMetAlaValAlaArgCysGlnSerGluLeuAla AspIleAlaLysAsnLeuMetAsnCysGlyIleThrValAspPheGlyIleHisProVal AlaGlyArgMetProGlyHisMetAsnValLeuLeuAlaGluAlaAspValProTyrLys IleValLysGluMetSerGluValAsnProGluMetSerSerTyrAspValValLeuVal ValGlyAlaAsnAspThrValAsnProAlaAlaLeuGluProGlySerLysIleSerGly MetProValIleGluAlaTrpLysAlaArgArgValPheValLeuLysArgSerMetAla AlaGlyTyrAlaSerIleGluAsnProLeuPheHisLeuGluAsnThrArgMetLeuPhe GlyAsnAlaLysAsnThrThrSerAlaValPheAlaArgValAsnAlaArgAlaGluGln MetProProSerAlaAlaArgAspAspLeuGluAlaGlyLeuLeuGluPheAspArgGlu GluArgValAspProSerSerTrpProTyrProArgMetAlaValGlyValLeuArgAsp SerAsnGlySerValMetValProValAlaProLysPheValProLysLeuArgLysLeu AlaPheArgValAsnValGluSerGlyAlaGlyAlaAspAlaGlyPheThrAspGluGlu TyrArgArgAlaGlyAlaGluValLeuSerGlyProAspAlaValIleAsnGlnSerGln ValLeuLeuArgValSerAlaProSerProAspLeuValSerArgIleProArgAspLys ValLeuIleSerTyrLeuPheProSerIleAsnGlnGlnAlaLeuAspMetLeuAlaArg GlnGlyValThrAlaLeuAlaValAspGluValProArgValThrArgAlaGlnLysLeu AspValLysSerAlaMetGlnGlyLeuGlnGlyTyrArgAlaValIleGluAlaPheAsn AlaLeuProLysLeuSerLysAlaSerIleSerAlaAlaGlyArgValGluAlaAlaLys ValPheValIleGlyAlaGlyValAlaGlyLeuGlnAlaIleSerThrAlaHisGlyLeu GlyAlaGlnValPheGlyHisAspValArgSerAlaThrArgGluGluValGluSerCys GlyGlyLysPheIleGlyLeuArgMetGlyGluGluGlyGluValLeuGlyGlyTyrAla ArgGluMetGlyAspAlaTyrGlnArgAlaGlnArgGluMetIleAlaAsnThrIleLys HisCysAspValValIleCysThrAlaAlaIleHisGlyArgProSerProLysLeuIle SerArgAspMetLeuArgSerMetLysProGlySerValValwalAspLeuAlaThrGlu PheGlyAspValArgSerGlyTrpGlyGlyAsnValGluValSerPfoLysAspAspGln IleValValAspGlyValThrValIleGlyArgArgArgIleGluThrArgMetProIle GlnAlaSerGluLeuPheSerMetAsnIleCysAsnLeuLeuGluAspLeuGlyGlyGly SerAsnPheArgIleAsnMetAspAspGluValIleArgGlyLeuValAlaValTyrGln GlyArgAsnValTrpGlnProSerGlnProThrProValSerArgThrProProArgGly GlnMetProProProSerAlaProGlyAlaProAlaProGluLysProGlyAlaPheAla GlnAlaLeuAlaSerAspAlaPhePheAlaMetCysLeuValValAlaAlaAlaValVal GlyLeuLeuGlyIleValLeuAspProValGluLeuLysHisLeuThrLeuLeuGlyLeu SerLeuIleValGlyTyrTyrCysValTrpAlaValThrProSerLeuHisThrProLeu MetSerValThrAsnAlaLeuSerGlyVallleVallleGlyCysMetLeuGluTyrGly ThrAlaMetIleSerGlyPheThrLeuLeuAlaLeuIleGlyThrPheLeuAlaSerVal AsnValAlaGlyGlyPhePheValThrHisArgMetLeuLysMetPheGlnIle
or a functional equivalent or partial sequence thereof.
81. The DNA sequence of claim 78 comprising all or part of the nucleotide sequence
GAATTCCGCC CCAGACAGCT AAGCGTGGCA ACATTCTTGG TCTTGTGGGC ATGGTAGCCG CTGTCGTCGT GACCTTCACG GAGGCAGGGT TTGGACAGCA TTACTTGCTG TTTTTCGCCA CTGCTGCACC GGCCCTTGGC CTGGGGCTGT ACATTGCGCA GTCTGTCAAC ATGACTGAGA TGCCTCAACT CGTGGCTCTT TTCCACAGTT TCGTCGGTCT TGCCGCCGTA ATGGTTGGGT TCGCGAACTT CCACTCCCCT GCTGGCGTGG AGCGCGCTTC CTCACTTCTA CGTCTGTTGG AGGTCTACGC CGGCGTTTTC GTCGCCGGTA TCACCTTCAC CGGATCAGTG GTCGCTGCGG CAAAGCTCCA TGGATCGATG GAGAGCCGCT CATTGAGGGT TCCCGGACGC CATGCGTTGA ATACTGCCAC TATTGCTGCC ATTGGCGTAC TTGGCGCTCT TTTTTGCGTC TCTTCTGGCC ACTTTACACG CATGCTTTGC CTTTATGTGA ATGCTGGCTT GAGCATGTGG CTTGGTTTTC ACCTGGTCGC CGCTATTGGT GGAGCTGACA TGCCCGTCGT GATCAGCTTG CTGAACTCGT ATTCCGGAGT GGCGTTGGCT GCCAGTGGCT TCATGTTGGA CAACAACTTG CTGATCATTG CTGGTGCTCT CATCGCGTCA TCTGGTGCCA TTCTGTCTTA CATCATGTGC AAAGGCATGA ACCGGAGTCT GTGGAATGTC GTTCTTGGTG GCTTCGAGGA GGCCGAGGAC GTTGGCGCAG CCAGCCCTCA GGGGGCTGTG CAGCAGGCCA CGGCTGATCA GGTCGCCGAC GAGTTGCTGG CTGCCCGCAA AGTTTTGATC GTGCCTGGAT ACGGAATGGC CGTTGCAAGG TGCCAGAGCG AGCTTGCAGA CATTGCCAAG AACTTGATGA ACTGCGGTAT CACCGTCGAT TTCGGCATCC ATCCAGTTGC TGGTCGCATG CCAGGCCACA TGAACGTCCT CCTCGCTGAG GCTGATGTTC CGTACAAGAT TGTCAAGGAG ATGTCTGAAG TCAACCCGGA AATGAGCTCC TACGACGTCG TCCTGGTTGT TGGAGCCAAC GACACCGTCA ATCCTGCAGC CCTTGAGCCA GGATCAAAGA TCTCAGGAAT GCCCGTTATA GAGGCCTGGA AAGCTAGACG CGTTTTTGTG CTGAAGCGGT CCATGGCTGC TGGATATGCC AGCATTGAAA ATCCACTTTT CCATCTGGAG AACACACGCA TGCTCTTCGG AAACGCAAAG AACACCACTT CTGCAGTCTT CGCCCGTGTC AATGCCAGAG CCGAGCAAAT GCCACCATCT GCTGCCCGTG ATGACCTCGA AGCTGGACTA CTTGAGTTCG ATAGGGAAGA ACGTGTTGAT CCCTCTTCTT GGCCATATCC CAGGATGGCT GTTGGTGTTC TGAGAGACTC CAATGGCTCT GTTATGGTGC CAGTAGCTCC GAAGTTTGTG CCCAAGCTGA GGAAGTTGGC ATTCCGTGTC AATGTCGAGT CTGGTGCTGG CGCCGATGCC GGCTTTACTG ACGAAGAGTA CAGGAGGGCT GGAGCAGAAG TCCTGTCGGG CCCCGATGCA GTCATTAACC AGTCTCAAGT CCTGCTCCGC GTTTCAGCGC CGTCGCCAGA TCTGGTTTCG CGCATTCCTA GGGACAAGGT CCTTATCAGT TACCTATTCC CCAGCATCAA CCAACAAGCT CTTGACATGC TAGCACGCCA AGGCGTCACC GCACTTGCTG TGGATGAGGT TCCTCGCGTC ACAAGAGCAC AGAAGCTAGA CGTGAAGTCT GCTATGCAAG GTCTCCAGGG ATACCGCGCC GTTATCGAAG CGTTCAACGC TCTTCCGAAG CTCAGCAAAG CATCTATCAG TGCTGCAGGC CGTGTAGAAG CCGCTAAAGT TTTCGTCATC GGTGCCGGTG TTGCTGGACT ACAGGCAATT TCTACCGCCC ATGGTTTGGG TGCACAAGTA 8TTGGCCACG ATGTGCGCTC TGCAACTCGT GAGGAAGTCG AATCTTGCGG TGGAAAGTTC ATTGGTTTGA GAATGGGAGA GGAGGGTGAA GTCCTCGGAG GATATGCACG CGAGATGGGT GATGCATATC AGAGAGCGCA ACGCGAGATG ATTGCCAACA CAATCAAGCA CTGCGATGTC GTCATCTGTA CCGCTGCTAT TCACGGCAGA CCTTCACCAA AGCTCATATC ACGCGACATG TTGCGTTCAA TGAAGCCTGG CTCCGTCGTC GTAGATCTTG CAACAGAGTT CGGTGATGTG CGCTCCGGCT GGGGTGGAAA CGTCGAGGTT TCGCCTAAGG ACGACCAGAT TGTCGTTGAT GGCGTCACTG TCATTGGTCG CAGACGCATT GAGACTCGCA TGCCCATTCA GGCGTCTGAG CTGTTCTCCA TGAACATATG CAACCTCCTT GAGGATCTTG GTGGTGGCAG CAACTTCCGC ATCAACATGG ACGACGAAGT CATCAGAGGA TTGGTCGCAG TCTACCAAGG TCGCAACGTG TGGCAGCCAT CGCAGCCCAC TCCTGTTTCC AGGACACCTC CGCGCGGCCA GATGCCGCCC CCGTCTGCAC CTGGTGCACC AGCTCCTGAG AAGCCTGGTG CCTTTGCTCA AGCACTTGCT TCGGATGCAT TCTTCGCAAT GTGTCTTGTT GTTGCTGCCG CTGTTGTCGG GCTCCTTGGC ATTGTCCTTG ACCCTGTGGA GCTCAAGCAT TTGACTCTCC TCGGCTTGTC TCTCATCGTC GGCTACTACT GCGTGTGGGC CGTTACGCCT TCGCTTCACA CACCATTGAT GTCTGTGACG AATGCCCTTT CGGGAGTCAT TGTCATCGGC TGCATGCTCG AGTACGGAAC CGCCATGATA TCCGGATTCA CTCTTCTCGC ACTCATTGGA ACCTTCTTGG CTTCCGTCAA CGTTGCTGGT GGATTCTTCG TAACTCACCG CATGCTGAAG ATGTTTCAGA TATAAGGGGA GAACCCCCTT GAGTTAATCT TAACTCAGAA TAACTCTTTT TCAATTGTAT AAACCTGTAC TCGTTGCAAA AAAAAAAGGA ATTC.
82. The DNA sequence of claim 78 comprising all or part of the nucleotide sequence
CC CCAGACAGCT AAGCGTGGCA ACATTCTTGG TCTTGTGGGC ATGGTAGCCG CTGTCGTCGT GACCTTCACG GAGGCAGGGT TTGGACAGCA TTACTTGCTG TTTTTCGCCA CTGCTGCACC GGCCCTTGGC CTGGGGCTGT ACATTGCGCA GTCTGTCAAC ATGACTGAGA TGCCTCAACT CGTGGCTCTT TTCCACAGTT TCGTCGGTCT TGCCGCCGTA ATGGTTGGGT TCGCGAACTT CCACTCCCCT GCTGGCGTGG AGCGCGCTTC CTCACTTCTA CGTCTGTTGG AGGTCTACGC CGGCGTTTTC GTCGCCGGTA TCACCTTCAC CGGATCAGTG GTCGCTGCGG CAAAGCTCCA TGGATCGATG GAGAGCCGCT CATTGAGGGT TCCCGGACGC CATGCGTTGA ATACTGCCAC TATTGCTGCC ATTGGCGTAC TTGGCGCTCT TTTTTGCGTC TCTTCTGGCC ACTTTACACG CATGCTTTGC CTTTATGTGA ATGCTGGCTT GAGCATGTGG CTTGGTTTTC ACCTGGTCGC CGCTATTGGT GGAGCTGACA TGCCCGTCGT GATCAGCTTG CTGAACTCGT ATTCCGGAGT GGCGTTGGCT GCCAGTGGCT TCATGTTGGA CAACAACTTG CTGATCATTG CTGGTGCTCT CATCGCGTCA TCTGGTGCCA TTCTGTCTTA CATCATGTGC AAAGGCATGA ACCGGAGTCT GTGGAATGTC GTTCTTGGTG GCTTCGAGGA GGCCGAGGAC GTTGGCGCAG CCAGCCCTCA GGGGGCTGTG CAGCAGGCCA CGGCTGATCA GGTCGCCGAC GAGTTGCTGG CTGCCCGCAA AGTTTTGATC GTGCCTGGAT ACGGAATGGC CGTTGCAAGG TGCCAGAGCG AGCTTGCAGA CATTGCCAAG AACTTGATGA ACTGCGGTAT CACCGTCGAT TTCGGCATCC ATCCAGTTGC TGGTCGCATG CCAGGCCACA TGAACGTCCT CCTCGCTGAG GCTGATGTTC CGTACAAGAT TGTCAAGGAG ATGTCTGAAG TCAACCCGGA AATGAGCTCC TACGACGTCG TCCTGGTTGT TGGAGCCAAC GACACCGTCA ATCCTGCAGC CCTTGAGCCA GGATCAAAGA TCTCAGGAAT GCCCGTTATA GAGGCCTGGA AAGCTAGACG CGTTTTTGTG CTGAAGCGGT CCATGGCTGC TGGATATGCC AGCATTGAAA ATCCACTTTT CCATCTGGAG AACACACGCA TGCTCTTCGG AAACGCAAAG AACACCACTT CTGCAGTCTT CGCCCGTGTC AATGCCAGAG CCGAGCAAAT GCCACCATCT GCTGCCCGTG ATGACCTCGA AGCTGGACTA CTTGAGTTCG ATAGGGAAGA ACGTGTTGAT CCCTCTTCTT GGCCATATCC CAGGATGGCT GTTGGTGTTC,TGAGAGACTC CAATGGCTCT GTTATGGTGC CAGTAGCTCC GAAGTTTGTG CCCAAGCTGA GGAAGTTGGC ATTCCGTGTC AATGTCGAGT CTGGTGCTGG CGCCGATGCC GGCTTTACTG ACGAAGAGTA CAGGAGGGCT GGAGCAGAAG TCCTGTCGGG CCCCGATGCA GTCATTAACC AGTCTCAAGT CCTGCTCCGC GTTTCAGCGC CGTCGCCAGA TCTGGTTTCG CGCATTCCTA GGGACAAGGT CCTTATCAGT TACCTATTCC CCAGCATCAA CCAACAAGCT CTTGACATGC TAGCACGCCA AGGCGTCACC GCACTTGCTG TGGATGAGGT TCCTCGCGTC ACAAGAGCAC AGAAGCTAGA CGTGAAGTCT GCTATGCAAG GTCTCCAGGG ATACCGCGCC GTTATCGAAG CGTTCAACGC TCTTCCGAAG CTCAGCAAAG CATCTATCAG TGCTGCAGGC CGTGTAGAAG CCGCTAAAGT TTTCGTCATC GGTGCCGGTG TTGCTGGACT ACAGGCAATT TCTACCGCCC ATGGTTTGGG TGCACAAGTA 8TTGGCCACG ATGTGCGCTC TGCAACTCGT GAGGAAGTCG AATCTTGCGG TGGAAAGTTC ATTGGTTTGA GAATGGGAGA GGAGGGTGAA GTCCTCGGAG GATATGCACG CGAGATGGGT GATGCATATC AGAGAGCGCA ACGCGAGATG ATTGCCAACA CAATCAAGCA CTGCGATGTC GTCATCTGTA CCGCTGCTAT TCACGGCAGA CCTTCACCAA AGCTCATATC ACGCGACATG TTGCGTTCAA TGAAGCCTGG CTCCGTCGTC GTAGATCTTG CAACAGAGTT CGGTGATGTG CGCTCCGGCT GGGGTGGAAA CGTCGAGGTT TCGCCTAAGG ACGACCAGAT TGTCGTTGAT GGCGTCACTG TCATTGGTCG CAGACGCATT GAGACTCGCA TGCCCATTCA GGCGTCTGAG CTGTTCTCCA TGAACATATG CAACCTCCTT GAGGATCTTG GTGGTGGCAG CAACTTCCGC ATCAACATGG ACGACGAAGT CATCAGAGGA TTGGTCGCAG TCTACCAAGG TCGCAACGTG TGGCAGCCAT CGCAGCCCAC TCCTGTTTCC AGGACACCTC CGCGCGGCCA GATGCCGCCC CCGTCTGCAC CTGGTGCACC AGCTCCTGAG AAGCCTGGTG CCTTTGCTCA AGCACTTGCT TCGGATGCAT TCTTCGCAAT GTGTCTTGTT GTTGCTGCCG CTGTTGTCGG GCTCCTTGGC ATTGTCCTTG ACCCTGTGGA GCTCAAGCAT TTGACTCTCC TCGGCTTGTC TCTCATCGTC GGCTACTACT GCGTGTGGGC CGTTACGCCT TCGCTTCACA CACCATTGAT GTCTGTGACG AATGCCCTTT CGGGAGTCAT TGTCATCGGC TGCATGCTCG AGTACGGAAC CGCCATGATA TCCGGATTCA CTCTTCTCGC ACTCATTGGA ACCTTCTTGG CTTCCGTCAA CGTTGCTGGT GGATTCTTCG TAACTCACCG CATGCTGAAG ATGTTTCAGA TATAA.
83. A recombinant vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712.
84. The recombinant vector of claim 83 comprising a DNA sequence encoding a protein having the amino acid sequence
ProGlnThrAlaLysArgGlyAsnIleLeuGlyLeuValGlyMetValAlaAlaValVal ValThrPheThrGluAlaGlyPheGlyGlnHisTyrLeuLeuPhePheAlaThrAlaAla ProAlaLeuGlyLeuGlyLeuTyrIleAlaGlnSerValAsnMetThrGluMetProGln LeuValAlaLeuPheHisSerPheValGlyLeuAlaAlaValMetValGlyPheAlaAsn PheHisSerProAlaGlyValGluArgAlaSerSerLeuLeuArgLeuLeuGluValTyr AlaGlyValPheValAlaGlyIleThrPheThrGlySerValValAlaAlaAlaLysLeu HisGlySerMetGluSerArgSerLeuArgValProGlyArgHisAlaLeuAsnThrAla ThrIleAlaAlaIleGlyValLeuGlyAlaLeuPheCysValSerSerGlyHisPheThr ArgMetLeuCysLeuTyrValAsnAlaGlyLeuSerMetTrpLeuGlyPheHisLeuVal AlaAlaIleGlyGlyAlaAspMetProValValIleSerLeuLeuAsnSerTyrSerGly ValAlaLeuAlaAlaSerGlyPheMetLeuAspAsnAsnLeuLeuIleIleAlaGlyAla LeuIleAlaSerSerGlyAlaIleLeuSerTyrIleMetCysLysGlyMetAsnArgser LeuTrpAsnValValLeuGlyGlyPheGluGluAlaGluAspValGlyAlaAlaSerPro GlnGlyAlaValGlnGlnAlaThrAlaAspGlnValAlaAspGluLeuLeuAlaAlaArg LysValLeuIleValProGlyTyrGlyMetAlaValAlaArgCysGlnSerGluLeuAla AspIleAlaLysAsnLeuMetAsnCysGlyIleThrValAspPheGlyIleHisProVal AlaGlyArgMetProGlyHisMetAsnValLeuLeuAlaGluAlaAspValProTyrLys IleValLysGluMetSerGluValAsnProGluMetSerSerTyrAspValValLeuVal ValGlyAlaAsnAspThrValAsnProAlaAlaLeuGluProGlySerLysIleSerGly MetProValIleGluAlaTrpLysAlaArgArgValPheValLeuLysArgserMetAla AlaGlyTyrAlaSerIleGluAsnProLeuPheHisLeuGluAsnThrArgMetLeuPhe GlyAsnAlaLysAsnThrThrSerAlaValPheAlaArgValAsnAlaArgAlaGluGln MetProProSerAlaAlaArgAspAspLeuGluAlaGlyLeuLeuGluPheAspArgGlu GluArgValAspProSerSerTrpProTyrProArgMetAlaValGlyValLeuArgAsp SerAsnGlySerValMetValProValAlaProLysPheValProLysLeuArgLysLeu AlaPheArgValAsnValGluSerGlyAlaGlyAlaAspAlaGlyPheThrAspGluGlu TyrArgArgAlaGlyAlaGluValLeuSerGlyProAspAlaValIleAsnGlnSerGln ValLeuLeuArgValSerAlaProSerProAspLeuValSerArgIleProArgAspLys ValLeuIleSerTyrLeuPheProSerIleAsnGlnGlnAlaIeuAspMetLeuAlaArg GlnGlyValThrAlaLeuAlaValAspGluValProArgValThrArgAlaGlnLysLeu AspValLysSerAlaMetGlnGlyLeuGlnGlyTyrArgAlaValIleGluAlaPheAsn AlaLeuProLysLeuSerLysAlaSerIleSerAlaAlaGlyArgValGluAlaAlaLys ValPheValIleGlyAlaGlyValAlaGlyLeuGlnAlaIleSerThrAlaHisGlyLeu GlyAlaGlnVal???GlyHisAspValArgSerAlaThrArgGluGluValGluSerCys GlyGlyLysPheIleGlyLeuArgMetGlyGluGluGlyGluValLeuGlyGlyTyrAla ArgGluMetGlyAspAlaTyrGlnArgAlaGlnArgGluMetIleAlaAsnThrIleLys HisCysAspValValIleCysThrAlaAlaIleHisGlyArgProSerProLysLeuIle SerArgAspMetLeuArgSerMetLysProGlySerValValValAspLeuAlaThrGlu PheGlyAspValArgSerGlyTrpGlyGlyAsnValGluValSerProLysAspAspGln IleValValAspGlyValThrValIleGlyArgArgArgIleGluThrArgMetproIle GlnAlaSerGluLeuPheSerMetAsnIleCysAsnLeuLeuGluAspLeuGlyGlyGly SerAsnPheArgIleAsnMetAspAspGluValIleArgGlyLeuValAlaValTyrGln GlyArgAsnValTrpGlnProSerGlnProThrProValSerArgThrProProArgGly GlnMetProProProSerAlaProGlyAlaProAlaProGluLysProGlyAlaPheAla GlnAlaLeuAlaSerAspAlaPhePheAlaMetCysLeuValValAlaAlaAlaValVal GlyLeuLeuGlyIleValLeuAspProValGluLeuLysHisLeuThrLeuLeuGlyLeu SerLeuIleValGlyTyrTyrCysValTrpAlaValThrProSerLeuHisThrProLeu MetSerValThrAsnAlaLeuSerGlyVallleValIleGlyCysMetLeuGluTyrGly ThrAlaMetIleSerGlyPheThrLeuLeuAlaLeuIleGlyThrPheLeuAlaSerVal AsnValAlaGlyGlyPhePheValThrHisArgMetLeuLysMetPheGlnIle
or a functional equivalent or partial sequence thereof.
85. The recombinant vector of claim 83 comprising a DNA sequence encoding a protein having the amino acid sequence
ThrAlaLysArgGlyAsnIleLeuGlyLeuValGlyMetValAlaAlaValVal ValThrPheThrGluAlaGlyPheGlyGlnHisTyrLeuLeuPhePheAlaThrAlaAla ProAlaLeuGlyLeuGlyLeuTyrIleAlaGlnSerValAsnMetThrGluMetProGln LeuValAlaLeuPheHisSerPheValGlyLeuAlaAlaValMetValGlyPheAlaAsn PheHisSerProAlaGlyValGluArgAlaSerSerLeuLeuArgLeuLeuGluValTyr AlaGlyValPheValAlaGlyIleThrPheThrGlySerValValAlaAlaAlaLysLeu HisGlySerMetGluSerArgSerLeuArgValProGlyArgHisAlaLeuAsnThrAla ThrIleAlaAlaIleGlyValLeuGlyAlaLeuPheCysValSerSerGlyHisPheThr ArgMetLeuCysLeuTyrValAsnAlaGlyLeuSerMetTrpLeuGlyPheHisLeuVal AlaAlaIleGlyGlyAlaAspMetProValValIleSerLeuLeuAsnSerTyrSerGly ValAlaLeuAlaAlaSerGlyPheMetLeuAspAsnAsnLeuLeuIleIleAlaGlyAla LeuIleAlaSerSerGlyAlaIleLeuSerTyrIleMetCysLysGlyMetAsnArgser LeuTrpAsnValValLeuGlyGlyPheGluGluAlaGluAspValGlyAlaAlaSerPro GlnGlyAlaValGlnGlnAlaThrAlaAspGlnValAlaAspGluLeuLeuAlaAlaArg LysValLeuIleValProGlyTyrGlyMetAlaValAlaArgCysGlnSerGluLeuAla AspIleAlaLysAsnLeuMetAsnCysGlyIleThrValAspPheGlyIleHisProVal AlaGlyArgMetProGlyHisMetAsnValLeuLeuAlaGluAlaAspValProTyrLys IleValLysGluMetSerGluValAsnProGluMetSerSerTyrAspValValLeuVal ValGlyAlaAsnAspThrValAsnProAlaAlaLeuGluProGlySerLysIleSerGly MetProValIleGluAlaTrpLysAlaArgArgValPheValLeuLysArgSerMetAla AlaGlyTyrAlaSerIleGluAsnProLeuPheHisLeuGluAsnThrArgMetLeuPhe GlyAsnAlaLysAsnThrThrSerAlaValPheAlaArgValAsnAlaArgAlaGluGln MetProProSerAlaAlaArgAspAspLeuGluAlaGlyLeuLeuGluPheAspArgGlu GluArgValAspProSerSerTrpProTyrProArgMetAlaValGlyValLeuArgAsp SerAsnGlySerValMetValProValAlaProLysPheValProLysLeuArgLysLeu AlaPheArgValAsnValGluSerGlyAlaGlyAlaAspAlaGlyPheThrAspGluGlu TyrArgArgAlaGlyAlaGluValLeuSerGlyProAspAlaValIleAsnGlnSerGln ValLeuLeuArgValSerAlaProSerProAspLeuValSerArgIleProArgAspLys ValLeuIleSerTyrLeuPheProSerIleAsnGlnGlnAlaLeuAspMetLeuAlaArg GlnGlyValThrAlaLeuAlaValAspGluValProArgValThrArgAlaGlnLysLeu AspValLysSerAlaMetGlnGlyLeuGlnGlyTyrArgAlaValIleGluAlaPheAsn AlaLeuProLysLeuSerLysAlaSerIleSerAlaAlaGlyArgValGluAlaAlaLys ValPheValIleGlyAlaGlyValAlaGlyLeuGlnAlaIleSerThrAlaHisGlyLeu GlyAlaGlnValPheGlyHisAspValArgSerAlaThrArgGluGluValGluSerCys GlyGlyLysPheIleGlyLeuArgMetGlyGluGluGlyGluValLeuGlyGlyTyrAla ArgGluMetGlyAspAlaTyrGlnArgAlaGlnArgGluMetIleAlaAsnThrIleLys HisCysAspValValIleCysThrAlaAlaIleHisGlyArgProSerProLysLeuIle SerArgAspMetLeuArgSerMetLysProGlySerValValValAspLeuAlaThrGlu PheGlyAspValArgSerGlyTrpGlyGlyAsnValGluValSerProLysAspAspGln IleValValAspGlyValThrValIleGlyArgArgArgIleGluThrArgMetProIle GlnAlaSerGluLeuPheSerMetAsnIleCysAsnLeuLeuGluAspLeuGlyGlyGly SerAsnPheArgIleAsnMetAspAspGluValIleArgGlyLeuValAlaValTyrGln GlyArgAsnValTrpGlnProSerGlnProThrProValSerArgThrProProArgGly GlnMetProProProSerAlaProGlyAlaProAlaProGluLysProGlyAlaPheAla GlnAlaLeuAlaSerAspAlaPhePheAlaMetCysLeuValValAlaAlaAlaValVal GlyLeuLeuGlyIleValLeuAspProValGluLeuLysHisLeuThrLeuLeuGlyLeu SerLeuIleValGlyTyrTyrCysValTrpAlaValThrProSerLeuHisThrProLeu MetSerValThrAsnAlaLeuSerGlyValIleValIleGlyCysMetLeuGluTyrGly ThrAlaMetIleSerGlyPheThrLeuLeuAlaLeuIleGlyThrPheLeuAlaSerVal AsnValAlaGlyGlyPhePheValThrHisArgMetLeuLysMetPheGlnIle
or a functional equivalent or partial sequence thereof.
86. The recombinant vector of claim 83 comprising all or part of the nucleotide sequence
GAATTCCGCC CCAGACAGCT AAGCGTGGCA ACATTCTTGG TCTTGTGGGC ATGGTAGCCG CTGTCGTCGT GACCTTCACG GAGGCAGGGT TTGGACAGCA TTACTTGCTG TTTTTCGCCA CTGCTGCACC GGCCCTTGGC CTGGGGCTGT ACATTGCGCA GTCTGTCAAC ATGACTGAGA TGCCTCAACT CGTGGCTCTT TTCCACAGTT TCGTCGGTCT TGCCGCCGTA ATGGTTGGGT TCGCGAACTT CCACTCCCCT GCTGGCGTGG AGCGCGCTTC CTCACTTCTA CGTCTGTTGG AGGTCTACGC CGGCGTTTTC GTCGCCGGTA TCACCTTCAC CGGATCAGTG GTCGCTGCGG CAAAGCTCCA TGGATCGATG GAGAGCCGCT CATTGAGGGT TCCCGGACGC CATGCGTTGA ATACTGCCAC TATTGCTGCC ATTGGCGTAC TTGGCGCTCT TTTTTGCGTC TCTTCTGGCC ACTTTACACG CATGCTTTGC CTTTATGTGA ATGCTGGCTT GAGCATGTGG CTTGGTTTTC ACCTGGTCGC CGCTATTGGT GGAGCTGACA TGCCCGTCGT GATCAGCTTG CTGAACTCGT ATTCCGGAGT GGCGTTGGCT GCCAGTGGCT TCATGTTGGA CAACAACTTG CTGATCATTG CTGGTGCTCT CATCGCGTCA TCTGGTGCCA TTCTGTCTTA CATCATGTGC AAAGGCATGA ACCGGAGTCT GTGGAATGTC GTTCTTGGTG GCTTCGAGGA GGCCGAGGAC GTTGGCGCAG CCAGCCCTCA GGGGGCTGTG CAGCAGGCCA CGGCTGATCA GGTCGCCGAC GAGTTGCTGG CTGCCCGCAA AGTTTTGATC GTGCCTGGAT ACGGAATGGC CGTTGCAAGG TGCCAGAGCG AGCTTGCAGA CATTGCCAAG AACTTGATGA ACTGCGGTAT CACCGTCGAT TTCGGCATCC ATCCAGTTGC TGGTCGCATG CCAGGCCACA TGAACGTCCT CCTCGCTGAG GCTGATGTTC CGTACAAGAT TGTCAAGGAG ATGTCTGAAG TCAACCCGGA AATGAGCTCC TACGACGTCG TCCTGGTTGT TGGAGCCAAC GACACCGTCA ATCCTGCAGC CCTTGAGCCA GGATCAAAGA TCTCAGGAAT GCCCGTTATA GAGGCCTGGA AAGCTAGACG CGTTTTTGTG CTGAAGCGGT CCATGGCTGC TGGATATGCC AGCATTGAAA ATCCACTTTT CCATCTGGAG AACACACGCA TGCTCTTCGG AAACGCAAAG AACACCACTT CTGCAGTCTT CGCCCGTGTC AATGCCAGAG CCGAGCAAAT GCCACCATCT GCTGCCCGTG ATGACCTCGA AGCTGGACTA CTTGAGTTCG ATAGGGAAGA ACGTGTTGAT CCCTCTTCTT GGCCATATCC CAGGATGGCT GTTGGTGTTC TGAGAGACTC CAATGGCTCT GTTATGGTGC CAGTAGCTCC GAAGTTTGTG CCCAAGCTGA GGAAGTTGGC ATTCCGTGTC AATGTCGAGT CTGGTGCTGG CGCCGATGCC GGCTTTACTG ACGAAGAGTA CAGGAGGGCT GGAGCAGAAG TCCTGTCGGG CCCCGATGCA GTCATTAACC AGTCTCAAGT CCTGCTCCGC GTTTCAGCGC CGTCGCCAGA TCTGGTTTCG CGCATTCCTA GGGACAAGGT CCTTATCAGT TACCTATTCC CCAGCATCAA CCAACAAGCT CTTGACATGC TAGCACGCCA AGGCGTCACC GCACTTGCTG TGGATGAGGT TCCTCGCGTC ACAAGAGCAC AGAAGCTAGA CGTGAAGTCT GCTATGCAAG GTCTCCAGGG ATACCGCGCC GTTATCGAAG CGTTCAACGC TCTTCCGAAG CTCAGCAAAG CATCTATCAG TGCTGCAGGC CGTGTAGAAG CCGCTAAAGT TTTCGTCATC GGTGCCGGTG TTGCTGGACT ACAGGCAATT TCTACCGCCC ATGGTTTGGG TGCACAAGTA 8TTGGCCACG ATGTGCGCTC TGCAACTCGT GAGGAAGTCG AATCTTGCGG TGGAAAGTTC ATTGGTTTGA GAATGGGAGA GGAGGGTGAA GTCCTCGGAG GATATGCACG CGAGATGGGT GATGCATATC AGAGAGCGCA ACGCGAGATG ATTGCCAACA CAATCAAGCA CTGCGATGTC GTCATCTGTA CCGCTGCTAT TCACGGCAGA CCTTCACCAA AGCTCATATC ACGCGACATG TTGCGTTCAA TGAAGCCTGG CTCCGTCGTC GTAGATCTTG CAACAGAGTT CGGTGATGTG CGCTCCGGCT GGGGTGGAAA CGTCGAGGTT TCGCCTAAGG ACGACCAGAT TGTCGTTGAT GGCGTCACTG TCATTGGTCG CAGACGCATT GAGACTCGCA TGCCCATTCA GGCGTCTGAG CTGTTCTCCA TGAACATATG CAACCTCCTT GAGGATCTTG GTGGTGGCAG CAACTTCCGC ATCAACATGG ACGACGAAGT CATCAGAGGA TTGGTCGCAG TCTACCAAGG TCGCAACGTG TGGCAGCCAT CGCAGCCCAC TCCTGTTTCC AGGACACCTC CGCGCGGCCA GATGCCGCCC CCGTCTGCAC CTGGTGCACC AGCTCCTGAG AAGCCTGGTG CCTTTGCTCA AGCACTTGCT TCGGATGCAT TCTTCGCAAT GTGTCTTGTT GTTGCTGCCG CTGTTGTCGG GCTCCTTGGC ATTGTCCTTG ACCCTGTGGA GCTCAAGCAT TTGACTCTCC TCGGCTTGTC TCTCATCGTC GGCTACTACT GCGTGTGGGC CGTTACGCCT TCGCTTCACA CACCATTGAT GTCTGTGACG AATGCCCTTT CGGGAGTCAT TGTCATCGGC TGCATGCTCG AGTACGGAAC CGCCATGATA TCCGGATTCA CTCTTCTCGC ACTCATTGGA ACCTTCTTGG CTTCCGTCAA CGTTGCTGGT GGATTCTTCG TAACTCACCG CATGCTGAAG ATGTTTCAGA TATAAGGGGA GAACCCCCTT GAGTTAATCT TAACTCAGAA TAACTCTTTT TCAATTGTAT AAACCTGTAC TCGTTGCAAA AAAAAAAGGA ATTC.
87. The recombinant vector of claim 83 comprising all or part of the nucleotide sequence
CC CCAGACAGCT AAGCGTGGCA ACATTCTTGG TCTTGTGGGC ATGGTAGCCG CTGTCGTCGT GACCTTCACG GAGGCAGGGT TTGGACAGCA TTACTTGCTG TTTTTCGCCA CTGCTGCACC GGCCCTTGGC CTGGGGCTGT ACATTGCGCA GTCTGTCAAC ATGACTGAGA TGCCTCAACT CGTGGCTCTT TTCCACAGTT TCGTCGGTCT TGCCGCCGTA ATGGTTGGGT TCGCGAACTT CCACTCCCCT GCTGGCGTGG AGCGCGCTTC CTCACTTCTA CGTCTGTTGG AGGTCTACGC CGGCGTTTTC GTCGCCGGTA TCACCTTCAC CGGATCAGTG GTCGCTGCGG CAAAGCTCCA TGGATCGATG GAGAGCCGCT CATTGAGGGT TCCCGGACGC CATGCGTTGA ATACTGCCAC TATTGCTGCC ATTGGCGTAC TTGGCGCTCT TTTTTGCGTC TCTTCTGGCC ACTTTACACG CATGCTTTGC CTTTATGTGA ATGCTGGCTT GAGCATGTGG CTTGGTTTTC ACCZGGTCGC CGCTATTGGT GGAGCTGACA TGCCCGTCGT GATCAGCTTG CTGAACTCGT ATTCCGGAGT GGCGTTGGCT GCCAGTGGCT TCATGTTGGA CAACAACTTG CTGATCATTG CTGGTGCTCT CATCGCGTCA TCTGGTGCCA TTCTGTCTTA CATCATGTGC AAAGGCATGA ACCGGAGTCT GTGGAATGTC GTTCTTGGTG GCTTCGAGGA GGCCGAGGAC GTTGGCGCAG CCAGCCCTCA GGGGGCTGTG CAGCAGGCCA CGGCTGATCA GGTCGCCGAC GAGTTGCTGG CTGCCCGCAA AGTTTTGATC GTGCCTGGAT ACGGAATGGC CGTTGCAAGG TGCCAGAGCG AGCTTGCAGA CATTGCCAAG AACTTGATGA ACTGCGGTAT CACCGTCGAT TTCGGCATCC ATCCAGTTGC TGGTCGCATG CCAGGCCACA TGAACGTCCT CCTCGCTGAG GCTGATGTTC CGTACAAGAT TGTCAAGGAG ATGTCTGAAG TCAACCCGGA AATGAGCTCC TACGACGTCG TCCTGGTTGT TGGAGCCAAC GACACCGTCA ATCCTGCAGC CCTTGAGCCA GGATCAAAGA TCTCAGGAAT GCCCGTTATA GAGGCCTGGA AAGCTAGACG CGTTTTTGTG CTGAAGCGGT CCATGGCTGC TGGATATGCC AGCATTGAAA ATCCACTTTT CCATCTGGAG AACACACGCA TGCTCTTCGG AAACGCAAAG AACACCACTT CTGCAGTCTT CGCCCGTGTC AATGCCAGAG CCGAGCAAAT GCCACCATCT GCTGCCCGTG ATGACCTCGA AGCTGGACTA CTTGAGTTCG ATAGGGAAGA ACGTGTTGAT CCCTCTTCTT GGCCATATCC CAGGATGGCT GTTGGTGTTC TGAGAGACTC CAATGGCTCT GTTATGGTGC CAGTAGCTCC GAAGTTTGTG CCCAAGCTGA GGAAGTTGGC ATTCCGTGTC AATGTCGAGT CTGGTGCTGG CGCCGATGCC GGCTTTACTG ACGAAGAGTA CAGGAGGGCT GGAGCAGAAG TCCTGTCGGG CCCCGATGCA GTCATTAACC AGTCTCAAGT CCTGCTCCGC GTTTCAGCGC CGTCGCCAGA TCTGGTTTCG CGCATTCCTA GGGACAAGGT CCTTATCAGT TACCTATTCC CCAGCATCAA CCAACAAGCT CTTGACATGC TAGCACGCCA AGGCGTCACC GCACTTGCTG TGGATGAGGT TCCTCGCGTC ACAAGAGCAC AGAAGCTAGA CGTGAAGTCT GCTATGCAAG GTCTCCAGGG ATACCGCGCC GTTATCGAAG CGTTCAACGC TCTTCCGAAG CTCAGCAAAG CATCTATCAG TGCTGCAGGC CGTGTAGAAG CCGCTAAAGT TTTCGTCATC GGTGCCGGTG TTGCTGGACT ACAGGCAATT TCTACCGCCC ATGGTTTGGG TGCACAAGTA 8TTGGCCACG ATGTGCGCTC TGCAACTCGT GAGGAAGTCG AATCTTGCGG TGGAAAGTTC ATTGGTTTGA GAATGGGAGA GGAGGGTGAA GTCCTCGGAG GATATGCACG CGAGATGGGT GATGCATATC AGAGAGCGCA ACGCGAGATG ATTGCCAACA CAATCAAGCA CTGCGATGTC GTCATCTGTA CCGCTGCTAT TCACGGCAGA CCTTCACCAA AGCTCATATC ACGCGACATG TTGCGTTCAA TGAAGCCTGG CTCCGTCGTC GTAGATCTTG CAACAGAGTT CGGTGATGTG CGCTCCGGCT GGGGTGGAAA CGTCGAGGTT TCGCCTAAGG ACGACCAGAT TGTCGTTGAT GGCGTCACTG TCATTGGTCG CAGACGCATT GAGACTCGCA TGCCCATTCA GGCGTCTGAG CTGTTCTCCA TGAACATATG CAACCTCCTT GAGGATCTTG GTGGTGGCAG CAACTTCCGC ATCAACATGG ACGACGAAGT CATCAGAGGA TTGGTCGCAG TCTACCAAGG TCGCAACGTG TGGCAGCCAT CGCAGCCCAC TCCTGTTTCC AGGACACCTC CGCGCGGCCA GATGCCGCCC CCGTCTGCAC CTGGTGCACC AGCTCCTGAG AAGCCTGGTG CCTTTGCTCA AGCACTTGCT TCGGATGCAT TCTTCGCAAT GTGTCTTGTT GTTGCTGCCG CTGTTGTCGG GCTCCTTGGC ATTGTCCTTG ACCCTGTGGA GCTCAAGCAT TTGACTCTCC TCGGCTTGTC TCTCATCGTC GGCTACTACT GCGTGTGGGC CGTTACGCCT TCGCTTCACA CACCATTGAT GTCTGTGACG AATGCCCTTT CGGGAGTCAT TGTCATCGGC TGCATGCTCG AGTACGGAAC CGCCATGATA TCCGGATTCA CTCTTCTCGC ACTCATTGGA ACCTTCTTGG CTTCCGTCAA CGTTGCTGGT GGATTCTTCG TAACTCACCG CATGCTGAAG ATGTTTCAGA TATAA.
88. The recombinant vector of claim 83 which recombinant vector is an E. coli vector.
89. The recombinant vector of claim 83 which is a pox virus vector.
90. A microorganism transformed with a recombinant vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712.
91. A method for producing a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712, which process comprises:
(a) culturing a microorganism transformed with a recombinant vector comprising a DNA sequence encoding the said protein in a culture medium under conditions in which the DNA sequence is expressed;
(b) isolating the said protein from the culture.
92. A vaccine for protecting poultry against coccidiosis comprising a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712 and a physiologically acceptable carrier.
93. A vaccine for protecting poultry against coccidiosis containing a recombinant poxvirus vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712 and a physiologically acceptable carrier.
94. A method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine comprising a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712 and a physiologically acceptable carrier to a young fowl that is susceptible to coccidiosis.
95. A method for protecting poultry against coccidiosis, which method comprises administering an effective amount of a vaccine for protecting poultry against coccidiosis containing a recombinant poxvirus vector comprising a DNA sequence encoding a protein having one or more immunoreactive and/or antigenic determinants of an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712 and a physiologically acceptable carrier to a young fowl that is susceptible to coccidiosis.
96. An isolated antibody which is directed against an Eimeria surface antigen, which surface antigen has an apparent molecular weight of greater than 200 kilodaltons and specifically binds to the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712.
97. The antibody of claim 96 which is a monoclonal antibody, such as the monoclonal antibody deposited with the American Type Culture Collection and assigned accession No. HB 9712.
US10/267,430 1988-06-03 2002-10-09 Recombinant coccidiosis vaccines Abandoned US20030175311A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/267,430 US20030175311A1 (en) 1988-06-03 2002-10-09 Recombinant coccidiosis vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20272188A 1988-06-03 1988-06-03
US07/812,349 US5661015A (en) 1988-06-03 1991-12-20 Recombinant coccidiosis vaccines
US74479396A 1996-11-01 1996-11-01
US10/267,430 US20030175311A1 (en) 1988-06-03 2002-10-09 Recombinant coccidiosis vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US74479396A Continuation 1988-06-03 1996-11-01

Publications (1)

Publication Number Publication Date
US20030175311A1 true US20030175311A1 (en) 2003-09-18

Family

ID=22750986

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/812,349 Expired - Lifetime US5661015A (en) 1988-06-03 1991-12-20 Recombinant coccidiosis vaccines
US10/267,430 Abandoned US20030175311A1 (en) 1988-06-03 2002-10-09 Recombinant coccidiosis vaccines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US07/812,349 Expired - Lifetime US5661015A (en) 1988-06-03 1991-12-20 Recombinant coccidiosis vaccines

Country Status (22)

Country Link
US (2) US5661015A (en)
EP (1) EP0344808B1 (en)
JP (1) JP3051130B2 (en)
KR (1) KR0156545B1 (en)
CN (3) CN1040126C (en)
AR (1) AR241942A1 (en)
AT (1) ATE120489T1 (en)
AU (1) AU635704B2 (en)
CA (1) CA1340538C (en)
DE (1) DE68921923T2 (en)
DK (1) DK272889A (en)
ES (1) ES2070866T3 (en)
FI (1) FI101453B1 (en)
HU (1) HU212505B (en)
IE (1) IE67544B1 (en)
IL (1) IL90489A0 (en)
MC (1) MC2039A1 (en)
NO (1) NO303876B1 (en)
NZ (1) NZ229377A (en)
PT (1) PT90727B (en)
YU (1) YU47880B (en)
ZA (1) ZA893740B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244946A1 (en) * 2004-03-31 2005-11-03 Hutchins James E Method of purifying oocysts using enzymatic digestion of fecal debris
US20080194006A1 (en) * 2007-02-08 2008-08-14 Embrex, Inc. Methods of releasing sporocysts from oocysts using controlled shear forces

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5279960A (en) * 1984-07-05 1994-01-18 Enzon Corp. 25 KD coccidial antigen of eimeria tenella
US5273901A (en) * 1984-07-05 1993-12-28 Enzon Corp. Genetically engineered coccidiosis sporozoite 21.5 Kb antigen, ac-6b
US5824656A (en) * 1988-01-15 1998-10-20 Merck & Co., Inc. Recombinant and native group B eimeria tenella immunogens useful as coccidiosis vaccines
ATE144146T1 (en) * 1988-07-05 1996-11-15 British Tech Group Usa GENETICALLY PRODUCED COCCIDIOSIS VACCINE
ZA902147B (en) * 1989-03-28 1990-12-28 Akzo Nv Coccidiosis vaccine
DE68909041T2 (en) * 1989-06-21 1994-01-13 Akzo Nv Eimeria tenella vaccine.
ZA9010461B (en) * 1990-01-26 1991-10-30 Hoffmann La Roche Recombinant coccidiosis vaccines-5-7 eimeria surface antigen
CA2106093A1 (en) * 1991-03-14 1992-09-15 David E. Harwood Recombinant anticoccidial vaccine
US5403581A (en) * 1991-07-12 1995-04-04 Hoffmann-La Roche Inc. Coccidiosis vaccines
US6008342A (en) * 1991-07-12 1999-12-28 Roche Vitamins Inc. DNA encoding eimeria antigen
CA2223699C (en) 1995-06-07 2002-07-02 Pfizer Inc. In ovo vaccination against coccidiosis
DK0831897T3 (en) 1995-06-07 2001-04-30 Pfizer In ovo vaccination against coccidiosis
ATE310747T1 (en) * 1995-07-03 2005-12-15 Akzo Nobel Nv VACCINE AGAINST POULTRY COCCIDOSE
EP0921814A4 (en) * 1996-03-29 2001-10-04 Life Technologies Inc Method for increasing viability and transformation efficiency of bacteria during storage at low temperatures
US6632923B1 (en) * 1996-11-27 2003-10-14 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
ZA200400479B (en) * 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
KR100490669B1 (en) * 2001-08-30 2005-05-19 (주)아비코아생명공학연구소 Recombinant ScFv Antibodies Specific to Eimeria spp. Responsible for Coccidiosis
US7166290B2 (en) 2001-08-30 2007-01-23 Embrex, Inc. Methods for producing oocysts
JP3995541B2 (en) * 2002-06-28 2007-10-24 株式会社ゲン・コーポレーション Anti-chicken coccidiosis composition
DE10330235A1 (en) * 2003-07-04 2005-01-20 Bayer Healthcare Ag New Eimeria gene and protein as well as their use
US7348401B2 (en) * 2003-09-10 2008-03-25 Innate Biotech, Inc. Peptides that inhibit complement activation
CA2559272C (en) * 2004-03-12 2015-12-01 University Of Georgia Research Foundation, Inc. Novel peanut skin extract as a vaccine adjuvant
US20110078828A1 (en) * 2004-09-10 2011-03-31 Guardian Biotechnologies Inc. Multi epitope vaccine for poultry
DE602005003429T2 (en) * 2004-12-01 2008-10-02 Zeon Corp. Coding DNA for an Eimeria Apical Membrane Antigen 1 and its uses
CN100398156C (en) * 2005-11-23 2008-07-02 南京农业大学 Immunity regulating type DNA vaccine for preventing and treating chicken coccidiosis
US11701683B2 (en) 2010-12-22 2023-07-18 The Procter & Gamble Company Methods for foil stamping parts having asymmetrical edges
US10758601B2 (en) 2016-12-22 2020-09-01 Intervet Inc. Eimeria vaccine with improved efficacy
JP2022535747A (en) * 2019-05-28 2022-08-10 ケース ウエスタン リザーブ ユニバーシティ Compositions and methods for preserving DNA methylation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
DE2814039C3 (en) 1978-03-31 1981-02-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig Process for the production of hybrid bacteria
US4650676A (en) 1983-08-19 1987-03-17 American Cyanamid Company Antigens and monoclonal antibodies reactive against merozoites of Eimeria spp.
US4710377A (en) * 1983-08-19 1987-12-01 American Cyanamid Company Antigens and monoclonal antibodies reactive against sporozoites of Eimeria spp.
EP0135073A3 (en) * 1983-08-19 1987-05-27 American Cyanamid Company Antigens and monoclonal antibodies reactive against merozites of eimeria spp.
EP0135712A3 (en) * 1983-08-19 1987-05-27 American Cyanamid Company Antigens and monoclonal antibodies reactive against sporozoites of eimeria spp.
US4874705A (en) * 1985-05-16 1989-10-17 Solvay & Cie, S.A. DNA encoding an antigenic protein derived from Eimeria tenella and vaccines for prevention of coccidiosis caused by Eimeria tenella
US5187080A (en) * 1984-06-05 1993-02-16 Solvay & Cie S.A. DNA encoding an antigenic protein derived from Eimeria tenella and vaccines for prevention of coccidiosis caused by Eimeria tenella
CA1340520C (en) * 1984-06-05 1999-05-04 Karel Z. Newman Jr. Antigenic proteins and vaccines containing them and protective antibodies directed to them for prevention of coccidiosis caused by eimeria tenella and eimeria necatrix
US4639372A (en) 1984-06-29 1987-01-27 Merck & Co., Inc. Coccidiosis vaccine
WO1986000528A1 (en) * 1984-07-05 1986-01-30 Genex Corporation Cloned gene and method for making and using the same
US5273901A (en) * 1984-07-05 1993-12-28 Enzon Corp. Genetically engineered coccidiosis sporozoite 21.5 Kb antigen, ac-6b
ATE73494T1 (en) * 1985-12-03 1992-03-15 Solvay ANTIGEN PROTEINS AND VACCINES CONTAINING THEM FOR THE PREVENTION OF COCCIDIOSIS.
EP0241139A3 (en) * 1986-03-13 1989-04-19 Merck & Co. Inc. Anti-idiotypic vaccine for coccidiosis
US5496550A (en) * 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
WO1988006629A1 (en) * 1987-03-06 1988-09-07 Synergen Incorporated Polypeptides useful in diagnosis of coccidia infection and recombinant-dna methods for manufacturing same
EP0315073A2 (en) * 1987-11-02 1989-05-10 Matsushita Electric Industrial Co., Ltd. A composition for pattern forming materials
NZ227595A (en) * 1988-01-15 1991-11-26 Merck & Co Inc Recombinant production of eimeria tenella antigens and their use
NZ227597A (en) * 1988-01-15 1991-11-26 Merck & Co Inc Eimeria tenella group b immunogens and their production
AU620366B2 (en) * 1988-02-12 1992-02-20 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cloned genes coding for avian coccidiosis antigens which induce a cell-mediated response and method of producing the same
DE3926461A1 (en) * 1989-07-15 1991-01-24 Suttner Gmbh & Co Kg VALVE GUN, ESPECIALLY FOR A HIGH PRESSURE CLEANING DEVICE

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244946A1 (en) * 2004-03-31 2005-11-03 Hutchins James E Method of purifying oocysts using enzymatic digestion of fecal debris
US7087425B2 (en) * 2004-03-31 2006-08-08 Embrex, Inc. Method of purifying oocysts using enzymatic digestion of fecal debris
US20080194006A1 (en) * 2007-02-08 2008-08-14 Embrex, Inc. Methods of releasing sporocysts from oocysts using controlled shear forces
WO2008118255A1 (en) * 2007-02-08 2008-10-02 Embrex, Inc. Methods of releasing sporocysts from oocysts using controlled shear forces

Also Published As

Publication number Publication date
AU3601689A (en) 1989-12-07
YU47880B (en) 1996-05-20
CN1186695A (en) 1998-07-08
FI892714A (en) 1989-12-04
MC2039A1 (en) 1990-05-30
FI101453B (en) 1998-06-30
DE68921923T2 (en) 1995-08-10
YU113889A (en) 1991-10-31
CA1340538C (en) 1999-05-11
HU212505B (en) 1996-07-29
KR910000183A (en) 1991-01-29
CN1076204C (en) 2001-12-19
DE68921923D1 (en) 1995-05-04
ZA893740B (en) 1990-02-28
NO892251D0 (en) 1989-06-02
IE891812L (en) 1989-12-03
JP3051130B2 (en) 2000-06-12
NZ229377A (en) 1992-06-25
DK272889A (en) 1989-12-04
AR241942A1 (en) 1993-01-29
FI892714A0 (en) 1989-06-02
EP0344808A1 (en) 1989-12-06
CN1040126C (en) 1998-10-07
CN1187368A (en) 1998-07-15
IE67544B1 (en) 1996-04-17
KR0156545B1 (en) 1998-11-16
ATE120489T1 (en) 1995-04-15
NO303876B1 (en) 1998-09-14
FI101453B1 (en) 1998-06-30
DK272889D0 (en) 1989-06-02
JPH037594A (en) 1991-01-14
US5661015A (en) 1997-08-26
PT90727B (en) 1994-11-30
PT90727A (en) 1989-12-29
CN1038837A (en) 1990-01-17
IL90489A0 (en) 1990-01-18
HUT52963A (en) 1990-09-28
ES2070866T3 (en) 1995-06-16
NO892251L (en) 1989-12-04
EP0344808B1 (en) 1995-03-29
CN1077438C (en) 2002-01-09
AU635704B2 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
US5661015A (en) Recombinant coccidiosis vaccines
JPH0699475B2 (en) Coccidial monoclonal antibody
EP0390267B1 (en) Coccidiosis vaccine
US5403581A (en) Coccidiosis vaccines
AU634335B2 (en) Recombinant coccidiosis vaccines -5-7 eimeria surface antigen
US5283191A (en) Mareks&#39; disease virus vaccine
US5597570A (en) Protein recognized by antibodies raised against native P28 of schistosoma mansoni
AU636290B2 (en) Recombinant eimeria tenella vaccines
CA2067469C (en) Recombinant vaccine against marek&#39;s disease
EP0992582A2 (en) Schistosoma recombinant fusion protein vaccine

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION